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Abstract
Ventricular arrhythmias are an important cause of morbidity and mortality and come in a variety of forms, from single premature ventricular
complexes to sustained ventricular tachycardia and ﬁbrillation. Rapid
developments have taken place over the past decade in our understanding of these arrhythmias and in our ability to diagnose and treat
them. The ﬁeld of catheter ablation has progressed with the development of new methods and tools, and with the publication of large clinical trials. Therefore, global cardiac electrophysiology professional
societies undertook to outline recommendations and best practices
for these procedures in a document that will update and replace the
2009 EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias. An expert writing group, after reviewing and discussing the
literature, including a systematic review and meta-analysis published
in conjunction with this document, and drawing on their own experience, drafted and voted on recommendations and summarized current
knowledge and practice in the ﬁeld. Each recommendation is presented in knowledge byte format and is accompanied by supportive
text and references. Further sections provide a practical synopsis of
the various techniques and of the speciﬁc ventricular arrhythmia sites
and substrates encountered in the electrophysiology lab. The purpose
of this document is to help electrophysiologists around the world to
appropriately select patients for catheter ablation, to perform procedures in a safe and efﬁcacious manner, and to provide follow-up and
adjunctive care in order to obtain the best possible outcomes for
patients with ventricular arrhythmias.
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Section 1 Introduction
1.1. Document Scope and Rationale
The ﬁeld of electrophysiology has undergone rapid progress
in the last decade, with advances both in our understanding of
the genesis of ventricular arrhythmias (VAs) and in the technology used to treat them. In 2009, a joint task force of the
European Heart Rhythm Association (EHRA) and the Heart
Rhythm Society (HRS), in collaboration with the American
College of Cardiology (ACC) and the American Heart Association (AHA), produced an expert consensus document that
outlined the state of the ﬁeld and deﬁned the indications,
techniques, and outcome measures of VA ablation (S1.1.1).
In light of advances in the treatment of VAs in the interim,
and the growth in the number of VA ablations performed
in many countries and regions (S1.1.2,S1.1.3), an updated
document is needed. This effort represents a worldwide
partnership between transnational cardiac electrophysiology
societies, namely, HRS, EHRA, the Asia Paciﬁc Heart
Rhythm Society (APHRS), and the Latin American Heart
Rhythm Society (LAHRS), and collaboration with ACC,
AHA, the Japanese Heart Rhythm Society (JHRS), the
Brazilian Society of Cardiac Arrhythmias (Sociedade
Brasileira de Arritmias Cardíacas [SOBRAC]), and the
Pediatric and Congenital Electrophysiology Society
(PACES). The consensus statement was also endorsed by
the Canadian Heart Rhythm Society (CHRS).
This clinical document is intended to supplement, not
replace, the 2017 AHA/ACC/HRS Guideline for Management
of Patients with Ventricular Arrhythmias and the Prevention
of Sudden Cardiac Death (S1.1.4) and the 2015 ESC Guidelines for the Management of Patients with Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death
(S1.1.5). The scope of the current document relates to ablation therapy for VAs, from premature ventricular complexes
(PVCs) to monomorphic and polymorphic ventricular tachycardia (VT) and triggers of ventricular ﬁbrillation (VF). Due
to its narrower scope, the consensus statement delves into
greater detail with regard to indications and technical aspects
of VA ablation than the above-mentioned guidelines.
Where possible, the recommendations in this document
are evidence based. It is intended to set reasonable standards
that can be applicable worldwide, while recognizing the
different resources, technological availability, disease prevalence, and health care delivery logistics in various parts of the
world. In addition, parts of this document, particularly
Section 9, present a practical guide on how to accomplish
the procedures described in a manner that reﬂects the current
standard of care, while recognizing that some procedures are
better performed, and some disease states better managed, in
settings in which there is speciﬁc expertise.
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1.2. Methods
The writing group was selected according to each society’s
procedures, including content and methodology experts representing the following organizations: HRS, EHRA,
APHRS, LAHRS, ACC, AHA, JHRS, PACES, and
SOBRAC. Each partner society nominated a chair and cochair, who did not have relevant relationships with industry
and other entities (RWIs). In accordance with HRS policies,
disclosure of any RWIs was required from the writing committee members (Appendix 1) and from all peer reviewers
(Appendix 2). Of the 38 committee members, 17 (45%)
had no relevant RWIs. Recommendations were drafted by
the members who did not have relevant RWIs. Members of
the writing group conducted comprehensive literature
searches of electronic databases, including Medline (via
PubMed), Embase, and the Cochrane Library. Evidence tables were constructed to summarize the retrieved studies,
with nonrandomized observational designs representing the
predominant form of evidence (Appendix 3). Case reports
were not used to support recommendations. Supportive text
was drafted in the “knowledge byte” format for each recommendation. The writing committee discussed all recommendations and the evidence that informed them before voting.
Initial failure to reach consensus was resolved by subsequent
discussions, revisions as needed, and re-voting. Although the
consensus threshold was set at 67%, all recommendations
were approved by at least 80% of the writing committee
members. The mean consensus over all recommendations
was 95%. A quorum of two-thirds of the writing committee
was met for all votes (S1.2.1).
Each recommendation in this document was assigned a
Class of Recommendation (COR) and a Level of Evidence
(LOE) according to the system developed by ACC and
AHA (Table 1) (S1.2.2). The COR denotes the strength of
the recommendation based on a careful assessment of the
estimated beneﬁts and risks; COR I indicates that the beneﬁt
of an intervention far exceeds its risk; COR IIa indicates that
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the beneﬁt of the intervention moderately exceeds the risk;
COR IIb indicates that the beneﬁt may not exceed the risk;
and COR III indicates that the beneﬁt is equivalent to or is exceeded by the risk. The LOE reﬂects the quality of the evidence that supports the recommendation. LOE A is derived
from high-quality randomized controlled trials (RCTs);
LOE B-R is derived from moderate-quality RCTs; LOE
B-NR is derived from well-designed nonrandomized studies;
LOE C-LD is derived from randomized or nonrandomized
studies with limitations of design or execution; and LOE
C-EO indicates that a recommendation was based on expert
opinion (S1.2.2).
Unique to this consensus statement is the systematic review commissioned speciﬁcally for this document as part
of HRS’s efforts to adopt the rigorous methodology
required for guideline development. The systematic review
was performed by an experienced evidence-based practice
committee based at the University of Connecticut, which

examined the question of VT ablation vs control in patients
with VT and ischemic heart disease (IHD) (S1.2.3). The
question, in PICOT format, was as follows: In adults with
history of sustained VT and IHD, what is the effectiveness
and what are the detriments of catheter ablation compared
with other interventions? Components of the PICOT were
as follows: P 5 adults with history of sustained VT and
IHD; I 5 catheter ablation; C 5 control (no therapy or antiarrhythmic drug [AAD]); O 5 outcomes of interest, which
included 1) appropriate implantable cardioverter deﬁbrillator (ICD) therapies (ICD shock or antitachycardia pacing
[ATP]), 2) appropriate ICD shocks, 3) VT storm (deﬁned as
three shocks within 24 hours), 4) recurrent VT/VF, 5) cardiac hospitalizations, and 6) all-cause mortality; and T 5
no time restrictions.
An industry forum was conducted to achieve a structured
dialogue to address technical questions and to gain a better
understanding of future directions and challenges. Because

Table 1 ACC/AHA Recommendation System: Applying Class of Recommendation and Level of Evidence to Clinical Strategies,
Interventions, Treatments, and Diagnostic Testing in Patient Care*

Reproduced with permission of the American College of Cardiology (ACC) and the American Heart Association (AHA) (S1.2.2).

Cronin et al. Catheter Ablation of Ventricular Arrhythmias
of the potential for actual or perceived bias, HRS imposes
strict parameters on information sharing to ensure that industry participates only in an advisory capacity and has no role in
either the writing of the document or its review.
The draft document underwent review by the HRS Scientiﬁc and Clinical Documents Committee and was approved
by the writing committee. Recommendations were subject
to a period of public comment, and the entire document underwent rigorous peer review by each of the participating societies and revision by the Chairs, before endorsement.
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Section 2 Background
2.1. History of Ventricular Arrhythmia Ablation
In 1959, Couch (S2.1.1) reported the elimination of VT with
the resection of a postinfarction left ventricular (LV) aneurysm. In the early to mid-1970s, standard LV aneurysmectomy was performed for patients with preoperative VT
episodes in the setting of prior infarction. Unfortunately,
the operative mortality rates were high and VT recurrences
were frequent (S2.1.2). Endocardial encircling ventriculotomy, introduced by Guiraudon et al. (S2.1.3), was designed
to isolate the arrhythmogenic tissue from the remainder of
the ventricle by creating a nearly transmural incision through
the edge of the border zone, sparing only the epicardium.
This operation was associated with marked postoperative
LV dysfunction, likely due to interference with coronary arterial blood supply. Guiraudon et al. (S2.1.4) also attempted to
disarticulate the right ventricular (RV) free wall from the rest
of the ventricles in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). Although the surgery
was successful in isolating the arrhythmogenic RV free
wall and in producing interesting 12-lead electrocardiogram
(ECG) recordings of sinus rhythm simultaneous with persistent sustained VT in the same patient, most patients ultimately did poorly because of progressive RV failure. In the
late 1970s, Josephson et al. (S2.1.5) developed the technique
of map-guided subendocardial resection. This procedure
was based on the observation that diastolic or presystolic
electrical activation could be recorded during VT on the
endocardium near or within the border between the
densely scarred aneurysm or infarct and more normal muscle
(S2.1.6–S2.1.8). The surgical procedure thus targeted
areas speciﬁed by mapping. As originally practiced,
subendocardial resection removed segments of endocardium
approximately 3 mm thick and 5 cm2 (S2.1.5). These areas
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were almost always within regions of visibly scarred endocardium, extending from the edge of a densely scarred aneurysm.
As the procedure evolved, a more extensive area of resection
was typically performed because of the ease of deﬁning a single plane of resection with the goal of eliminating other
arrhythmogenic areas within the visual scar. Adjunctive cryoablation was applied to locations that were not easily resected,
such as the papillary muscles or the deep myocardial layers
beneath the removed subendocardium when VT was localized
to these regions. Cryoablation targeting an isthmus of surviving myocardium between a more densely scarred inferior
infarction and the mitral annulus improved the outcome of
VT ablation associated with this substrate (S2.1.9). More
extensive cryoablation of the entire visually scarred endocardial surface was also used with some success (S2.1.10).
Although success rates approached 90% with surgery in terms
of VT elimination, a mortality rate of 5%–15% limited the procedure to a few select patients (S2.1.11).
In 1983, endocardial catheter ablation of VT using direct
current energy electrical shock delivered via the distal electrode of a standard quadripolar endocardial catheter positioned in the area to be modiﬁed was ﬁrst described by
Hartzler (S2.1.12). One of the largest early studies was by
Fontaine et al. (S2.1.13), who referred to direct current shock
ablation as fulguration and reported their results in 43 patients. One to 8 R-wave-synchronous shocks of preselected
energy ranging from 160 to 320 joules were delivered per
session, with 23 patients undergoing at least one repeat procedure. Of note, a success rate of 87% in preventing VT
recurrence was achieved, and no deaths were thought to be
related to the endocardial shock itself. Strategies for
analyzing the 12-lead ECG during VT and pace mapping to
mimic the QRS of VT were ﬁrst described in the early
1980s to help to regionalize areas of interest for more detailed
activation mapping for surgical or early catheter-based VT
ablation (S2.1.14–S2.1.16).
Concern about barotrauma and the need for general anesthesia with direct current shock ablation led to the use of radiofrequency (RF) energy for catheter ablation for all
arrhythmias, including VT, by the end of the 1980s (S2.1.
17,S2.1.18). The safety and short-term effectiveness of RF
catheter ablation for VT occurring either in the absence or
presence of structural heart disease (SHD) was ﬁrst reported
in observational reports by Klein et al. (S2.1.19) and Morady
et al. (S2.1.20), respectively. Activation mapping to identify
diastolic activation coupled with entrainment mapping techniques to identify critical components of the VT circuit
ultimately proved most useful to deﬁne a critical isthmus
through which a VT circuit must pass. This isthmus identiﬁcation allowed for successful targeted ablation using RF
ablation techniques for hemodynamically tolerated VT
(S2.1.21–S2.1.25). Using both computer simulations and
catheter mapping of stable VT in humans, Stevenson et al.
(S2.1.22) elucidated a schematic model of the postinfarction
VT circuit that endures.
Unfortunately, detailed activation and entrainment mapping is not always feasible when VT is hemodynamically
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poorly tolerated (S2.1.26,S2.1.27). A successful substratebased ablation strategy that did not require detailed mapping
of VT was ﬁrst described by Marchlinski et al. (S2.1.28,S2.1.
29). Linear ablation created by sequential point lesions
transected the border zone, extending into the region of
dense infarction deﬁned by detailed bipolar voltage
mapping with a color-coded display on a three-dimensional
(3D) mapping system. The mapping system facilitated the
ability to track lesion deployment. The location of the ablation line was guided by analyzing the 12-lead QRS of VT
and by pace mapping to mimic the QRS complex. Subsequent substrate-based VT targets, which were reported to
be effective surrogates of the VT circuit, included 1) late potentials (LPs); 2) channels deﬁned by high voltage surrounded by lower voltage or by areas of pace capture
surrounded by myocardium that could not be captured at
10 mA pacing output; 3) local abnormal ventricular activity
(LAVA) that could demonstrate more abnormality with pacing; 4) paced map QRS morphologies that matched VT and
demonstrated a long stimulus to QRS duration; and 5) regions in which pace mapping demonstrates abrupt transition
in paced QRS morphologies (S2.1.30–S2.1.41). More
recently, isolation of abnormal myocardium demonstrating
critical components of the VT circuit or extensive direct
ablation of all low-voltage areas have been reported as
successful techniques for possibly improving substratebased ablation outcome (S2.1.42,S2.1.43). The integration
of anatomical imaging of ventricular myocardial scar
by computed tomography (CT) or cardiac magnetic
resonance imaging (CMR) with electroanatomical
mapping (EAM) has further contributed to the ability to
recognize and eliminate disrupted and potentially slowly
conducting regions of myocardium that are critical to the
maintenance of VT.
The documentation of basal, perivalvular, low-voltage
scar serving as the substrate for VT in nonischemic LV and
RV cardiomyopathy focused attention on these regions for
VT localization (S2.1.44–S2.1.46). The basal involvement
frequently included the septum, and not uncommonly the
substrate was intramurally located in the septum or
midmyocardial with epicardial extension if located in the
free wall (S2.1.47–S2.1.49).
The percutaneous technique for accessing the pericardial
space to allow mapping of the epicardium as described by
Sosa et al. (S2.1.50) provided the opportunity to deﬁne the
epicardial substrate in patients with SHD. Epicardial mapping and ablation proved particularly valuable in patients
with nonischemic RV and LV cardiomyopathy, where the
predominant substrate and VT circuits are frequently located
(S2.1.51–S2.1.56). Endocardial unipolar voltage mapping
helped to identify the probable epicardial substrate when
normal endocardial bipolar voltage was demonstrated in
patients with VT and nonischemic cardiomyopathy
(NICM) (S2.1.57,S2.1.58). The value of epicardial
mapping and ablation in select patients with postinfarction
and idiopathic VT has also been demonstrated (S2.1.
59–S2.1.61).
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In an attempt to overcome the biophysical limitations of
lesion formation in scar, irrigated ablation for VT was introduced with closed-loop, internal irrigation in the late 1990s
(S2.1.62). This was followed by reports of even more extensive experience with open irrigated catheter ablation (S2.1.
63,S2.1.64). More recently, techniques have been described
to further enhance lesion formation in scar and/or deep to
the endocardium, including alcohol infusion in the
coronary arteries or coronary veins; bipolar and
simultaneous unipolar ablation at both endocardial and
epicardial sites; ablation with near freezing saline; half
normal saline as the irrigant; and needle electrode ablation
(S2.1.65–S2.1.70). Simultaneously, small, multipolar
electrode recording techniques have been proven to further
enhance the accuracy of activation and entrainment
mapping (S2.1.71–S2.1.73).
Idiopathic VT ablation with RF ablation also evolved
from the initial catheter ablation experience. The most common anatomical sites of origin of frequent PVCs and VF triggers were described (S2.1.74). Twelve-lead ECG QRS
assessment provided reasonably precise characterization of
origin for these focal arrhythmias occurring in the absence
of SHD, with an emphasis on clues to identify left versus
RV outﬂow tract (RVOT) origin and epicardial origin
(S2.1.75). New techniques to overcome the challenges of
idiopathic VT ablation associated with the sinuses of Valsalva (SV), the coronary venous system, the LV summit,
and papillary muscle arrhythmias have been described (S2.
1.76–S2.1.79). The importance of PVC-induced cardiomyopathy has been recognized, and the potential for improvement in LV function with ablation has been demonstrated
(S2.1.80,S2.1.81).
Of note, this brief historical summary of VT ablation provides only an overview. There have been many important
contributions related to VT ablation, the details of which
will be further highlighted elsewhere in this document.
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2.2. Mechanisms of Ventricular Arrhythmia
2.2.1. Mechanisms and Basis for Catheter Ablation of
Ventricular Tachycardia
Catheter ablation has an important role in reducing or preventing VAs both in patients with heart disease and in those
with idiopathic VTs not associated with SHD. The approach
to ablation and the efﬁcacy are determined by the characteristics of the arrhythmia and the anatomy and location of the
arrhythmia substrate, which can often be anticipated from
the ECG of the VT and the nature of any underlying heart disease. Focal VTs are susceptible to ablation with discrete RF
lesions (S2.2.4.1–S2.2.4.8). Relatively large scar substrates
requiring more extensive ablation are common in VT
associated with SHD; however, VT origin can appear focal
if the reentry circuit is small, or if it is due to a focal
endocardial breakthrough from an epicardial or intramural
reentry circuit. Automatic VTs can also occur in some
patients with SHD and ventricular scars.
Focal VT has a point source of earliest ventricular activation with a spread of activation away in all directions from that
site. The mechanism can be automaticity, triggered activity,
or microreentry. Focal origin arrhythmias should be particularly suspected in patients without SHD who have repetitive
monomorphic and nonsustained VTs and PVCs or who
have sustained VT from the outﬂow tract (OT) and other
more stereotypical sites of origin (S2.2.4.6–S2.2.4.8). A
focal origin is conﬁrmed by mapping that shows spread of
activation away in all directions from the site of earliest
activation relative to the QRS onset. Unipolar unﬁltered
(or minimally high pass ﬁltered at 0.5 Hz) electrograms
typically display a QS conﬁguration at the site of origin
(SOO) (S2.2.4.9,S2.2.4.10). Pacing at the origin will
replicate the VT/PVC QRS morphology if the origin is on
the surface; however, matching pace maps are frequently
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found within 1 cm of the site of earliest activation. Pace
mapping is particularly unreliable for VTs originating from
the aortic sinuses (S2.2.4.11).
2.2.2. Triggered Activity and Automaticity
Triggered activity arises from oscillations in membrane potential during (early afterdepolarizations) or following (delayed afterdepolarizations) an action potential and can give
rise to focal VA. Experimental evidence implicates early
afterdepolarizations in the initiation of polymorphic tachycardias in long QT syndromes (S2.2.4.12). However, the
mechanism of the premature ventricular beats targeted for
ablation in these syndromes is unknown (S2.2.4.13).
Delayed afterdepolarizations can be caused by intracellular
calcium overload, which activates the Na1/Ca21 exchanger,
resulting in the transient inward current Iti (S2.2.4.14). Factors
that increase intracellular calcium include increases in heart
rate, beta-adrenergic stimulation, and digitalis. Beta-adrenergic
effects are mediated through a cyclic adenosine monophosphate (cAMP)-induced increase in intracellular calcium and
are antagonized by adenosine, which effects a decrease in
cAMP. Termination of idiopathic RVOT tachycardias by an
intravenous bolus of adenosine, by infusion of calcium channel
blockers, or by vagotonic maneuvers is consistent with triggered activity as the likely mechanism for some of these tachycardias (S2.2.4.3). These tachycardias can be difﬁcult to induce
at electrophysiology testing; rapid burst pacing and/or isoproterenol infusion is often required. Aminophylline, calcium
infusion, and atropine can also be useful (S2.2.4.2).
Less commonly, focal VT can be due to automaticity provoked by adrenergic stimulation that is not triggered (S2.2.4.
2,S2.2.4.14). This type of VT can become incessant under
stress or during isoproterenol administration, and it cannot
be initiated or terminated by programmed electrical
stimulation (PES); however, it can sometimes be
suppressed by calcium channel blockers or beta blockers.
In contrast to its effects on triggered RVOT tachycardia,
adenosine transiently suppresses, but does not terminate,
the arrhythmia. Automaticity from damaged Purkinje ﬁbers
has been suggested as a mechanism for some
catecholamine-sensitive, focal origin VTs (S2.2.4.15,S2.2.
4.16). Whether these VTs are due to abnormal
automaticity, originating from partially depolarized
myocytes, as has been shown for VTs during the early
phase of myocardial infarction (MI), is not clear (S2.2.4.17).
Although automaticity is frequently considered as a mechanism of VT in the absence of overt SHD, disease processes
that diminish cell-to-cell coupling are likely to facilitate automaticity (S2.2.4.18). Automatic VTs can occur in SHD, and
automatic premature beats can initiate reentrant VTs.
2.2.3. Scar-Related Reentry
Scar-related reentry is the most common cause of sustained
monomorphic VT in the presence of SHD (S2.2.4.19).
Evidence supporting reentry includes initiation and
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termination by programmed stimulation (although this does
not exclude triggered activity), demonstrable entrainment or
resetting with fusion, and continuous electrical activity that
cannot be dissociated from VT by extrastimuli (S2.2.4.20,
S2.2.4.21). Prior MI is the most common cause of the
substrate, but scar-related VT also occurs in other myocardial
diseases, including ARVC, sarcoidosis, Chagas disease
(ChD), dilated cardiomyopathy (DCM) including laminopathies, and after cardiac surgery for congenital heart disease
(CHD) (particularly, tetralogy of Fallot) or valve replacement
(S2.2.4.22–S2.2.4.28).
Regions of ﬁbrosis with surviving myocyte bundles create
ﬁxed and/or functional conduction block and disrupted or
slow conduction that are the substrate for reentry. Stable circuits can be modeled as having an isthmus or channel
comprised of a small mass of tissue that does not contribute
to the surface ECG. QRS onset occurs when the excitation
wave front emerges from an exit along the border of the
scar and spreads across the ventricles (S2.2.4.29,S2.2.4.30).
Scars associated with VT are often close to a valve
annulus and together can form the borders of the isthmus
of a VT circuit (S2.2.4.31,S2.2.4.32). The 3D structure of
the reentry circuit and substrate can be subendocardial,
intramural, or subepicardial, or it can span the width of
the entire ventricular wall (S2.2.4.33,S2.2.4.34). The
entire circuit or only a portion of it might be accessible to
ablation.
The substrate supporting scar-related reentry is characterized by 1) regions of slow conduction; 2) unidirectional
conduction block at some point in the reentry path that
allows initiation of reentry; and 3) areas of conduction
block that often deﬁne parts of the reentry path. Some of
the substrate might exhibit functional rather than ﬁxed
conduction block (S2.2.4.35–S2.2.4.37). VT after MI has
been extensively studied in canine models and in humans
(S2.2.4.35,S2.2.4.38). Reentry occurs through surviving
muscle bundles, commonly located in the subendocardium;
however, this can also occur in the midmyocardium and
epicardium. Evidence has shown ongoing ion channel
remodeling within scar, at least early after MI, resulting in
regional reductions in ionized sodium and ionized calcium
currents (S2.2.4.39), although action potential characteristics
of surviving myocytes late after infarction can be normal
or near normal (S2.2.4.38). Coupling between myocyte
bundles and myocytes is reduced by increased collagen
and connective tissue, diminished gap junction density, and
alterations in gap junction distribution, composition, and
function (S2.2.4.40). Surviving ﬁbers can be connected by
side to side connections in regions where the collagenous
sheaths are interrupted, resulting in a “zig-zag” pattern
of transverse conduction along a pathway lengthened by
branching and merging bundles of surviving myocytes
(S2.2.4.41). The ﬁbrosis pattern might be important in
determining the degree of conduction delay; patchy ﬁbrosis
between strands of surviving muscle produces greater delay
than diffuse ﬁbrosis (S2.2.4.36). These aspects of scar
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remodeling contribute to the formation of channels and regions in which conduction time is prolonged, facilitating
reentry (S2.2.4.42).
Unidirectional conduction block can occur after a properly timed PVC and is often functional (S2.2.4.35,S2.2.4.
43,S2.2.4.44); it can present only during tachycardia,
when the refractory period of the tissue exceeds the
tachycardia cycle length (CL) or is maintained by
collision of excitation waves. Regions of conduction
block can also be anatomically ﬁxed such that they are
present during tachycardia and sinus rhythm; dense,
nonexcitable ﬁbrosis, calciﬁcations, surgical scars, or
valve annuli create these types of anatomical boundaries
for reentry (S2.2.4.31,S2.2.4.32,S2.2.4.45). Multiple VTs
with various QRS morphologies can be due to multiple
exits from the same region of scar, or to changes in
activation remote from the circuit due to functional
regions of block. Ablation at one region can abolish more
than one VT. Multiple reentry circuits from widely
separated areas also occur.
It is possible that other reentry mechanisms cause some
VTs. Spiral wave reentry can be induced in excitable tissue
in the absence of tissue discontinuities and could cause VF
or polymorphic VT (S2.2.4.46); anchoring to a discontinuity
or to a region of slow conduction could theoretically cause
monomorphic VT (S2.2.4.47).
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2.3. Deﬁnitions
The previous EHRA/HRS expert consensus on catheter ablation of VA in 2009 proposed several deﬁnitions to standardize nomenclature in the ﬁeld (S2.3.1). The current
consensus statement repeats the majority of these recommendations for VT ablation. In the last 10 years, knowledge and
experience of PVC ablations have signiﬁcantly increased. In
the current report, new proposals are made to facilitate understanding of clinical characteristics and reporting of the ablation outcomes of these arrhythmias (Table 2). Note that
different cutoff rates for VT and (accelerated) idioventricular
rhythm could be appropriate for children, who have a higher
resting sinus rate than adults: the mechanism, symptoms, and
clinical setting of the VA are more important than the rate
(S2.3.2).
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Deﬁnitions

Clinical Characteristics
Clinical ventricular tachycardia (VT): VT that has occurred spontaneously based on analysis of 12-lead ECG QRS morphology.
Hemodynamically unstable VT: causes hemodynamic compromise requiring prompt termination.
Idiopathic VT: used to indicate VT that is known to occur in the absence of clinically apparent SHD.
Idioventricular rhythm: three or more consecutive beats at a rate of up to 100 per minute that originate from the ventricles independent of
atrial or atrioventricular (AV) nodal conduction. Although various arbitrary rates have been used to distinguish it from VT, the mechanism of
ventricular rhythm is more important than the rate. Idioventricular rhythm can be qualiﬁed as “accelerated” when the rate exceeds 40 bpm.
Incessant VT: continuous sustained VT that recurs promptly despite repeated intervention for termination over several hours.
Nonclinical VT: VT induced by PES that has not been documented previously.
Nonsustained VT: terminates spontaneously within 30 seconds.
PVC: premature ventricular complex; it is an early ventricular depolarization with or without mechanical contraction. We recommend avoiding
the use of the terms “ventricular premature depolarization” and “premature ventricular contraction” to standardize the literature and
acknowledge that early electrical activity does not necessarily lead to mechanical contraction.
Presumptive clinical VT: similar to a spontaneous VT based on rate, limited ECG, or electrogram data available from ICD interrogation, but
without the 12-lead ECG documentation of spontaneous VT.
PVC burden: the amount of ventricular extrasystoles, preferably reported as the % of beats of ventricular origin of the total amount of beats
over a 24-hour recording period.
Repetitive monomorphic VT: continuously repeating episodes of self-terminating nonsustained VT.
Sustained VT: continuous VT for 30 seconds, or which requires an intervention for termination (such as cardioversion).
VT: a tachycardia (rate .100 bpm) with 3 or more consecutive beats that originates from the ventricles independent of atrial or AV nodal
conduction.
VT storm: three or more separate episodes of sustained VT within 24 hours, each requiring termination by an intervention.
VT Morphologies
Monomorphic VT: a similar QRS conﬁguration from beat to beat (Figure 1A). Some variability in QRS morphology at initiation is not uncommon,
followed by stabilization of the QRS morphology.
Monomorphic VT with indeterminate QRS morphology: preferred over ventricular ﬂutter; it is a term that has been applied to rapid VT that has
a sinusoidal QRS conﬁguration that prevents identiﬁcation of the QRS morphology.
Multiple monomorphic VTs: more than one morphologically distinct monomorphic VT, occurring as different episodes or induced at different
times.
Pleomorphic VT: has more than one morphologically distinct QRS complex occurring during the same episode of VT, but the QRS is not
continuously changing (Figure 1B).
Polymorphic VT: has a continuously changing QRS conﬁguration from beat to beat, indicating a changing ventricular activation sequence
(Figure 1C).
Right bundle branch block (RBBB)- and left bundle branch block (LBBB)-like VT conﬁgurations: terms used to describe the dominant
deﬂection in V1, with a dominant R wave described as “RBBB-like” and a dominant S wave with a negative ﬁnal component in V1 described as
“LBBB-like” conﬁgurations.
Torsades de pointes: a form of polymorphic VT with continually varying QRS complexes that appear to spiral around the baseline of the ECG lead
in a sinusoidal pattern. It is associated with QT prolongation.
Unmappable VT: does not allow interrogation of multiple sites to deﬁne the activation sequence or perform entrainment mapping; this could
be due to hemodynamic intolerance that necessitates immediate VT termination, spontaneous or pacing-induced transition to other
morphologies of VT, or repeated termination during mapping.
Ventricular ﬁbrillation (VF): a chaotic rhythm deﬁned on the surface ECG by undulations that are irregular in both timing and morphology,
without discrete QRS complexes.
PVC Morphologies
Monomorphic PVC: PVCs felt reasonably to arise from the same focus. Slight changes in QRS morphology due to different exit sites from the
same focus can be present.
Multiple morphologies of PVC: PVCs originating from several different focal locations.
Predominant PVC morphology: the one or more monomorphic PVC morphologies occurring most frequently and serving as the target for
ablation.
Mechanisms
Focal VT: a point source of earliest ventricular activation with a spread of activation away in all directions from that site. The mechanism can be
automaticity, triggered activity, or microreentry.
Scar-related reentry: arrhythmias that have characteristics of reentry that originate from an area of myocardial scar identiﬁed from
electrogram characteristics or myocardial imaging. Large reentry circuits that can be deﬁned over several centimeters are commonly referred
to as “macroreentry.”
AV 5 atrioventricular; ECG 5 electrocardiogram; ICD 5 implantable cardioverter deﬁbrillator; LBBB 5 left bundle branch block; PES 5 programmed electrical
stimulation; PVC 5 premature ventricular complex; RBBB 5 right bundle branch block; SHD 5 structural heart disease; VT 5 ventricular tachycardia.
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Figure 1 Monomorphic (A), pleomorphic (B), and polymorphic (C) VT. Reproduced with permission of the Heart Rhythm Society (S2.3.1). VT 5 ventricular
tachycardia.

References
S2.3.1.

Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. EHRA/HRS expert
consensus on catheter ablation of ventricular arrhythmias: developed in a partnership with the European Heart Rhythm Association (EHRA), a registered
branch of the European Society of Cardiology (ESC), and the Heart Rhythm
Society (HRS); in collaboration with the American College of Cardiology

S2.3.2.

(ACC) and the American Heart Association (AHA). Heart Rhythm 2009;
6:886–933.
Crosson JE, Callans DJ, Bradley DJ, et al. PACES/HRS expert consensus
statement on the evaluation and management of ventricular arrhythmias in
the child with a structurally normal heart. Heart Rhythm 2014;
11:e55–e78.

e18

Heart Rhythm, Vol 17, No 1, January 2020

2.4. Standard Anatomical Terminology
The following are the suggested anatomical terminology for
use in the description of catheter ablation of VA (Table 3).
Table 3

While these generally represent the most commonly used
terms, the writing committee recognizes that several variants
or alternatives are in use and may also be valid.

Anatomical terminology

Term

Deﬁnition

RV inﬂow
RV outﬂow tract (RVOT)

The part of the RV containing the tricuspid valve, chordae, and proximal RV.
The conus or infundibulum of the RV, derived from the bulbus cordis. It is bounded by the
supraventricular crest and the pulmonic valve.
Area immediately adjacent to the tricuspid valve, including septal, free wall, and para-Hisian regions.
A muscular band in the RV, typically located in the mid to apical RV, connecting the interventricular
septum to the RV free wall, supporting the anterior papillary muscle. It typically contains a
subdivision of the right bundle branch (RBB).
Three muscles connecting the RV myocardium to the tricuspid valve via the tricuspid chordae
tendineae, usually designated as septal, posterior, and anterior papillary muscles. The septal
papillary muscle is closely associated with parts of the RBB.
Muscular ridge in the RV between the tricuspid and pulmonic valves, representing the boundary
between the conus arteriosus and the rest of the RV. The exact components and terminology are
controversial; however, some characterize it as being composed of a parietal band that extends
from the anterior RV free wall to meet the septal band, which extends from the septal papillary
muscle to meet it.
The pulmonic valve includes three cusps and associated sinus, variously named right, left, and
anterior; or anterolateral right, anterolateral left, and posterior sinuses. The posterior-right
anterolateral commissure adjoins the aorta (junction of the right and left aortic sinuses). Muscle is
present in each of the sinuses, and VA can originate from muscle ﬁbers located within or extending
beyond the pulmonary valve apparatus.
The right (R), left (L), and noncoronary aortic valve cusps are attached to the respective SV. The left
sinus of Valsalva (LSV) is posterior and leftward on the aortic root. The noncoronary sinus of
Valsalva (NCSV) is typically the most inferior and posterior SV, located posterior and rightward,
superior to the His bundle, and anterior and superior to the paraseptal region of the atria near the
superior AV junctions, typically adjacent to atrial myocardium. The right sinus of Valsalva (RSV) is
the most anterior cusp and may be posterior to the RVOT infundibulum. VAs can also arise from
muscle ﬁbers at the commissures (connections) of the cusps, or from myocardium accessible to
mapping and ablation from this location, especially from the RSV/LSV junction.
The aortic vestibule, composed of an infra-valvular part, bounded by the anterior mitral valve leaﬂet,
but otherwise not clearly distinguishable from the rest of the LV; the aortic valve; and a supravalvular part.
The opening at the base of the LV to which the mitral and aortic valves attach.
Continuation of the anteromedial aspect of the mitral annulus to the aortic valve; a curtain of ﬁbrous
tissue extending from the anterior mitral valve leaﬂet to the left and noncoronary aortic cusps. The
AMC is connected by the left and right ﬁbrous trigones to ventricular myocardium, the right ﬁbrous
trigone to the membranous ventricular septum.
Area immediately adjacent to the mitral valve. This can be approached endocardially, or epicardially,
either through the coronary venous system or percutaneously.
Muscles connecting the mitral valve chordae tendineae to the LV, typically with posteromedial and
anterolateral papillary muscles. Papillary muscle anatomy is variable and can have single or multiple
heads.
A ﬁbrous or ﬁbromuscular chord-like band that crosses the LV cavity, attaching to the septum,
papillary muscles, trabeculations, or free wall of the LV. They may contain conduction tissue and
may impede catheter manipulation in the LV.
The posterior-superior process of the LV is the most inferior and posterior aspect of the basal LV,
posterior to the plane of the tricuspid valve. VAs originating from the posterior-superior process of
the LV can be accessed from the right atrium, the LV endocardium, and the coronary venous system.
Inner lining of the heart.
The specialized conduction system of the ventricles, which includes the His bundle, RBB and left
bundle branches (LBB), and the ramiﬁcations of these, found in the subendocardium. The Purkinje
system can generate focal or reentrant VTs, typically manifesting Purkinje potentials preceding QRS
onset.
Muscular wall between the LV and RV.
The ventricular septum beneath the RSV and NCSV, through which the penetrating His bundle reaches
the ventricular myocardium.

Tricuspid annulus
Moderator band
RV papillary muscles
Supraventricular crest

Pulmonary valves

Sinuses of Valsalva, aortic cusps,
aortic commissures

LV outﬂow tract (LVOT)
LV ostium
Aortomitral continuity (AMC);
aortomitral curtain, or mitralaortic intervalvular ﬁbrosa
Mitral valve annulus
LV papillary muscles
LV false tendon
(or LV moderator band)
Posterior-superior process
Endocardium
Purkinje network

Interventricular septum
Membranous ventricular septum

(Continued )
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(Continued )

Term

Deﬁnition

LV summit

Triangular region of the most superior part of the LV epicardial surface bounded by the left circumﬂex
coronary artery, the left anterior descending artery, and an approximate line from the ﬁrst septal
coronary artery laterally to the left AV groove. The great cardiac vein (GCV) bisects the triangle. An
area superior to the GCV is considered to be inaccessible to catheter ablation due to proximity of the
coronary arteries and overlying epicardial fat.
Epicardial area formed by the junction of the AV groove and posterior interventricular groove, at the
base of the heart, approximately at the junction of the middle cardiac vein and coronary sinus (CS)
and near the origin of the posterior descending coronary artery.
The outer layer of the heart—the visceral layer of the serous pericardium.
Adipose tissue variably present over the epicardial surface around coronary arteries, LV apex, RV free
wall, left atrial appendage, right atrial appendage, and AV and interventricular grooves.
The potential space between the parietal and visceral layers of serous pericardium, which normally
contains a small amount of serous ﬂuid. This space can be accessed for epicardial procedures.
The layer of the serous pericardium that is attached to the inner surface of the ﬁbrous pericardium and
is normally apposed to the visceral pericardium, separated by a thin layer of pericardial ﬂuid.
Thick membrane that forms the outer layer of the pericardium.
Area inferior to the xiphoid process; typical site for percutaneous epicardial access.
The right phrenic nerve lays along the right atrium and does not usually pass over ventricular tissue.
The course of the left phrenic nerve on the ﬁbrous pericardium can be quite variable and may run
along the lateral margin of the LV near the left obtuse marginal artery and vein; inferior, at the base
of the heart; or anterior over the sternocostal surface over the L main stem coronary artery or left
anterior descending artery.
The CS and its branches comprise the coronary venous system with the ostium of the CS opening into
the right atrium. Tributaries of the CS, which runs along the left AV groove, may be used for
mapping. These include the anterior interventricular vein (AIV), which arises at the apex and runs
along the anterior interventricular septum, connecting to the GCV that continues in the AV groove
to the CS; the communicating vein located between aortic and pulmonary annulus; various posterior
and lateral marginal branches or perforator veins; and the middle cardiac vein that typically runs
along the posterior interventricular septum from the apex to join the CS or empty separately into the
right atrium. The junction of the GCV and the CS is at the vein or ligament of Marshall (or persistent
left superior vena cava, when present), and the valve of Vieussens (where present).

Crux of the heart (crux cordis)
Epicardium
Epicardial fat
Pericardial space or cavity
Parietal pericardium
Fibrous pericardium
Subxiphoid area
Phrenic nerve

Coronary sinus (CS) and branches

Anatomical terminology (S2.4.1–S2.4.9). See also Figures 3, 4, 7, and 8.
AIV 5 anterior interventricular vein; AMC 5 aortomitral continuity; AV 5 atrioventricular; CS 5 coronary sinus; GCV 5 great cardiac vein; LBB 5 left bundle
branch; LSV 5 left sinus of Valsalva; LV 5 left ventricle; LVOT 5 left ventricular outﬂow tract; NCSV 5 noncoronary sinus of Valsalva; RBB 5 right bundle branch;
RSV 5 right sinus of Valsalva; RV 5 right ventricle; RVOT 5 right ventricular outﬂow tract; SV 5 sinus of Valsalva; VA 5 ventricular arrhythmia; VT 5 ventricular
tachycardia.
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Section 3 Clinical Evaluation
3.1. Clinical Presentation

Recommendation for clinical evaluation of patients with VAs
COR

LOE

Recommendation

I

C-EO

1. A careful clinical evaluation including history, physical examination, review of available
cardiac rhythm data, prior imaging, and relevant laboratory workup should be performed in
patients presenting with VAs.
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Recommendation-Speciﬁc Supportive Text
1. History should identify the onset, duration, frequency, and
trigger of any symptoms and should include medication
use as well as comorbidities and family history. Available
cardiac rhythm data include interrogation of cardiovascular
implantable electronic devices (CIEDs) to assess
arrhythmia burden, morphologies, and duration as well as
treatment. Electrogram storage may be programmed to
include far- and near-ﬁeld electrograms to allow superior
assessment of VA morphologies. The laboratory workup
should be individualized to the patient’s presentation and
may include electrolytes, troponin, brain natriuretic peptide,
genetic testing, or drug screening as appropriate.
Synopsis
The clinical presentations of patients with VAs encompass a
wide spectrum, ranging from asymptomatic to VT/VF storm
or sudden cardiac death (S3.1.1).
Presenting symptoms can be classiﬁed into 5 groups: due
to the VA itself (eg, PVCs, VT or VF); due to a secondary disease caused by the VAs (eg, PVC-induced cardiomyopathy);
due to an underlying pathology associated with the VAs (eg,
ischemia); due to ICD therapy; and a combination of these
causes.
Idiopathic VA is frequently asymptomatic, especially when
presenting as PVCs or nonsustained VT. In those cases, VAs are
commonly detected coincidentally during routine exams. If
symptomatic, symptoms can often be secondary to post-PVC
augmentation of contractility or a post-PVC compensatory
pause, and commonly consist of palpitations, dizziness, shortness of breath, fatigue, or chest discomfort. With increasing
duration or VA rate (eg, VT or VF), hemodynamic compromise
can result in more severe symptoms, such as pre-syncope,
syncope, or even sudden cardiac death (S3.1.1,S3.1.2).
Secondary diseases caused by VA include PVC-induced
cardiomyopathy, which can present with typical symptoms
of heart failure and reduced ejection fraction (EF) (S3.1.3,
S3.1.4). If PVCs are asymptomatic, the diagnosis is
commonly made by a routine physical exam and is
conﬁrmed by a 12-lead ECG.
Underlying pathologies resulting in VA are numerous and
include ischemia (S3.1.5); cardiomyopathy (S3.1.6); genetic
diseases (eg, inherited arrhythmia syndromes) (S3.1.7); hypertrophic cardiomyopathy (HCM) (S3.1.8); ARVC
(S3.1.9); CHD (S3.1.10); inﬁltrative, inﬂammatory, or infectious diseases (S3.1.11); and correctible causes, such as electrolyte abnormalities or medication adverse effects (S3.1.12).
If VAs themselves are asymptomatic, the presenting symptoms will mostly depend on the underlying pathology and
might include chest pain, heart failure, dizziness, syncope,
and sudden cardiac death. A careful history and physical
exam with a review of the family history, ECG, imaging,
and laboratory data (S3.1.13) will direct diagnosis and
speciﬁc treatment (eg, immunosuppression in cardiac
sarcoidosis) (S3.1.11). If inherited arrhythmia syndromes
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are suspected (eg, long QT syndrome), genetic testing should
be considered (S3.1.7).
ICD therapy including shocks is an increasingly common
presentation of VAs in patients with CIEDs, and appropriate
ICD therapy occurs in the ﬁrst year in .50% of patients with
secondary and approximately 5% of patients with primary
prevention ICDs (S3.1.14,S3.1.15).
Combined presentations of those scenarios are common,
such as worsening heart failure status with increased arrhythmias burden (S3.1.3,S3.1.4) or acute MI presenting with
sudden cardiac death as a manifestation of the VAs (S3.1.5).
Given that presenting symptoms of VA vary widely, careful documentation and correlation of the speciﬁc arrhythmia
(ECG, telemetry, Holter or event monitor, electrograms) with
the presenting symptoms is important to guide further
workup and therapy. Symptoms commonly attributed to
VA (eg, palpitations, dizziness, chest pain, syncope) are
nonspeciﬁc and can either be due to other arrhythmias
(S3.1.16) (eg, supraventricular tachycardia [SVT] or bradycardia), other cardiac diseases, noncardiac conditions, anxiety, or have no clear identiﬁable cause (S3.1.17).
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3.2. Diagnostic Evaluation
3.2.1. Resting 12-Lead Electrocardiogram
Recommendations for resting 12-lead ECG
COR

LOE

I

B-NR

I

B-NR

Recommendations

References

1. In patients with wide complex tachycardia, a 12-lead ECG during tachycardia should be
obtained whenever possible.
2. In patients with suspected or documented VA, a 12-lead ECG should be obtained in
sinus rhythm to look for evidence of underlying heart disease.

S3.2.1.1–S3.2.1.15

Recommendation-Speciﬁc Supportive Text
1. A 12-lead ECG during tachycardia is the ﬁrst diagnostic
test that should be performed for any patient with a stable,
wide, QRS complex tachycardia to differentiate VT from
SVT prior to attempts to terminate the tachycardia.
Criteria that support a diagnosis of VT include AV dissociation, a QRS complex .0.14 seconds, monophasic R
wave in aVR, positively or negatively concordant QRS
complexes in the precordial leads, the absence of an RS
complex in all precordial leads, and an RS interval .100
ms in at least 1 precordial lead (S3.2.1.1–S3.2.1.3). For
patients with preexisting bundle branch block,
comparison of the QRS morphology during sinus rhythm
with QRS morphology during wide complex tachycardia
is important. Various QRS morphologies (eg, bundle
branch block pattern) strongly support the diagnosis of
VT. An identical QRS complex during sinus rhythm and
broad QRS tachycardia, however, does not rule out the
presence of bundle branch reentry (BBR) tachycardia.
Patients without SHD can present with idiopathic VT
(eg, fascicular VT) that can be easily recognized by
12-lead ECG (S3.2.1.4). For nonsustained VAs (PVCs
or nonsustained VT), the 12-lead QRS morphology is
critical to allow for identiﬁcation of the SOO. Idiopathic
VAs (eg, right and left OT VAs, PVCs from the aortic
SV, papillary muscle VAs) can be recognized, given
they exhibit characteristic ECG patterns (see Section 5.2)
(S3.2.1.5–S3.2.1.10).
2. A 12-lead ECG during sinus rhythm is helpful to evaluate
the presence of underlying heart disease and might be a
clue for scar location and origins of related VAs, such
as inferior wall or anterior wall Q waves. An inherited
arrhythmia disorder can also be identiﬁed, such as
ARVC (epsilon waves and/or inverted T waves in right
precordial leads), long QT syndrome, Brugada syndrome
(coved-type ST-segment elevation in the right precordial

S3.2.1.16

leads), and ChD (right bundle branch block [RBBB]
and/or left anterior hemiblock) (S3.2.1.17). In patients
with SHD, QRS duration and the presence of conduction
abnormalities might provide additional prognostic information (S3.2.1.18–S3.2.1.23).
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3.2.2. Assessment of Structural Heart Disease and Myocardial
Ischemia
Recommendations for assessment of SHD and myocardial ischemia
COR

LOE

I

B-NR

IIa

B-NR

IIa

C-EO

III: No
Beneﬁt

B-NR

Recommendations

References

1. In patients with known or suspected VA, echocardiography is
recommended for evaluation of cardiac structure and function.
2. In patients presenting with VA who are suspected of having SHD, even
after normal echocardiographic evaluation, advanced cardiac imaging
can be useful to detect and characterize underlying SHD.
3. In patients with VA in whom myocardial ischemia is suspected, stress
testing and/or coronary angiography and subsequent revascularization
can be beneﬁcial before catheter ablation to avoid signiﬁcant
ischemia during induced VT.
4. In patients presenting with monomorphic VT, revascularization alone
is not effective to prevent VT recurrence.

S3.2.2.1–S3.2.2.2

Recommendation-Speciﬁc Supportive Text
1. Assessment of global and regional myocardial function,
valvular structure and function, along with testing for
adult CHD is required in patients with or at high risk for
VA or sudden cardiac death. Echocardiography is the
most readily available and commonly used imaging technique (S3.2.2.1,S3.2.2.2). Accurate assessment of LV
ejection fraction (LVEF) using CMR is hindered by the
presence of frequent PVCs (S3.2.2.11). In these patients,
echocardiographic evaluation of LVEF may be superior
to CMR.
2. Advanced cardiac imaging, such as cardiac CT, CMR, and
ﬂuorodeoxyglucose positron emission tomography (PET),
is useful for the evaluation of SHD and assessment of LV
and RV function (S3.2.2.3–S3.2.2.7). CMR with
assessment of late gadolinium enhancement (LGE) is the
gold standard technique for determination of location and
the extent of scarring. This information has implications
for planning the ablation strategy (see Section 5.4) (S3.2.
2.7,S3.2.2.12). The use of this imaging technique is
limited in some patients with CIEDs (S3.2.2.13) (see
Section 5.4). Additional myocardial inﬂammation or

S3.2.2.3–S3.2.2.7

S3.2.2.8–S3.2.2.10

inﬁltrative diseases can be detected with CMR or ﬂuorodeoxyglucose PET (S3.2.2.14).
3. Transient myocardial ischemia is a known cause of polymorphic rather than monomorphic sustained VT. Monomorphic VT in the setting of prior MI is typically due to
scar-related reentry and not due to acute ischemia. For patients suspected to have myocardial ischemia, stress
testing and/or coronary angiography and subsequent
revascularization should be performed when possible
before catheter ablation to avoid signiﬁcant ischemia during VT induction, mapping, and ablation.
4. Revascularization alone is unlikely to reduce the recurrence of monomorphic VT (S3.2.2.8–S3.2.2.10).
However, revascularization might be beneﬁcial in
patients with IHD and VF, polymorphic VT, or
exercise-induced arrhythmias associated with ischemia
(S3.2.2.15). Revascularization for prognostic indications
may also be indicated.
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3.2.3. Risk Stratiﬁcation in the Setting of Frequent Premature
Ventricular Complexes
Recommendations for CMR in patients with frequent PVCs and for PES in patients with SHD and frequent PVCs
COR

LOE

IIa

B-NR

IIa

C-LD

Recommendations

References

1. CMR can be useful for risk stratiﬁcation for sudden cardiac death in patients with frequent
PVCs.
2. PES can be useful for risk stratiﬁcation for sudden cardiac death in patients with SHD
undergoing ablation of frequent PVCs.

S3.2.3.1,S3.2.3.2

Recommendation-Speciﬁc Supportive Text
1. CMR has been reported to identify patients at increased
risk for adverse outcomes in the presence of frequent
PVCs (S3.2.3.1,S3.2.3.2). One study assessed the value
of CMR in an Italian patient population with frequent
LBBB PVCs (S3.2.3.1). Patients without RV CMR abnormalities had better outcomes than patients with CMR
abnormalities. Another study assessed the beneﬁt of
CMR for risk stratiﬁcation in patients with frequent
PVCs undergoing ablation procedures for PVCs
(S3.2.3.2). Except for 1 patient who had inducible idiopathic VT, 14 of 15 patients with inducible, sustained,
monomorphic VT had scarring identiﬁed by CMR. All patients with inducible VT except the patient with idiopathic
VT underwent ICD implantation, and 50% had appropriate ICD therapy during follow-up.
2. Programmed stimulation has been reported to identify patients at increased risk for adverse outcomes in the presence of frequent PVCs (the PVC burden was 20% 6
13% in the cited study), but without prior documented
VT, and who are undergoing PVC ablation procedures
(S3.2.3.2). All but one patient with inducible VT had
SHD prompting ICD implantation, and 50% of the
patients had appropriate ICD therapy during follow-up
(S3.2.3.2).

S3.2.3.2

Synopsis
LVEF continues to be the main prognostic clinical variable
for VA. The presence and extent of myocardial ﬁbrosis, assessed by CMR-LGE, predict ventricular tachyarrhythmias
in patients with ischemic and nonischemic LV dysfunction
(S3.2.3.3–S3.2.3.8). In a meta-analysis including 2850 patients with IHD and nonischemic heart disease from 19
studies, the composite arrhythmic endpoint was signiﬁcantly
higher in the patients with LGE (annualized event rate of
8.6%) than in the patients without LGE (annualized event
rate of 1.7%; P , .0001) (S3.2.3.8). In a larger metaanalysis including 7882 patients from 36 studies (both
ischemic cardiomyopathy [ICM] and NICM), LGE was associated with an increase in all-cause mortality (hazard ratio
[HR] 2.96; 95% CI 2.37–3.70; P , .001), cardiovascular mortality (HR 3.27; 95% CI 2.05–5.22; P , .001), VA and sudden
cardiac death (HR 3.76; 95% CI 3.14–4.52; P , .001), and
major adverse cardiovascular events (HR 3.24; 95% CI
2.32–4.52; P , .001) (S3.2.3.6). In both studies, the predictive value of LGE was independent of LVEF and whether
the cardiomyopathy was of ischemic or nonischemic etiology.
Patients with PVC-induced cardiomyopathy show
improvement (even normalization) of LVEF after effective
PVC treatment. As opposed to patients with NICM, the
absence of LGE is a common ﬁnding in these patients;
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thus, absence of LGE could be used to identify patients with
greater chance of LVEF recovery (S3.2.3.9). Patients with
frequent PVCs in the presence of LGE still have a possibility
of LVEF improvement (S3.2.3.10) post ablation, although
the LVEF might not completely normalize (S3.2.3.11). An
RBBB morphology of the PVC has been associated with
an increased prevalence of LGE-deﬁned ﬁbrosis
(S3.2.3.12). This ﬁnding has prognostic implications. CMR
has been reported to identify patients at increased risk for
adverse outcomes in the presence of frequent PVCs (S3.2.
3.1,S3.2.3.2). In addition, CMR provides important
information about the underlying ﬁbrotic substrate and
facilitates ablation procedure planning. Inducible VT can
have prognostic implications in patients with frequent
PVCs and LGE-CMR. Over 80% of the writing committee
members perform programmed stimulation to induce VT at
the time of PVC or VT ablation in patients without known
SHD.
The arrhythmogenic substrate can also be recognized
by voltage mapping at the time of the procedure. Lowvoltage areas have been correlated with scar tissue identiﬁed as LGE-CMR (S3.2.3.13,S3.2.3.14). Although OT
PVCs typically occur in patients with normal heart,
identiﬁcation of low-voltage areas and transitional zones
could provide helpful information at the time of ablation
(S3.2.3.15). Two-thirds of the writing committee members perform voltage mapping of the relevant ventricle
at the time of PVC or VT ablation in patients without
known SHD.
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3.2.4. Longitudinal Follow-up in the Setting of Frequent
Premature Ventricular Complexes
Recommendation for longitudinal follow-up of patients with frequent PVCs
COR

LOE

IIa

B-NR

Recommendation

Reference

1. Periodic monitoring of PVC burden and LV function and dimensions can be useful in
patients with frequent, asymptomatic PVCs and normal LV function and dimensions.

S3.2.4.1

Recommendation-Speciﬁc Supportive Text
1. Frequent PVCs can be associated with the development of
cardiomyopathy in susceptible individuals. Despite extensive study, the predictors of future deterioration of LV
function are unclear. In one study of 249 patients, all of

whom were followed for at least 4 years, none developed
overt congestive heart failure, but the LVEF decreased in
20% of patients with very frequent PVCs (.20,000 per 24
hours) (S3.2.4.1). Therefore, until the development of
PVC-induced cardiomyopathy can be predicted with

Cronin et al. Catheter Ablation of Ventricular Arrhythmias
more precision, periodic measurement of LVEF and LV
end-diastolic dimensions, along with quantiﬁcation of
PVC burden, may be useful for patients with a high
PVC burden [approximately 10% or higher (S3.2.4.2)]
to identify deteriorating LV function before symptoms
appear.
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Section 4 Indications for Catheter Ablation
Following are the consensus recommendations for catheter
ablation of VAs organized by underlying diagnosis and substrate. These recommendations are each assigned a COR and
an LOE according to the current recommendation classiﬁcation system (S4.1). In drafting each of these recommendations, the writing committee took into account the
published literature in the speciﬁc area, including the methodological quality and size of each study, as well as the collective clinical experience of the writing group when
published data were not available. Implicit in each recommendation are several points: 1) the procedure is being performed by an electrophysiologist with appropriate training
and experience in the procedure and in a facility with appropriate resources; 2) patient and procedural complexity vary
widely, and some patients or situations merit a more experienced operator or a center with more capabilities than others,
even within the same recommendation (eg, when an epicardial procedure is indicated and the operator or institution
has limited experience with this procedure, it might be pref-
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erable to refer the patient to an operator or institution with
adequate experience in performing epicardial procedures);
3) the patient is an appropriate candidate for the procedure
(as outlined in Section 5.1), recognizing that the level of patient suitability for a procedure will vary widely with the clinical scenario; and 4) the patient’s (or designee’s) informed
consent, values, and overall clinical trajectory are fundamental to a decision to proceed (or not) with any procedure.
Therefore, in some clinical scenarios, initiation or continuation of medical therapy instead of an ablation procedure
may be the most appropriate option, even when a class 1
recommendation for ablation is present. There may also be
scenarios not explicitly covered in this document, and on
which little or no published literature is available, in which
the physician and patient must rely solely on their own judgment.
In drafting these recommendations, the writing committee
also referenced several other relevant clinical documents,
including the 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (S4.2), among others.
The exclusive focus of the current document on VA ablation
led to the opportunity to develop more detailed and nuanced
recommendations.
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4.1. Idiopathic Outﬂow Tract Ventricular
Arrhythmia
Recommendations for catheter ablation of idiopathic OT VA
COR

LOE

Recommendations

References

I

B-R

S4.1.1

I

B-NR

I

B-NR

IIa

B-NR

IIa

B-NR

1. In patients with frequent and symptomatic PVCs originating from the RVOT in an
otherwise normal heart, catheter ablation is recommended in preference to metoprolol or
propafenone.
2. In patients with symptomatic VAs from the RVOT in an otherwise normal heart for whom
antiarrhythmic medications are ineffective, not tolerated, or not the patient’s preference,
catheter ablation is useful.
3. In patients with symptomatic idiopathic sustained monomorphic VT, catheter ablation is
useful.
4. In patients with symptomatic VAs from the endocardial LVOT, including the SV, in an
otherwise normal heart for whom antiarrhythmic medications are ineffective, not
tolerated, or not the patient’s preference, catheter ablation can be useful.
5. In patients with symptomatic VAs from the epicardial OT or LV summit in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated, or not
the patient’s preference, catheter ablation can be useful.

S4.1.2–S4.1.12
S4.1.13–S4.1.17
S4.1.18–S4.1.27
S4.1.28–S4.1.32
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Recommendation-Speciﬁc Supportive Text
1. In symptomatic patients with frequent PVCs from the
RVOT, catheter ablation had a higher rate of efﬁcacy
than pharmacotherapy with either metoprolol or propafenone in an RCT (S4.1.1). Ablation success rates are reported at 80%–95%, with low complication rates (S4.1.
1,S4.1.12,S4.1.21,S4.1.33–S4.1.35). Catheter ablation
can be considered as a preferred therapy in suitable,
symptomatic patients. However, some patients with
minimal or tolerable symptoms might prefer medical
therapy or no therapy.
2. RVOT and LVOT are the most common SOOs for idiopathic VA in patients without SHD. VAs arising from
these locations mostly present with a unique pattern on
12-lead surface ECG. The most common underlying pathophysiological mechanism is triggered activity, and RF
catheter ablation is highly effective and has low complication rates (S4.1.2–S4.1.12). Multiple studies have shown
that for RVOT VAs, catheter ablation is effective for
prevention of arrhythmia recurrences.
3. In patients with symptomatic, idiopathic, sustained monomorphic VT, catheter ablation might be preferable to medical therapy. It is a more deﬁnitive treatment option, given
its high success and low recurrence rates (S4.1.13–S4.1.17).
4. LVOT VA is reported to account for 12%–45% of all idiopathic VAs (S4.1.18–S4.1.22). Compared with VAs
originating from the RVOT, ablation of LVOT VAs is
more complex (S4.1.18–S4.1.22). Rarely, LVOT VA
sites require epicardial ablation via the GCV/AIV or
subxiphoid puncture. Clinically, ablation of LVOT VA
can involve greater procedural complexity as well as
periprocedural risk (stroke or coronary artery injury)
compared with RVOT VA. However, many studies
report good results pertaining to the safety, feasibility,
and potential curative ability of RF catheter ablation
(S4.1.18–S4.1.22).
5. Although most idiopathic VAs originate from the RVOT or
LVOT, in some cases, RF catheter ablation cannot successfully be performed from either site. In such cases, the VAs
might originate from the LV summit (see Section 2 for deﬁnition). VAs originating from this area can present challenges for successful RF catheter ablation, and the failure
rate is high due to epicardial fat and the proximity of coronary arteries if a subxiphoid epicardial access is used (S4.1.
14–S4.1.16). Appropriate patient selection for this
approach is key, and the initial approach should focus on
the endocardium and adjacent structures, including the
coronary venous system, the aortic cusps, and the RVOT.
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4.2. Idiopathic Nonoutﬂow Tract Ventricular
Arrhythmia
Recommendations for catheter ablation of nonoutﬂow tract VAs in the absence of SHD
COR
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1. In patients with symptomatic VAs from the RV at sites other than the OTs (tricuspid
annulus, moderator band, parietal band, or papillary muscles) in an otherwise
normal heart for whom antiarrhythmic medications are ineffective, not tolerated,
or not the patient’s preference, catheter ablation is useful.
2. In patients with symptomatic VAs from the LV at sites other than the OTs (mitral
annulus, papillary muscles, or AMC) in an otherwise normal heart for whom
antiarrhythmic medications are ineffective, not tolerated, or not the patient’s
preference, catheter ablation is useful.
3. In patients with symptomatic VAs from the epicardial coronary venous system in an
otherwise normal heart for whom antiarrhythmic medications are ineffective, not
tolerated, or not the patient’s preference, catheter ablation can be useful.
4. In patients with symptomatic VAs from para-Hisian sites in an otherwise normal
heart for whom antiarrhythmic medications are ineffective, not tolerated, or not
the patient’s preference, catheter ablation can be useful.
5. In patients with symptomatic VAs from the posterior-superior process of the LV in
an otherwise normal heart for whom antiarrhythmic medications are ineffective,
not tolerated, or not the patient’s preference, catheter ablation from the LV
endocardium, right atrium, or CS, can be useful.

S4.2.1–S4.2.14

Recommendation-Speciﬁc Supportive Text
1. Among idiopathic RV arrhythmias presenting for catheter
ablation, approximately 10%–15% arise at sites other
than the RVOT (S4.2.1). Sites that can be ablated with a
high level of success include any of the three RV papillary
muscles (S4.2.3,S4.2.6), the parietal band (S4.2.7,S4.2.
9–S4.2.11), the tricuspid annulus (S4.2.5,S4.2.8,S4.2.12,
S4.2.13), and the moderator band (S4.2.2,S4.2.14).
Although frequent PVCs, nonsustained VT, and
sustained monomorphic VT are the most common
idiopathic VAs at these sites of origin, VF triggered by
PVCs arising from the moderator band (S4.2.2) can occasionally occur. Successful catheter ablation is achieved in
over 90% of patients with RV VAs arising outside the

S4.2.15–S4.2.31

S4.2.32–S4.2.43
S4.2.7,S4.2.13,S4.2.14,
S4.2.44–S4.2.49
S4.2.50–S4.2.52

RVOT, with a low risk of complications. The recurrence
rate and need for repeat procedures are higher for VAs
arising from the moderator, septal, and parietal bands
than from other sites (S4.2.2,S4.2.7). In addition, the
probability of successful ablation is higher for tricuspid
annular VAs arising from the free wall than the septal
regions, which are closer to the conduction system (S4.2.5).
2. Idiopathic VAs arising from the LV papillary muscles account for approximately 15% of idiopathic LV arrhythmias referred for catheter ablation and are characterized
by frequent PVCs or recurrent monomorphic VT with a
catecholamine-sensitive focal mechanism. VT can arise
from either the posteromedial papillary muscles or the anterolateral papillary muscles (S4.2.15–S4.2.23). These

e28
arrhythmias often require several RF applications for
successful ablation. A change in QRS morphology of
the VA after ablative applications to either side of the
involved papillary muscle is common. Due to the
thickness of the papillary muscles and their vigorous
contraction, catheter stability can be challenging and
might be improved by the use of intracardiac ultrasound
and possibly cryoablation (S4.2.18,S4.2.22). The
recurrence risk after initial successful ablation of
papillary muscle VAs is higher than for many other
idiopathic VA sites, and repeat procedures are required
in approximately 30% of patients (S4.2.16,S4.2.18).
The mitral annulus is the SOO for approximately 20% of
idiopathic LV arrhythmias, with the majority being PVCs
or nonsustained VT rather than sustained VT (S4.2.24,
S4.2.25). Mitral annular VAs are based on a focal,
catecholamine-sensitive mechanism. A superior-anterior
mitral annular origin is more common than an inferiorposterior origin (S4.2.23–S4.2.26). Successful ablation is
achieved in approximately 90% of mitral annular VAs,
with a very low risk of complications (S4.2.23–S4.2.29).
The AMC is a common location of mitral annular VAs at
the base of the LV ostium. Most patients with VA from
the AMC have frequent PVCs rather than sustained VT
(S4.2.30). Endocardial mapping demonstrates a prepotential in the majority of VAs originating in this location,
with successful ablation in over 90% of patients with a
low risk of complications (S4.2.30,S4.2.31).
3. VAs that can be mapped and ablated within the GCV or
AIV are relatively common SOOs near or within the LV
summit (S4.2.32–S4.2.36). Proximity to the coronary
arteries needs to be assessed (see Sections 9.3 and 11.1)
prior to ablation. If the SOO is too close (,5–10 mm)
to a coronary artery, ablation from the adjacent endocardium might be successful when within 1 cm of the SOO
(S4.2.37). These arrhythmias from the superior portion
of the coronary venous system are usually based on a focal
mechanism and typically require an irrigated-tip ablation
catheter due to high impedance within the coronary
vein. Mapping and ablation from the LSV or LV endocardium might also be successful, even if the local ECG in
the coronary venous system is earlier (S4.2.38). For
VAs with an intramural location, ablation within the
perforator veins from within the LV septum (S4.2.39),
simultaneous bipolar or simultaneous unipolar RF energy
from the coronary venous system and the LV endocardium might be required to achieve successful ablation.
Sustained monomorphic VT arising from the crux of the
heart is typically very rapid, based on a focal
catecholamine-sensitive mechanism, and often produces
syncope (S4.2.40–S4.2.43). The QRS morphology is
characterized by an abrupt transition from negative in
lead V1, to positive in lead V2, to more negative in lead
V3 (S4.2.40). Ablation can be achieved within the
coronary venous system, including the middle cardiac
vein (S4.2.40,S4.2.41,S4.2.43) and the adjacent
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endocardium, or might require epicardial access (S4.2.
40–S4.2.42). The proximity of the coronary venous
system to the posterior descending coronary artery
requires imaging to prevent arterial injury.
4. VAs arising from the RV septum near the His bundle can be
successfully ablated in approximately 70%–90% of patients, with several series reporting a higher likelihood of
abandoning attempts at ablation due to concerns about
inducing AV block (S4.2.7,S4.2.13,S4.2.14,S4.2.44–S4.2.
49). The appearance of an accelerated junctional rhythm
is common during RF application in this region, though
AV block is not (S4.2.7). Catheter stability and the need
to prevent injury to the AV node are issues that are carefully
considered for these VAs (S4.2.49). Pacing maneuvers may
be beneﬁcial to prevent damage to the AV node (S4.2.53).
The careful use of cryoablation can help to prevent damage
to the conduction system if ablative therapy is delivered in
close proximity to the conduction system.
5. The posterior-superior process of the LV is the most inferior and posterior aspect of the basal LV, posterior to the
plane of the tricuspid valve (S4.2.50). Ablation of VAs in
this region can be accomplished from the LV endocardium (S4.2.51). However, VAs arising from this region
can also be successfully ablated from the inferior septal
surface of the right atrium, where a small atrial signal
and a larger ventricular signal, earlier than the earliest
site in the LV endocardium, can be recorded (S4.2.50).
Reports also describe ablation from within the CS
(S4.2.52). Successful ablation can be achieved with either
RF or cryoablation energies. The risk of complications
appears to be low, although data are limited, and caution
is required due to the proximity to the AV node and the
AV nodal artery (S4.2.50).
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4.3. Premature Ventricular Complexes With or
Without Left Ventricular Dysfunction
Recommendations for catheter ablation of PVCs in patients with or without LV dysfunction
COR

LOE

I

B-NR

IIa

B-NR

IIa

B-NR

IIa

C-LD

Recommendations

References

1. In patients with cardiomyopathy suspected to be caused by frequent and
predominately monomorphic PVCs and for whom AADs are ineffective, not
tolerated, or not preferred for long-term therapy, catheter ablation is
recommended.
2. In patients with SHD in whom frequent PVCs are suspected to be contributing to a
cardiomyopathy and for whom AADs are ineffective, not tolerated, or not preferred
for long-term therapy, catheter ablation can be useful.
3. In patients with focally triggered VF refractory to AADs and triggered by a similar
PVC, catheter ablation can be useful.
4. In nonresponders to cardiac resynchronization therapy (CRT) with very frequent
unifocal PVCs limiting optimal biventricular pacing despite pharmacological
therapy, catheter ablation can be useful.

S4.3.1–S4.3.10

Recommendation-Speciﬁc Supportive Text
1. In patients with a suspected PVC-induced cardiomyopathy, catheter ablation can be considered an alternative to
long-term AAD therapy, particularly for patients with
monomorphic PVCs, or PVCs of an RVOT origin
(S4.3.1). PVC-induced cardiomyopathy should be suspected when cardiomyopathy and frequent PVCs are present and a comprehensive cardiac evaluation fails to
identify alternate etiologies. Several studies have
conﬁrmed a correlation between a higher PVC burden
and development of cardiomyopathy, although no precise
burden of PVCs consistently predicts the development of
a cardiomyopathy. Several studies have demonstrated a
higher incidence of cardiomyopathy with PVC burdens
.15%–25% (S4.3.3,S4.3.5,S4.3.8,S4.3.19); however,
patients with similarly high PVC burdens can also
maintain normal cardiac function. Reversible PVCinduced cardiomyopathy has also been reported in patients with PVC burdens as low as 4%–5% (S4.3.9,S4.3.
20). When PVC-induced cardiomyopathy is suspected
in these patients with relatively low PVC burdens, other
etiologies for cardiomyopathy should be thoroughly
investigated and addressed, and the persistence of the
PVC burden established. Other risk factors for the development of a PVC-induced cardiomyopathy to consider
include epicardial origin of PVCs, PVCs with a longer
QRS duration, longer exposure to PVCs, asymptomatic
PVCs, interpolated PVCs, and male sex (S4.3.1,S4.3.5,
S4.3.21,S4.3.22). In patients with PVC-induced cardiomyopathy, PVC ablation has an overall reported success
rate of 65%–90%, with a low complication rate (S4.3.1,
S4.3.3–S4.3.7,S4.3.9,S4.3.10). Predictors of ablation
success include an RVOT PVC origin and a uniform
PVC morphology. Following successful ablation, the
majority of patients with PVC-induced cardiomyopathy
experience signiﬁcant improvement and, possibly,
normalization of their LVEF. Based on a review of
current data, routine catheter ablation of frequent PVCs

S4.3.3,S4.3.11,S4.3.12
S4.3.13–S4.3.17
S4.3.18

in asymptomatic patients without evidence of LV
dysfunction is not presently recommended. In some
asymptomatic patients with very frequent PVCs and preserved cardiac function who express a strong preference
for ablation, approximately half of the writing committee
members agreed that an ablation can be considered after
adequate counseling on the risks, beneﬁts, and alternatives to ablation, whereas half would not offer ablation.
Additional clinical features that may portend worsening
LV function that should be considered include LV dilation
or a relative decrease in EF that may still be considered in
the normal range.
2. In patients with underlying SHD, the presence of frequent
PVCs can contribute to a cardiomyopathy, and successful
PVC elimination by ablation can improve cardiac function (S4.3.3,S4.3.11,S4.3.12). Detailed cardiac imaging
(such as CMR to quantify scarring) in conjunction with
a comprehensive cardiac history, including the time
course of cardiomyopathy development and onset of
PVCs, can help to estimate the contribution of the PVCs
to the cardiomyopathy and guide treatment decisions
targeting the PVCs.
3. In patients with recurrent VF refractory to antiarrhythmic
medications and triggered by PVCs from a potentially
identiﬁable site, successful ablation of the PVC can lead
to VF suppression (S4.3.13–S4.3.15). The triggering
PVC is often located in the Purkinje system and can
exhibit slight variations in morphology. It is important
to recognize that despite an initially successful ablation,
PVC and VF recurrences are possible, and recurrent
PVCs can arise from an alternate focus (S4.3.14). Successful ablation, therefore, often does not eliminate the
need for an ICD.
4. In patients who are clinical nonresponders to CRT, with
limited biventricular pacing due to frequent PVCs despite
pharmacological therapy, successful PVC ablation has
demonstrated an improvement in heart failure class and
a modest improvement in LVEF. In one prospective
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multicenter study in which CRT nonresponders with
frequent and primarily monomorphic PVCs were ablated,
the improvements in LV function and New York Heart
Association (NYHA) class were proportional to the preprocedural PVC burden, and the greatest improvement
was noted in patients with a preablation PVC burden
.22% (S4.3.16).
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4.4. Ventricular Arrhythmia in Ischemic Heart
Disease

Recommendations for catheter ablation of VAs in patients with IHD
COR

LOE

Recommendations

References

I

B-R

S4.4.1

I

B-NR

I

B-NR

IIa

C-EO

IIb

A

IIb

C-LD

1. In patients with IHD who experience recurrent monomorphic VT despite chronic
amiodarone therapy, catheter ablation is recommended in preference to escalating
AAD therapy.
2. In patients with IHD and recurrent symptomatic monomorphic VT despite AAD therapy,
or when AAD therapy is contraindicated or not tolerated, catheter ablation is
recommended to reduce recurrent VT.
3. In patients with IHD and VT storm refractory to AAD therapy, catheter ablation is
recommended.
4. In patients with IHD and recurrent monomorphic VT, in whom AADs are not desired,
catheter ablation can be useful.
5. In patients with IHD and an ICD who experience a ﬁrst episode of monomorphic
VT, catheter ablation may be considered to reduce the risk of recurrent VT or ICD
therapies.
6. In patients with prior MI and recurrent episodes of symptomatic sustained VT for whom
prior endocardial catheter ablation has not been successful and who have ECG,
endocardial mapping, or imaging evidence of a subepicardial VT substrate, epicardial
ablation may be considered.

S4.4.2–S4.4.4
S4.4.5–S4.4.9

S4.4.10–S4.4.14
S4.4.15–S4.4.19

e32
Recommendation-Speciﬁc Supportive Text
1. For patients presenting with VT despite AAD therapy,
which often results in ICD therapies (shocks or ATP),
therapeutic options include escalating AAD therapy by
increasing the dose, changing the drug, adding a new
drug, and catheter ablation. The VANISH trial (S4.4.1)
compared the strategies of escalating AAD therapy according to a predeﬁned protocol versus catheter ablation
in 259 patients and followed them for a mean (6 standard
deviation [SD]) of 27.9 6 17.1 months. The composite
primary endpoint of death, VT storm, or appropriate
ICD shock was reduced by catheter ablation. Beneﬁt
was observed in the subgroup on amiodarone at baseline,
for whom escalated drug therapy was an increase in amiodarone or an addition of mexiletine (HR 0.55; 95% CI
0.38–0.80; P 5 .001), but not in the subgroup of patients
who were on sotalol at baseline, for whom escalation of
drug therapy was initiation of amiodarone (HR 1.14;
95% CI 0.65–2.02; P 5 .64) (S4.4.1). Further analysis
found that catheter ablation was markedly superior
to the addition of mexiletine in a small subgroup of patients with VT refractory to high dose (300 mg daily)
amiodarone (S4.4.20). There were no procedure-related
deaths.
2. In addition to the VANISH trial described above (S4.4.1),
3 large, prospective, multicenter cohort studies have
examined the role of catheter ablation in reducing recurrent VT in patients with IHD, most of whom had recurrent
VT despite AAD therapy (S4.4.2–S4.4.4). In these trials,
the patient served as his/her own control, and VT episodes
were reported for the 6 months before and the 6 months
after ablation. In each study, a consistent reduction in
VT episodes was observed post ablation. In the EuroVT study, VT recurrence occurred in 49% of the patients
(S4.4.3). A reduction in device therapies (ATP and
shocks) was observed in 79% of these patients, with the
mean number of therapies falling from 60 6 70 in the 6
months prior to ablation to 14 6 15 in the same period
of time after ablation (P 5 .02). In the Multicenter Thermocool VT Ablation Trial, and the similarly designed
Post-Approval THERMOCOOL VT Trial, the number
of VT episodes in the 6 months before and after ablation
was reduced from a median of 11.5 to 0 episodes (P ,
.0001), and from 13 to 0 episodes (P , .0001), respectively (S4.4.2,S4.4.4).
3. There are limited comparative data on catheter ablation vs
other therapies in the management of VT storm. AAD therapy is almost universally used as ﬁrst-line therapy for these
patients; however, catheter ablation is a particularly important therapy when VA recurs. Two small, single-center,
nonrandomized studies found that patients treated with
ablation had a lower risk of recurrence than those treated
medically (S4.4.21), or they had a similar risk of recurrence but lower mortality (S4.4.22); however, these
studies were limited by their retrospective study design
and the small number of patients. Several other large series
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(S4.4.5–S4.4.8) and a systematic review and metaanalysis (S4.4.9) have shown a reduction in ICD therapies
after catheter ablation and reasonable success in controlling arrhythmia, with a nonetheless signiﬁcant mortality.
A common ﬁnding is that unsuccessful ablation (persistent
VT inducibility) is associated with poor outcomes.
4. Patients who do not tolerate or are unsuitable for AAD
therapy have not generally been included in RCTs. However, the writing committee felt it was reasonable to
recommend catheter ablation in such patients over no therapy, in view of the reduction in recurrent VT demonstrated in multiple clinical trials. Examples of
contraindications to AAD therapy include signiﬁcant
renal dysfunction or QT prolongation in the case of sotalol, and severe pulmonary disease, which might be worsened by amiodarone.
5. Four RCTs have examined the role of catheter ablation in
patients who have experienced their ﬁrst episode of VT
(S4.4.10–S4.4.14). In these studies, an ICD has been a
mandatory part of the protocol. Two of these trials have
shown a reduction in the primary endpoint with catheter
ablation (S4.4.10,S4.4.11). The CALYPSO pilot study
found an increased time to ﬁrst VT recurrence with
ablation versus AADs (S4.4.12). The Substrate Modiﬁcation Study (SMS) failed to meet its primary endpoint of
time to ﬁrst VT/VF recurrence; however, catheter ablation
reduced the total number of ICD interventions (S4.4.13).
A meta-analysis of these trials, commissioned to guide
recommendations in this consensus document, showed a
reduction in the risk of appropriate ICD therapies with
catheter ablation (S4.4.14). However, in drafting this
recommendation, the writing committee also considered
that only the CALYPSO pilot study randomized patients
to either catheter ablation or AAD therapy (S4.4.12).
The other trials (S4.4.10,S4.4.11,S4.4.13) compared
catheter ablation without specifying antiarrhythmic
therapy in the control group. Prospective trials have not
shown that catheter ablation reduces mortality, and the
risks of the procedure must be carefully weighed against
the beneﬁts in this population. In a large study using the
US National Inpatient Sample database, the overall rate
of any in-hospital complication was 11.2% in patients
with prior MI undergoing catheter ablation, and inhospital mortality was 1.6%, without changes over a
decade (S4.4.23). The VANISH2 trial is currently
comparing these two strategies in patients with prior MI
and VT while not on AAD therapy (S4.4.24). There are
limited data exploring the feasibility of managing VT
with catheter ablation without an ICD in selected patients
with IHD and relatively preserved LV function (S4.4.
25–S4.4.27). Of 302 patients with IHD who underwent
a catheter ablation procedure sufﬁciently successful to
make ICD implantation unnecessary, approximately 3%
experienced sudden death during 3–4 years of follow-up
(S4.4.25–S4.4.27). The writing group did not feel there
was sufﬁcient evidence to make a recommendation
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regarding ablation as a stand-alone therapy without an
ICD for patients with IHD and sustained VT.
6. It has long been recognized that the epicardial surface can
contain critical elements of VT circuits in patients with
IHD (S4.4.15,S4.4.16). However, the VT substrate can
be accessed from the endocardium in most cases, and
endocardial mapping and ablation have been the
mainstay of therapy. A number of studies have shed
light on the incidence of epicardial substrate in IHD. In
the initial description of epicardial mapping and ablation
in patients with inferior wall MI, an epicardial circuit
was found in 7 of 30 VTs (S4.4.16). In another series of
11 patients with 1 to 4 prior unsuccessful endocardial
ablation procedures, epicardial access was successful in
10, and 7 required epicardial ablation, which abolished
the clinical VT in all patients. However, 40% had recurrence during follow-up, and there was one periprocedural
death (S4.4.17). Two larger, single-center observational
studies have reported similar or improved VT-free survival in patients with IHD undergoing combined endocardial and epicardial ablation (S4.4.28,S4.4.29). A
prospective study of patients undergoing catheter
ablation for electrical storm, in which epicardial access
was obtained in all patients in one arm being treated
with a scar homogenization technique (n 5 43), found
that ablation was performed in one-third. However,
whether the epicardial substrate participated in clinical
or inducible VT was not assessed (S4.4.18). There are
limited data on the use of combined endocardial and
epicardial ablation as a ﬁrst-line approach in patients
with IHD and VT (S4.4.19); an RCT is currently examining this question (S4.4.30). Preprocedural imaging can
be useful to determine the presence of epicardial substrate,
and therefore the likelihood of requiring epicardial access
for complete substrate ablation (S4.4.31).
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4.5. Nonischemic Cardiomyopathy
Recommendations for catheter ablation of VT in NICM
COR
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C-EO

IIb

B-NR

Recommendations

References

1. In patients with NICM and recurrent sustained monomorphic VT for whom
antiarrhythmic medications are ineffective, contraindicated, or not tolerated, catheter
ablation is useful for reducing recurrent VT and ICD shocks.
2. In patients with NICM and electrical storm refractory to AAD therapy, catheter ablation
is useful for reducing recurrent VT and ICD shocks.
3. In patients with NICM, epicardial catheter ablation of VT can be useful after failure of
endocardial ablation or as the initial ablation approach when there is a suspicion of an
epicardial substrate or circuit.
4. In patients with cardiac sarcoidosis and recurrent VT despite medical therapy, catheter
ablation can be useful to reduce the risk of VT recurrence and ICD shocks.
5. In patients with NICM and recurrent sustained monomorphic VT for whom
antiarrhythmic medications are not desired, catheter ablation can be useful for
reducing recurrent VT and ICD shocks.
6. In patients with NICM related to lamin A/C (LMNA) mutations and recurrent VT,
catheter ablation may be considered as a palliative strategy for short-term arrhythmia
control.

S4.5.1–S4.5.6

Recommendation-Speciﬁc Supportive Text
1. Patients with NICM represent a heterogeneous population
with diverse etiologies, including undifferentiated dilated
NICM and valvular, hypertensive, hypertrophic, toxic,
genetic, inﬂammatory, tachycardia-induced, peripartum,
and inﬁltrative cardiomyopathy. Several retrospective
and prospective cohort studies have shown VT-free
survival of 40.5% to 70% at 1 year post ablation (S4.5.
1–S4.5.6).
VTs in the context of NICM are more often pleomorphic
and polymorphic; they are less hemodynamically tolerated, are more difﬁcult to induce, and are faster compared
with postinfarction VT (S4.5.20,S4.5.21). Differences in
the results of VT catheter ablation between NICM and
ICM could be due to a substrate that is less favorable to
ablation with NICM (S4.5.22). The substrate is often
intramurally located and can involve the epicardium; it
is typically located at the basal perivalvular regions and
at the interventricular septum. The intramural substrate
makes the arrhythmogenic substrate less accessible for
identiﬁcation of optimal ablation target sites based on
pace mapping and identiﬁcation of abnormal electrograms.
Although sustained VT occurs in only 5% of patients with
NICM, it is an important cause of sudden cardiac death
(S4.5.23). Recurrent VT is associated with signiﬁcantly
increased mortality in NICM (S4.5.24).

S4.5.7–S4.5.9
S4.5.4,S4.5.10–S4.5.13
S4.5.14–S4.5.18

S4.5.19

2. Electrical storm with recurrent VT/VF episodes in patients
with NICM and ICD can adversely affect hospitalization
rates and long-term survival (S4.5.24,S4.5.25). Catheter
ablation of patients with NICM and electrical storm
refractory to, or intolerant of, AADs eliminates recurrent
VT in most cases (S4.5.7–S4.5.9). Whether ablation
reduces mortality in this population is unclear at present.
3. In multicenter registries, 30% of epicardial VT catheter
ablations were performed on patients with NICM (S4.
5.12,S4.5.13). Epicardial mapping and catheter
ablation can signiﬁcantly reduce VT recurrence in
patients with NICM (S4.5.3,S4.5.4) and long-term success rates reach 55% to 70% after epicardial ablation
(S4.5.11,S4.5.13). However, due to an increased risk of
complications or late adhesions preventing future
pericardial accesses, epicardial ablation may be
reserved to ﬁrst-line endocardial approach failures
(S4.5.1), except when ECG or imaging suggests a predominant epicardial substrate (S4.5.1). Consideration
should be given to the ability to proceed to epicardial access during the initial procedure.
4. Cardiac sarcoidosis is associated with a poor prognosis.
VT is frequently resistant to AADs and immunosuppression, requiring ICDs. Recurrent VT is common in cardiac
sarcoidosis and is associated with a poorer prognosis.
Catheter ablation decreases VT recurrence and ICD
shocks in cardiac sarcoidosis (S4.5.14–S4.5.18).
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5. AADs are not as effective as the ICD at decreasing mortality in patients with SHD and sustained VAs. Even if
successful at acutely terminating VT or VF, ICD shocks
have been associated with increased heart failure and mortality in NICM (S4.5.26,S4.5.27). To date, there has
been no RCT comparing catheter ablation with AADs
for preventing VT recurrences in NICM. Indirect
comparisons have found similar reductions in VT
recurrences with catheter ablation or amiodarone in
patients with SHD (S4.5.28). Amiodarone might increase
mortality in patients with cardiomyopathy (S4.5.28,S4.5.
29) and can cause serious long-term adverse effects. Catheter ablation of VT appears to be safe and effective in
NICM, achieving long-term arrhythmia control in 50%
to 70% (S4.5.1,S4.5.6,S4.5.23,S4.5.30) (with AADs in
one-third), with a survival rate of 70% (S4.5.1,S4.5.6).
Retrospective series show that acute success of catheter
ablation and freedom from recurrent VT after catheter
ablation are associated with a signiﬁcant reduction in
mortality and heart transplantation in NICM (S4.5.1,S4.
5.6,S4.5.31,S4.5.32).
6. Mutations in the lamin A/C (LMNA) gene are an important
cause of NICM, with a disease course more aggressive
than other forms of idiopathic NICM in terms of progression to end-stage heart failure or the tendency toward malignant VAs (S4.5.33,S4.5.34). Catheter ablation can be
beneﬁcial as a palliative strategy to allow transient
arrhythmia control in patients with NICM related to
LMNA mutations before aggressive heart failure
management is proposed (S4.5.19). However, acute and
chronic success are low, due to frequent intramural substrate, and complication rates are high in the published
literature (S4.5.19). Disease progression to end-stage
heart failure requiring mechanical support or transplant
is also common, and VT ablation might be best targeted
toward those with relatively earlier stage disease, rather
than being a means to delay progression in those approaching end-stage heart failure.
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4.6. Ventricular Arrhythmia Involving the HisPurkinje System, Bundle Branch Reentrant
Ventricular Tachycardia, and Fascicular Ventricular
Tachycardia
Recommendations for catheter ablation of bundle branch reentrant VT and for catheter ablation of fascicular VT
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Recommendations

References

1. In patients with bundle branch reentrant VT, catheter ablation is useful for reducing
the risk of recurrent VT.
2. In patients with idiopathic left fascicular reentrant VT for whom medications are
ineffective, not tolerated, or not the patient’s preference, catheter ablation is useful.
3. In larger pediatric patients (‡15 kg) with idiopathic left fascicular reentrant VT in
whom medical treatment is ineffective or not tolerated, catheter ablation is useful.
4. In patients with focal fascicular VT with or without SHD, catheter ablation is useful.
5. In patients with postinfarction reentrant Purkinje ﬁber-mediated VT, catheter
ablation is useful.

S4.6.1–S4.6.9

Recommendation-Speciﬁc Supportive Text
1. Bundle branch reentrant VT (BBRVT) is curable by catheter ablation, which is successful in almost all patients
(S4.6.1–S4.6.4). However, for patients with SHD or
conduction system disease, long-term outcome depends
on the type of underlying cardiac disease. Despite successful BBRVT ablation, many patients remain at risk of sudden
death due to concomitant scar-related VTs and/or LV
dysfunction. An ICD with or without cardiac resynchronization should be considered (S4.6.4–S4.6.6). On the other
hand, for patients with BBRVT who have unacceptably
frequent shocks from their ICD, catheter ablation can be
helpful in preventing or reducing the shocks (S4.6.3).
Even for patients with terminal heart failure and incessant
BBRVT, catheter ablation can function as a bridge to cardiac transplantation (S4.6.3).
BBRVT can be cured by catheter ablation for patients with
normal heart structure and function (S4.6.3–S4.6.5,S4.6.7,
S4.6.8). Although data are limited, some reports suggest
that patients with preserved LV systolic function and no
other inducible VT might not further beneﬁt from ICD
insertion after successful ablation. This subgroup had
excellent long-term outcomes for VT-free survival without
deterioration of conduction properties during follow-up.
However, further study is required before a speciﬁc recommendation can be formulated (S4.6.4).
For patients with BBRVT who have a normal HV interval,
catheter ablation is also a curative approach. Approximately

S4.6.10–S4.6.22
S4.6.23–S4.6.26
S4.6.11,S4.6.27–S4.6.29
S4.6.30–S4.6.32

22%–46% of patients with BBRVT had a normal baseline
HV interval, and signiﬁcant prolongation of the HV interval
only developed during tachycardia. This result suggests that
either a functional or ﬁxed conduction block in the HisPurkinje system could be sufﬁcient to maintain a BBRVT
mechanism. Long-term outcome depends on the underlying
cardiac disease (S4.6.4,S4.6.6). Patients with normal LV
systolic function and HV interval have excellent longterm outcomes after ablation (S4.6.4).
Myocardial VT is the most common type of inducible sustained monomorphic VT in patients with valvular heart disease. The majority of these patients have underlying
coronary artery disease and signiﬁcant LV dysfunction.
However, in almost one-third of the patients, sustained
BBRVT is the only type of inducible VT. This type of VT
is facilitated by the valve procedure occurring within 4 weeks
after surgery in most patients. In these patients, LV function
is relatively well preserved, and the RBBB-type of BBRVT
is frequently induced. Because a curative intervention can be
offered to these patients (eg, bundle branch ablation),
BBRVT should be seriously considered as the VT mechanism in patients with valvular heart disease, particularly if
the arrhythmia occurs soon after valve surgery (S4.6.5).
Catheter ablation of the RBB or LBB interrupts the circuit
and is usually curative. However, severely impaired antegrade conduction in the remaining bundle is often present,
requiring permanent pacing, which can have hemodynamic consequences. Consideration should be given to
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future CIED requirements when selecting the ablation
target. In patients with baseline complete or incomplete
LBBB, anterograde slow conduction over the LBB is present, and ablation of the LBB might leave adequate residual anterograde conduction over the right bundle.
Ablation targeting the portion of the distal LBB (left posterior or anterior fascicle) that has slow conduction can
potentially preserve the residual AV conduction. Close
follow-up for recurrent arrhythmias, progressive conduction deterioration, or LBBB-induced ventricular dysfunction is important (S4.6.9).
2. In the published literature, the overall success rate of ablation for idiopathic left fascicular reentrant VT is .95%.
Although complications related to left heart catheterization might be encountered, no serious complications
were reported. Left posterior hemiblock was observed
when a line of RF lesions was applied through the posterior septal region (S4.6.10–S4.6.22).
Left upper septal fascicular VT often presents as narrow
QRS complex tachycardia, but some left upper septal
fascicular VTs occur after catheter ablation targeting left
posterior fascicular VT. Such VTs can be managed successfully by focal ablation at the left upper septum with
some risk of fascicular injury (S4.6.22).
3. In pediatric patients with fascicular reentrant VT (age 10.0
6 5.1 years, 62% males), nondihydropyridine calcium
channel blockers were effective at terminating and preventing VT in 80% of the patients; however, 21% of the
patients experienced recurrence during chronic oral therapy. Catheter ablation was successful in 71% of fascicular
VTs. After a follow-up period of 2 years (1 day to 15
years), 72% of all patients with fascicular VT were off
medications, with no tachycardia recurrence (S4.6.23).
Two small series reported an acute success rate for catheter ablation for fascicular VT of 100%. However, the
overall recurrence rate was 0%–50% over 2–3 years’
follow-up. Major complications included 1 case of complete AV block and 1 case of LBBB (S4.6.24,S4.6.25).
In smaller patients (less than 15 kg) with fascicular reentrant VT that either is controlled medically or is hemodynamically well tolerated without ventricular dysfunction,
ablation is generally not pursued (S4.6.26,S4.6.33).
As with many other forms of arrhythmia, infants with this
VT frequently experience resolution of the VT with time;
such resolution is much less common in older children and
adolescents. Idiopathic VAs are often well tolerated, minimally symptomatic, and are not associated with a risk of
sudden death (S4.6.33).
A case series of 2 patients showed that oral verapamil suppressed VTs in newborns. Following discontinuation of
verapamil at 1 year of age, both children remained free
of tachycardia recurrence at 3 and 4 years of age (S4.6.34).
4. Among idiopathic VT cases referred for ablation, 2.8%
were focal nonreentrant fascicular tachycardia, which
had distinct clinical characteristics and usually originated
from the left posterior fascicle (LPF), and less commonly
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from the left anterior fascicle (LAF) and RV Purkinje
network. Catheter ablation guided by activation mapping
is effective, whereas a pace map–guided approach is less
effective. VT recurrence was observed in 27% of patients,
and among them, pace mapping was used to target VT
during the initial ablation attempt (S4.6.27).
Another small series reported two focal Purkinje VT cases
with IHD in whom complete AV block occurred after the
successful ablation of the VT. This outcome suggests that
ablation often is not sufﬁcient as the sole therapy due to
other induced VTs and conduction abnormalities,
requiring pacemaker and/or deﬁbrillator implantation for
these VT patients with SHD (S4.6.28).
5. The Purkinje system might be part of the reentry circuit in
patients with postinfarction monomorphic VT, resulting
in a type of VT with a relatively narrow QRS complex
that mimics fascicular VT. Catheter ablation is effective
(S4.6.31,S4.6.33).
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4.7. Congenital Heart Disease
Recommendations for catheter ablation of VA in patients with CHD
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1. In patients with CHD presenting with sustained VAs, evaluation for potential residual
anatomical or coronary abnormalities should be performed.
2. In patients with CHD presenting with sustained VT in the presence of important
hemodynamic lesions, treatment of hemodynamic abnormalities as feasible should
be performed in conjunction with consideration for ablation.
3. In patients with repaired tetralogy of Fallot and sustained monomorphic VT or
recurrent appropriate ICD therapy for VAs, catheter ablation is effective.
4. In select patients with CHD and clinical episodes of sustained VT who are undergoing
surgical repair of residual hemodynamic abnormalities, surgical ablation of VT
guided by preoperative or intraoperative EAM can be beneﬁcial.

S4.7.1–S4.7.6

Recommendation-Speciﬁc Supportive Text
1. The substrate for VAs in patients with repaired CHD is
typically reentry related to ventricular hypertrophy and
areas of scar from prior incisions, patches, and conduit
placement. The development of VAs in patients with
CHD can be a manifestation of hemodynamic abnormalities, including valvar obstruction or regurgitation, ventricular dysfunction, or coronary abnormalities.
Identiﬁcation of the underlying abnormality contributing
to ischemia, ventricular dysfunction, and VAs is important to therapeutic planning, given that interventions for
the substrate may reduce the frequency of recurrent VAs
and/or improve the hemodynamic status.
2. Most data regarding reoperation for patients with CHD and
sustained VAs are from patients with tetralogy of Fallot.

S4.7.2,S4.7.7–S4.7.16
S4.7.17–S4.7.24
S4.7.2,S4.7.8,S4.7.9,
S4.7.11,S4.7.25

Treatment of underlying hemodynamic abnormalities
may reduce the incidence of recurrent VAs and allow for
ventricular remodeling or improvement in ventricular function. In studies of patients with tetralogy of Fallot and sustained VT undergoing reoperation for hemodynamic
abnormalities without speciﬁc arrhythmia intervention,
late postoperative VT was reduced to 11%–33% during
mid-term follow-up (S4.7.2,S4.7.7–S4.7.9,S4.7.13).
Given the incomplete protection from recurrent VA,
consideration should also be given to catheter and
surgical ablation and/or ICD therapy as indicated (Figure 2).
3. The majority of reports of successful VT ablation in adults
with repaired CHD include patients with tetralogy of Fallot, with small numbers of patients with transposition of
the great arteries, ventricular septal defects (VSDs), and
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other lesions (S4.7.17,S4.7.18,S4.7.26,S4.7.27). VT
circuits tend to be multiple and related to prior
ventriculotomies and VSD patches in patients with
complex CHD (S4.7.19–S4.7.22,S4.7.24,S4.7.26,S4.7.
28). In patients with tetralogy of Fallot, anatomical
isthmuses (AIs) critical to the reentrant circuit have been
identiﬁed between the septal defect patch or
ventriculotomy and the pulmonary valve, and between
the tricuspid annulus and the OT patch or septal defect
patch (S4.7.19,S4.7.22,S4.7.24). EAM to identify and
ablate reentrant channels, with veriﬁcation of
conduction block and occasionally ablation from the left
side of the ventricular septum, have procedural success
rates of approximately 80% (S4.7.21,S4.7.24,S4.7.28).
Patients with procedural success from catheter ablation

and with preserved biventricular ventricular function
have not experienced recurrent VT or sudden cardiac
death in up to 10-year follow-up (S4.7.22,S4.7.28).
4. Several small studies have demonstrated the effectiveness of map-guided surgical ablation of VT during
concomitant repair of SHD, with recurrent VT
reported in 15%–20% of patients (S4.7.2,S4.7.8,S4.7.9,
S4.7.11). To date, in patients with tetralogy of
Fallot empiric surgical cryoablation lesions for
sustained VT without electrophysiological mapping of
the tachycardia circuit have shown recurrent VT in
18%–45% of patients (S4.7.25,S4.7.29). The role of
prophylactic empiric cryoablation of the OT in selected
high-risk patients with tetralogy of Fallot is evolving
(S4.7.16,S4.7.25).

CHD and Sustained Ventricular
Tachycardia

Evaluate residual anatomical
abnormalities, coronary
arteries, ventricular function,
exercise capacity

Residual
abnormalities

Catheter or surgical
intervention for
correctable lesions;
± ablation
± ICD

Yes

No

ACA or
severe ventricular
dysfunction

No

Yes

Recurrent ICD
therapies

ICD
implantation,
heart failure
consult

Polymorphic VT
or single ventricle or
severe CHD

Yes

Yes

No

High-risk
CHD or recurrent
VT

Simple or
moderate CHD,
TOF/DORV

Yes

Ablation

Yes

Figure 2 Congenital heart disease and sustained VT. For further discussion of ICD candidacy, please see PACES/HRS Expert Consensus Statement on the
Recognition and Management of Arrhythmias in Adult Congenital Heart Disease (S4.7.14) and 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines
for Device-Based Therapy of Cardiac Rhythm Abnormalities (S4.7.30). ACA 5 aborted cardiac arrest; CHD 5 congenital heart disease; DORV 5 double outlet
right ventricle; ICD 5 implantable cardioverter deﬁbrillator; TOF 5 tetralogy of Fallot; VT 5 ventricular tachycardia.
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4.8. Inherited Arrhythmia Syndromes
Recommendations for catheter ablation of VA in inherited primary arrhythmia disorders
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Recommendations
1. In patients with ARVC who experience recurrent sustained VT or frequent
appropriate ICD interventions for VT in whom AAD therapy is ineffective or not
tolerated, catheter ablation, at a center with speciﬁc expertise, is recommended.
2. In patients with ARVC who have failed one or more attempts of endocardial
VT catheter ablation, an epicardial approach for VT ablation is recommended.
3. In patients with ARVC who experience recurrent sustained VT or frequent
appropriate ICD interventions for VT in whom AAD therapy is not desired or
preferred, catheter ablation, at a center with speciﬁc expertise, is reasonable.
4. In patients with Brugada syndrome who experience recurrent sustained VAs
or frequent appropriate ICD interventions, catheter ablation can be useful.
5. In patients with ARVC, a ﬁrst-line combined endocardial/epicardial approach
for VT ablation is reasonable.
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Recommendation-Speciﬁc Supportive Text
1. In patients with ARVC, recurrent VT or frequent appropriate ICD interventions for VT can be seen despite the
use of multiple AAD therapies, including amiodarone
and sotalol. Catheter ablation has demonstrated an
acceptable acute success rate and over time with development of different techniques (substrate vs. conventional mapping) and approaches (endocardial,
epicardial, or combined endo-epicardial) has reduced
recurrence rates and appropriate ICD interventions (S4.
8.1–S4.8.11). The writing committee felt that earlier
consideration could be given to ablation, as opposed to
further AAD therapy, in centers with speciﬁc expertise
in VA ablation in ARVC, including epicardial access.
Reference should also be made to the 2019 HRS Expert
Consensus
Statement
on
Evaluation,
Risk
Stratiﬁcation, and Management of Arrhythmogenic
Cardiomyopathy (S4.8.19).
2. In patients with ARVC, scar location is heterogeneous
based on the chamber (mainly RV dominant but can
involve the LV), the number of foci, and depth (epicardial
and/or endocardial) (S4.8.7). Over time, the need for
repeat catheter ablation is common and due to the scar
location, and an epicardial approach is often necessary.
Long-term freedom from VA is achieved in approximately one-third of patients with an endocardial approach
(S4.8.4). An endocardial followed by an epicardial
ablation approach if the patient remains inducible for
VT may avoid unnecessary epicardial access and associated procedural risk. However, strong consideration
should be given to performing the procedure in a setting
where it is possible to proceed to epicardial ablation
during the same procedure, if endocardial ablation fails
to terminate the clinical VA, or if the patient remains
inducible.
3. In patients with ARVC, recurrent VT or frequent appropriate ICD interventions for VT can be seen despite the
use of multiple AAD therapies (S4.8.20). The majority
of patients undergoing catheter ablation are on antiarrhythmic therapy, including beta blockade before and after ablation. However, some patients in the published
series were not on AAD therapy at the time of ablation
(S4.8.1,S4.8.3–S4.8.6,S4.8.8). The overall acute success
rates are acceptable, especially when an epicardial
approach is used, and indeed are superior to that
reported for other substrates like NICM (S4.8.2). Patients
are often younger and might not be on other medications,
which could inﬂuence the choice between AAD therapy
and ablation. Two studies have assessed whether the substrate underlying VAs in ARVC progressed over time. In
the ﬁrst, scar progression, as assessed by bipolar voltage
mapping in patients undergoing repeat ablation, was
observed in 2 of 11 patients over a mean follow-up of
approximately 6 years (S4.8.21). In the second, similar
progression occurred in 2 of 7 patients over a 30-month
follow-up, and recurrent VTs were ablated within the
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previously documented scar, suggesting incomplete ablation at the index procedure (S4.8.22). This outcome suggests that with a comprehensive initial procedure that
achieves noninducibility, substrate progression and recurrent VA are not inevitable, at least over the medium term.
Strong consideration should be given to performing such a
procedure in a center that can proceed to an epicardial
ablation during the same procedure should an endocardial
ablation be insufﬁcient to eliminate VT. However, to
achieve long-term freedom from AADs, patients might
require repeated ablation procedures and rely on ICD interventions for treatment of hemodynamically unstable
VT. The writing committee felt that stronger consideration could be given to catheter ablation as a ﬁrst-line
approach without preceding AAD therapy by experienced
operators and centers, and with fully informed patients.
Reference should also be made to the 2019 HRS Expert
Consensus Statement on Evaluation, Risk Stratiﬁcation,
and Management of Arrhythmogenic Cardiomyopathy
(S4.8.19).
The role of catheter ablation in new-onset single
morphology VT without ICD therapy prior to or after
ablation was examined only in a small number of patients
(S4.8.20). Catheter ablation has not been shown to reduce
sudden cardiac death in patients with ARVC; thus, ICD
therapy remains the mainstay for sudden cardiac death
prevention (S4.8.20,S4.8.23–S4.8.25).
4. Patients with Brugada syndrome and a type I Brugada
ECG pattern (spontaneous or drug induced) have an arrhythmogenic substrate located in the anterior epicardial
RVOT that can be further unmasked with provocative
drug testing (S4.8.16). Targeted catheter ablation can
normalize the electrographic abnormalities and reduce
VA inducibility during programmed stimulation (S4.8.
14–S4.8.17). Use of ablation with substrate modiﬁcation
in the most symptomatic patients (recurrent VF/VT, VF
storm, or frequent ICD interventions) with Brugada
syndrome and a type I Brugada ECG pattern
(spontaneous or drug induced) has demonstrated a
reduction in arrhythmic events (S4.8.14–S4.8.17). Longterm follow-up has been limited, and generalizability is
unknown, given that procedures have been performed at
highly specialized centers with expertise in Brugada syndrome and epicardial ablations (S4.8.14–S4.8.17). Drug
therapy with quinidine should be considered as a ﬁrstline alternative (S4.8.26).
5. In patients with ARVC, combined endocardial and epicardial substrate catheter ablation has improved acute success and lowered recurrence rates compared with
endocardial-only catheter ablation. A combined
endocardial-epicardial approach might be a reasonable
ﬁrst-line approach, although not all patients require
epicardial catheter ablation for elimination of VT. Risks
associated with epicardial access and ablation should be
considered, and these procedures should be performed
at centers with expertise (S4.8.27,S4.8.28).
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4.9. Ventricular Arrhythmia in Hypertrophic
Cardiomyopathy
Recommendation for VA ablation in HCM
COR

LOE

IIa

B-NR

Recommendation

References

1. In patients with HCM and recurrent monomorphic VT in whom AAD therapy is
ineffective or not tolerated, catheter ablation can be useful.

S4.9.1–S4.9.5

Recommendation-Speciﬁc Supportive Text
1. Although a less common arrhythmia in HCM, the reported ablation experience is largely limited to monomorphic VT (S4.9.1–S4.9.5). Most patients in these series had
already failed AAD therapy. Ablation can be challenging
due to the thickness of the myocardium, and epicardial
access has been required in the majority of patients (S4.
9.1–S4.9.4), along with adjunctive techniques such as
intracoronary ethanol ablation and surgical epicardial
cryoablation (S4.9.3,S4.9.4). Satisfactory results have

been reported, although multiple procedures were
required in some patients (S4.9.1–S4.9.5). VAs
associated with apical aneurysms are mostly ablated
from the LV endocardium.
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Section 5 Procedural Planning
5.1. Patient Selection and Preprocedural Risk
Assessment
RF catheter ablation is an important therapeutic option in patients with different forms of VA. Over the last decade, signiﬁcant improvements in the techniques and technologies
available for catheter ablation have been paralleled by an
increasing number of procedures performed for high-risk
and complex patient subsets (S5.1.3.1–S5.1.3.4). In these
cases, the competing risks associated with the concomitant
presence of advanced heart failure syndromes and high
burden of associated comorbidities pose substantial
periprocedural and postprocedural management challenges.
A proper preprocedural risk stratiﬁcation is crucial to
minimize the risk of adverse periprocedural outcomes such
as acute hemodynamic decompensation (AHD), which can
have devastating consequences (S5.1.3.2,S5.1.3.5,S5.1.3.6).
5.1.1. The PAAINESD Risk Score
The PAAINESD risk score (chronic obstructive Pulmonary
disease [5 points], Age .60 years [3 points], General anesthesia [4 points], Ischemic cardiomyopathy [6 points], New
York Heart Association class III or IV [6 points], Ejection
fraction ,25% [3 points], presentation with VT Storm [5
points], Diabetes mellitus [3 points]) has been demonstrated
to be helpful to identify patients undergoing scar-related VT
ablation who are at increased risk of adverse periprocedural
outcomes, and represents the most studied risk stratiﬁcation
tool in this context (Table 4) (S5.1.3.2,S5.1.3.3,S5.1.3.
5–S5.1.3.8). In a single center, the risk of acute
hemodynamic deterioration increased across tertiles of the
score, with values 17 (or 15 when “general anesthesia”
is excluded) being associated with a risk of 24%. Another
single-center report found that, when excluding general anesthesia, a score between 9 and 14 points was associated with a
6% risk of acute hemodynamic collapse, and that risk
increased to 24% in patients with a score 15 (S5.1.3.6). A
multicenter cohort found the score (excluding general anesthesia) was higher in those who died early post procedure
versus those who survived to the end of follow-up (16 6 7
vs 9 6 6; P , .001), although chronic obstructive pulmonary
disease was not included in the calculation (S5.1.3.3). These
ﬁndings were mirrored in another single-center cohort, which
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found a higher score (excluding general anesthesia) in those
who died early post ablation (17.4 6 6.3 vs 11.6 6 7.6; P 5
.012) and in patients who experienced complications (16.4 6
6.7 vs 11.6 6 7.6; P , .001) (S5.1.3.7). Of note, intraprocedural mechanical hemodynamic support (HS) was commonly
used in two of these series, which could limit the generalizability of these ﬁndings (S5.1.3.6,S5.1.3.7).
The cumulative evidence arising from published studies
suggests that a PAAINESD score 15–17 (depending on
whether the variable “general anesthesia” is included in the
risk score calculation or not) identiﬁes patients with SHD
and VT at particularly high risk of adverse periprocedural
and postprocedural outcomes (S5.1.3.2,S5.1.3.3,S5.1.3.6,
S5.1.3.8). Careful consideration of the optimal sedation or
anesthesia strategy could further help to prevent AHD in
patients with multiple other risk factors.
5.1.2. The Seattle Heart Failure Model
Another potentially useful risk stratiﬁcation tool is the Seattle
Heart Failure Model (SHFM), given its established role in
predicting mortality in patients with heart failure. The major
limitation of the SHFM is that it has been developed from cohorts of patients with heart failure without recurrent VAs, and
it remains a complex risk score to calculate due to the number
of variables included. Evidence from a single observational
study has shown that the SHFM may help to identify patients
with scar-related VT undergoing catheter ablation at high risk
of midterm (ie, 6 months) postprocedural mortality
(S5.1.3.9). Other institutional risk assessment protocols
combining variables included in the PAAINESD and
SHFM with other risk features, such as hemodynamic status
during recurrent VT episodes, have also been proposed to
determine which patients are best managed in the setting of
dedicated intensive care units or with the aid of HS devices,
and whether prolonged postablation surveillance may be
helpful (S5.1.3.1,S5.1.3.10).

Table 4 The PAAINESD Score, developed to predict the risk of
periprocedural hemodynamic decompensation
Variable

Points

Pulmonary disease (COPD)
Age .60
General anesthesia
Ischemic cardiomyopathy
NYHA class III/IV
EF ,25%
VT storm
Diabetes mellitus

5
3
4
6
6
3
5
3

The PAAINESD Score, developed to predict the risk of periprocedural hemodynamic decompensation, has values that range from 0 to 35 points (or
0 to 31 [PAINESD] when the modiﬁable intraprocedural variable “general
anesthesia” is excluded) (S5.1.3.2).
COPD 5 chronic obstructive pulmonary disease; EF 5 ejection fraction;
NYHA 5 New York Heart Association; VT 5 ventricular tachycardia.
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5.1.3. Multidisciplinary Involvement
The optimal management of high-risk patients extends
well beyond the treatment of recurrent VAs and typically
involves shared treatment plans and close collaboration
between multiple disciplines, including interventional
electrophysiologists, cardiologists, heart failure specialists, cardiac anesthesiologists, cardiothoracic surgeons,
and pediatric electrophysiologists or those with expertise
in CHD (especially in young patients ,16 years of age
or those with moderate/complex CHD) as appropriate.
As such, it is preferable that high-risk patients with
recurrent VAs for whom a catheter ablation procedure
is planned are managed in centers with proﬁciency in
these procedures, and that they receive prompt access
to advanced therapies, including percutaneous HS
devices, permanent ventricular assist devices (VADs),
and/or heart transplantation. Ongoing heart failure management is a critical component of the management of
such patients both immediately after VA ablation and
in the longer term.
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5.2. 12-Lead Electrocardiogram and Body Surface
Mapping Before Ventricular Tachycardia Ablation
5.2.1. Standard 12-Lead Electrocardiogram
The standard 12-lead ECG has been shown to be a valuable
tool in planning catheter ablation procedures for treatment
of VAs, including VT and PVC, and in the case of hemodynamically tolerated VAs, every effort should be taken to record the 12-lead ECG. In cases of focal VA in the absence
of SHD, the 12-lead ECG is a relatively accurate indicator
of the source location, whereas in the presence of myocardial
scarring from whatever cause (in which reentry is the predominant mechanism of arrhythmia), the ECG reﬂects the
exit site from the reentrant circuit, rather than the diastolic
corridor that typically represents the best ablation target. In
some cases, the distance between these two locations can
be several centimeters.
5.2.2. Ventricular Tachycardia and Premature Ventricular
Complex in the Absence of Structural Heart Disease
Features of the 12-lead ECG during VT or PVC occurring in
the absence of SHD have been reported, which suggest endocardial catheter-accessible origins in the RV vs LV outﬂow
regions (including the aortic SV), idiopathic fascicular
(verapamil-sensitive) VT related to the LV Purkinje system,
and other LV sources, including anterior and posterior papillary muscle VT, para-Hisian VT, mitral annular VT, AMC
VT, and GCV/AIV VT; and other RV sources, including
tricuspid annular VT, moderator band VT, and papillary muscle VT. Certain ECG patterns can indicate these regions of
origin. An LBBB inferior axis morphology with late transition (.lead V3) indicates an origin in the RVOT. Lead I indicates whether the origin is anteriorly (negative) or
posteriorly (positive) located (S5.2.8.1). Notching in the inferior leads indicates a lateral (free wall) position in the OT
(S5.2.8.1). A Q wave in lead V1, combined with an
R wave in lead aVL and an R wave in lead I, together with
smaller R waves in the inferior leads, has been found for
VAs originating from close to the conduction system
(S5.2.8.2). An early transition (lead V3) in the presence
of an LBBB pattern could indicate a left-sided origin
(S5.2.8.3), and a broader and taller R wave in V1 or V2 could
indicate an origin from the SV (S5.2.8.4).
Epicardial origins from the LVOT, in addition to displaying a broad QRS complex with a pseudodelta wave (see
below), often have a Q wave in lead I. An epicardial origin
close to the AIV, however, can closely resemble the ECG
pattern of an origin from the RVOT. An RBBB and inferior
axis pattern with positive concordance is the hallmark for
VAs originating from the anterior mitral annulus (S5.2.8.5).
A transition to a precordial rS pattern, usually in lead V3–
V4, has been observed for origins from the papillary muscles
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with a leftward axis, indicating an origin from the posteromedial, or with a rightward axis, indicating an origin from the
anterolateral papillary muscle (S5.2.8.6). Papillary muscle
sources often produce a small Q wave in lead V1 (S5.2.8.7,
S5.2.8.8). In contradistinction to papillary muscle origins, a
fascicular origin has a much narrower QRS complex
(S5.2.8.6).
Despite the range of heart positions in the chest and body
habitus, and variations of ECG lead positions, these ECG
features can be remarkably accurate at indicating the SOO
to within a 1- to 2-cm radius. Reﬁnement of the exact site
of impulse formation using activation or pace mapping
is still needed prior to ablation (S5.2.8.9–S5.2.8.13).
Examples of PVC morphologies from several common
SOOs in the RV and LV are shown in Figure 3 and
Figure 4.

5.2.3. Postinfarction Ventricular Tachycardia
Several algorithms have been devised to predict the exit
site in post-MI VT. As noted above, these all have the
important limitation that (to the degree they can reveal
localizing information about the arrhythmia) they indicate
the exit site of the circuit, not the location of the midportion of the diastolic corridor (S5.2.8.14–S5.2.8.17).
Although the distance from the exit site to a vulnerable
portion of the diastolic corridor can be 1 cm or less, it
could be more. In addition, the existing algorithms are
not applicable in all cases, and in those cases in which
they are, only approximately 75% of VTs can be
regionalized to a 2- to 5-cm2 area. In general, correlation
of exit sites with VT morphology conforms to rather intuitive principles:
1. The majority of post-MI VT exit sites are LV endocardial.
2. LBBB VTs tend to have exit sites on, or within 1 cm of,
the intraventricular septum.
3. Patients with inferior infarctions often have Q waves in
the inferior leads, indicating inferior wall scarring and
an inferior wall exit site, which tend to be located on the
inferobasal septum or the inferolateral free wall, with a
common diastolic corridor on the inferobasal free wall
along the mitral annulus.
4. VTs with a predominant inferior axis tend to have
exit sites on the anterior wall (cranial half of the LV).
5. VTs with a predominant superior axis tend to have exit
sites on the inferior half of the LV.
6. VTs with a leftward axis tend to have exit sites on or
within 1 cm of the septum.
7. VTs with concordant positive precordial QRS complexes
tend to have basal exit sites.
8. VTs with concordant negative precordial QRS complexes
tend to have apical exit sites.
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There can sometimes be disagreement among observers
about speciﬁc features of ECGs, such as whether an axis is
leftward or rightward (ie, discordance between vector of
leads I and aVL/lateral precordial leads). Automated algorithms can remove some of the subjectivity of VT ECG analysis (S5.2.8.18–S5.2.8.20).
5.2.4. Epicardial Sources
Several ECG criteria have been proposed that indicate an
epicardial source of VT in patients without SHD or with
NICM. These include several interval measurements that
reﬂect slow, muscle-to-muscle propagation at the beginning
of the QRS complex, the maximum deﬂection index in precordial leads, and presence of Q waves where they would
not ordinarily be expected (indicating propagation away
from the epicardial surface of the ventricular wall recorded
by that chest lead) (S5.2.8.21–S5.2.8.24). Of these, the raw
interval measurements are subject to false-positive errors in
that they can be nonspeciﬁcally prolonged by sodiumchannel blocking effects of AADs or hyperkalemia as well
as by CL (less accurate with faster VTs) (S5.2.8.25). The
maximum deﬂection index (time to earliest peak in any precordial lead divided by the total QRS duration (S5.2.8.26), at
least in principle, prevents this problem by indexing the intrinsicoid deﬂection to the total QRS duration, which will
be subject to the same effects.
5.2.5. Ventricular Tachycardia in Nonischemic
Cardiomyopathy
The 12-lead ECG of a VT could be less helpful in NICM to
direct ablation; however, target areas can be estimated in a
fashion comparable to post-MI VT. In many cases of
NICM, successful ablation sites are on the epicardial surface;
however, NICM VTs originating from anteroseptal scar typically have an LBBB inferior axis morphology, and these patients (who might also present with AV conduction
disturbances due to septal scarring in the region of the bundle
branches) might not beneﬁt from an epicardial approach for
ablation (S5.2.8.27).
5.2.6. Bundle Branch Reentrant Ventricular Tachycardia
Patients with BBRVT typically have some form of SHD
(nonischemic more than ICM), with an LBBB pattern in
the baseline conducted rhythm (sinus or atrial ﬁbrillation
[AF]), although RBBB or nonspeciﬁc interventricular conduction delay can also occur. During BBRVT, the QRS
generally closely resembles the baseline QRS, with characteristically rapid initial forces (in contrast to the delayed upstrokes in most other myocardial VTs). This is an important
entity to recognize because of its prevalence as well as its
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curability with a rather simple ablation procedure (targeting
RBBs or LBBs).
Many patients with SHD have an ICD in place that terminates the majority of VT episodes with pacing or shock, thus
precluding recording of a full 12-lead ECG of the arrhythmia.
Only when the device is disabled, or when the VT rate or
episode duration is below the device’s programmed detection
levels, is it possible to record the ECG during VT. In patients
with SHD, having the 12-lead ECG of all spontaneously
occurring VTs is especially important during procedures in
which multiple morphologies of VT are induced and the
operator must decide which morphology (or morphologies)
are most important to target for ablation. In the absence of
a 12-lead ECG, ICD electrograms of the recorded VT episodes have been particularly helpful to identify the clinical
VT when multiple VTs are induced during an ablation procedure (S5.2.8.28).

5.2.7. Body Surface Mapping
Body surface mapping has been used for many years as a predictor of VA exit site, starting with skin surface potential
minima and more recently as electrocardiographic imaging
(ECGI). The latter integrates unipolar electrograms obtained
during the arrhythmia while the patient is wearing a 256electrode vest, with ventricular anatomy derived from a CT
or CMR scan with the vest in place. An activation map during
the arrhythmia is then mathematically derived using the inverse solution and is plotted on the epicardial surface as
designated by the CT or CMR scan. Although experience
with this modality in VAs is limited, ECGI maps have shown
good correlations with endo- and epicardial mapping results
in a variety of settings, in patients with and without SHD (S5.
2.8.29–S5.2.8.32). Correlations appear to be very good for
OT arrhythmias (right vs left) and for those with epicardial
sources, and poorer for reentrant VTs (many of which have
septal diastolic corridors with variable epicardial
breakthrough sites that can be detected by ECGI), and with
origin from sites close to scar (S5.2.8.33).

5.2.8. Summary
In most settings, ECG tracings provide important insights
regarding location of either the source of focal arrhythmias
or the exit site for reentrant VTs; when possible, a 12-lead
ECG should be obtained of the target VA(s) (PVC or VT)
and be used as a guide for where to concentrate mapping efforts based on published algorithms. However, no matter
how speciﬁc the ECG algorithm or ECGI map is, it remains
as a guide to where mapping efforts should begin or focus,
rather than pinpointing an actual site at which ablation will

Figure 3 Examples of 12-lead ECGs of premature ventricular complexes
from different LV sites, as corroborated by successful focal ablation. (A)
shows 12-lead ECG patterns of common ventricular arrhythmia origins in patients without SHD [1–9] from the left ventricle. All leads are displayed at the
same ampliﬁcation and sweep speed. These locations are illustrated in (B)
based on 3D reconstruction of a cardiac computed tomography using the
MUSIC software that was developed at the University of Bordeaux. The
reconstruction shows an anterolateral view of the left ventricle, aorta, and
left atrium. Also shown are the coronary arteries (red), the coronary venous
system (blue), and the phrenic nerve (green). AIV 5 anterior interventricular
vein; AL PAP 5 anterolateral papillary muscle; AMC 5 aortomitral continuity; GCV 5 great cardiac vein; ant. MA 5 anterior mitral valve annulus;
PM PAP 5 posteromedial papillary muscle; R/L 5 right-left; SHD 5 structural heart disease; SoV 5 sinus of Valsalva.

be certain to eliminate the arrhythmia. Careful mapping is
still needed in all situations.
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Figure 4 Examples of 12-lead ECGs of premature ventricular complexes
from different right ventricular sites, as corroborated by successful focal
ablation. All leads are displayed at the same ampliﬁcation and sweep speed.
(A) shows the 12-lead ECG pattern of common origins of right ventricular
arrhythmias in patients without SHD [1–6]. The locations are detailed in a
3D reconstruction of the computed tomography using the MUSIC software
that was developed at the University of Bordeaux. The reconstruction shown
in (B) illustrates the septal view of the right ventricle. Indicated are the pulmonary artery, the tricuspid valve annulus, and the right ventricular apex.
ECGs 5 electrocardiograms; PA 5 pulmonary artery; RVOT5 right ventricular outﬂow tract; SHD 5 structural heart disease; TVA 5 tricuspid valve
annulus.
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5.3. Facilities for the Procedure
5.3.1. Facilities
VT ablation can be a complex electrophysiological procedure, especially in patients suffering from deterioration of
LV function or from cardiogenic shock. In addition, many
patients with scar-related VT have comorbidities that impact
on procedural planning. Adequate preprocedural planning
and standardization of procedural steps are crucial in this
population with advanced heart disease. Preprocedural planning should involve communication with other subspecialties, including cardiothoracic surgeons and physicians
with expertise in heart failure management, to optimize patient safety. In general, VT ablation in patients with advanced
heart disease should only be performed by experienced operators in centers with expertise for complex electrophysiological procedures with onsite cardiosurgical backup and
expertise in HS.
All personnel and equipment should meet institutional requirements and training requirements for treating patients
with complex cardiac pathologies. Integrity and functionality
of the equipment should be regularly maintained as required
by institutional standards.
5.3.2. Laboratory Equipment
The electrophysiology laboratory for VT ablation should
meet standard requirements for any type of catheter ablation
procedure, with availability of emergent echocardiography to
rule out cardiac tamponade. Laboratory speciﬁcations
include a dedicated work space and ﬂuoroscopy system
(mono- or biplane, capability of cineﬂuoroscopy or angiography), a programmed stimulator, an electrophysiology
recording system with EAM ability, as well as the possibility
to perform cardiac catheterization procedures with hemodynamic monitoring capabilities. Institutional and societal requirements for electrophysiology laboratories should be
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met, and regular maintenance is imperative (S5.3.4.1). The
electrophysiology lab should be equipped with a biphasic
deﬁbrillator and an ECG monitor, and a backup deﬁbrillator
should be immediately accessible. Continuous connection of
the deﬁbrillator to the patient (eg, using attached deﬁbrillator
pads) is used in many labs for fast and easy deﬁbrillation. A
code cart with standard advanced cardiac life support medications is mandatory. For surgical access, such as epicardial
surgical windows, institutional hygienic standards should
be maintained.
Programming devices for the patient’s speciﬁc ICDs
should be available in the electrophysiology lab to allow
pre- and intraprocedural programming and device interrogation as well as emergency internal shock delivery if required.
For patients with implanted left or right VADs, the appropriate equipment and personnel should be available as
required.
Epicardial access for mapping and ablation might be
needed in a subgroup of patients with VT. Epicardial instrumentation is a complex part of VT ablation and requires high
expertise and experience with epicardial puncture or surgical
access. Continuous availability of an ICD programmer and
the capability of delivering internal shocks can be crucial to
terminate VAs in case of external deﬁbrillation failure due
to pericardial ﬂuid and/or air and in cases of suboptimal deﬁbrillator pad location.
Patient monitoring is crucial for safety during ablation of
VT, independent of the underlying cardiac disease. A physiological recorder capable of monitoring pulse oximetry,
noninvasive and invasive arterial blood pressure, and ECG
is recommended. Vital signs in addition to oxygen saturation
should be displayed for the operator and assisting staff
throughout the procedure. For longer procedures involving
patients with SHD, invasive intra-arterial blood pressure
monitoring might be superior to noninvasive noncontinuous
measurement. Noninvasive monitoring of cerebral tissue oxygen saturation has been used to reﬂect end organ perfusion
when longer episodes of VT were required, to allow for
adequate mapping (S5.3.4.2,S5.3.4.3).

5.3.3. Personnel
Credentialing of personnel involved in VT ablation procedures is speciﬁc to institutions and can vary by country. The
personnel in the electrophysiology lab typically consist of a
nurse and a technician involved in patient care and monitoring; possibly a person handling the ICD programmer
(approximately 15% of the writing committee have a representative from the device company assisting with intraprocedural management of the ICD) during the ablation; an expert
operator for manipulation and placement of catheters; and
one or two operators managing the electrophysiology
recording system, the stimulator, and the mapping system.
When a 3D EAM system is used, as is the case in most VA
ablation procedures, a highly trained professional (eg, a manufacturer’s representative, a technician, or a physician) is
usually present to operate this system and assist with
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acquisition, editing, and interpretation of data. With respect
to sedation, different requirements exist in different countries
and societies. An anesthesiologist, a nurse anesthetist, or an
equivalent person experienced with sedation and intubation
should be present if deeper sedation is required. In this regard, sedation during VT ablation by trained cardiologists
has been shown to be safe (S5.3.4.4–S5.3.4.6).
Personnel involved in VT ablations should be trained for
complex electrophysiology maneuvers and mapping maneuvers for monitoring severely impaired patients under sedation
and administration of antiarrhythmic as well as inotropic
drugs (S5.3.4.4–S5.3.4.6). Recognizing any potential
complication or prolonged hemodynamic compromise is a
key feature to patient safety. Personnel involved in VT
ablation should be proﬁcient in using cardiac deﬁbrillators
and in performing advanced life support and
cardiopulmonary resuscitation.
Operators performing VT ablation procedures should be
certiﬁed interventional electrophysiologists with expertise
for RV and LV mapping and ablation. Coronary angiography
by the operator him- or herself or by another physician might
be needed during epicardial or aortic SV ablation procedures
to delineate anatomy of the coronary arteries. In addition, physicians capable of inserting percutaneous HS devices should
be available in case of prolonged hemodynamic compromise.
A cardiac surgeon should be available in case cardiopulmonary bypass, surgical HS, or sternotomy is required.
Epicardial VT procedures can be more complex than
endocardial VT ablation procedures; these are discussed in
more detail in Section 6.3. For adequate treatment of possible
complications and also for surgical epicardial access, cardiac
surgical backup is warranted.
5.3.4. Patient Safety
Due to procedural complexity and risks, catheter ablation for
VAs should have appropriate patient safety and pertinent
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laboratory protocols in place. Electrophysiology laboratory
equipment should undergo routine maintenance by a biomedical engineering department to ensure appropriate functionality and should be available for troubleshooting. In
particular, routine assessment for external deﬁbrillator functionality should be performed according to regulatory, manufacturer, and institutional policies. Radiation exposure should
be minimized to the operator and patient with the use of
digital-pulsed, low pulse rate ﬂuoroscopy if feasible, and implementation of ALARA (as low as reasonably achievable)
principles. Safety protocols should be in place for management of emergent complications, with a focus on those pertaining to higher-risk VA ablation (eg, epicardial access
with surgical backup, hemodynamically unstable VAs
requiring HS, acute coronary injury requiring coronary intervention).
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5.4. Preprocedural Imaging
Recommendations for preprocedural imaging for VA catheter ablation
COR

LOE

I

B-NR

IIa

B-NR

IIa

B-NR

IIa

C-EO

IIb

C-EO

Recommendations

References

1. In patients with LV dysfunction undergoing catheter ablation of VA, preprocedural
or intraprocedural imaging is recommended to rule out cardiac thrombi.
2. In patients with NICM or ICM undergoing catheter ablation of VT, preprocedural CMR
can be useful to reduce VT recurrence.
3. In patients with NICM or ICM undergoing catheter ablation of VA, preprocedural
imaging can be useful for procedural planning.
4. In patients with NICM, CMR can be useful prior to ICD implantation to allow imaging
without device-related artifact for diagnostic purposes and identiﬁcation of
potential arrhythmogenic substrate.
5. In patients with ICM, CMR may be considered prior to ICD implantation to allow
imaging without device-related artifact for identiﬁcation of the potential
arrhythmogenic substrate.

S5.4.1–S5.4.6

Recommendation-Speciﬁc Supportive Text
1. In patients with LV dysfunction, recent preprocedural imaging should be performed if LV catheter manipulation is

S5.4.7–S5.4.9
S5.4.10–S5.4.26

anticipated to assess for LV thrombi to prevent thromboembolic events. Typically, a transthoracic echocardiogram is performed to assess for intracardiac thrombi
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(S5.4.27,S5.4.28), and contrast echocardiography has
further been shown to improve the yield of
echocardiography to detect cardiac thrombi, especially
in high-risk patients (S5.4.4,S5.4.29) and in patients
with poor echocardiographic windows. CMR has been
shown to be superior to transthoracic echocardiography
for the detection of intracardiac thrombi (S5.4.5,S5.4.6,
S5.4.30), especially in the presence of small and mural
thrombi. To further minimize the possibility of
thromboembolic events, for patients with concomitant
AF, it might be prudent to also obtain a preprocedural
transesophageal echocardiogram to rule out left atrial
thrombi if deﬁbrillation or cardioversion might be
required during the ablation procedure (S5.4.27). An
intracardiac echocardiography (ICE) can alternatively be
performed prior to LV catheter manipulation if no recent
imaging is available to rule out LV thrombi.
2. Preprocedural imaging with CMR and use of CMR for targeting the arrhythmogenic substrate has resulted in
reduced VT recurrence and reduced mortality in a few
observational studies (S5.4.7–S5.4.9). Patients with
contraindications to CMR were excluded, and in one
study, only patients with good image quality beneﬁted
from the preprocedural CMR (S5.4.9). CIEDs have long
been considered as being contraindicated for magnetic
resonance imaging (MRI). However, provided that appropriate precautions are taken, MRIs in patients with CIEDs
have been demonstrated to be safe in multiple studies and
registries (S5.4.31–S5.4.33), and a recent HRS expert
consensus statement details speciﬁc recommendations
for MRIs in patients with CIEDs (S5.4.34).
3. By demonstrating location (S5.4.12,S5.4.25,S5.4.26) and
extent (S5.4.26) of delayed enhancement, CMR helps to
identify the location of the arrhythmogenic substrate and
therefore is beneﬁcial in periprocedural planning
regarding the need for obtaining epicardial access. Other
imaging modalities, such as CT and nuclear imaging,
have been correlated with electroanatomical voltage mapping data to identify scarring by detecting areas of delayed
enhancement (S5.4.10–S5.4.17,S5.4.19), wall thinning
(S5.4.21), hypoperfusion (S5.4.20), and lack of metabolic
activity (S5.4.24). Contrary to CMR, CT and nuclear imaging do not provide speciﬁc information about the precise extent of scarring within the myocardial wall; these
imaging techniques might be preferable for preprocedural
imaging in case of contraindications to CMR.
4,5. Prior to implantation of a cardioverter deﬁbrillator, performing a CMR might be beneﬁcial in patients with
NICM and ICM. Especially for patients with NICM,
the writing committee felt that in addition to localizing
scar in the event of future VT development, a CMR
will be beneﬁcial for diagnostic reasons to clarify the
etiology of NICM. In the 2013 ACC/AHA Guideline for
Management of Heart Failure, CMR is considered a class
IIa recommendation to assess for inﬁltrative disorders
(S5.4.35). In general, it was felt that the higher the odds
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that patients might have recurrent VTs, the stronger the
indication for a CMR prior to ICD implantation (for
example, in patients with a secondary prevention indication for ICD implantation). Concerns about cost implications were the main reason why the writing committee
issued a class IIb recommendation for patients with ICM.
Synopsis
Although randomized studies that demonstrate that the use
of imaging results in improved procedural outcomes are lacking, pre-, intra- and postprocedural imaging is routinely used
for VA ablation procedures.
Advances in imaging technology, image integration, and
image analysis have paved the way for CMR and CT to
take the lead as imaging modalities to deﬁne the presence
and extent of SHD as well as to reﬁne the characteristics of
the arrhythmogenic substrate.
Due to the high spatial resolution of ex vivo MRI, myocardial scarring can be characterized with an almost histological
precision (S5.4.36,S5.4.37). Therefore, LGE-CMR is often
referred to as the gold standard for scar assessment. Unfortunately, a clinical CMR study obtained for a patient has a much
lower spatial resolution due to the motion of the beating heart
compared with an ex vivo MRI. Several studies have reported
on the accuracy of CMR-deﬁned scar by correlating CMRdeﬁned scar with areas of low voltage from EAM data (S5.
4.10–S5.4.17). Although differences exist between these
studies, there is general agreement between imaging deﬁned
scar and the abnormal substrate deﬁned by EAM. Important
limitations of the EAM-deﬁned substrate, however, need to
be kept in mind, and there is mounting evidence for improved
procedural outcomes with an imaging-guided ablation
compared with an EAM-guided ablation approach (S5.4.
7–S5.4.9). EAM-derived data reﬂect the 3D surface of the
myocardium and lack information about the 3D anatomical
and pathological integrity of the heart. Hence, CMR offers a
more comprehensive assessment of the entire heart, especially
of the intramural and epicardial myocardium, which is difﬁcult, if not impossible, to assess with endocardial voltage
mapping alone. Lack of adequate catheter contact with the
myocardium can further impact on accuracy of EAM. These
limitations can be overcome by integrating the CMR data
into the EAM. Accurate registration of the CMR with the electroanatomical map is of critical importance to have reliable information about location and extent of myocardial scarring.
The information about scar location has been supplemented
by further characterization of the tissue heterogeneity within
the scar that contains the surviving myoﬁber bundles as the arrhythmogenic substrate (S5.4.38–S5.4.40).
Two methods have been described to characterize tissue
heterogeneity: the SD method, which uses the remote, unenhanced myocardium as a reference, deﬁning scar if the signal
intensity is above normal myocardium (usually .2–3 SD)
(S5.4.11,S5.4.12,S5.4.41); and the signal intensity method
(full-width at half maximum technique), which uses .50%
of the maximal signal intensity within a region of interest
to deﬁne scar. Various cutoff values have been used to
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distinguish the border zone from the scar core and have been
correlated with outcomes (S5.4.38–S5.4.40). Controversy
exists, however, about which of the methods and which of
the cutoff values is preferable for assessment of tissue
heterogeneity. It is important to note that quantiﬁcation of the
border zone still awaits histologic validation. Limitations of
LGE-CMR include the limited spatial resolution that is in the
1- to 2-mm range, making it difﬁcult to characterize tissue heterogeneity if the wall thickness is in this range. This, among
others, is one of the reasons why the assessment for LGE in
the thinner RV is challenging when using standard LGECMR techniques. In the past, CIEDs have been considered to
be contraindications for CMR. This is no longer the case, and
provided that certain precautions are followed, CMR has
been shown to be safe in several studies (S5.4.33) and registries
(S5.4.31,S5.4.32). However, in the presence of a CIED,
artifacts from the device generator, especially from ICDs, can
obscure the myocardium and render a CMR study
completely or partially nondiagnostic (S5.4.42). It is therefore
recommended to perform CMRs prior to ICD implantation.
The prevalence and extent of artifact can be minimized by
wideband CMR sequences (S5.4.43). CMR in patients with
NICM has been particularly helpful despite the presence of
ICDs, and improved outcomes have been described in patients
who underwent CMR prior to VT ablation procedures (S5.4.
7–S5.4.9).
The advantage of multidetector cardiac CT (MDCT) over
LGE-CMR is the higher spatial resolution that is in the submillimeter range. Various MDCT characteristics indicative
of scarring have been described, including a degree of wall
thinning with a cutoff wall thickness of ,5 mm (S5.4.22),
hypoattenuation (S5.4.20), and delayed enhancement
(S5.4.19). More recently, thanks to the higher spatial resolution of MDCT, thicker ridges of tissue separating areas of
thinning have been described within the myocardial scar
harboring the majority of VT target sites in patients post
infarction (S5.4.18). Hence, MDCT imaging has been found
to be beneﬁcial as an alternative to CMR to indicate the location of myocardial scarring, especially in the presence of contraindications for CMR. Although assessment of wall
thickness in MDCT imaging has been used successfully in
patients with prior infarctions, the ability to identify scarring
based on wall thickness alone has been less successful (S5.4.
21,S5.4.44) in patients with NICM, and might require a
different approach (S5.4.19). MDCT is the imaging technique of choice for preprocedural imaging of the coronary arteries, the coronary veins, and the phrenic nerve. The ability
to image the coronary arteries in conjunction with the ability
to image epicardial fat thickness has been especially valuable
for epicardial ablation procedures to enhance safety and to
quantify epicardial fat thickness covering potential epicardial
VT target sites (S5.4.45,S5.4.46).
Nuclear imaging for the purpose of facilitating VT
ablation procedures has been described for PET and singlephoton emission computerized tomography (SPECT) scanning, using CT for image integration. Although there is a correlation between PET/CT deﬁned scar and EAM (S5.4.23,
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S5.4.24), the correlation of SPECT perfusion imaging with
low-voltage areas on EAM is lower (S5.4.47). It is intriguing
that metabolically active areas corresponding to critical VT
sites have been identiﬁed; however, they might not correspond to areas of low voltage on the EAM (S5.4.23). Furthermore, sympathetic denervation can be imaged using tracers,
such as 11C-meta-hydroxyepinephrine and iodine-123metaiodobenzylguanidine. Regional sympathetic denervation has been recognized as an imaging marker for an
increased risk of sudden cardiac death (S5.4.48). Viable but
denervated myocardium has been shown to be particularly
sensitive to development of arrhythmias (S5.4.49,S5.4.50).
Klein et al. (S5.4.51) have demonstrated that critical VT ablation sites were located in denervated areas, some of which
were located in areas with preserved bipolar voltage.
Finally, echocardiography is typically used to rule out
the presence of cardiac thrombi (S5.4.27,S5.4.28) prior
to an ablation in patients with SHD in whom
catheter manipulation in the LV is anticipated. Although
transthoracic echocardiography has been beneﬁcial in
identifying intracardiac thrombi (S5.4.1–S5.4.3), the use of
contrast has been shown to further increase the yield of
cardiac thrombi (S5.4.4,S5.4.29) and should be used if the
LV endocardium is not well visualized. Although ablation
procedures might be safe in the presence of laminated
thrombi (S5.4.52), it would be prudent in the absence of an
urgent indication for VT ablation, and especially in the presence of a mobile thrombus, to anticoagulate the patient for a
period of time and reassess for LV thrombus prior to the ablation procedure. Not every patient has optimal echocardiographic windows that allow for comprehensive assessment
of the entire endocardium to rule out LV thrombi, even if
sonographic contrast is used. LGE-CMR and Cine-CMR
are alternative imaging techniques that have a higher accuracy in identifying myocardial thrombi (S5.4.5,S5.4.6,S5.4.
30), which should be kept in mind, particularly in patients
for whom transthoracic echocardiography is considered
insufﬁcient to rule out an LV thrombus. The sensitivity of
ICE for detection of LV thrombus has not been
systematically studied, but it can provide real-time assessment immediately before catheter placement. To minimize
the risk of thromboembolic events for patients with concomitant AF, a preprocedural transesophageal echocardiogram
will be helpful to exclude a left atrial thrombus if a cardioversion is required during the ablation procedure (S5.4.27).
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5.5. Patient Preparation
Heart failure, electrolyte abnormalities, and myocardial
ischemia should be adequately treated and controlled, if
possible, before the patient is subjected to an invasive electrophysiology study. Similarly, associated SHDs should be clearly
deﬁned, given that patients with conditions such as severe LV
systolic dysfunction, severe coronary artery disease, critical
aortic stenosis, and advanced renal impairment might not
tolerate induction of arrhythmia, prolonged procedures, or ﬂuid
overload resulting from the use of saline-irrigated catheters.
Although some of these conditions can be optimized prior to
an elective procedure, this is often not possible for more emergent procedures. In these cases, a substrate-based ablation
approach without repeated VT inductions might be preferable.
AADs, with the exception of amiodarone, should, if at all
possible, be discontinued for at least 5 half-lives prior to the
ablation procedure. This is almost mandatory for cases in
which the primary strategy of mapping is not substratebased, but it might not be possible for emergency cases.
Oral anticoagulants are generally discontinued prior to the
ablation to achieve an international normalized ratio ,1.5 at
the time of the study. Direct oral anticoagulants should be
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withheld for 24–48 hours before the procedure, depending
on anticipated access, and bridging with heparin can be used
for patients with mechanical heart valves or other features
that place them at high risk of thrombosis. The majority of
the writing committee (60%) usually use bridging in patients
with mechanical valves, where possible, but many distinguish
between mechanical aortic valves, in which transseptal access
with continued anticoagulation can be used, and mechanical
mitral valves, in which retrograde access is used. For elective
procedures, imaging with ultrasound can help to deﬁne the
feasibility of an arterial closure device, and therefore
continued anticoagulation. Routine perioperative bridging in
patients with AF who interrupted warfarin for procedures,
including percutaneous transvascular procedures, was noninferior to no bridging in a large RCT with respect to the occurrence of thromboembolic events (S5.5.1). Approximately half
of the writing committee do not use bridging in similar patients, and a further 20% do not use bridging in patients taking
direct oral anticoagulants.
Informed consent needs to be obtained from the patient or
his or her surrogate after discussing the risks and beneﬁts
involved in the procedure, as well as alternatives. The patient
should fast overnight or for at least for 6 hours prior to the
procedure (S5.5.2,S5.5.3).
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Section 6 Intraprocedural Patient Care
6.1. Anesthesia
Recommendations for anesthesia during catheter ablation of VA
COR

LOE

Recommendations

I

C-EO

I

C-EO

IIa

C-LD

IIb

B-NR

1. Provision of variable depth of sedation, analgesia, and anesthesia during mapping and
ablation of VA is recommended.
2. In patients undergoing VA ablation, careful preprocedural assessment is indicated to
deﬁne the ideal strategy for sedation and analgesia.
3. It is reasonable to avoid general anesthesia and deeper levels of sedation in patients
with idiopathic VA, particularly if the arrhythmia is suspected to be catecholaminesensitive or was not inducible at a prior procedure.
4. Moderate to deep sedation under close hemodynamic and respiratory monitoring might
be considered for VA ablation in stable patients with idiopathic or scar-related VAs
expected to have a longer procedure or undergo a painful technique, such as epicardial
access.
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Recommendation-Speciﬁc Supportive Text
1. The American Society of Anesthesiologists deﬁnes levels
of sedation in a continuum, varying from minimal sedation (anxiolysis), to moderate sedation or analgesia
(conscious sedation), to deep sedation or analgesia, to
general anesthesia (S6.1.4). Careful preprocedural assessment is indicated to deﬁne the ideal strategy for sedation
and analgesia based on age and comorbidities, targeted
arrhythmia, planned procedure, risk for airway obstruction, and patient wishes. General anesthesia ensures patient comfort that facilitates vascular and especially
epicardial access, and also ensures immobility during
catheter manipulation for mapping and ablation, especially for procedures of long duration. However, a major
disadvantage of general anesthesia is its potential suppression of VA. Elimination of mental stress and the related
changes in the autonomic tone during general anesthesia
or deep sedation can potentially decrease the spontaneous
manifestation of catecholamine-sensitive VA and the induction/maintenance of reentrant VT (S6.1.5–S6.1.8).
Inhaled anesthetics that prolong action-potential duration
and ventricular refractoriness (sevoﬂurane and isoﬂurane)
and intravenous anesthetics that reduce sympathetic tone
(dexmedetomidine) are commonly avoided for ablation
procedures (S6.1.5,S6.1.6). Additionally, most of the
anesthetic agents used for sedation and analgesia reduce
myocardial contractility and systemic vascular
resistance, causing hypotension that could be
exacerbated during VT, requiring pharmacological or
mechanical HS. Those cardiovascular effects are more
intense at the anesthetic doses needed for general
anesthesia, which additionally produce higher
attenuation of sympathetic tone. General anesthesia or
the use of cardiodepressive medications, such as
propofol for anesthesia in patients with severely
compromised LV function, can result in acute
hemodynamic compromise during the ablation
procedure, and its use needs to be carefully considered
for these patients. If general anesthesia is used during
epicardial ablation procedures, the concomitant use of
muscle relaxants could preclude identiﬁcation of the
phrenic nerve during epicardial ablation. Use of a shortacting muscle relaxant during induction of anesthesia is
acceptable, without redosing; however, it could necessitate a deeper level of anesthesia with resultant exaggeration of the above-mentioned hypotensive effects.
Nevertheless, the effects of propofol on cardiac electrophysiological proprieties are diverse and could include
arrhythmia suppression. In fact, propofol has been associated with suppression of VT and VT storm (S6.1.7).
The need for sedation and analgesia varies throughout the
procedure, being higher during vascular and epicardial ac-
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cess and cardioversion or deﬁbrillation. On the other hand,
a more superﬁcial level of sedation (or any) is desirable to
prevent VA suppression and to assure VT induction and
maintenance for mapping. Short-acting agents are considered more suitable to provide those rapid changes in the
requirements of sedation level during mapping and ablation of VAs (S6.1.9). Intravenous boli of midazolam and
fentanyl at repeated doses as needed was reported by a
single-center observational study as a feasible and safe
strategy for minimal sedation in patients with idiopathic
PVC or VT planned for shorter procedures (S6.1.1). However, even shorter-acting sedatives such as midazolam
have the potential for suppressing idiopathic VA for prolonged periods of time and need to be used with caution
during procedures targeting idiopathic VAs, such as
frequent PVCs. A strategy to use shorter-acting sedatives
such as propofol for allowing temporary deeper sedation
is frequently used initially, and if VAs are suppressed,
sedation can be reduced or discontinued to allow for arrhythmias to reappear as necessary. For patients with
scar-related VTs, sedatives such as midazolam, which
has the additional beneﬁt of amnesia, do not impact on
inducibility of VT and can be used in conjunction with analgesics and/or other sedatives such as propofol to achieve
the desired level of sedation. Continuous infusion of propofol, alone or complemented with repeated boli of fentanyl (as needed), has been proposed for deep sedation of
stable patients during ablation of idiopathic or scarrelated VT that are expected to have a longer duration or
that require more painful and challenging techniques,
such as epicardial access. Two single-center observational
studies reported that this strategy can be safely performed
in this subset of patients under close hemodynamic monitoring (S6.1.1,S6.1.2). Propofol had to be discontinued
(switched to midazolam) in 11.7% of the procedures,
predominantly due to hypotension presenting in elderly
patients and prolonged procedural duration (S6.1.2). Respiratory depression resulting in sustained oxygen saturation of ,90% requiring reduction of propofol and
transitory mechanical maneuvers to assist ventilation
was present in 1.5% of the patients in the same study.
2. The selection of sedation strategy for patients undergoing
ablation of VAs requires a balance between the desire of
assuring a comfortable and safe procedure and the need
to induce the targeted arrhythmia (S6.1.9). Proactive
communication between the operator and the anesthesia
team and with the patient about the patient’s needs and desires, as well as the electrophysiological requirements,
helps to select a sedation strategy that is in the best interest
of the patient.
3. In the prospective arm of a large observational study, in
which patients with sustained, monomorphic VT and
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SHD underwent noninvasive programmed stimulation
(NIPS) under minimal sedation, followed by invasive programmed stimulation under general anesthesia using propofol or isoﬂurane, .90% remained inducible under
general anesthesia, although in half, a different VT was
induced (S6.1.10). General anesthesia was associated,
however, with less hemodynamic stability and greater
use of vasopressor support with phenylephrine, without
an adverse effect on procedural outcomes. More aggressive stimulation was often required with general anesthesia than with conscious sedation (S6.1.10). In another
cohort of 25 patients referred for epicardial ablation in
the setting of NICM, a strategy of initial programmed
stimulation under sedation with midazolam, fentanyl, or
remifentanil led to induction of tolerated VT in 15 patients, and avoidance of epicardial access (which was performed under general anesthesia) altogether occurred in
10 (40%) (S6.1.3).
On the basis of the cited single-center observational
studies (S6.1.1–S6.1.3,S6.1.5–S6.1.11) about the
various sedative and analgesic strategies for ablation of
VAs, it is reasonable to avoid general anesthesia and
deeper levels of sedation in patients with idiopathic VAs
(PVC or VT) planned for shorter procedures,
particularly when the arrhythmia is suspected to be
catecholamine-sensitive (typically, automatic and triggered arrhythmias) or was not inducible during a prior
procedure. In these patients, a minimal sedation strategy
with short-acting sedatives and analgesics, with repeated
doses as needed, can be useful to ensure adequate sedation
without VA suppression.
4. Epicardial scar-related VT mapping and ablation under
deep sedation with sufentanil or remifentanil and intermittent boli of midazolam was reported as a feasible and safe
strategy in a single-center prospective series and a case
report (S6.1.9,S6.1.11). Interestingly, no respiratory
failure resulting in endotracheal intubation or prolonged
periods of hypotension requiring HS were observed
(except during periods of unstable VT) in these cases
(combined 79 procedures in 73 patients). Importantly,
this strategy allowed epicardial access with comfort,
preventing the need for general anesthesia and muscle
relaxants (facilitating the identiﬁcation of the phrenic
nerve during epicardial ablation), and providing rapid
recuperation of consciousness with no recall of
punctures or cardioversions. Remifentanil is an opioid
with an analgosedative effect that can have advantages
for ablation of VAs, including a lack of negative
inotropic effect, comparatively little effect on
arrhythmogenicity, time-to-peak effect of approximately
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90 seconds and a half-life of 3–4 minutes (S6.1.9). This
agent is also associated with hypotension likely secondary
to vasodilatation and bradycardia.
Moderate to deep sedation with continuous infusion of
propofol and repeated boli of fentanyl under close hemodynamic and respiratory monitoring might be considered
for stable patients with ablation of idiopathic or scarrelated VA with no indication for general anesthesia
who are expected to undergo a procedure of longer duration or for patients who require more painful techniques,
such as epicardial access. Another short-action anesthetic,
such as remifentanil or sufentanil, could also be considered. Of note, patients with severe hemodynamic compromise, severe life-threatening comorbidities or acute
illness, respiratory failure, high risk for airway obstruction, or who were intubated before the procedure for
arrhythmia storm or cardiogenic shock were excluded in
the cited studies and are also traditionally considered candidates for general anesthesia. Hospital and regulatory
guidance varies widely on the training and specialization
required for different levels of sedation and administration
of various drugs (see Section 11).
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6.2. Vascular Access
Recommendation for vascular access during catheter ablation of VA
COR

LOE

I

B-NR

Recommendation

References

1. Ultrasound-guided femoral arterial and venous access is recommended to reduce
the incidence of vascular access complications during VA ablation.

S6.2.1–S6.2.5

Recommendation-Speciﬁc Supportive Text
1. Signiﬁcant vascular complications occur in approximately
2% of VT ablation procedures (S6.2.6), which are further
detailed in Section 10. Ultrasound-guided femoral arterial
and venous access has been widely implemented in electrophysiological procedures in an effort to reduce vascular
complications. Several observational studies of electrophysiological procedures, mostly examining AF ablation,
one RCT, and a meta-analysis have shown an association
of ultrasound guidance with a reduction in major and minor vascular access complications and bleeding (S6.2.
1–S6.2.4). One observational study reported the rate of
major complications in the subgroup undergoing VA
ablation, which was 8.9% in the conventional group and
0% in the ultrasound-guided group (S6.2.1). In a single
RCT in patients undergoing AF ablation, ultrasound guidance reduced time, additional punctures, arterial puncture,
and unsuccessful access. Although it increased ﬁrst pass
success, however, it was underpowered for the primary
endpoint of major vascular access complications due to
a lower than expected observed complication rate
(S6.2.3). Similarly, a meta-analysis of nonrandomized
controlled trials of ultrasound- vs ﬂuoroscopy- or
palpation-guided femoral arterial access found it was
associated with a reduction in the number of attempts
and vascular complications (S6.2.4). An RCT of ultrasound- vs ﬂuoroscopic-guided retrograde femoral arterial
access in patients undergoing angiography or interventional procedures found that ultrasound guidance reduced
the number of attempts, time to access, risk of venipuncture, and vascular complications (S6.2.5).
Synopsis
For VA ablation, standard percutaneous vascular access techniques are used. The choice of peripheral vascular access depends upon several factors, including the arrhythmia’s SOO,
the location of any substrate identiﬁed on pre- or intraprocedural imaging, the patient’s anatomy, and the presence of
peripheral vascular disease or venous occlusion or agenesis.

LV access can be achieved through either retrograde transaortic or antegrade transseptal approaches, depending on patient speciﬁcs and operator preference, the latter especially in
the presence of mechanical aortic valve replacement or severe aortic or peripheral vascular disease. Although most
areas of the endocardial LV can be accessed by either
approach, the degree of contact force can vary (eg, contact
force was signiﬁcantly higher transseptally in the midanteroseptum, mid-lateral, and apical segments, and signiﬁcantly higher with a retrograde approach in the basalanteroseptum, basal-inferoseptum, basal-inferior, and the
basal-lateral segments) (S6.2.7). If a retrograde access to
the LV endocardium has been chosen, the use of long sheaths
can be helpful in the presence of tortuosity of the iliac arteries
or the distal aorta. Once vascular access has been obtained,
heparin can be administered to prevent clotting of the
sheaths.
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6.3. Epicardial Access
Recommendations for epicardial access for catheter ablation
COR

LOE

Recommendations

I

C-EO

I

C-EO

I

C-EO

I

C-EO

1. In patients undergoing epicardial VT ablation, imaging of the epicardial coronary
arteries by coronary arteriography or coronary CT angiogram prior to ablation is
recommended to reduce the risk of arterial injury.
2. In patients undergoing epicardial VT ablation via a percutaneous approach,
provision for immediate echocardiography, blood transfusion, and onsite
cardiothoracic surgical backup is recommended.
3. In patients with prior cardiac surgery or pericardial adhesions for whom epicardial
VT ablation via a percutaneous approach is considered, careful assessment of the
risk/beneﬁt ratio and alternative therapies such as surgical dissection are
recommended.
4. In patients undergoing epicardial VT ablation, pacing with high stimulus intensity
from the ablation electrode to rule out diaphragmatic stimulation is
recommended to avoid phrenic nerve injury.

Recommendation-Speciﬁc Supportive Text
1. Inadvertent injury to an epicardial coronary artery can
occur by puncture or laceration with a needle and is recognized by aspiration of arterial blood from the pericardial
space. Arterial injury can require arterial stenting or surgical repair. In addition, application of RF current within 5
mm of an epicardial coronary artery can result in stenosis,
spasm, or occlusion of the vessel (S6.3.4.1–S6.3.4.3).
Because of the risk of arterial injury, imaging of the
coronary arteries with arteriography is essential. The use
of other coronary artery imaging techniques assumes
that an adequate registration of imaging data has been
accomplished. Hence, coronary angiography is the
preferred technique.
2. Epicardial ablation requires considerable preparation
prior to the procedure. Major complications occur in
approximately 5% of epicardial ablation procedures
(S6.3.4.4). Unintended puncture of the RV can occur in
up to 17% of cases (S6.3.4.4), although bleeding is usually self-limited provided that a sheath has not been
introduced through the RV free wall. The patient’s
blood should be typed and cross-matched for immediate
transfusion should signiﬁcant bleeding occur. Because
bleeding within the pericardial space is common, intracardiac or transthoracic echocardiography should be immediately available. In addition, cardiothoracic surgical
backup should be readily available. A potentially serious
complication of percutaneous subxiphoid transpericardial
puncture is laceration of the liver or intra-abdominal
arteries. Thus, unexplained hypotension should
prompt imaging of these structures to evaluate possible
intra-abdominal bleeding that could necessitate surgical
repair.
3. The presence of pericardial adhesions can severely restrict
the ability to maneuver a guidewire or catheter within the
pericardial space. Thus, patients with prior cardiac surgery or a history of pericarditis can present signiﬁcant
challenges for epicardial ablation. Although dissection
of pericardial adhesions using a guidewire, deﬂectable
catheter, or deﬂectable sheath can be useful to allow

epicardial mapping (S6.3.4.5–S6.3.4.7), access to the
entire epicardial surface might not be possible, and
loculated pericardial effusions that are challenging to
drain percutaneously can occur in this setting. A
planned surgical dissection of pericardial adhesions can
allow dense adhesions to be safely lysed and allow
epicardial ablation in selected cases (S6.3.4.8,S6.3.4.9).
4. Damage to the phrenic nerves can occur if the ablation
electrode lies adjacent to these structures (S6.3.4.10)
and can be minimized by pacing from the ablation electrode using high stimulus intensity to identify phrenic
nerve stimulation. If phrenic nerve stimulation is observed
during pacing, mechanical means to protect the phrenic
nerve might be required, such as inﬂation of an intrapericardial balloon (S6.3.4.11).

6.3.1. Background
VA can originate from the endocardium, the midmyocardium, or might involve the epicardium. The latter is particularly true for patients with NICMs, including idiopathic
DCM (S6.3.4.12–S6.3.4.14), ARVC (S6.3.4.15–S6.3.4.19),
myocarditis (S6.3.4.20), sarcoidosis (S6.3.4.21,S6.3.4.22),
and ChD (S6.3.4.23–S6.3.4.26), as well as Brugada
syndrome (S6.3.4.27–S6.3.4.30). Also, for patients with
VT following MI, the arrhythmogenic substrate can be
located in the midmyocardium or in the subepicardial
region (S6.3.4.31–S6.3.4.36). Finally, idiopathic VA can
originate from the LV epicardium (S6.3.4.37–S6.3.4.40).
The percutaneous technique for epicardial mapping and
ablation in patients with Chagas cardiomyopathy (CCM)
was described by Sosa et al. in 1996 (S6.3.4.23). Since that
initial description, epicardial ablation has become an important technique to effectively treat VA in a variety of diseases.
Despite mapping data implicating an epicardial origin of
postinfarction VT in up to one-third of cases (S6.3.4.31,S6.
3.4.32,S6.3.4.41), epicardial ablation procedures are
typically performed in only a small minority of patients
post infarction. This is most likely due to the predominant
endocardial involvement of postinfarction scarring and the
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three-dimensionality of reentry circuits that can include the
endocardium. The anatomical distribution of post-MI epicardial VTs is highly associated with infarctions in the distribution of the left circumﬂex or right coronary arteries
(S6.3.4.42). The prevalence of epicardial VT in patients
with NICMs appears to be signiﬁcantly higher than for VT
following MI (S6.3.4.13,S6.3.4.43,S6.3.4.44). The site of
scarring and slowed conduction supporting VT in NICM is
most often located on the epicardial surface of the basal
lateral LV (S6.3.4.43,S6.3.4.44). Thus, epicardial ablation
is an important technique to address VT in a variety of
SHDs, particularly in those with NICM.
6.3.2. Criteria Suggesting Epicardial Substrate
Several factors suggest an epicardial substrate for VT,
including the anatomical location of scar on CMR or CT imaging (S6.3.4.12,S6.3.4.45,S6.3.4.46), unipolar voltage
mapping from the endocardium (S6.3.4.14), and the lack of
identiﬁable scarring or regions of slow conduction with endocardial mapping. The presence of a subepicardial or midmyocardial scar with contrast-enhanced CT or CMR is a valuable
tool to identify potential epicardial substrates for VT and correlates with voltage mapping (S6.3.4.45,S6.3.4.46).
Preprocedural imaging is therefore useful to select patients
for epicardial mapping and ablation and to guide the
operator to the regions of interest. The surface ECG (S6.3.
4.47–S6.3.4.51) during VT provides important clues to an
epicardial origin, including the presence of a pseudo-delta
wave (34 ms in duration) in the precordial leads, an intrinsicoid deﬂection to the peak of the R wave in lead V2 85
ms, and an RS duration of 121 ms, although with limited
speciﬁcity in patients with ICM (S6.3.4.47,S6.3.4.48). An
ECG algorithm to identify epicardial VT in patients with
NICM includes the absence of Q waves in the inferior
leads with either pseudo-delta waves (75 ms), a maximum
deﬂection index 0.59, or a Q wave in lead I (S6.3.4.51). The
reported sensitivity and speciﬁcity of these criteria to predict
successful epicardial ablation in NICM can exceed 90%
(S6.3.4.51). ICE has also been shown to be useful for identifying epicardial scar as VT substrate with increased echogenicity strongly correlating with the results of EAM
(S6.3.4.52). Although the origin of epicardial VTs in patients
with SHD depends on scar location, in patients without SHD,
the SOO is often in close proximity to the mitral annulus and
the LV summit. This area can be reached and mapped via the
coronary venous system. Scar-related VTs are often beyond
the reach of the coronary venous system and hence require
different access to the pericardial space.
6.3.3. Epicardial Access Technique
Access to the epicardium is most often achieved with a subxiphoid, transpericardial puncture using either a 17–18gauge, 6-inch Tuohy or similar needle with a beveled tip
(S6.3.4.23), a thinner 21-gauge needle (S6.3.4.53), or a
needle-in-needle technique (S6.3.4.53,S6.3.4.54). Threequarters of the writing committee who perform epicardial
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access use a Tuohy needle, whereas the rest use the needlein-needle technique. The latter approach uses a 7-cm, 18gauge needle for support while puncturing the skin and subcutaneous tissues, while a longer (15–20-cm) 21-gauge
micropuncture needle is inserted through the 18-gauge needle to puncture the parietal pericardium (S6.3.4.54). With
either approach, small amounts of radiographic contrast are
injected to conﬁrm that the needle is within the pericardial
space and that contrast moves freely within this space. A
long guidewire is then advanced through the needle, with
care taken to ensure that it moves freely to surround the cardiac silhouette. The angle of entry into the pericardial space
can be either anterior, in which case the guidewire travels superiorly over the free wall of the RV, or posterior (inferior
approach), in which the guidewire travels beneath the LV
inferior wall before traveling superiorly toward the posterobasal LV. Transpericardial access should be guided by ﬂuoroscopy, including a steep left anterior oblique or lateral
view; the latter being useful for an anterior access. Once successful entry within the pericardial space is achieved, a sheath
is advanced over the guidewire, allowing the mapping and
ablation catheter to be moved across the epicardial surface.
Percutaneous subxiphoid access to the pericardial space
might not be feasible in patients with dense pericardial adhesions, including patients with prior cardiac surgery, previous
pericarditis, or prior epicardial ablation procedures (S6.3.4.
5–S6.3.4.7). For these patients, a limited thoracotomy with
a small subxiphoid or larger left lateral thoracotomy might
be required that allows for manual lysis of adhesions and
control of bleeding (S6.3.4.8,S6.3.4.9). Thus, a
collaborative approach with a cardiothoracic surgeon and
an electrophysiologist might be required for patients in
whom a percutaneous approach is not feasible because of
pericardial adhesions. The presence of less extensive
pericardial adhesions can be approached percutaneously,
using a deﬂectable catheter and sheath for adhesion lysis.
Insufﬂation of carbon dioxide or contrast via intentional
exit into the pericardial space from the right atrium
(S6.3.4.55) or coronary venous system (S6.3.4.56) could
have a role in determining the extent of adhesions in patients
with prior cardiac surgery (S6.3.4.55) and can facilitate
epicardial access; however, further study is required.
Catheter ablation on the epicardial surface is usually performed with irrigated RF current, though cryoablation has
also been reported (S6.3.4.57–S6.3.4.61). Use of a low
irrigation ﬂow rate (5–7 mL/min) appears to result in a
similar lesion size as the higher ﬂows used in endocardial
ablation while limiting intrapericardial ﬂuid accumulation,
which reduces lesion size (S6.3.4.58). Frequent aspiration
of irrigant is also important to prevent hemodynamic
compromise. The use of contact force-sensing catheters can
improve orientation of the ablation electrode so that current
is directed toward the epicardial surface rather than toward
the parietal pericardium (S6.3.4.62–S6.3.4.64). Epicardial
fat .5 mm in thickness results in reduced electrogram
voltage and increased stimulation threshold, and could limit
the depth of RF lesions (S6.3.4.41,S6.3.4.65–S6.3.4.70).

Cronin et al. Catheter Ablation of Ventricular Arrhythmias
Epicardial fat is typically clustered along the course of
epicardial coronary arteries, within the AV grooves, and
along the free wall of the RV.

6.3.4. Epicardial Access Complications
The complications of epicardial ablation are important to
consider. Major complications have been reported in approximately 5% of patients (S6.3.4.4,S6.3.4.44). The most
common complication of epicardial mapping and ablation
is pericarditis, which can occur in over 20% of patients
(S6.3.4.44). The use of systemic or intrapericardial steroids
can decrease the risk and severity of pericarditis (see
Section 10.1). Inadvertent puncture of the RV can occur in
up to 17% of cases and usually results in self-limited bleeding
of ,80 cc venous blood (S6.3.4.4). Avoidance of dual antiplatelet therapy can reduce periprocedural bleeding during
epicardial ablation. Inadvertent puncture of the RV can be
recognized if a guidewire can be advanced into the pulmonary artery. This is managed by withdrawing the guidewire
from the RV, withdrawing the needle, and readvancing
the wire until the pericardial space is accessed. If the
needle enters and then exits the RV before pericardial access
is obtained, a “through and through” puncture of the RV can
result. In this case, hemodynamic collapse might occur
only on removal of the sheath at the end of the procedure.
This complication can be detected when bleeding occurs
after withdrawal of the pericardial sheath with the guide
wire still in place. It is recommended to advance a guide
wire into the pericardial space prior to sheath removal
and to observe the puncture site for bleeding before
removing the guide wire. Other complications of percutaneous, subxiphoid pericardial access include laceration or
puncture of an epicardial coronary artery or vein (which
could necessitate coronary stenting or surgical repair),
RV pseudoaneurysm, and coronary spasm (S6.3.4.71).
RF current that is applied within 5 mm of an epicardial
coronary artery can produce occlusion, spasm, or stenosis
of the artery (S6.3.4.1–S6.3.4.3). Because of this risk,
imaging of the coronary arteries with arteriography or
preprocedural CT angiography is essential to accurately
localize the ablation electrode relative to the position of
the coronary arteries. The left phrenic nerve has a
variable course and can be damaged by RF or
cryoablation energy (S6.3.4.10,S6.3.4.11). Preprocedural
imaging (see Section 5) has been particularly helpful to
display the anatomical course of the coronary arteries and
the phrenic nerve, thereby preventing damage to these structures. Reliance on imaging only, however, might cause
damage to these structures in case of imperfect image registration. Also, pacing from the ablation electrode with high
stimulus intensity prior to ablation should be performed to
exclude phrenic nerve stimulation. In some cases in which
the ablation target is in close proximity to the phrenic nerve,
a balloon or steerable catheter can be advanced into the
pericardial space to shield the nerve from ablation-related
injury (S6.3.4.10,S6.3.4.72); the use of air and ﬂuid in the
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pericardial space has also been reported to reduce the risk
of phrenic nerve damage (S6.3.4.11). Of note, the presence
of air in the pericardial space can increase the deﬁbrillation
threshold, requiring emergent decompression or internal
deﬁbrillation if deﬁbrillation is required (S6.3.4.73).
Esophageal injury can also occur if ablation is performed
in the posterior LV (S6.3.4.74–S6.3.4.76). Although the
exact mechanism and risk factors are unclear, esophageal
temperature monitoring might be warranted before ablating
near the esophagus. A signiﬁcant complication of
subxiphoid transpericardial access is bleeding within the
abdomen from laceration of the liver or an intra-abdominal
artery (S6.3.4.71). Unexplained hypotension during or after
epicardial ablation should lead to prompt investigation of
possible intra-abdominal bleeding, which could require surgical repair.
Because of the many important complications that can
occur with epicardial ablation, extensive experience with
this procedure is required. Careful preprocedural planning
is essential, including immediate access to echocardiography,
imaging of the coronary arteries, provision for immediate
blood transfusion of cross-matched blood, and backup
cardiothoracic and general surgical support.
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6.4. Intraprocedural Hemodynamic Support
Recommendations for catheter ablation of VA with mechanical HS
COR

LOE

Recommendations

I

C-EO

IIa

B-NR

IIb

B-NR

1. In select patients at risk of requiring HS, a decision to proceed with catheter
ablation of VA should be made in collaboration with specialists in advanced heart
failure management.
2. In select patients, HS with a percutaneous VAD and extracorporeal membrane
oxygenation during VT ablation can be useful to avoid acute hemodynamic
deterioration.
3. Mechanical HS may be considered in select cases to allow mapping and ablation of
unstable VTs.

Recommendation-Speciﬁc Supportive Text
1. In patients with VAs and severe comorbidities, incessant or
recurrent VTs treated by multiple ICD shocks might cause
end organ hypoperfusion and further deterioration in cardiac function (S6.4.8,S6.4.9). Planning for a VA ablation
procedure, in which there is a signiﬁcant risk that it will
be complicated by hemodynamic deterioration, should
involve specialists in heart failure. The patient’s values
regarding the various temporary and permanent HS
options and their feasibility should be considered.
2. Data about strategies for HS during VT ablation are available from single and multicenter, nonrandomized, retrospective, and observational trials, which have
demonstrated feasibility and safety (S6.4.1–S6.4.6).
Mapping of nontolerated VTs can be performed for
longer periods of time when HS with either percutaneous

References

S6.4.1–S6.4.7
S6.4.1–S6.4.6

left ventricular assist device (pLVAD) (Tandem Heart,
CardiacAssist, Pittsburgh, PA; and Impella, Abiomed,
Danvers, MA) or extracorporeal membrane oxygenation
is performed as opposed to no support or intra-aortic
balloon pump (IABP) (S6.4.1,S6.4.2). A large
retrospective multicenter report, however, has
demonstrated that the use of HS was associated with
higher acute ablation failure rates, increased
periprocedural complications, higher mortality, and a
higher rate of VT recurrence (S6.4.6). It is possible that
HS was used in patients with more severe disease in this
study, and outcome data were similar between the HS and
no HS groups compared with patients with severely
compromised EF (20%) and advanced heart failure
(NYHA class III and IV). Hence, the use of HS in these patients needs to be carefully considered. Of note, data
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supporting HS as a bailout strategy during or right after VT
ablation are poor and do not demonstrate a beneﬁt for procedural outcomes and survival (S6.4.3,S6.4.5,S6.4.7).
3. The beneﬁt of HS to allow mapping of unstable VTs needs
to be weighed against the potential detrimental effects of
HS, depending on the type of support that is used,
including vascular damage due to large-bore venous and
arterial access sites, among others (S6.4.1). Prevention
of hemodynamic deterioration during the ablation procedure by cautious use of cardiodepressive medications such
as propofol could obviate the necessity for HS; also, the
use of general anesthesia has been identiﬁed as a factor
associated with hemodynamic deterioration and needs to
be carefully considered in patients with severely impaired
myocardial function. Adequate patient selection using
risk assessment algorithms (see Section 5) could help to
identify patients for whom HS might be beneﬁcial.
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6.5. Intraprocedural Anticoagulation
Recommendations for intraprocedural anticoagulation
COR

LOE

I

B-NR

I

C-EO

IIa

C-LD

Recommendations

References

1. In patients undergoing endocardial LV catheter mapping and/or ablation,
intraprocedural systemic anticoagulation with intravenous heparin is recommended.
2. In patients undergoing RV endocardial mapping and/or ablation who are considered
high risk for thromboembolism, intraprocedural systemic anticoagulation with
intravenous heparin is recommended.
3. In patients undergoing epicardial access after systemic heparinization, reversal of
heparin with protamine is reasonable.

S6.5.1–S6.5.6

Recommendation-Speciﬁc Supportive Text
1. Catheter ablation of VA can be associated with risk of
thrombus formation and thromboembolism. Although
the individual risk varies with type and site of ablation
and patient factors, the risk of clinically apparent stroke
or thromboembolism in patients with SHD undergoing
VT ablation in RCTs has ranged from 0% to 1.9% (S6.
5.1–S6.5.5) and is lower in patients without SHD
(S6.5.9). A small study with diffusion-weighted magnetic
resonance brain imaging demonstrated the presence of a
new brain lesion in 58% of patients undergoing LV endocardial ablation (S6.5.10). These lesions were detected in
the absence of clinically apparent stroke; no brain lesion
was identiﬁed in patients undergoing RV ablation.
Although systemic heparinization has been routine for
LV endocardial ablation since the earliest large-scale investigations, few studies have compared different
approaches to anticoagulation before, during, or after
the VT ablation procedure (S6.5.6,S6.5.7) (Table 9).

S6.5.7,S6.5.8

Systemic anticoagulation with heparin is recommended
for all procedures that last more than several minutes
involving left heart catheterization. Intraprocedural anticoagulation schemes differ between centers. Unfractionated heparin is commonly administered after sheath
insertion as an initial bolus (empirical dose 5000–
10,000 IU or 50–100 IU/kg) followed by intermittent
boli and/or continuous infusion to maintain a target activated clotting time (ACT) longer than 250–350 seconds
(S6.5.4,S6.5.6–S6.5.8,S6.5.10,S6.5.11). In a survey
regarding intraprocedural anticoagulation among the
writing committee members, for idiopathic VA, 48% of
the responders use ACT levels longer than 250 seconds,
39% longer than 300 seconds, and 13% longer than
350 seconds. For patients with SHD, 25% of the
committee members use an ACT target of 250 seconds,
58% use a target longer than 300 seconds, and 17% use
a target longer than 350 seconds. The ACT level
should be checked at 15-minute intervals until therapeutic
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anticoagulation is achieved, and then at 15- to 30-minute
intervals for the duration of the procedure. Approximately
90% of the surveyed committee members routinely check
for ACT during VT ablation procedures. Most members
use either a Hemochron ACT (Instrumentation Laboratory, Bedford, MA) or an i-STAT (Abbott Point of Care
Inc., Princeton, NJ) device for ACT monitoring. For transseptal access, heparin should be administered prior to or
immediately following the transseptal puncture. More
than 70% of the writing committee members surveyed
routinely administer heparin before the transseptal puncture, and approximately 20% use a higher target ACT
when a transseptal approach is used. Among the writing
committee members, 85% use continuous ﬂushing for
sheaths, especially if a transseptal approach is used. Heparin infusion can be discontinued once all catheters are
removed from left sided chambers. In the event of significant persistent bleeding or cardiac tamponade, protamine
should be administered to reverse heparin. In patients with
a history of heparin-induced thrombocytopenia or allergy,
a direct thrombin inhibitor, such as bivalirudin or argatroban, can be considered as an alternative for intraprocedural anticoagulation; however, limited experience
exists in patients undergoing VA ablation (S6.5.11).
2. During RV endocardial mapping, systemic anticoagulation with heparin is not necessary unless other factors
are present that increase the thromboembolic risk. The
use of heparin can, however, prevent deep venous thrombosis or pulmonary embolism, especially when a prolonged procedure with multiple venous catheters and
extensive ablation is anticipated. Similarly, patients with
a history of deep venous thrombosis, pulmonary embolism, hypercoagulable state (eg, factor V Leiden), rightto-left cardiac shunt, severe RV dilatation, and advanced
heart failure should undergo systemic anticoagulation.
Among the writing committee members, 65% reported
routine use of heparin for VT ablation procedures even
in the absence of risk factors for thromboembolism.
3. Anticoagulation is not required solely for epicardial mapping and/or ablation. If LV mapping is planned, epicardial
access can be obtained prior to LV instrumentation and
systemic anticoagulation (see Section 6.3). When epicardial access is required after therapeutic heparinization,
reversal of heparin anticoagulation with protamine is typically performed (S6.5.12,S6.5.13). Two small studies
reported epicardial access in fully anticoagulated
patients without a major increase in risk of bleeding
complications (S6.5.14,S6.5.15). When the writing
committee was surveyed about epicardial access after
full heparinization, half of the writing committee would
administer protamine for heparin reversal even when
extensive endocardial ablation had been performed,
20% would administer protamine only after limited LV
endocardial ablation, and another 20% of the writing
committee members would terminate the procedure and
schedule an epicardial ablation as a separate procedure.
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6.6. Antibiotic Prophylaxis
Prophylactic antibiotics are not generally indicated for sterile
procedures such as VA ablation (S6.6.1). However, patients
with ICDs undergoing VA ablation, in which catheters might
be in direct contact with the intravascular leads, could present
a special circumstance. No data exist to support this practice,
nor is a speciﬁc antibiotic preferred over another. Approximately 40% of the writing committee members administer
prophylactic antibiotics to patients with a pacemaker or
ICD undergoing VA ablation, whereas a quarter never do,
and the remaining do in select patients based on potential
risk factors for device infection, such as a prosthetic valve
or use of a Foley catheter. Thirty percent of the writing committee use antibiotic prophylaxis for patients undergoing
epicardial access.
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6.7. Fluid Balance
Careful monitoring of ﬂuid balance is essential in patients undergoing VA ablation, especially given that many have
impaired ventricular function, putting them at risk of volume
overload, and they might have renal impairment. Various irrigated catheters are currently in use, allowing for different
ﬂow rates, and hence, different volume loads. A urinary catheter might not be required for cases performed under sedation
when the anticipated procedure duration is short, but for
longer ablation procedures, it should be considered. This permits more precise assessment of the ﬂuid balance, which becomes particularly important for patients in whom irrigatedtip RF catheters are used. However, urinary catheters can
cause urinary tract infection and bleeding; thus, a sterile technique is essential during insertion and after-care. After measurement of volume infused and eliminated (“ins and outs”),
an intravenous loop diuretic should be considered, especially
with a large infused volume, a signiﬁcantly positive procedural ﬂuid balance, and impaired LV function.

Section 7 Electrophysiological Testing
PES is a key component of the VT ablation procedure, allowing for mapping of induced arrhythmias. In addition, a baseline assessment of arrhythmia induction can be useful by
comparison for the eventual assessment of procedural
outcome (see Section 9.17). Given the majority of idiopathic
VAs are caused by cAMP-mediated delayed afterdepolarizations, they can be provoked with catecholamine infusion and
burst pacing (S7.1,S7.2). Although purely substrate-based
ablation (without arrhythmia induction) can be performed,
many laboratories perform programmed stimulation in select
patients with reentrant scar-related VT for several reasons: 1)
to perform activation and entrainment mapping in tolerated
VT; 2) to identify the clinical VT morphologies to better
focus substrate-based ablation; and 3) to limit the extent of
ablation delivery. Although “legacy” protocols for programmed stimulation have been proposed (S7.3,S7.4), most
laboratories that perform programmed stimulation would
hold to a minimal standard of at least 1 site and 2 drive
CLs, with the delivery of 1–4 ventricular extrastimuli at
coupling intervals limited by local refractoriness or a
minimum of 180–200 ms. Given known site dependence
for induction of reentrant VT, additional sites of
stimulation (particularly the LV) can be useful. The use of
long–short sequences during programmed stimulation has
been particularly helpful to induce BBRVT that can easily
be addressed with an ablation procedure.
The most important objective of the ablation procedure is to
identify and eliminate the clinical VT. Prior studies have

demonstrated that programmed stimulation results in VT induction in 93%–95% of patients with healed MI and a history
of sustained VT (S7.4,S7.5). Importantly, these studies were
concerned with induction of any VT, but not necessarily the
clinical VTs. Limited data are available to address the
question of how reliable PES is in reproducing all clinically
pertinent VT morphologies. Given that 12-lead ECGs of the
clinical VT are frequently not available, ICD electrograms
have been described to reliably identify the clinical VT when
induced in the electrophysiology lab (S7.6). Unfortunately,
the clinical VT is not always inducible: 7%–24% of patients
are completely noninducible (S7.7–S7.9), and the clinical VT
cannot be induced in another 13%–30% of patients (S7.6,S7.
7,S7.10). Furthermore, induction of VTs that have not been
previously documented occurs frequently, depending on
whether the PES protocol is completed, until all extrastimuli
are delivered from multiple sites and refractoriness has been
reached. Elimination of all inducible VTs has been found to
result in improved outcomes (S7.11,S7.12); hence, this is the
ideal objective of the ablation procedure. Inducibility of
nonclinical VTs post ablation has been found to be
associated with a high VT recurrence rate (S7.13). Risks and
beneﬁts will need to be weighed, however, given it might
take performance of longer procedures to reach this objective.
A major concern about the reliability of PES is that VTs often
recur even when patients have been rendered completely noninducible post ablation (S7.12). Edema formation in a critical
area can render a targeted VT temporarily noninducible; however, incomplete lesions can also form a new or modiﬁed substrate, generating new VTs. The former can be addressed with
NIPS a few days after the ablation procedure, which has been
found to predict VT recurrence in patients who were noninducible at the conclusion of the ablation procedure (S7.14). PES is
typically performed at the onset of the procedure, but it might
need to be deferred to the conclusion of the procedure if there is
concern about the patient’s hemodynamic status.
Despite there being less complete characterization of the
effectiveness of PES to guide ablation of VT in nonischemic
substrates, noninducibility has also been demonstrated to
result in superior outcomes post ablation (S7.15). Only
limited data and anecdotal reports exist on the use of other
agents (aminophylline, epinephrine, calcium, dobutamine,
caffeine) to induce idiopathic arrhythmias when isoproterenol and burst pacing fail (S7.16).
A survey of the writing committee is summarized here to
give some perspective. For induction of VT in SHD, all the
members routinely stimulate from the RV apex, 66% from the
RVOT and 59% from the LV if LV access has already been obtained. Up to 3 extrastimuli are routinely performed in 76%, and
up to 4 in 24%. For induction of idiopathic arrhythmias, the majority of the committee uses isoproterenol frequently (93%), followed by epinephrine (21%), phenylephrine (14%), atropine
(11%), and calcium (7%). In addition, some members of the
committee at least considered dobutamine and caffeine.
At this point, PES remains a key tool of the mapping and ablation procedure. The use of PES, however, often needs to be complemented by alternative strategies, given its many limitations.
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Section 8 Mapping and Imaging Techniques
8.1. Mapping Catheters
8.1.1. Multielectrode Mapping
The use of multielectrode mapping catheters has gained
popularity over the past several years with the introduction
of mapping systems capable of acquiring data from multiple
sites for each beat. These catheters offer several advantages,
particularly in respect to mapping density, resolution, and
speed. The ability to record electrograms from multiple sites
at each beat increases the number of data points and can
shorten the duration of mapping.
Multielectrode catheters often use small electrodes with
short interelectrode spacing, thereby increasing mapping resolution, which can be advantageous for substrate mapping
(S8.1.1.1–S8.1.1.3), facilitating identiﬁcation of surviving
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myocardial bundles within heterogeneous scar tissue that
may escape detection when mapping with standard ablation
catheters with larger electrodes and spacing is performed
(S8.1.1.3–S8.1.1.5). Multielectrode catheters allow pacing
from multiple electrodes positioned in and around areas of
scar. The increased current density during pacing from
smaller electrodes can achieve capture at relatively low
pacing stimulus strength (S8.1.1.1). In addition, pacing
from one site while recording from surrounding sites allows
investigation of propagation in multiple directions that can
identify anisotropy and areas prone to slow conduction
and/or block (S8.1.1.6,S8.1.1.7). These catheters can also
be useful for activation mapping during VT, given they
allow rapid acquisition of multiple sites at high spatial
resolution that can facilitate identiﬁcation of a reentry
isthmus or VT focus (S8.1.1.5).
Currently, several multielectrode catheters are available.
The Pentaray catheter (Biosense Webster, Diamond Bar,
CA) is shaped like a ﬂower and has 5 splines, each with 4
electrodes (a total of 20 electrodes), which can be used
with the CARTO EAM system. This catheter frequently
causes ectopic beats in areas of contracting myocardium,
and spatial sampling is nonuniform due to variable spread
of the splines and limited contact with the myocardium. A
linear catheter with 20 electrodes is also available for use
with this mapping system. This catheter has uniform spatial
spread of electrodes and a relatively large area of contact,
although during endocardial mapping the proximal
electrodes are often not in contact. It is well suited for mapping of the epicardial surface. A duodecapolar catheter
with tighter interelectrode spacing (Livewire, Abbott Laboratories, Abbott Park, IL) has been used to map endocardial and
epicardial ventricular surfaces in vivo and has been validated
against histology in an animal model (S8.1.1.8,S8.1.1.9). The
Advisor HD Grid catheter (Abbott Laboratories, Abbott
Park, IL) is a novel 4-by-4 unipolar electrode array with
1-mm (diameter) electrodes, equidistantly spaced 3 mm apart
from each other, which can be used in conjunction with the
EnSite Precision system (S8.1.1.10). A potential advantage
is the uniform spatial sampling; however, collection of
ventricular mapping data in humans in vivo is currently not
available. The fourth catheter is a small basket catheter
with 64 very small electrodes arranged on 8 splines that
can be used with the Rhythmia EAM system (Orion, Boston
Scientiﬁc, Marlborough, MA) (S8.1.1.5,S8.1.1.11). This
catheter has a low noise level, facilitating recording of low
amplitude signals. However, the basket is not well suited
for mapping the papillary muscles, the RV, or the
epicardium.
Common limitations of multielectrode mapping catheters
include mechanical trauma with frequent ectopy, transient
injury of the superﬁcial conduction bundles, limited maneuverability, lack of tissue contact information, and the potential for thrombus formation with the need for careful
anticoagulation. In addition, the potential beneﬁt of mapping
with smaller electrodes in patients with NICM and high prevalence of intramyocardial substrate is unclear. Currently,
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ablation is performed with a second catheter, necessitating
integration of the anatomy and physiology acquired with
the multielectrode catheter in a mapping system that can
also support data acquisition with an ablation catheter. Newer
catheter designs integrating very small electrodes positioned
at the circumference of a standard ablation catheter could
allow combining high-resolution mapping with ablation on
a single catheter (S8.1.1.2).
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8.2. Activation Mapping
Mapping of the electrical activation sequence during VT is a
valuable mapping strategy for patients with hemodynamically stable monomorphic tachycardia (S8.2.1). It can localize
the origin for focal tachycardias and potentially reentry circuits, depending on their anatomy (S8.2.2).
Activation mapping is performed by recording of local
electrograms from multiple sites during VT and is facilitated
by the use of 3D mapping systems, allowing display of the
position and relative timing on the EAM system. For focal
VTs, the earliest site of activation identiﬁes the SOO and is
the target of ablation. At this site, the local bipolar electrogram precedes the QRS onset, and the unipolar signal (with
high-pass ﬁlter setting ,1 Hz) demonstrates a QS conﬁguration, consistent with a centrifugal spread of activation away
from the SOO. In intramural focal tachycardias, the bipolar
electrogram often inscribes with or after the onset of the
QRS and the unipolar electrogram demonstrates an rS conﬁguration, consistent with an initial activation propagating toward the recording electrode. In a true intramyocardial

origin, mapping from all opposing surfaces demonstrate relatively late bipolar activations with rS unipolar conﬁgurations.
The most common VT mechanism in patients with SHD is
scar-related reentry with continuous excitation of the circuit
throughout the tachycardia CL (S8.2.1). The QRS onset typically occurs when the impulse reaches the exit from the scar
to activate the contractile myocardium (S8.2.3). In “exit
sites,” electrograms can be fractionated and immediately precede the onset of the QRS complex. Ablation at exit sites can
terminate the tachycardia; however, it can also result in a
change of the tachycardia conﬁguration and/or CL in which
the diastolic pathway exits at different locations from the
scar (S8.2.4). Ablation of the diastolic pathway “isthmus”
is therefore a more desirable target, given it can eliminate
the machinery required for reentry. Electrograms at isthmus
sites occur earlier during diastole, are typically of very lowvoltage amplitude (,0.5 mV), and can have multiple potentials. Mapping of these circuits with multielectrode mapping
catheters can be helpful for identifying low amplitude signals, for differentiating near-ﬁeld from far-ﬁeld potentials,
and for shortening the time required for mapping (see
Section 8.1). It should be noted that the mere presence of diastolic potentials does not suggest an isthmus location. These
can also be recorded in dead-end pathways and adjacent bystanders unrelated to the circuit. It is therefore important to
carefully review and interpret the activation map in order to
understand the location and complexity of the circuit. In principle, an activation map of a macroreentrant VT circuit
should demonstrate distinct entrance, isthmus, and exit sites
that all serve as obligatory parts of the circuit, such that it
cannot continue without all of these elements. However,
scar-related circuits (particularly in patients with a nonischemic substrate) can have intramural component(s) that might
not be recorded on the surface. These usually exhibit a
“gap” in the activation sequence, such that part of the circuit
is “concealed” from the surface map, residing deep in the
myocardium or on the opposing surface.
Activation mapping of scar-related VTs can be highly
valuable for identifying the isthmus. However, it is often
limited to patients with hemodynamically stable VT. In patients with less tolerated VTs, limited activation mapping
can be performed in conjunction with substrate, entrainment,
and/or pace mapping. The utility of HS to allow extended
mapping during VT can improve the acute procedural endpoint of noninducibility; however, it has limited impact on
the long-term outcome (see Section 6.4) and has not reduced
VT recurrence (S8.2.5,S8.2.6).
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8.3. Entrainment Mapping
8.3.1. Entrainment Mapping: Overview
Entrainment is a pacing maneuver that helps to distinguish
reentrant from nonreentrant arrhythmias and can be used as
a mapping tool to target ablation to critical parts of the reentry
circuit. Entrainment involves the continuous resetting of a
reentry circuit during pacing at sites that are either within
or outside the reentry circuit. This technique is used to identify critical sites of the arrhythmia circuit, through the analysis of the QRS morphology, the measured intervals, and
the recorded electrograms (S8.3.2.1):
1. The QRS conﬁguration during entrainment provides information about whether the pacing site is within or
outside the protected zone of the reentry circuit. With
the pacing site being located outside the reentry circuit,
during entrainment, the stimulated wavefronts that propagate out from the pacing site collide with the orthodromically propagating wavefront of the reentry circuit and
fuse; therefore, the QRS complex is due to the fusion of
wavefronts propagating directly away from the pacing
site with those emerging from the tachycardia circuit
(classic entrainment). During pacing from within a protected region in or near the reentry circuit, pacing entrains
VT without changing the QRS conﬁguration (concealed
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entrainment or entrainment with concealed fusion) (S8.
3.2.2–S8.3.2.4).
2. The stimulus-QRS interval during entrainment with concealed fusion: Entrainment with concealed fusion indicates that the pacing site is within a protected region of
the reentry circuit, and can be located in the common
pathway of the reentry circuit (also referred to as a critical
isthmus or channel), or in a bystander site that communicates with a critical isthmus. If pacing is performed from a
site in the circuit, the stimulus-QRS interval should be
equal to the electrogram-QRS interval during VT. On
the other hand, if stimulation is performed from a
bystander site, the stimulus-QRS interval is longer than
the electrogram-QRS interval during tachycardia (S8.3.
2.5,S8.3.2.6). A difference in stimulus-QRS and
electrogram-QRS up to 30 ms was superior to other
criteria for distinguishing bystander sites from critical
sites in one study (S8.3.2.7). The stimulus-QRS interval
indicates the conduction time from the pacing site to the
VT exit site (S8.3.2.8). Similarly, the stimulus-QRS/VT
CL ratio is a reﬂection of the pacing site location within
the critical zone of the reentry circuit (Figures 5 and 6).
The exit site is deﬁned as a stimulus-QRS/VT CL ratio
,0.3, the common pathway and entry sites have a
stimulus-QRS/VT CL ratio 0.3–0.7, and the inner loop
sites have a stimulus-QRS/VT CL ratio .0.7. There is,
however, an important exception to keep in mind: a longer
stimulus-QRS/VT CL ratio of .0.7 can occur at critical
sites within the reentry circuit. Discrete potentials located
in electrical systole rather than diastole that match with the
stimulus-QRS interval are present in these situations and
reﬂect that the catheter is within the VT entrance zone
(S8.3.2.9).

Figure 5 Entrainment responses from components of reentrant VT circuit. CL 5 cycle length; PPI 5 postpacing interval; VT 5 ventricular tachycardia. Adapted
with permission from Elsevier (S8.3.2.1).
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entrainment mapping can only be used for short time periods
to conﬁrm that a particular site is critical.

Figure 6 Pacing from the protected isthmus of a VT circuit. Entrainment
mapping during VT. The VT CL is 620 ms, and pacing is performed at a CL
of 580 ms. A low-voltage electrogram is located in diastole on the recordings
of the ablation catheter (Map). The stimulus-QRS interval is 230 ms and
matches with the electrogram-QRS interval. The postpacing interval (PPI)
is equal to the VT CL. The stimulus-QRS/VT CL ratio is 0.37, indicating
that the catheter is located in the common pathway. CL 5 cycle length;
PPI 5 postpacing interval; VT 5 ventricular tachycardia.

3. The postpacing interval (PPI): The PPI is also an indication of the proximity of the pacing site to the reentry circuit (S8.3.2.6); the PPI measures the interval from the
pacing stimulus to the following nonstimulated depolarization recorded at the pacing site. The PPI can be used
during entrainment to verify whether the pacing site is
within the circuit or is in a bystander area. At a site with
concealed entrainment, a PPI that matches the VT CL
(630 ms) is consistent with a site where delivery of RF
energy is likely to terminate VT; a PPI .30 ms is often
an adjacent bystander (S8.3.2.1) when ablation fails to
terminate VT. The PPI includes the conduction time for
a full revolution of the propagating wavefront through
the reentry circuit. Several factors can impact PPI accuracy. A faster pacing rate can result in slower conduction
and a prolongation of the PPI. The measurement of the
PPI assumes that the recorded electrogram indicates a depolarization at the pacing site. Electrograms generated by
remote tissue represent far-ﬁeld electrograms and can
result in erroneous measurements of the PPI. Distinction
of local electrograms from far-ﬁeld electrograms is hence
key to accurately measuring the PPI (S8.3.2.10).
Both the PPI and the comparison of the stimulus-QRS interval to the electrogram intervals are methods to differentiate
bystander sites from critical ablation sites. The method using
stimulus-QRS and electrogram-QRS interval assesses a
smaller part of the reentry circuit (pacing site to exit site);
thus, it could be less susceptible to error than the PPI that assesses a full revolution of the reentry circuit.
Entrainment mapping is most easily used to select ablation
sites during mapping of hemodynamically tolerated VTs and
is particularly useful in patients with incessant VTs
(S8.3.2.4). Unfortunately, the majority of inducible VTs in
patients with SHD are not hemodynamically tolerated, and

8.3.2. How to Perform Entrainment Mapping
Ideally, the VT is hemodynamically tolerated in order to
perform entrainment mapping. Furthermore, the VT must
have regular RR intervals to prevent erroneous PPI measurements. Pacing is performed at a CL faster than the VT, with
care taken to ensure that all QRS complexes and electrograms
are accelerated to the pacing rate. Pacing at faster rates can
facilitate detection of QRS fusion; however, it can further
slow conduction in the circuit, resulting in termination of
VT or resulting in acceleration to a different VT. A pacing interval 10–50 ms shorter than the VT CL is frequently used for
pacing. Pacing can be performed either in a unipolar manner
from the tip electrode or in a bipolar manner from the 2 distal
electrodes. Theoretically, the optimal pacing output is
slightly above threshold to limit capture to the tissue immediately beneath the distal electrode, which is also the source of
the near-ﬁeld signal. Determining threshold at each site is not
practical, however, and some centers use an initial output of
10 mA and a pulse width of 2 ms, which can increase until
capture is achieved or which can decrease if capture of a large
area is suspected (S8.3.2.11). Pacing for a sufﬁcient duration
to be certain that reliable capture is achieved is important.
Limitations of entrainment mapping are as follows:
1) Inducibility of sustained and stable VT is required if
pacing maneuvers are to be attempted.
2) Pacing during VT can either interrupt, accelerate, or
modify the ongoing VT.
3) AADs can decrease conduction velocity during pacing, increasing the postpacing and stimulus-QRS intervals (S8.3.2.5).
4) Electrograms indicating local depolarization need to
be distinguished from far-ﬁeld signals, and this is subject to error in regions of fractionated, complex electrograms (S8.3.2.1,S8.3.2.2,S8.3.2.6,S8.3.2.12).
5) Incomplete ablation can create areas where conduction
slows or blocks during pacing, creating misleading,
increased postpacing and stimulus-QRS intervals.
The advantage of entrainment mapping over a substrate
mapping approach is that individual VTs can be reliably
and permanently eliminated with few RF ablation lesions
when reentry circuit targets are identiﬁed (S8.3.2.7,S8.3.2.
13). An approach targeting only VT exit sites in the border
zone based on QRS morphology and presystolic activity in
VT, for example, can fail to eliminate VT if the exit site is
deep to the endocardium. Entrainment mapping can
potentially identify critical components of the reentry
circuit other than the exit site that might be within the
reach of the ablation catheter. Unfortunately, most patients
with heart disease have multiple VTs that are not
hemodynamically tolerated; hence, entrainment mapping as
the only mapping technique is insufﬁcient to eliminate
most of the VTs encountered in a given patient. In the
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modern era of VT ablation in the setting of complex VAs and
multiple etiologies with different substrates, in which 3D
mapping is routinely adopted, entrainment mapping is only
one component of the ablation strategy. Ablation guided by
entrainment and activation mapping of hemodynamically
tolerated VT has not been shown to be superior to
substrate-based ablation (S8.3.2.14). Therefore, entrainment
mapping is typically combined with substrate mapping in patients with VT associated with scars and SHD.
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8.4. Pace Mapping
Pace mapping is a technique used to locate the origin of a
PVC or VT by stimulating the myocardium to reproduce
the clinical 12-lead morphology in the absence of VT; it is
particularly useful if the targeted arrhythmia is difﬁcult to
induce or is hemodynamically unstable. The optimal site
should exactly match the tachycardia QRS, including
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individual notches as well as major deﬂections. Comparison
of the 12-lead ECG during pace mapping and VT is usually
expressed with a scale from 0 to 12; however, computerassisted comparison allows its quantiﬁcation (S8.4.1).
Manufacturer-speciﬁc algorithms (Labsystem Pro, Boston
Scientiﬁc, Arden Hills, MN [formerly Bard]; PaSo CARTO
module, Biosense Webster, Diamond Bar, CA; Rhythmia,
Boston Scientiﬁc, Marlborough, MA; and EnSite Precision,
Abbott Laboratories, Abbott Park, IL) exist that use
template-matching algorithms to generate a correlation
coefﬁcient between VT morphology and pace maps
(S8.4.2,S8.4.3). These algorithms allow computational
comparisons between pace maps; however, careful external
validation is currently lacking.
Pace mapping indicates the location of the origin of focal
VAs (S8.4.4), although activation sequence mapping is more
accurate (S8.4.5). Furthermore, pace mapping is used to identify the exit of the VT in reentrant VTs (S8.4.6–S8.4.8).
Critical sites of the reentry circuit and regions of slow
conduction can be identiﬁed based on pace mapping and
electrogram characteristics (S8.4.9). Pacing in noncritical
areas adjacent to the exit can generate an adequate pace
match that is similar in morphology to a pace map from the
VT exit. On the other hand, pacing at sites close to the
entrance of the reentry circuit during sinus rhythm often generates markedly different QRS complexes, given the stimulated wavefront propagates away from the pacing site via
paths that are blocked during VT (S8.4.7,S8.4.10,S8.4.11).
Thus, sites without matching pace maps could still be
critical for the reentry circuit, and identiﬁcation of a
transition from an adequate to a poor matching pace map
might indicate the isthmus orientation (S8.4.3). Importantly,
the pacing rate has been reported to alter the QRS
morphology; therefore, a pacing rate close to the VT rate
should be used (S8.4.12).
Within scar, the spatial resolution of pace mapping is heterogeneous and can indicate a region of interest that measures
up to 18 cm2 (S8.4.13). Even in patients without SHD, a perfect pace map can be observed at sites up to 2 cm away from
the VT origin (S8.4.5,S8.4.14). Most electrophysiologists of
the writing committee perform pacing in a bipolar manner,
starting with an output of 10 mA at 2 ms pulse width.
Limitations to bipolar pacing, including anodal capture,
and the limitations to pacing with a minimal ﬁxed output,
including generation of a virtual electrode that captures
more tissue with higher stimulus strength, need to be
recognized (S8.4.15). Pacing at stimulus strengths only
slightly greater than threshold is desirable to avoid capture
over a large area, which can reduce accuracy; however,
checking the threshold at each mapping point is time
consuming and might not be practical.
Smaller interelectrode spacing, smaller electrode size, and
unipolar pacing could increase the accuracy of pace mapping
(see Section 8.1) (S8.4.16).
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8.5. Sinus Rhythm Substrate Mapping
8.5.1. Substrate Mapping in Sinus Rhythm
Recommendations for substrate mapping in sinus rhythm
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1. In patients with scar-related VT, substrate-guided ablation is useful for prevention of
arrhythmia recurrences.
2. High-density multielectrode mapping to obtain a more comprehensive
characterization of the arrhythmogenic tissue during catheter ablation of scarrelated VT can be useful.
3. In patients with no or minimal endocardial bipolar electrogram abnormalities,
reduced unipolar voltage can be useful for detection of epicardial or intramural scar.

S8.5.2.1–S8.5.2.11

Recommendation-Speciﬁc Supportive Text
1. Substrate-guided mapping and ablation during sinus
rhythm are intended to overcome the limitations of conventional mapping and ablation. They allow ablation of
multiple VT morphologies irrespective of inducibility or
hemodynamic tolerance. Multiple studies have shown
that substrate-guided ablation is effective for prevention
of arrhythmia recurrences in scar-related unmappable
VT (S8.5.2.1–S8.5.2.11).
2. Multielectrode mapping has been shown to increase mapping density and to shorten mapping and RF delivery time
(S8.5.2.12–S8.5.2.14). Although in retrospective studies
the use of multielectrode mapping has been associated
with better outcome, no effect on acute and long-term
outcome has yet been prospectively demonstrated (S8.5.
2.12,S8.5.2.14).
3. Bipolar electrograms have a limited ﬁeld of view to detect
epicardially or intramurally located scar. Unipolar voltage
mapping can be used to extend ﬁeld of view of endocardial mapping, and low unipolar voltages can indicate

S8.5.2.12–S8.5.2.14
S8.5.2.15–S8.5.2.19

regions of epicardial or intramural involvement in patients
with no or minimal endocardial abnormalities evident on
bipolar electrogram analysis; however, there is substantial
overlap of unipolar low voltage between scar zones and
regions without scar (S8.5.2.15–S8.5.2.19).
8.5.2. Summary
The majority of patients with SHD presenting for catheter ablation have hemodynamically unstable VTs that prevent accurate
delineation of the critical part of the reentrant circuit with activation or entrainment mapping (S8.5.2.20). Substrate mapping
is an approach to characterize areas likely to support reentry
based on electrophysiological characteristics that can be determined during stable sinus or paced rhythm. It allows for elimination of VT, irrespective of inducibility or hemodynamic
tolerance. Even for hemodynamically stable VTs, substrate
mapping is often used to limit activation mapping or entrainment to a region of interest (S8.5.2.7,S8.5.2.10,S8.5.2.11).
The concept of substrate mapping has developed from
the success of surgical subendocardial resection for

Cronin et al. Catheter Ablation of Ventricular Arrhythmias
postinfarction VT, which has established the physical link
between the VT circuit and the infarction scar (S8.5.2.21).
Current criteria to deﬁne the abnormal arrhythmogenic substrate rely on a combination of lower bipolar or unipolar
voltage and abnormal electrogram characteristics (eg, fragmented, split, and late electrograms). These abnormal electrogram features can represent slow or delayed activation
that constitute surrogate markers for potential VT circuits
(S8.5.2.22,S8.5.2.23).
Voltage criteria for scar identiﬁcation: Scar tissue can be
identiﬁed based on bipolar electrogram amplitude. Using a 4mm tip mapping catheter and 1-mm ring interelectrode
spacing with a 2-mm ring ﬁltered at 10–400 Hz, 95% of
normal LV endocardial electrograms have a peak-to-peak
amplitude .1.55 mV (S8.5.2.24). Conversely, bipolar
voltage ,0.5 mV has been designated as “dense scar,” but
it is important to recognize that these regions can still contain
viable myocytes (S8.5.2.25) that can be captured by pacing.
Use of cutoff values has important limitations as shown by
recent work integrating voltage mapping and full human
heart histology (S8.5.2.26). This is particularly relevant in
patients with NICM with patchy scar, in whom larger bundles
of surviving myocytes are mixed with ﬁbrotic tissue. Bipolar
voltage and electrogram characteristics can be further
affected by different electrode size and/or interelectrode distance of the mapping catheter (S8.5.2.13), direction of activation wavefront (S8.5.2.27), and wall thickness (S8.5.2.26).
Bipolar voltage mapping can have a limited ﬁeld of view
to detect epicardially or intramurally located scar, typically
observed in patients with NICM. Under these circumstances,
unipolar voltage mapping can be used to extend the ﬁeld of
view of endocardial mapping (S8.5.2.15,S8.5.2.16,S8.5.2.19).
Endocardial low unipolar voltages could indicate regions
of epicardial or intramural involvement in patients with no
or minimal endocardial abnormalities evident on bipolar
electrogram analysis. Although various studies have
reported different cutoff values to identify deeper scar tissue,
validation studies with CMR-deﬁned scar have demonstrated
that there is a substantial overlap of unipolar low voltage
between scar zones and regions without scar. CMR-deﬁned
scar remains the gold standard for precise demarcation of
scar and is preferable over unipolar voltage mapping for
deﬁning scar. Furthermore, cutoff values are impacted by
electrode size, wall thickness, surrounding anatomical
structures, and ventricular hypertrophy, or are region speciﬁc
(S8.5.2.16,S8.5.2.18,S8.5.2.26,S8.5.2.28).
Other electrogram characteristics as ablation targets:
Low-voltage areas in patients with SHD are often large,
and not all are related to VT. To limit the extent of ablation,
several other electrogram features obtained during spontaneous rhythm or elicited by pacing maneuvers have been
studied to identify areas within the scar potentially related
to VT. In the seminal study of de Bakker et al. (S8.5.2.22),
the authors have demonstrated the presence of inhomogeneous “zig-zag” conduction within the infarcted area, which
was related to the presence of poor cell-to-cell coupling
of surviving myocyte bundles interspersed among ﬁbrous
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tissue. In these regions, abnormal fractioned and LPs were recorded. Although fragmented electrograms can be typically
recorded throughout the whole scar, isolated and LPs have
been demonstrated to be a more speciﬁc marker of the VT
circuit (S8.5.2.29–S8.5.2.33). However, clinical studies
have adopted heterogeneous deﬁnitions of abnormal
electrograms, with nonuniform use of terms such as
“fragmented,” “split,” and “late,” and the relationship
between these surrogate markers and the VT circuits
remains to be thoroughly explored (S8.5.2.34). In this
respect, LAVA has been proposed as a global term that incorporates all abnormal ventricular signals that represent nearﬁeld signals from poorly coupled ﬁbers within scar, representing potential VT isthmus sites (S8.5.2.35).
Importantly, the lines of block delimiting the channels
responsible for arrhythmias can be both ﬁxed and functional
(S8.5.2.34), and the participation of functional barriers in VT
circuits challenges the identiﬁcation of potential VT circuits
during substrate mapping. Abnormal local electrograms can
be hidden in far-ﬁeld signals, preventing their recognition
during sinus rhythm or RV pacing. Identiﬁcation of such
electrograms might require pacing maneuvers to demonstrate
their poorly coupled nature (S8.5.2.35–S8.5.2.37). This
could be relevant in the presence of smaller, nontransmural
scars, in which subepicardial viable myocardium can
overlay the subendocardial scar, creating far-ﬁeld obscuration of the local signal (S8.5.2.38).
Some abnormal electrograms can be disclosed only by
catheters with small electrodes and shorter interelectrode distance, which allow for higher near-ﬁeld resolution
(S8.5.2.39) (see Section 8.1).
Most of the studies concerning substrate mapping
were performed on patients after MI, and signiﬁcant differences exist with respect to the arrhythmogenic substrate characteristics between patients with ICM and NICM (see
Section 9).
There is currently no standardized approach for substrateguided ablation. A number of substrate-based ablation
approaches have been developed, with the main purpose of
targeting and eliminating areas of slow conduction within
the abnormal substrate deﬁned during sinus rhythm (S8.5.
2.24,S8.5.2.29,S8.5.2.30,S8.5.2.35,S8.5.2.40–S8.5.2.44) or
evoked by pacing (S8.5.2.36–S8.5.2.38) (see Section 9.5).
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8.6. Intraprocedural Imaging: Intracardiac
Echocardiography, Fluoroscopy, Cardiac Magnetic
Resonance Imaging
8.6.1. Intraprocedural Imaging During Catheter Ablation of
Ventricular Arrhythmias
Recommendations for intraprocedural imaging during catheter ablation of VAs
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1. Coronary angiography or ICE is recommended to localize the ostia of the
coronary arteries prior to ablation within the SV.
2. Coronary angiography is recommended to identify the course of the coronary
arteries when ablation is performed in the coronary venous system or in the
epicardium.
3. ICE is beneﬁcial to identify and target the papillary muscles with ablation and
to assess for catheter stability.
4. ICE or transthoracic echocardiography is useful to assess for pericardial
effusion in case of hemodynamic deterioration of the patient.
5. ICE is useful for early recognition of complications, including pericardial
effusion.
6. ICE may be useful as an adjuvant technique to identify wall segments with wall
thinning, wall motion abnormalities, and segments with increased
echogenicity, and also to identify intracardiac thrombi.

S8.6.2.1–S8.6.2.4

Recommendation-Speciﬁc Supportive Text
1. For the coronary ostia, a distance of 1 cm of the catheter
tip from a coronary ostium is considered a safe distance
(S8.6.2.3), although ablations have been reported to be
as close as 7.3 mm (S8.6.2.1) and 7.5 mm (S8.6.2.4)
from the coronary ostium, without resulting complications.
2. In the epicardial space, coronary angiography should be
considered prior to ablation to ensure that there is no coronary artery in the proximity of the ablation catheter (S8.
6.2.7,S8.6.2.8); a minimal distance of .5 mm from the
ablation catheter tip to an epicardial coronary artery has
been considered safe (S8.6.2.7).
3. No randomized studies have shown improved outcomes if ICE is used to target papillary muscle arrhythmias. Several case series, however, have
demonstrated that ICE is useful for targeting papillary
muscle arrhythmias with real-time localization of the
papillary muscle apparatus and the ablation catheter
tip (S8.6.2.9–S8.6.2.20). Catheter stability on the
papillary muscles or other parts of the myocardium
can be assessed with ICE.
4,5,6. ICE further can help to identify complications such as
pericardial effusions, allowing for early intervention
(S8.6.2.21–S8.6.2.23). It also can be used to assess
intracardiac structures, including wall thickness, wall
motion abnormalities, increased echogenicity to identify
scarring, and intracardiac thrombi (S8.6.2.24–S8.6.2.
26). Furthermore, ICE is beneﬁcial in monitoring
catheter contact during ablation for arrhythmias not
related to papillary muscles and could be useful to
assess for tissue changes preceding steam pops
(S8.6.2.27).

S8.6.2.5–S8.6.2.8
S8.6.2.9–S8.6.2.20
S8.6.2.21–S8.6.2.23
S8.6.2.21–S8.6.2.23
S8.6.2.24,S8.6.2.25

8.6.2. Summary
For intraprocedural imaging during catheter ablation of VAs,
several technologies have been used: ﬂuoroscopy (including
coronary angiography), echocardiography (intracardiac,
transthoracic, or transesophageal), and real-time CMR.
Although no randomized studies have demonstrated the
beneﬁt of intraprocedural imaging, there are data supporting
the use of coronary angiography or ICE to enhance procedural
safety for selected cases, allowing for real-time imaging while
mapping and ablation are performed (S8.6.2.1–S8.6.2.20).
Fluoroscopy is routinely used for catheter placement and
catheter manipulations during mapping and ablation procedures. With the development and improvement of EAM systems, the need for ﬂuoroscopy can be minimized (S8.6.2.
28,S8.6.2.29).
Integration of ﬂuoroscopic cine loops into electroanatomical maps has further helped to shorten ﬂuoroscopy times (S8.
6.2.30–S8.6.2.32).
With respect to the coronary arteries, the use of coronary
angiography or ICE to localize the ostia of the coronary arteries has been found useful when ablation is directed toward
the SV (S8.6.2.1–S8.6.2.3). Although data are limited, a
minimal distance of 10 mm from the coronary ostia has
been considered to be safe for RF ablation (S8.6.2.9). The
coronary ostia can also be identiﬁed by ICE and can be
marked in the electroanatomical map. This could obviate
the need for coronary angiography. Coronary angiography
is the preferred technique to identify the course of the coronary arteries when ablation is performed in the coronary
venous system or the epicardium. A distance of .5 mm of
the ablation catheter to an epicardial coronary artery is
considered safe (S8.6.2.3). A coronary angiogram is often
repeated at the conclusion of the procedure to document
patency of the coronary arteries.
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ICE is beneﬁcial to identify and target VAs originating
from the papillary muscles (S8.6.2.10–S8.6.2.21). No
randomized studies, however, have shown improved
outcomes when ICE was used. Several case series,
however, have demonstrated that ICE is useful for targeting
papillary muscle arrhythmias. The main beneﬁt is the realtime localization of the papillary muscle apparatus in conjunction with the ablation catheter tip being visualized in the EAM
system. Integration of ICE images into the EAM system
together with the mapping or ablation catheter is particularly
helpful (S8.6.2.16). ICE helps to deﬁne the level of the
pulmonary valve when arrhythmias are targeted in the
RVOT or in the pulmonary artery. This is of importance
when ablation needs to be performed in the pulmonary artery,
which can be in close proximity to the coronary arteries.
Furthermore, ICE can be used as an adjuvant technique to
identify scarring by identifying wall segments with wall thinning, wall motion abnormalities, excessive trabeculations
(S8.6.2.23), segments with increased echogenicity (S8.6.2.
24,S8.6.2.26), and also to identify intracardiac thrombi
(S8.6.2.25). Furthermore, predictors for steam pops can be
identiﬁed with ICE (S8.6.2.27), which might help to prevent
complications.
ICE further can help to identify complications such as
pericardial effusions, allowing for early intervention (S8.6.
2.21–S8.6.2.23). Transthoracic echocardiography, as well
as ICE, can be useful to assess for pericardial effusion in
case of intraprocedural hemodynamic deterioration of the
patient (S8.6.2.33).
Real-time CMR can enable visualization of lesion formation. It has the advantage of avoiding ionizing radiation and
of imaging the whole heart in real time, and it has been
used to target typical atrial ﬂutter (S8.6.2.34,S8.6.2.35).
However, real-time imaging during VT ablation in humans
has not yet been reported and has thus far been limited to
postablation image acquisition (S8.6.2.36). A laboratory
with real-time CMR capabilities requires a major ﬁnancial investment, adaptation, and commitment to a work ﬂow that is
very different from that of a standard electrophysiology laboratory. At this time, real-time CMR is used only in a few
centers on an investigational basis. Other investigational imaging techniques include the use of endoscopy in the epicardial space for visualization of catheters, epicardial structures,
and ablation lesions (S8.6.2.37).
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8.7. Electroanatomical Mapping Systems and
Robotic Navigation
Recommendations for the use of EAM systems and remote navigation in ablation procedures for VAs
COR

LOE

I
IIa
IIa

B-NR
B-NR
B-NR

Recommendations

References

1. In patients with VA due to SHD undergoing an ablation procedure, EAM is useful.
2. In patients with idiopathic VA undergoing an ablation procedure, EAM can be useful.
3. In patients undergoing an ablation procedure for VA, magnetic catheter navigation
can be useful to reduce ﬂuoroscopy use.

S8.7.1–S8.7.9
S8.7.4,S8.7.6
S8.7.10–S8.7.14

Recommendation-Speciﬁc Supportive Text
1. EAM systems combine cardiac electrical information obtained from catheter-mounted electrodes and 3D spatial
location information to reconstruct an image that represents the targeted cardiac chamber (S8.7.15). Several
EAM systems are commonly used in clinical practice.
The CARTO mapping system (current version CARTO 3,
Biosense-Webster, Diamond Bar, CA) makes use of magnetic ﬁeld differences for accurate localization of proprietary mapping and ablation catheters. This system also uses
an impedance-based algorithm to visualize the electrodes
and shafts of various diagnostic catheters. A proprietary
intracardiac ultrasound catheter can interface with the
mapping system to further deﬁne cardiac geometry within
the mapping ﬁeld (S8.7.1). The EnSite Precision system
(Abbott Laboratories, Abbott Park, IL; formerly EnSite
Velocity and EnSite NavX, St. Jude Medical, St. Paul,
MN) uses voltage and impedance measurements to
localize diagnostic and ablation catheters. With the use
of proprietary catheters, the EnSite Precision system can
now also provide magnetic-based navigation. The Rhythmia HDx mapping system (Boston Scientiﬁc, Marlborough, MA) uses both magnetic- and impedance-based
methods for catheter tracking. A prominent feature of
this system is the proprietary 64-pole mini basket catheter
with closely spaced electrodes. The Topera mapping
system (Abbott Laboratories, Abbott Park, IL) combines

unipolar electrogram data from an intracavitary basket
catheter with proprietary electrogram analysis software algorithms to identify focal and rotational activity during
cardiac ﬁbrillation. Though it is marketed for atrial mapping, it has been used in cases of idiopathic VF
(S8.7.16). Access to EAM systems worldwide is limited,
largely due to the high cost of systems, necessary peripherals, and proprietary catheters.
Regardless of the type of EAM available, knowledge of
the ﬁrst principles of cardiac electrophysiology remains
essential to create maps that accurately represent the physiology and anatomy. Maps created using EAM systems
are subject to considerable variability depending on a
number of factors, including (but not limited to) accurate
annotation of electrogram qualities, consistent catheter
contact with tissue, distributed sampling of the entire
structure of interest, density of location “points” in the
map, type of rhythm being mapped, direction of activation
wavefront propagation, and the size and spacing of the
electrodes used to acquire the data. Numerous technologies have been developed or are in development to
improve mapping quality and user experience. These
include automated chamber segmentation, imported scar
delineation from alternative cardiac imaging, such as
CMR, CT, and echocardiography, and automated electrogram analysis tools. Ultra high-density mapping catheters
have signiﬁcantly changed the resolution of scar features
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and, as a result, our understanding of VT circuit
physiology.
EAM has proven to be a versatile technology to guide
treatment of a wide range of arrhythmias. Prospective randomized trials with and without EAM in patients with
SVT demonstrate similar acute procedural success rates
and substantial reduction in ﬂuoroscopy use (S8.7.2,S8.
7.3). No such randomized trials with and without EAM
exist for VAs, and no prospective trial has demonstrated
superior outcomes with the use of EAM. It is generally
accepted that the use of EAM can reduce ﬂuoroscopy
time and allow for more precise mapping, with
comparative analyses of nearby locations during VA
ablation procedures. Particularly for more complex
strategies of mapping ventricular scar, EAM enables the
user to perform the necessary mapping to achieve a
successful result, which would otherwise be impossible
without EAM (S8.7.4).
In patients with SHD undergoing catheter ablation for VA,
EAM is particularly helpful. EAM is especially versatile
in this setting, offering the operator the possibility of using
various mapping strategies, including activation maps,
entrainment maps, pace maps, electrogram amplitude
(voltage) maps, and tagging location of speciﬁc electrograms of interest. A prospective multicenter trial for VA
ablation in patients with IHD has used EAM (S8.7.6).
Several retrospective reports have used EAM for a wide
range of SHDs and locations within the heart (S8.7.7,
S8.7.8,S8.7.17–S8.7.25).
2. In patients with idiopathic VA undergoing catheter ablation, EAM can be useful. It is technically feasible to
perform successful ablation for idiopathic VA without
EAM, using 12-lead ECG, ﬂuoroscopy, and careful analysis of intracardiac electrograms. Common examples
include ablation of BBRVT and idiopathic VT originating
from RVOT or LV fascicular system locations. For most
centers, when EAM is available, it has become a mainstay
in the procedure workﬂow for VA ablation procedures.
EAM systems allow activation mapping of idiopathic
VA to support catheter ablation in the RV, LV, aortic
sinuses, and coronary venous system (S8.7.4,S8.7.5,S8.
7.26). Reasons to not choose EAM for ablation of
idiopathic VA include increased cost and limited access.
3. Catheter-based ablation of VA requires signiﬁcant demands on the skill and experience of the operator. The
concept of remote or robotic catheter navigation is
appealing to reduce the physical demands of the procedure while developing more advanced abilities to achieve
stable and precise catheter location than traditional catheters can afford. Several technologies have been developed
to achieve these goals. The Niobe magnetic navigation
system (Stereotaxis, St. Louis, MO) remotely controls
the tip of a proprietary ablation catheter using changes
in magnetic ﬁeld direction from large rotating earth magnets (S8.7.27). This system can be combined with robotic
catheter manipulation components (Vdrive system) to
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control various diagnostic catheters remotely as well. Previous technologies include a second magnetic navigation
system, the Catheter Guidance Control and Imaging system (Magnetecs, Inglewood, CA), which used 8 electromagnets to guide a proprietary magnetically tipped
catheter. The Sensei robotic system (Hansen Medical,
Mountain View, CA) robotically steered a deﬂectable
sheath. A stand-alone robotic catheter manipulation system (Amigo, Catheter Precision, Ledgewood, NJ), interacted with a wide range of diagnostic and ablation
catheter handles via a handheld remote control. Use of
such technologies is a matter of operator preference: the
potential advantages are offset by additional costs for
the navigation systems, disposables, and maintenance
contracts.
For patients undergoing ablation for VA, the use of an
approved magnetic navigation system can be useful to
reduce ﬂuoroscopy exposure. One small prospective randomized trial comparing magnetic navigation to manual
ablation demonstrated reduced use of ﬂuoroscopy without
clear differences in procedure outcome (S8.7.13). A retrospective case series supported similar conclusions, with a
low rate for procedural complication (S8.7.28). A multicenter, single-arm study using remote navigation for patients with ischemic VT has demonstrated favorable
procedural outcomes of VT noninducibility and longerterm VT freedom rates that are comparable to published
results for manual catheter ablation (S8.7.29). Several
retrospective comparison studies and single-arm series
in patients with SHD consistently support reduced ﬂuoroscopy times during the procedure and low rates of procedural complication (S8.7.14,S8.7.30–S8.7.36). None of
the remote navigation systems are speciﬁcally indicated to
facilitate the catheter ablation procedure for VAs, though
a prospective clinical trial using the Niobe remote
magnetic navigation system is underway (S8.7.37).
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Section 9 Mapping and Ablation
9.1. Ablation Power Sources and Techniques

Key Points
 An impedance drop 10 ohms or a contact force 10 g
is commonly used as a target for RF energy delivery.
 The use of half normal saline generates larger ablation
lesions but can result in steam pops.
 Simultaneous bipolar or unipolar ablation can result in
larger ablation lesions.
 Cryoablation can be beneﬁcial for achieving more stable contact on the papillary muscles.
 Ethanol ablation can generate lesions in areas where the
arrhythmogenic substrate cannot be otherwise reached,
provided that suitable target vessels are present.
 Stereotactic radiotherapy is an emerging alternative to
ablation, requiring identiﬁcation of a region of interest
that can be targeted prior to the radiation treatment.

9.1.1. Introduction
Successful ablation requires the creation of durable lesions of
adequate size (S9.1.9.1). When successful ablation cannot be
achieved from the endocardium, percutaneous access of the
pericardial space (discussed in Section 6.3) that permits
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contact mapping and ablation of the arrhythmogenic substrate, which is close to the epicardial surface, can be effective but is limited when there are pericardial adhesions,
overlying fat (S9.1.9.2), or critical structures nearby (S9.1.
9.3,S9.1.9.4), or when the substrate is located deeper
within the myocardium (S9.1.9.5). Innovative techniques intended to reach deeper arrhythmogenic substrates have been
developed.

with contact force sensors have become common and can
help to ensure lesion creation at intended sites (S9.1.9.18).
Although a clear improvement in clinical outcomes for catheter ablation for VA is difﬁcult to demonstrate (S9.1.9.19),
RF applications with a mean contact force .10 g are more
likely to result in electrical unexcitability in scar areas
(S9.1.9.20), and contact force sensing has become an integral
part of RF catheter ablation (S9.1.9.21).

9.1.2. Unipolar Radiofrequency Catheter Ablation
Unipolar RF energy has been the mainstay of catheter ablation technologies since the early 1990s. This technology
was reﬁned with the addition of temperature sensing and
larger tip catheters and further with catheter tip cooling.
Lesion depth is limited by the amount of power that can be
safely delivered: too much power will result in overheating
at the tip-tissue interface and consequent protein denaturation
with thrombus formation (S9.1.9.6,S9.1.9.7). Irrigation of
the ablation electrode reduces temperature at this interface
and allows greater power delivery and thus the creation of
larger lesions (S9.1.9.8–S9.1.9.10). Several catheter tip
designs and irrigation rates have been made available, each
of which generates similar myocardial lesion depth and
volume (S9.1.9.11). Some degree of surface sparing is
observed with irrigation, more so at higher ﬂow rates and
with tip designs that direct more irrigant at the surface (S9.
1.9.11,S9.1.9.12). Power delivery, however, remains
limited by the risk of deep tissue overheating and steam
pops (S9.1.9.9). Catheter tip designs with greater irrigant
dispersion might permit lower irrigation ﬂow rates and less
volume load for patients with reduced ventricular function.
Ablation lesion size increases with the duration of current
application (S9.1.9.13), and although short duration applications are sufﬁcient for ablation in thin structures, 60–90 seconds or longer applications are usually employed for VT. The
optimal duration has not yet been deﬁned.
Steam pops can occur when excessive heating of myocardial tissue occurs and can occasionally result in harmful tissue disruption (S9.1.9.14). However, the methods for
avoiding steam pops are limited. Catheter tip irrigation
partially attenuates the correlation between tip temperature
and tissue temperature. Steam pops can still occur when tip
temperatures rise excessively, although higher ﬂow catheters
with more irrigation ports could reduce the incidence of
steam pops (S9.1.9.15). Monitoring the impedance could
be useful in preventing steam pops, most of which occur
when the impedance decreases more than 18 ohms from baseline or when greater power is delivered for longer durations
(S9.1.9.16). A typical initial power setting for ablation with
an open irrigated catheter in the LV is 30 watts and can be
adjusted up to 50 watts to achieve an impedance drop of
10 ohms.

9.1.4. Hypotonic External Irrigation
Most ablation catheter tips are 3.5–4 mm in length and are
typically irrigated with 0.9% sodium chloride solution. The
efﬁciency of delivering current to myocardial tissue can be
increased by using smaller electrode tip sizes (S9.1.9.22)
and less conductive irrigant, such as 0.45% sodium chloride
(S9.1.9.23,S9.1.9.24). These techniques deliver greater
current to myocardial tissue for any given applied power
but remain limited by the potential for tissue steam pops.
The effectiveness and safety of using a higher impedance
irrigant has been supported by a multicenter, prospective,
observational human study; however, direct clinical
comparisons are still pending (S9.1.9.25). The use of hypotonic saline irrigant can have the additional advantage of a
reduced salt load for patients with compromised ventricular
function.

9.1.3. Contact Force Sensing
Lesion size is critically dependent on the contact of the
ablating electrode with the tissue (S9.1.9.17). Catheters

9.1.5. Simultaneous Unipolar or Simultaneous Bipolar
Radiofrequency Delivery
Conventional unipolar RF catheter ablation delivers current
between the catheter tip and a dispersive skin electrode.
Two catheters placed on either side of the target tissue, delivering simultaneous unipolar RF energy (using two RF generators), have been employed to reach deeper myocardial
substrates, which could create larger lesions than sequential
ablations at each of these sites by raising the temperature of
tissue deep to either ablation site, limiting its heat sink effect,
and increasing the conductive heating zone (S9.1.9.26). This
method provides independent control and monitoring of RF
delivery from each ablating catheter but can pose technical
challenges with device interactions. The efﬁcacy and risks
of this procedure have not been completely characterized.
Bipolar ablation is performed by replacing the dispersive
skin electrode with a second catheter that is closely apposed
to tissue with culprit substrate between the catheters. This
technique concentrates current density between the catheters.
Lesion creation extends from both catheters, and lesions are
larger and more likely to be conﬂuent than those achieved
with sequential unipolar energy delivery (S9.1.9.27). The efﬁcacy of this technique has been demonstrated in both preclinical models (S9.1.9.28,S9.1.9.29) and in humans (S9.1.
9.30,S9.1.9.31). Bipolar ablation can be delivered between
catheters that are positioned across the interventricular
septum from one another, on either side of a papillary
muscle, or with catheters in the endocardial and epicardial
spaces. Bipolar ablation is limited by the requirement for
custom cabling and the technical challenges of visualizing
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and placing two catheters sufﬁciently close with target tissue
between them. The catheter tip temperature cannot be
monitored simultaneously for both catheters, and
impedance will be inﬂuenced by both tip-tissue interfaces.
Optimal power and current settings have not yet been
deﬁned, and the risk of coagulation has not yet been fully
characterized. An investigational system is under evaluation.

Although experience is limited, ventricular ablation can be
performed by injecting alcohol in a retrograde manner into the
coronary venous system, which can lead to a lower risk than in
the coronary arterial system. Reports from small series have
been promising, although collateral myocardial injury and
recurrence are still a concern (S9.1.9.49–S9.1.9.51). Further
study could help to reﬁne the technique.

9.1.6. Needle Ablation
Infusion needle ablation has been reported as a means to
achieve intramural ablation lesions. A catheter with an
extendable/retractable needle at the tip can function as an intramural electrode for the temperature-controlled delivery of
RF energy (S9.1.9.32), which can create large, deep lesions
during saline irrigation (S9.1.9.33,S9.1.9.34). This
approach has been demonstrated to be effective for select
patients with treatment-refractory VA in small series
(S9.1.9.35). The efﬁcacy and procedural risks of this technique have not been fully characterized. Investigational systems are under evaluation (S9.1.9.36).

9.1.9. Stereotactic Radiotherapy
The use of stereotactic motion-gated external beam radiation
for ablation has been explored in animal models (S9.1.9.52),
and its feasibility has been demonstrated in humans (S9.1.9.
53–S9.1.9.56). Tissue injury is likely the result of a
combination of cell nuclear damage and vascular damage,
the results of which can manifest within days or weeks
(S9.1.9.53). This method requires the accurate preprocedure
identiﬁcation of the culprit arrhythmogenic substrate, using
either intracardiac mapping, imaging, or noninvasive ECGI
(S9.1.9.53). Limiting the radiation to the target is complicated by cardiac and respiratory motion. Further study is
required to quantify the risk of injury to nontarget myocardial
and adjacent structures and to further deﬁne the methods and
efﬁcacy.

9.1.7. Cryoablation
Catheter cryoablation has been infrequently employed for
treating VA. Compared with RF ablation, focal cryoablation
lesions are smaller and take longer to develop. Larger lesions
can be created with larger tip cryoablation catheters
(S9.1.9.37), but the clinical effectiveness and recurrence
rates are less favorable than those achieved with RF ablation
(S9.1.9.38,S9.1.9.39), likely because of the smaller lesion
size. Cryoablation catheters become adherent to the tissue
during lesion creation, which enhances catheter stability
and can provide additional utility in the catheter ablation
for VA arising from highly mobile papillary muscles,
which can be difﬁcult to ablate using RF ablation catheters
(S9.1.9.40). Although surgical cryoablation for VA has
been used for decades (S9.1.9.41,S9.1.9.42), currently
available technology will likely be limited to specialized
circumstances unless further innovation enables larger
cryoablation lesion delivery from catheter platforms
(S9.1.9.43).
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9.2. Idiopathic Outﬂow Tract Ventricular
Arrhythmia

Key Points
 The RVOT, pulmonary arteries, SVs, LV epicardium
and endocardium contain most of the OT arrhythmias.
 Activation mapping and pace mapping can be used to
guide ablation in the RVOT.
 Imaging of coronary artery ostia is essential before
ablation in the aortic SVs.
 The LV summit is a challenging SOO, often requiring
mapping and/or ablation from the RVOT, LVOT, SVs,
coronary venous system, and sometimes the epicardial
space.
 Deep intraseptal VA origins can be challenging to
reach.

9.2.1. Introduction
Approximately two-thirds of idiopathic VAs originate from
the ventricular OTs, accounting for 10% of all patients
referred for VA ablation (S9.2.7.1). OT VAs comprise a
wide spectrum of VAs, ranging from premature ventricular
beats to sustained monomorphic VT. Approximately threequarters originate from the RVOT, with the remaining from
the LVOT and adjacent structures, including the pulmonary
artery, the area surrounding the His bundle, the aortic SVs,
the epicardium and GCV region, LV summit, AMC, and
the superior mitral and tricuspid valve annuli (S9.2.7.1–S9.
2.7.11). OT VAs usually exhibit either an RBBB or LBBB
morphology with an inferior axis. OTs and adjacent areas
have a broad and complex 3D anatomical structure, accounting for some of the unique challenges in arrhythmia localization and ablation (S9.2.7.2,S9.2.7.4–S9.2.7.6).
Most idiopathic OT VAs have a focal origin and are
thought to be due to adenosine-sensitive, cAMP-mediated
triggered activity (S9.2.7.12,S9.2.7.13).
9.2.2. General Approach
The success of ablation depends largely on the presence of
VA at the time of the procedure. All AADs should be discontinued for at least 5 half-lives before the procedure. Sedation
with long-acting sedatives can decrease spontaneous or
inducible VA and should be avoided if possible. If spontaneous VA is absent, limited physical activities, including
hand grip and leg-rising exercises, programmed stimulation,
burst pacing, and the administration of isoproterenol,
epinephrine, or phenylephrine, can be helpful in eliciting
the arrhythmia (Section 7).

e81
Ablation is based on activation mapping and pace mapping (S9.2.7.4,S9.2.7.14), the latter of which is helpful
when the VA is infrequent. Activation mapping is,
however, more accurate (S9.2.7.15), given a similar paced
QRS morphology can be observed over a relatively large
area (S9.2.7.14) and can be misleading in the SV (S9.2.7.
14,S9.2.7.16).
The most frequent SOO remains the RVOT (S9.2.7.1),
but failure of catheter ablation at the earliest RVOT
site should raise concerns that the RVOT breakthrough
is not sufﬁciently close to the focus, warranting
further mapping, including adjacent structures. A stepwise approach to the detailed and careful mapping of
the region of interest, avoiding futile ablation at inappropriate sites, shortens the procedure and enhances success
(S9.2.7.4,S9.2.7.17).
Detailed knowledge of OT anatomy is required, and the
use of ﬂuoroscopy alone is often sufﬁcient for guiding catheter position. However, preprocedure CT or CMR can help to
exclude myocardial disease and deﬁne the anatomy that can
be registered in the mapping system. ICE can help to precisely determine the catheter location in relation to the valves
and the adjacent coronary arteries at risk of injury from ablation in the SV or pulmonary artery.
For VA with LBBB morphology, mapping should start at
the RVOT and pulmonary artery. When mapping indicates a
focus outside the RVOT and pulmonary artery, mapping of
the GCV via the CS provides useful information prior to
left heart catheterization. Mapping can then include the
AIV and its septal branches followed by the SV and endocardial LVOT.
9.2.3. Right Ventricular Outﬂow Tract and Pulmonary Artery
VAs ablated at the RVOT typically display LBBB
morphology and transition at or .V3, without broad initial
r waves in the right precordial leads. Most VAs arise from
the septal anterior aspect of the RVOT. ECG algorithms
can help to suggest the speciﬁc region (S9.2.7.18) and identify those with this morphology that can arise outside the
RVOT or in the pulmonary artery (S9.2.7.17,S9.2.7.19,S9.
2.7.20). Given that the posterior RVOT abuts the RSV,
mapping of this structure is useful when ablation in the
RVOT fails (S9.2.7.5). Some RVOT VAs originate from a
conus papillary muscle that can be identiﬁed by ICE
(S9.2.7.21).
Myocardial ﬁbers extend along the pulmonary artery and
can give rise to VAs that can be ablated from within the pulmonary artery. ECG and electrophysiological characteristics
of pulmonary artery VAs are not well delineated (S9.2.7.3).
Mapping at the pulmonary artery should be considered while
performing catheter ablation at the RVOT. ICE or angiography is required to know with certainty whether the catheter
is above or below the valve.
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Acute procedural success is in the range of 90% (S9.2.7.
14,S9.2.7.22,S9.2.7.23), with more than 80% free of
recurrent VA during follow-up. Serious complications occur
in approximately 1% of patients and are usually related to
cardiac perforation (S9.2.7.14). The left main coronary artery
is directly posterior to the distal RVOT and is at risk of injury
when ablating in the distal posterior RVOT (S9.2.7.24) or the
pulmonary artery. The left anterior descending artery can be
damaged when ablation is performed at the insertion of the
anterior free wall to the septum of the RVOT, especially
when high power (.30 watts) is used for ablation.

9.2.4. Aortic Sinuses of Valsalva
The aortic root lies posterior and rightward of the RVOT and is
comprised of the SVs and commissures. Both the RSV and the
anterior part of the LSV are connected to the adjacent LVOT,
while both the posterior LSV and the NCSV are in ﬁbrous continuity with the mitral annulus at the AMC (S9.2.7.5,S9.2.7.6,
S9.2.7.25). Although this is a ﬁbrous structure, rare VAs can
arise from this region. Myocardial sleeves can cross the aortic
valve plane and extend a few millimeters above the basal
valvular attachment, most commonly adjacent to the RSV
and sometimes at the LSV. Myocardial sleeves are rarely
observed adjacent to the NCSV (S9.2.7.5,S9.2.7.6,S9.2.7.25).
The ECG characteristics of VAs from the SV vary, but
relatively common features that are not usually encountered
in RVOT VAs include a QRS transition ,V3, prominent
tall or broad R waves in V1 or V2 (S9.2.7.4,S9.2.7.8,S9.2.
7.25–S9.2.7.28), qrS or notched complexes in V1–V2 (S9.
2.7.29,S9.2.7.30), and a large R wave in lead I (S9.2.7.31).
A single focus can result in VAs with different QRS morphologies (RBBB and LBBB), suggesting a ﬁber with multiple OT connections (S9.2.7.32).
Initial mapping should include the LVOT and SVs
(S9.2.7.33). ICE is useful for conﬁrming the catheter position
and the relation to adjacent structures. Local electrograms are
helpful indications of catheter location: in NCSV, the atrial
electrograms are larger than the ventricular electrogram,
whereas the ventricular electrogram is larger in the other
SVs, particularly in the RSV (S9.2.7.5,S9.2.7.25,S9.2.7.34,
S9.2.7.35). SV foci are typically characterized by a small
pre-QRS fragmented electrogram that precedes a large farﬁeld ventricular electrogram during the VA and follows the
QRS and far-ﬁeld ventricular potential during sinus rhythm
(S9.2.7.5,S9.2.7.25,S9.2.7.30).
Prior to ablation, ICE imaging or coronary angiography is
required to ensure that the distance between the ablation catheter and the nearest coronary ostia exceeds 10 mm (S9.2.7.25,
S9.2.7.26,S9.2.7.36). Coronary angiography can be repeated
after the ablation to conﬁrm the absence of injury or spasm.
Injury to the aortic valve is theoretically possible. An RF
power of 25–35 W and a duration of 30–60 seconds for each
RF energy application are commonly employed for irrigated
or nonirrigated RF ablation catheters (S9.2.7.25).
The compact AV node and His bundle are potentially at risk
during ablation from the NCSV or commissure between the
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NCSV and RSV and can be identiﬁed by the presence of a
His potential (S9.2.7.6,S9.2.7.25). AV conduction should be
monitored during ablation, which might necessitate the
delivery of RF energy during sinus rhythm rather than during
tachycardia, as well as gradually increasing power (S9.2.7.25).
Ablation for VAs at the aortic root is usually successful
(S9.2.7.8,S9.2.7.15,S9.2.7.35). In rare cases, earliest
activation is identiﬁed at a coronary artery ostium or even
within the proximal coronary artery, precluding ablation
directly on the focus (S9.2.7.26,S9.2.7.35). Potential
complications include aortic valve injury, coronary artery
injury and thromboemboli; with appropriate precautions,
however, these complications appear to be rare.

9.2.5. Left Ventricular Outﬂow Tract and Left Ventricular
Summit
Endocardial left OT VAs can originate from the superior
basal regions of the interventricular septum or the LV free
wall, near the aortic annulus, including the area adjacent to
the His-bundle region where ablation carries a risk of AV
block. The QRS typically has an LBBB inferior axis conﬁguration, with R waves in V1, V2 and dominant R waves in
these leads for those originating in the more leftward aspect
of the LVOT near the AMC.
The epicardial area bounded by the left anterior descending
and circumﬂex coronary arteries has been termed the LV summit (Figure 7) (S9.2.7.4). Ablation for VAs in this region can be
challenging and less successful than other OT VAs. The GCV
divides the LV summit into two parts: the inferior part can be
accessible to epicardial catheter ablation, while the superior
one—the triangle of Brocq and Mouchet (S9.2.7.37)—is inaccessible due to the close proximity of the coronary arteries and
overlying epicardial fat (S9.2.7.38). One group has reported
success in mapping and identifying origins of VA from the
summit region within communicating veins between the aortic
cusp and the pulmonary artery in half of the patients allowing
for anatomic targeting of these VAs (S9.2.7.39). Ablation in
the adjacent endocardium is occasionally successful even
when activation is later than 10 ms prior to the QRS onset at
that site (S9.2.7.40–S9.2.7.42). VAs originating from the
apical summit are rightward of those in the basal part and
tend to have a longer QRS duration, more rightward axis,
and more often an RBBB conﬁguration compared with those
from the basal part of the summit (S9.2.7.41). Ablation from
within the GCV or epicardium can be successful for VAs
arising from the inferior part of the summit.
Epicardial VAs often cluster at perivascular sites, with the
majority at the junction of the GCV/AIV or at the proximal
AIV
(S9.2.7.26,S9.2.7.28,S9.2.7.43,S9.2.7.44).
ECG
characteristics can be similar to those of VAs originating
from the SVs. Mapping within the GCV/AIV can be
performed using standard RF catheters or small-diameter
(2-Fr) multipolar electrode catheters (S9.2.7.26,S9.2.7.28).
RF ablation in the coronary veins has a risk of perforation
or injury to adjacent coronary arteries, or, in some patients,
injury to the left phrenic nerve. Some physicians perform
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ablation in the GCV only after failure of RF energy application
at the adjacent LVOT endocardium and SV, even if activation
at these sites occurs later. Coronary angiography prior to
ablation in the vein is essential, and a distance of 5 mm from
the adjacent artery is recommended for ablation to be
considered (S9.2.7.26,S9.2.7.44). An irrigated catheter is
needed due to the low ﬂow in the vein, and the impedance
cutoff is usually disabled given that impedance in the vein
might exceed the set parameters. Some physicians limit the
maximum power to 20 W, the maximum temperature to
43 C, and the RF duration to 60 seconds (S9.2.7.26). Cryoablation has been considered when the target site is very close to the
artery, but arterial injury is also possible with cryoablation (S9.
2.7.26,S9.2.7.42). To avoid phrenic nerve injury, ablation
should not be attempted if there is diaphragmatic capture
while pacing at the site at 20 mA.
In some cases, VAs in the apical portion of the LV summit
are sufﬁciently leftward to be accessible from the pericardial
space (S9.2.7.26,S9.2.7.38,S9.2.7.41). Proximity to major
coronary arteries and overlying epicardial fat can limit
ablation (S9.2.7.38). When proximity to the epicardial coronary artery precludes catheter ablation, a direct surgical
approach can be an option (S9.2.7.45–S9.2.7.47).
9.2.6. Para-Hisian Ventricular Arrhythmias
The His bundle is located at the most proximal and rightward
part of the RVOT in the region of the perimembranous septum.
VAs originating from this area often have distinctive ECG
characteristics, including a QS in V1–V2, relatively narrow
QRS, and tall R waves in the lateral leads (S9.2.7.10). Ablation
risks include damage to the His bundle or RBB and the possibility of complete AV block. When earliest activation is recorded near the His bundle, mapping at the RSV and NCSV
should be performed, given that earlier activation can be identiﬁed at these sites (S9.2.7.34,S9.2.7.35,S9.2.7.48). Ablation
with careful monitoring of AV conduction can be successful.
Cryoablation can be an option to avoid AV block (S9.2.7.49).
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Figure 7 Anatomical boundaries of the LV summit, with the inaccessible
[1] and accessible [2] parts. Shown are the left anterior descending artery
(LAD), the circumﬂex artery (Cx), the great cardiac vein (GCV), the anterior
interventricular vein (AIV) and the ﬁrst and second diagonal branch of the
LAD (D1, D2).

Ablation is attempted by RF application at the earliest
endocardial breakthrough sites or as close as possible to the
site identiﬁed by intraseptal mapping. If this is ineffective,
simultaneous unipolar (S9.2.7.54) or simultaneous bipolar
RF ablation (investigational) between two RF catheters positioned at both breakthrough sites (S9.2.7.26), or between
RVOT and SV (S9.2.7.55), or RF ablation directly within a
septal perforator vein (S9.2.7.50) have been reported. Intracoronary ethanol infusion (S9.2.7.4) and the use of an investigation needle ablation catheter have been reported (S9.2.7.56).
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9.3. Idiopathic Nonoutﬂow Tract Ventricular
Arrhythmia

Key Points
 VAs originating from the papillary muscles can be
challenging due to multiple morphologies of the VA
and the difﬁculty in achieving and maintaining sufﬁcient contact during ablation.
 VAs originate in LV papillary muscles more often than
in RV papillary muscles; they more often originate
from the posteromedial than the anterolateral papillary
muscle and occur more often at the tip than at the base.
 Pace mapping is less accurate than in other focal VAs.
 ICE is particularly useful for assessing contact and stability.
 Cryoablation can also aid in catheter stability during
lesion delivery.
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for the arrhythmias (S9.3.1.6). Use of a deﬂectable sheath
can help to improve catheter contact, and exploration of
the LV or SV and the coronary venous system should be
considered when ablation at the RV septum is unsuccessful
(S9.3.1.7). The risk of AV block should be considered,
and careful mapping of the conduction system prior to
ablation at the septal tricuspid annulus is warranted.
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9.3.1. Ventricular Arrhythmias from the Tricuspid and Mitral
Annuli
Arrhythmias arising from the mitral annulus occur in approximately 5% of patients presenting for ablation for idiopathic
VAs and can arise from anywhere around the mitral annulus,
with a slight predilection for the superior aspect (S9.3.1.
1–S9.3.1.3). In the surface ECG, VAs from the mitral
annulus have an RBBB morphology, with dominant R
waves from V1 to V5, and can have an S wave in V6 (S9.
3.1.2–S9.3.1.4). Successful ablation has been reported in
80%–100% of cases (S9.3.1.1–S9.3.1.3). Some cases have
an epicardial origin and can be approached from the CS or
GCV, in which case the use of coronary angiography to
verify a sufﬁcient distance from the adjacent coronary
arteries is warranted.
VAs from the tricuspid annulus are encountered in 8%–
10% (S9.3.1.5) of patients with idiopathic VA referred for
ablation (S9.3.1.6). VAs from the tricuspid annulus have
an LBBB morphology, positive polarity in leads I, V5,
and V6, and a QS or rS pattern in aVR. Compared
with RVOT arrhythmias, lead I has a taller R wave. A
precordial R wave transition .V3 favors a free wall
location, and a QS pattern in V1 favors a septal location
(S9.3.1.5,S9.3.1.6).
Outcomes from ablation for VAs from the free wall of
the tricuspid annulus are favorable, with success rates of
approximately 90% (S9.3.1.5,S9.3.1.6). Ablation for VAs
from the septal side of the tricuspid annulus are more
challenging due to difﬁcult catheter contact, proximity to
the conduction system, and a possible intramural origin
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9.3.2. Mapping and Ablation of Ventricular Arrhythmia from
the Papillary Muscles
Ablation of papillary muscle arrhythmias presents unique
anatomical challenges that can result in long procedural,
ﬂuoroscopy, and RF times (S9.3.2.1). Idiopathic VAs
from the papillary muscles comprise up to 5% of patients
presenting for PVC ablation (S9.3.2.1), typically have a
focal origin consistent with triggered activity or abnormal
automaticity as the mechanism, and are more likely to be
provoked by catecholamine administration than by programmed stimulation (S9.3.2.2–S9.3.2.4). Postinfarction
VAs from the papillary muscle can arise from an area of
scar tissue and can have a reentrant mechanism
(S9.3.2.5). Preprocedural imaging including CMR is helpful for identifying areas of scar tissue or ﬁbrosis that are
potential sources of arrhythmia.
Although most idiopathic PVCs from the papillary muscles are benign, they have the potential to cause cardiomyopathy (S9.3.2.6,S9.3.2.7), and rarely they are triggers for
VF (S9.3.2.8). Patients with frequent papillary muscle arrhythmias are also more likely to have mitral valve prolapse
(S9.3.2.7,S9.3.2.9). While the large majority of these patients
have benign outcomes, sudden death can occasionally occur,
and this condition has been associated with the female sex,
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bileaﬂet prolapse, complex VAs, inverted or biphasic
T waves in the inferior ECG leads of sinus beats, and
LGE-CMR, typically in the inferior LV (S9.3.2.10,S9.3.2.
11). Further studies on risk stratiﬁcation are therefore needed.
Papillary muscle arrhythmias can arise from either
ventricle, but the LV is the most common origin, with the
posteromedial papillary muscle being the most frequent
(S9.3.2.12). Papillary muscle arrhythmias originate more
frequently toward the tip of the muscle, in its distal third
(S9.3.2.13). QRS morphology can suggest the origin, but
variable papillary muscle anatomy and exit sites into the
myocardium limit ECG accuracy. PVCs from the posteromedial papillary muscles have RBBB QRS morphology with a
superior axis and a transition in leads V3–V5. PVCs from the
anterolateral papillary muscles have RBBB QRS
morphology, a rightward axis, and inferior leads, demonstrating an inferior or discordant axis (S9.3.2.4,S9.3.2.14).
A small initial q wave in V1 is common. Papillary muscle
PVCs have a longer QRS duration compared with
fascicular PVCs (153 6 27 ms vs 127 6 25 ms, P , .05)
(S9.3.2.14), and fascicular PVCs frequently exhibit an rsR0
morphology in V1, which is more consistent with a typical
RBBB morphology.
Papillary muscle VAs in the same patient often exhibit
variability in QRS morphology, which can be due to variable
exits from the same origin (S9.3.2.15). Pacing can produce
the same QRS over a relatively large area on the papillary
muscle, and ablation at a site with a pace map identical
to the VA might not eliminate the arrhythmia, leading to
ablation over larger areas (S9.3.2.15). In some patients, the
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VA can originate in a deep intramural location, and the electrograms with the earliest activation time can have a far-ﬁeld
appearance or be difﬁcult to deﬁne. In these patients, ablation
at sites with a matching pace map and prolonged S-QRS
might be successful, although longer and higher-powered
RF application might be necessary (S9.3.2.16).
Deﬁning the anatomy and maintaining consistent catheter
contact and stability during ablation delivery are signiﬁcant
challenges. The use of ICE integrated with EAM systems
can help to identify papillary muscle surfaces within the
ventricle and provide real-time visualization of catheter contact on the papillary muscle during ablation (Figure 8) (S9.3.
2.4,S9.3.2.12,S9.3.2.17). Catheter instability often induces
PVCs that complicate mapping. Steerable sheaths can be
useful when a transseptal approach is employed, although
there is a lack of comparative data. Cryoablation has the
advantage of achieving stable contact with the papillary
muscle during freezing and can be effective; however, data
are limited (S9.3.2.18).
Lower success rates and higher recurrence rates have
been reported for the catheter ablation of papillary muscle
arrhythmias, compared with other idiopathic VAs, with
one study citing a 60% long-term success rate for ablation
in patients with idiopathic papillary muscle PVCs
(S9.3.2.1). Although worsening mitral regurgitation
following ablation of the papillary muscles has been reported, this is a rare occurrence, and complications from
ablation of papillary muscle arrhythmias are generally
not signiﬁcantly different from ablation at other LV locations (S9.3.2.4,S9.3.2.19,S9.3.2.20).

Figure 8 Intraprocedural imaging during ablation of papillary muscle arrhythmias. (A): Anatomical map of the left ventricle (CARTO, Biosense Webster)
showing contact of the ablation catheter (Abl) with the posteromedial papillary muscle (PMPAP). (B): Intracardiac echocardiogram showing real-time visualization of the ablation catheter during ablation on the anterolateral papillary muscle (ALPAP).
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9.4. Bundle Branch Reentrant Ventricular
Tachycardia and Fascicular Ventricular Tachycardia

Key Points
 BBR can occur in a variety of patients in whom the conduction system can be affected, including patients with
DCM, valvular heart disease, MI, myotonic dystrophy,
Brugada syndrome, and ARVC, among others.
 Ablation of either the RBB or LBB eliminates BBRVT
but does not eliminate other arrhythmic substrates.
 A correct diagnosis of BBRVT is crucial and should
employ established criteria prior to ablation of either of
the bundle branches.
 Ablation of the AV node does not cure BBRVT.
 Ablation of either bundle branch does not cure interfascicular VT.
 For posterior fascicular VTs, the P1 potential is targeted
during VT; if P1 cannot be identiﬁed or VT is not tolerated, an anatomical approach can be used.
 Purkinje ﬁbers can extend to the papillary muscles, and
these can be part of the VT circuit.
 For anterior fascicular VTs, the P1 potential is targeted
with ablation.
 Focal nonreentrant fascicular VT is infrequent and can
occur in patients with IHD; however, it cannot be
induced with programmed stimulation, and the target
is the earliest Purkinje potential during VT.

9.4.1. Introduction
There are 4 distinct groups of Purkinje-related monomorphic
VTs: 1) BBR including interfascicular reentry VTs; 2)
idiopathic fascicular reentrant VT; 3) fascicular reentrant
VT post infarction; and 4) focal nonreentrant fascicular VT.
The mechanism of focal nonreentrant fascicular VT is
abnormal automaticity from the distal Purkinje system, and
the ablation target is the earliest Purkinje activation during
the VT. The other VTs are caused by macroreentry and
usually occur in speciﬁc locations with speciﬁc QRS
morphologies.
9.4.2. Bundle Branch Reentrant Ventricular Tachycardia
9.4.2.1. Recognition
BBRVT is a unique, typically fast (200–300 bpm), monomorphic tachycardia, which is usually associated with
hemodynamic collapse, syncope, and/or cardiac arrest
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(S9.4.2.4.1). BBRVT is caused by a macroreentry circuit
involving the RBB and LBB, and septal ventricular muscle
(S9.4.2.4.1–S9.4.2.4.5). BBR is often associated with
advanced heart disease and has been observed in DCM
(S9.4.2.4.3), coronary artery disease (S9.4.2.4.3), valvular
heart disease (S9.4.2.4.3,S9.4.2.4.6,S9.4.2.4.7), muscular
dystrophy (S9.4.2.4.8–S9.4.2.4.10), CHD (S9.4.2.4.11),
LV noncompaction (LVNC) (S9.4.2.4.12), ARVC
(S9.4.2.4.13), and Brugada syndrome (S9.4.2.4.14).
BBRVT can also occur in association with His-Purkinje
system disease in the absence of SHD (S9.4.2.4.15–S9.4.2.
4.17). Although classically associated with DCM, BBRVT
can also occur in the setting of isolated, unexplained
conduction system disease (S9.4.2.4.15,S9.4.2.4.18,S9.4.2.
4.19). Recently, 6 cases of idiopathic BBRVT were identiﬁed
in patients with normal biventricular size and function. All
patients were noted to have His-Purkinje system disease,
with prolonged HV at baseline (mean 69.2 ms), and underwent successful ablation targeting the RBB. Mutations
were identiﬁed in 3 of the 6 patients: 2 in the SCN5A
gene and 1 in the LMNA gene (S9.4.2.4.19). Idiopathic
BBRVT can be a genetic conduction disease, manifested
by isolated conduction system disease and curable with catheter ablation.
The reported incidence of BBRVT is 3.5%, representing
6% of VTs in separate series and 20% in a series of patients
with NICM alone undergoing evaluation for ablation (S9.4.2.
4.20–S9.4.2.4.22). The incidence of BBRVT is likely underestimated.
BBRVT can have a typical LBBB (S9.4.2.4.23) or RBBB
pattern, depending on which bundle forms the anterograde
limb (Table 5); however, both morphologies can occur in
the same patient (S9.4.2.4.24). Tchou and Mehdirad
(S9.4.2.4.25) described 3 categories of BBRVT (Table 5).
Type A and type C are the classic counterclockwise and
clockwise BBRVT circuits, respectively. Type B is reentry
within the LBB fascicles (interfascicular reentry). Counterclockwise BBR (type A) accounts for 98% of BBRVTs and
has a typical LBBB pattern with an R-wave transition between leads V4 and V5 (S9.4.2.4.26). Alternatively, activation can proceed in an anterograde manner via the LBB
and then through the septum, with retrograde activation via
the RBB, creating an RBBB morphology (“clockwise”
reentry, type C) (S9.4.2.4.20,S9.4.2.4.27). Interfascicular
reentry tachycardia often has an RBBB and left hemiblock
QRS pattern.
Patients with BBR generally have a prolonged PR interval, QRS duration, and H-V interval. LBBB, or less
commonly RBBB, on the sinus rhythm ECG, is due to conduction slowing in the bundle rather than complete block.
Single BBR beats can occur in patients who have apparently normal His-Purkinje conduction during sinus rhythm
but who have functional conduction impairment
(S9.4.2.4.28). This condition is observed as a normal
response to premature ventricular extrastimuli in patients undergoing PES and has been called a V3 phenomenon (S9.4.2.
4.2,S9.4.2.4.29).
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In the electrophysiology laboratory, ventricular extrastimuli delivered with short–long–short coupling intervals (pacing train of 400 ms with a delay of 600 or 800 ms before the
short-coupled premature coupling intervals are introduced)
tend to cause unidirectional block in the bundle branches
facilitating the initiation of BBR (S9.4.2.4.30). Atrial pacing
and/or isoproterenol might be required (S9.4.2.4.18).

9.4.2.2. Speciﬁc Considerations
Several criteria help in diagnosing BBRVT:
1) The typical 12-lead ECG morphology during tachycardia is LBBB or RBBB.
2) A critical delay in His-Purkinje system conduction is
needed to initiate tachycardia.
3) Although AV dissociation can be present, there is usually persistent 1:1 His-bundle or QRS activation, with
the H-V interval during the tachycardia equal to or
longer than the H-V interval in sinus rhythm (and no
H-V dissociation) (S9.4.2.4.31).
4) Tachycardia stops and cannot be reinitiated if conduction in one of the bundle branches is interrupted.
5) During BBR, the His-bundle, RBB, and LBB activation sequences during an LBBB morphology tachycardia (or the His-bundle, LBB, and RBB activation
sequences during an RBBB morphology tachycardia)
remain stable.
6) If the CL ﬂuctuates, then the H-H interval oscillations
precede the V-V interval oscillations. The H-V timing
remains constant.
7) Entrainment with constant fusion (manifest entrainment) is present during pacing from the RV apex
(S9.4.2.4.32). However, it results in a PPI within 30
ms of the tachycardia cycle (S9.4.2.4.33).
8) Entrainment with concealed fusion is present during
atrial pacing faster than the tachycardia, provided that
AV nodal conduction allows 1:1 conduction.
In type A and C BBRVTs, the onset of ventricular depolarization is preceded by His-bundle, RBB, or LBB potentials
with an appropriate sequence of His-bundle.RBB.LBB
activation. Spontaneous variations in V-V intervals are preceded by similar changes in H-H/RBB-RBB/LBB-LBB intervals. Recording from both sides of the septum can help
to identify the BBR mechanism.
Interfascicular tachycardia is an uncommon type (S9.4.2.
4.3,S9.4.2.4.18,S9.4.2.4.34–S9.4.2.4.37) in which one of the
fascicles serves as the anterograde limb while the other serves
as the retrograde circuit. The distal link between fascicles
occurs through the ventricular myocardium. The LAF is
usually the anterograde limb and the LPF is the retrograde
limb (S9.4.2.4.16,S9.4.2.4.37). BBRVT and interfascicular
tachycardia can be present in the same patient (S9.4.2.4.2,
S9.4.2.4.34,S9.4.2.4.38). In contrast to BBR, the H-V
interval during interfascicular tachycardia is usually shorter
by more than 40 ms than that recorded in sinus rhythm
(S9.4.2.4.39). This condition occurs because the upper
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turnaround point of the circuit (the LBB point) is relatively
far from the His bundle activated in the retrograde direction.
It is important to recognize BBRVT and interfascicular
tachycardia because they can be cured with catheter ablation.
The differential diagnosis for BBR includes 1) VT due to
myocardial reentry, 2) idiopathic left intrafascicular VT, 3)
SVT with aberrant conduction, and 4) atriofascicular reentry.
With myocardial reentry, the His potential usually does
not precede the QRS complex, and variations in the H-H interval follow changes in the V-V interval because there is
retrograde passive activation of the His-Purkinje system.
The PPI after entrainment of tachycardia from the RV apex
will usually be long, unless the myocardial reentrant VT involves the apex (S9.4.2.4.3,S9.4.2.4.33).
The possibilities of other Purkinje-related VTs
(S9.4.2.4.40), such as idiopathic fascicular VT
(S9.4.2.4.41), fascicular VT post-MI (S9.4.2.4.42–S9.4.2.4.
44), automatic His-Purkinje VT, focal Purkinje VT (S9.4.2.
4.45,S9.4.2.4.46), and AV node/His-Purkinje reentry
(S9.4.2.4.47), should also be considered (see below).
9.4.2.3. Catheter Ablation
Pharmacological antiarrhythmic therapy is usually ineffective; however, RF catheter ablation of a bundle branch can
cure BBRVTs and is currently regarded as ﬁrst-line therapy
(S9.4.2.4.3,S9.4.2.4.20,S9.4.2.4.48). Given that signiﬁcant
underlying structural disease is usually present,
concomitant placement of an ICD should be strongly
considered.
The technique of choice is ablation of the RBB (S9.4.2.4.
3,S9.4.2.4.38,S9.4.2.4.49). BBRVT can be prevented by
ablating the right or left main bundle branch (S9.4.2.4.16,
S9.4.2.4.25). Although most patients demonstrate
conduction system disease in the LBB, the RBB is
typically the target for ablation because of the technical
ease and desire to avoid complete LBBB. In patients with a
complete LBBB pattern during sinus rhythm, anterograde
ventricular activation occurs solely via the RBB due to
slow anterograde conduction over the LBB, potentially
with retrograde LBB activation due to transseptal
concealed conduction (S9.4.2.4.16,S9.4.2.4.50). Complete
AV block can develop with RBB ablation, and the LBB
may be targeted in such patients (S9.4.2.4.16,S9.4.2.4.50).
Complete RBB or LBB develops with successful ablation,
although QRS changes can be subtle in patients with preexisting conduction abnormalities. Elimination of retrograde
V-H conduction has been used as a marker of successful ablation.
In interfascicular reentry, RBB ablation will not cure
the tachycardia because the RBB is a bystander. Similarly,
ablation of the main LBB would not be expected to terminate the tachycardia because the circuit is distal to this
point. Catheter ablation of the LAF or LPF will result in
termination of the tachycardia (S9.4.2.4.35,S9.4.2.4.37,
S9.4.2.4.38). A change of electrical axis might be the
only manifestation during sinus rhythm after fascicular
ablation.
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9.4.2.4. Outcomes and Risks
In the 2 largest reported series, acute success rates for
BBRVT and interfascicular reentry were 100% (S9.4.2.4.3,
S9.4.2.4.51). After ablation, BBRVT recurrence is uncommon but has not been thoroughly assessed with follow-up
testing (S9.4.2.4.3,S9.4.2.4.37,S9.4.2.4.51).
The reported incidence of clinically signiﬁcant conduction
system impairment requiring implantation of a permanent
pacemaker varies from 0% to 30% (S9.4.2.4.3,S9.4.2.4.6,
S9.4.2.4.8,S9.4.2.4.29–S9.4.2.4.31,S9.4.2.4.39).
Despite the success of BBRVT ablation, patients with cardiomyopathy and heart failure continue to have a high mortality rate. Despite the impressive success of ablation for
BBRVT, progressive heart failure is a common cause of
death (S9.4.2.4.3,S9.4.2.4.6,S9.4.2.4.20,S9.4.2.4.26,S9.4.2.
4.28,S9.4.2.4.38,S9.4.2.4.48,S9.4.2.4.49). Therefore, a
CRT deﬁbrillator should be considered after ablation based
on the status of the residual conduction system and the
severity of the underlying SHD. Furthermore, VT of
myocardial origin can be induced in 36% to 60% of
patients after successful ablation for BBR (S9.4.2.4.26,S9.
4.2.4.37).
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Table 5

Types of bundle branch reentrant tachycardia

Type A
ECG morphology
Anterograde
limb
Retrograde limb

Type B
(Interfascicular
tachycardia)

Type C

LBBB pattern RBBB pattern
RBB
LAF or LPF

RBBB pattern
LBB

LBB

RBB

LPF or LAF

LAF 5 left anterior fascicle; LBB 5 left bundle branch; LBBB 5 left
bundle branch block; LPF 5 left posterior fascicle; RBB 5 right bundle
branch; RBBB 5 right bundle branch block.
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9.4.3. Idiopathic Fascicular Reentrant Ventricular Tachycardia
9.4.3.1. Recognition
Verapamil-sensitive fascicular reentrant VT is the most common form of idiopathic left-sided VT and was ﬁrst recognized as an electrocardiographic entity in 1979 by Zipes
et al. (S9.4.4.3.1), who identiﬁed the following characteristic
diagnostic triad: 1) induction with atrial pacing, 2) RBBB and
left-axis conﬁguration, and 3) manifestation in patients
without SHD. In 1981, Belhassen et al. (S9.4.4.3.2) were
the ﬁrst to demonstrate the verapamil sensitivity of the tachycardia, a fourth identifying feature. In 1988, Ohe et al.
(S9.4.4.3.3) reported another type of this tachycardia, with
RBBB and a right-axis conﬁguration. Nogami (S9.4.4.3.4)
and Talib et al. (S9.4.4.3.5) subsequently reported on upper
septal fascicular tachycardia. According to the QRS
morphology, verapamil-sensitive left fascicular reentrant
VT can be divided into 3 subgroups (S9.4.4.3.4): 1) left posterior fascicular reentrant VT, in which the QRS morphology
exhibits a RBBB conﬁguration and a superior axis; 2) left
anterior fascicular reentrant VT, in which the QRS
morphology exhibits an RBBB conﬁguration and inferior
axis; and 3) upper septal fascicular VT, in which the QRS
morphology exhibits a narrow QRS conﬁguration and
normal or right-axis deviation (S9.4.4.3.4–S9.4.4.3.6). The
left posterior type is most common, the left anterior type is
uncommon, and left upper fascicular VT is very rare but
sometimes occurs after catheter ablation of other fascicular
reentrant VTs.
The reentrant circuit of verapamil-sensitive fascicular
reentrant VT can involve the Purkinje network around the
papillary muscles (S9.4.4.3.7). In addition to the current classiﬁcation with 3 subtypes, papillary muscle fascicular VT is
another identiﬁable verapamil-sensitive fascicular reentrant
VT. Finally, verapamil-sensitive left fascicular reentrant
VT can be classiﬁed into 5 subgroups (Table 6). Papillary
muscle VTs originating from the Purkinje ﬁber system and
VT originating from myocardial tissue of the papillary muscle appear to be different entities, although there can be some
overlap.
9.4.3.2. Speciﬁc Considerations
The anatomical basis of this tachycardia has provoked considerable interest, with data suggesting that the tachycardia can
originate from a false tendon or ﬁbromuscular band in the
LV (S9.4.4.3.8–S9.4.4.3.11). Using ICE and 3D mapping
systems, the successful ablation site appears to be at the
connection of a false tendon and ventricular wall in some
cases. The Purkinje networks in these small anatomical
structures can be important parts of the circuit. In papillary
muscle fascicular VTs, ﬁbromuscular bands near papillary
muscles can potentially be the substrate of the circuit.
During tachycardia, 2 distinct groups of potentials, P1 and
P2, are typically recorded from a catheter lying along the
midseptum (S9.4.4.3.12–S9.4.4.3.14). The mid-diastolic potentials (P1) show proximal to distal activation along the
septum, and the fused presystolic Purkinje potential (P2)
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shows distal to proximal activation. During sinus rhythm,
the P2 potentials are later than the His-bundle potential and
earlier than the onset of the QRS, which is consistent with
an origin in the LPF. P1 represents the activation from tissue
that has decremental properties and verapamil sensitivity that
constitutes the anterograde limb of the circuit in VT. P2 represents the activation of the LPF or a Purkinje ﬁber near the
LPF and is a bystander during VT. The LV septal muscle is
likely the retrograde limb.
9.4.3.3. Catheter Ablation
VT can be initiated with atrial extrastimuli or burst pacing, or
ventricular extrastimuli or burst pacing, facilitated by an
isoproterenol infusion, if necessary. When evaluating these
tachycardias, a multipolar catheter placed along the left
septum can be helpful in delineating parts of the reentry circuits (S9.4.4.3.12–S9.4.4.3.14).
Left posterior septal fascicular reentrant VT mapping
along the LV septum identiﬁes 2 distinct groups of potentials
(P1 and P2) during the VT (S9.4.4.3.4,S9.4.4.3.12). The
apical third of the septum with a P1 potential is usually
targeted to avoid creating LBBB or AV block. If the VT or
ventricular echo beats are not inducible, an empirical
anatomical approach can be effective (S9.4.4.3.14). First,
the VT exit site is determined by pace mapping during sinus
rhythm, and RF energy is delivered to that site. Second, a
linear lesion is placed at the midseptum, perpendicular to
the long axis of the LV, approximately 10–15 mm proximal
to the VT exit. This anatomical approach is also useful in patients in whom diastolic Purkinje potentials cannot be recorded during VT.
Reported cases of left posterior papillary muscle fascicular
VT presented an RBBB conﬁguration and right-axis deviation QRS conﬁguration. A diastolic Purkinje potential (P1)
is recorded at the papillary muscle with the location
conﬁrmed by ICE imaging. Ablation at this site is highly
effective for suppressing this VT (S9.4.4.3.7).
Left anterior septal fascicular VT exhibits an RBBB QRS
morphology with Rs pattern in V5–V6. A Purkinje potential
is recorded in the diastolic phase during the VT at the midanterior LV septum (S9.4.4.3.13). In this circuit, P1 potentials
represent activation in the proximal portion of the specialized
Purkinje tissue, which has decremental conduction properties. During VT, the anterograde limb is the Purkinje tissue
exhibiting P1, and the retrograde limb is the LV muscle.
The circuits of the left anterior and posterior fascicular reentrant VTs are mirror images.
Left anterior papillary muscle fascicular VTs have RBBB
with deep S waves in V5–V6. LV endocardial mapping during left anterior fascicular reentrant VT identiﬁes the earliest
ventricular activation in the anterolateral wall of the LV,
where ablation suppresses VT (S9.4.4.3.7,S9.4.4.3.13).
Upper septal fascicular VT has a narrow QRS and inferiorly directed frontal plane axis. P1 represents the activation
potential of the specialized Purkinje tissue at the LV septum
(S9.4.4.3.5). P2 represents the activation of the left anterior
and posterior fascicles. Both the left anterior and posterior

e92
fascicles are the anterograde limbs of the reentrant circuit in
VT, producing the narrow QRS conﬁguration and inferior
axis. This VT is successfully ablated at the LV midseptum.
9.4.3.4. Outcomes and Risks
In the largest series of reentrant fascicular VTs, which
included 160 patients with left posterior septal fascicular
VT, 30 patients with left anterior septal fascicular VT, and
8 patients with left upper septal fascicular VT
(S9.4.4.3.15), the success and recurrence rates were 97%
and 4%, respectively, for left posterior septal fascicular VT;
90% and 11%, respectively, for left anterior septal fascicular
VT; and 100% and 2.5%, respectively, for left upper septal
fascicular VT. Recurrence of papillary muscle fascicular
VT after ablation was high (S9.4.4.3.7), with 3 of 8 patients
(38%) with posterior papillary muscle fascicular VT and 1 of
5 patients (20%) with anterior papillary muscle fascicular VT
requiring a second ablation session for VT recurrences.
Aside from the complications that can result from any LV
electrophysiological procedure, the only complications speciﬁcally associated with catheter ablation of idiopathic left
fascicular VT have been LBBB and AV block. Tsuchiya
et al. (S9.4.4.3.16) have reported that 2 patients in their series
of 16 patients (12.5%) had transient LBBB after ablation. The
authors targeted the left basal septum, and the LBBB disappeared within 10 minutes without VT recurrence. In a larger
series (S9.4.4.3.15), 1 (0.5%) of 198 patients had a transient
AV block. This patient presented with left posterior fascicular VT, and the diastolic potential (P1) at the midseptum
was targeted for ablation. Before the ablation, the patient
had catheter-induced RBBB. The AV block disappeared
immediately after discontinuing the RF energy delivery.
9.4.4. Focal Nonreentrant Fascicular Ventricular Tachycardia
and Premature Ventricular Complex
9.4.4.1. Recognition
Focal nonreentrant fascicular VT is classiﬁed as propranololsensitive automatic VT (S9.4.4.3.17,S9.4.4.3.18) and is
usually observed in patients with IHD (S9.4.4.3.19),
although it has been observed in patients with structurally
normal hearts (S9.4.4.3.20,S9.4.4.3.21). VT can be induced
by exercise and catecholamines (eg, isoproterenol and
phenylephrine); however, it cannot be induced or
terminated by PES (S9.4.4.3.17). VT is transiently suppressed by adenosine and with overdrive pacing. Although
this VT is responsive to lidocaine and beta blockers, it is usually not responsive to verapamil. These features can be employed to distinguish it from reentrant fascicular VT. The
clinical and electrophysiological characteristics of this VT
have not yet been well deﬁned. Gonzalez et al.
(S9.4.4.3.20) have reported the electrophysiological spectrum of Purkinje-related monomorphic VT in 8 patients
and have shown the mechanism to be consistent with
abnormal automaticity or triggered activity in 5 patients. Talib et al. (S9.4.4.3.17) have reported on 11 patients (2.8%)
with idiopathic nonreentrant fascicular VT among 530 pa-
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tients with idiopathic VT without SHD. All patients had
monomorphic VT with a relatively narrow QRS (123 6 12
ms) and did not respond to verapamil. The VT exhibited
RBBB and superior-axis conﬁguration in 11 patients
(73%), inferior axis in 3 (20%), and LBBB and superioraxis conﬁguration in 1 (7%). The VT could not be entrained.
9.4.4.2. Catheter Ablation
The ablation target of nonreentrant fascicular VT is the
earliest Purkinje activation during VT. If the VT was not
induced by ventricular stimulation and catecholamines, isolated PVCs with a similar QRS morphology to that observed
during the VT can be targeted. At the earliest Purkinje activation during VT/PVC, a Purkinje potential is also recorded
during sinus rhythm (S9.4.4.3.17).
9.4.4.3. Outcomes and Risks
Although VT and PVC had been suppressed by catheter ablation in 1 series, the acute success rate is unclear because this
VT is difﬁcult to induce (S9.4.4.3.17). VT recurrence was
observed in 4 patients (27%), 3 of whom underwent
pace map–guided ablation during the ﬁrst session. A second
ablation with activation mapping guidance eliminated the VT
during the 88 6 8–month follow-up. Catheter ablation
guided by activation mapping appears effective, whereas
the pace map–guided approach is less efﬁcacious.
LBBB and AV block have been associated with catheter
ablation of nonreentrant fascicular VT. In verapamilsensitive reentrant fascicular VTs, the creation of LBBB or
AV block is rare because the ablation target is the diastolic
abnormal Purkinje potential (P1) during VT, and the abolition of the normal Purkinje or fascicle potential (P2) is not
needed to suppress the VT. By contrast, abolition of a portion
of the Purkinje network is usually necessary to suppress the
nonreentrant fascicular VT. After successful ablation, the
amplitude of the local myocardium is diminished, and the
Purkinje potential appears after the myocardial potential.
When the ablation site is located at the distal portion of the
left fascicle, there is no change in the surface QRS
morphology or H-V interval after ablation. If the VT arises
from a more proximal portion of the fascicle, there is a potential risk for causing LBBB or AV block by the ablation. Rodriguez et al. (S9.4.4.3.21) have reported cases of
nonreentrant fascicular VT with an RBBB conﬁguration
and right-axis deviation in patients who presented left anterior fascicular block after the ablation. Lopera et al.
(S9.4.4.3.19) have reported on 2 patients with nonreentrant
fascicular VT and IHD in whom complete AV block occurred
after successful ablation for VT.
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Table 6

Fascicular ventricular tachycardias

I. Verapamil-sensitive fascicular reentrant VT
1. Left posterior type
i. Left posterior septal fascicular reentrant VT
ii. Left posterior papillary muscle fascicular reentrant VT
2. Left anterior type
i. Left anterior septal fascicular reentrant VT
ii. Left anterior papillary muscle fascicular reentrant VT
3. Upper septal type
II. Nonreentrant fascicular VT
VT 5 ventricular tachycardia.
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9.5. Postinfarction Ventricular Tachycardia

Key Points
 In cases of multiple inducible VTs, the clinical VT
should be preferentially targeted.
 Elimination of all inducible VTs reduces VT recurrence
and is associated with prolonged arrhythmia-free
survival.
 For tolerated VTs, entrainment mapping allows for
focal ablation of the critical isthmus.
 For nontolerated VTs, various ablation strategies have
been described, including targeting abnormal potentials, matching pace mapping sites, areas of slow conduction, linear lesions, and scar homogenization.
 Imaging can be beneﬁcial in identifying the arrhythmogenic substrate.
 Epicardial ablation is infrequently required, but epicardial substrate is an important reason for VT recurrence
after VT ablation in patients with prior infarcts.

9.5.1. General Considerations
The mechanism for most VTs after MI is macroreentry
involving ventricular scar areas, and initial events commonly
occur several years after the acute MI (S9.5.5.1–S9.5.5.4).
Focal nonreentrant mechanisms have been described in up
to 9% of cases (S9.5.5.5). The chronic scar pattern observed
after coronary occlusion has been most widely described as
compact in architecture, extending from the subendocardium
to the epicardium, with increasing ischemia duration, typically sparing the endocardial rim close to the cavity. Along
the border of the scar, viable myocardium is interspersed
with ﬁbrous tissue, providing the substrate for slow conduction (S9.5.5.1,S9.5.5.2,S9.5.5.6,S9.5.5.7). Although most
reentry circuits appear to involve the subendocardium,
intraoperative mapping studies have demonstrated that a
substantial number of VT circuits involve or are conﬁned
to the subepicardial layer (S9.5.5.3).
Early reperfusion therapy, which has been increasingly
adopted for effective management of acute MI, has not
only resulted in myocardial salvage but also less LV aneurysm formation, scar transmurality, and wall thinning. Less
conﬂuent histological and electroanatomical scars
(S9.5.5.8) are associated with the induction of faster VTs
(S9.5.5.8,S9.5.5.9) and pose additional challenges for
mapping and ablation for post-MI VT.
9.5.2. Clinical, Unknown Clinical, and Nonclinical Ventricular
Tachycardia
The ﬁrst goal of VT ablation is to abolish the clinical VT,
which can be accomplished in 90%–100% of patients inducible at baseline (S9.5.5.10–S9.5.5.13). However,
determining which VT is clinical can often be challenging.
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Although a 12-lead VT ECG is not available for most patients, the stored ICD electrograms, if available, can act as
an accurate surrogate for the 12-lead ECG (S9.5.5.14). CL
of both spontaneous and induced VTs can vary, and CL alone
is often insufﬁcient for recognizing clinical VT (S9.5.5.14).
Adding to the challenge of determining the area of interest
and the endpoint for ablation is the lack of up-front inducibility of any VT in 7%–24% of patients (S9.5.5.12,S9.5.5.
15,S9.5.5.16) and speciﬁcally that of clinical VT in 13%–
30% of patients (S9.5.5.12,S9.5.5.14,S9.5.5.17). It is
important to note that most patients are inducible for
multiple previously undocumented VTs, with separate
circuits and variable exit sites from the scar (S9.5.5.12,S9.
5.5.18–S9.5.5.20). The clinical relevance of VTs induced
in the electrophysiology laboratory without prior
documentation is unclear; numerous laboratories have only
targeted induced VTs with CL equal to or longer than that
of clinically observed VT(s) but not those with
comparatively shorter CLs (S9.5.5.18,S9.5.5.20). In these
multicenter trials, the VT rate could be markedly reduced
in a substantial number of patients; however,
approximately 50% of patients experienced VT recurrence
within 6 months (S9.5.5.18–S9.5.5.20).
The association between noninducibility following ablation for any VT, including nonclinical VTs and the subsequent greater freedom from VT recurrence, supports the
clinical relevance of nonclinical VTs. However, as many as
41% of the patients who remain inducible for nonclinical
VT do not present with recurrence during short-term
follow-up (see Section 9.17) (S9.5.5.12,S9.5.5.21). A
potentially useful electrophysiological characteristic in
distinguishing relevant from nonrelevant induced VTs is
the similarity between VT CL and the baseline ventricular
refractory period, given that VTs with a CL within 30 ms
of the ventricular refractory period CL (fast VT based on
the individual ventricular refractory period) rarely occur
spontaneously (S9.5.5.22). The presence of only the latter
VTs has been associated with low VT recurrence, comparable to that of patients who were rendered noninducible by
ablation (S9.5.5.22).

9.5.3. Mapping and Ablation Strategy
Mapping and ablation strategies are determined by the type of
VT and substrate. After MI, a minority of patients have only
mappable VTs (hemodynamically tolerated, reproducibly
inducible, with stable morphology) that allow for extended
activation and entrainment mapping (S9.5.5.12,S9.5.5.18,
S9.5.5.20). Hence, for most patients, additional mapping
methods need to be employed in conjunction with
entrainment mapping to identify critical components of the
reentry circuit. Although there is no single gold standard
approach, a reasonable workﬂow is presented in Figure 9.
Voltage mapping facilitated by 3D EAM systems
(Section 8) is considered the standard for invasive identiﬁcation of scar tissue during sinus rhythm and has been validated
by histology in postinfarct animal models (S9.5.5.23–S9.5.5.
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26). For electroanatomically conﬂuent and dense scars
typical of nonreperfused infarcts (S9.5.5.8), VT-related sites
are often but not exclusively located in low-voltage areas (S9.
5.5.27,S9.5.5.28). To provide additional guidance in
identifying putative isthmus sites in low-voltage areas,
especially for unmappable VTs, several additional
strategies have been suggested focusing on electrogram
characteristics (split, late, fractionated potentials) and pace
mapping (S9.5.5.18,S9.5.5.20,S9.5.5.23,S9.5.5.24,S9.5.5.
29,S9.5.5.30). Mapping within regions of low voltage
while pacing with extrastimuli at sites remote from lowvoltage regions has also been demonstrated to be useful for
exposing abnormal conduction regions that can be critical
for VT (S9.5.5.31–S9.5.5.34).
Various RF lesion delivery strategies have been described,
ranging from focal ablations guided by entrainment mapping
to ablation of the entire scar (S9.5.5.13,S9.5.5.18). Suggested
strategies include short linear lesions from the putative VT
exit sites toward the center of the substrate, across the
presumed critical isthmus and/or along the scar border zone
(S9.5.5.23,S9.5.5.24,S9.5.5.30). However, the endpoint for
these short linear lesions is often arbitrary. Circumferential
isolation of the identiﬁed scar (bipolar voltage ,1.5 mV)
(S9.5.5.35) or the “core” containing potential VT isthmus elements (regions with bipolar voltage ,0.5–1 mV and potentially important sites identiﬁed by entrainment, activation,
and pace mapping) (S9.5.5.36), conﬁrmed by demonstrating
exit block from the core, has been suggested as an incrementally useful ablation endpoint beyond VT noninducibility.
Other methods incorporate the goal of demonstrating functional entrance block into regions of scar tissue, as demonstrated by the elimination of all previously identiﬁed LPs or
local abnormal ventricular activities, either by targeting channels of conduction or by direct ablation at all abnormal sites
(S9.5.5.13,S9.5.5.37–S9.5.5.39). These approaches often
involve more comprehensive substrate modiﬁcation than
the initial strategy of transecting potential circuits with
linear lesion sets.
Although substrate-based ablation for clinical and induced
VTs remains a probabilistic approach to VT ablation, the
technique has been successfully performed after a presumed
ﬁrst VT episode and in patients with recurrent VT despite
AAD therapy (S9.5.5.18,S9.5.5.29,S9.5.5.30,S9.5.5.40).
After substrate modiﬁcation guided by clinical and
induced nonclinical VT, a signiﬁcant number of patients
experience recurrence of symptomatic VT, including 30%
of patients who have been rendered noninducible after
ablation (S9.5.5.21). The number of induced VTs is a
potential surrogate for a larger and complex substrate (S9.
5.5.12,S9.5.5.18), and larger scars have been associated
with VT recurrence (S9.5.5.12). Recurrent VT can be due
to lesion recovery or incomplete lesions with local modiﬁcation of the substrate (S9.5.5.16,S9.5.5.41). Although
some of these VTs originate from a previously targeted
area, they can have a different morphology based on 12lead ECGs or ICD electrograms (S9.5.5.16,S9.5.5.41).
However, recurrent VT can also originate from unmapped
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Figure 9 Overview of the workﬂow for catheter ablation of VT in patients
with IHD. Not all of these steps might be required, and steps can be performed in a different sequence. For instance, repeat VT induction can be deferred in patients with hemodynamic instability. In addition, the operator
might have to adapt to events that arise during the case, for instance, to
take advantage of spontaneous initiation of stable VT during substrate mapping and switch to activation mapping. IHD 5 ischemic heart disease;
PES 5 programmed electrical stimulation; SR 5 sinus rhythm; VT 5 ventricular tachycardia.

areas or from those areas not considered relevant during the
index ablation (S9.5.5.41).
9.5.4. Substrate-Based Ablation Strategies Without Upfront
Ventricular Tachycardia Induction
Substrate-based approaches that target some or all abnormal
electrograms, irrespective of clinical and/or induced VTs,
have been suggested (Table 7), which can also be performed
if VT is not inducible or if VT induction is not desired because
of safety concerns (S9.5.5.13,S9.5.5.15,S9.5.5.31,S9.5.5.37).
These strategies have targeted sites with abnormal
electrograms, either of the entire scar in the endocardium
and epicardium (S9.5.5.13) or, more selectively, target sites
with LPs (S9.5.5.15) anywhere within the scar or sites with
fractionated potentials predominantly located in the border
zone, which are markers for conducting channels
(S9.5.5.37), or that have targeted sites with abnormal potentials that are poorly coupled to the myocardium (ie, LAVA)
(S9.5.5.31). These techniques have been demonstrated to be
superior to those employed in the control groups in the previously cited studies. There is, however, no generally accepted
control group, and it is therefore difﬁcult to compare the
beneﬁt of the various approaches with each other.
There is currently no standardized approach for
substrate-guided ablation, and deﬁnitive comparisons between different techniques and endpoints are not available. The procedural outcomes (eg, noninducibility,
elimination of LPs or LAVA, substrate or core isolation,
scar dechanneling) are acute endpoints that cannot be
easily randomized and/or applied to all patients with
VT. The association between a procedure’s endpoint

e95
and favorable VT-free survival might simply reﬂect a
less complex substrate in patients for whom the desired
endpoint can be achieved. However, success with more
comprehensive ablation strategies has been consistently
observed (S9.5.5.42).
It is important to note that studies have suggested various
deﬁnitions for abnormal electrograms as surrogates for the
VT substrate targeted by ablation (S9.5.5.15,S9.5.5.16,S9.
5.5.31–S9.5.5.34,S9.5.5.38,S9.5.5.39,S9.5.5.43,S9.5.5.44).
Validation is challenging and usually limited to mappable
VTs (S9.5.5.38). The speciﬁcity and sensitivity of these
abnormal electrograms for identifying the VT substrate
throughout the range of observed post-MI scars recorded
with different catheters, electrode sizes, and interelectrode
spacings remain to be determined.
High-resolution mapping of post-MI reentrant VT in an
animal model of reperfused MI indicates that functional conduction block during VT can play an important role
(S9.5.5.45), and these areas might not be detectable during sinus rhythm or pacing at slow rates. Targeting sites that show
delayed conduction after delivering extrastimuli has been
shown to be beneﬁcial, with a smaller target area and lower
VT recurrence than when other sites were targeted (S9.5.5.
33,S9.5.5.34).
This result might be particularly relevant for patients
with small, less conﬂuent or nontransmural scars after
MI, in whom parts of the VT substrate might be functional,
and a systematic application of an RV short-coupled extrastimuli can be useful for identifying hidden substrate
components.
High-density multielectrode mapping with smaller electrode sizes and spacings can be helpful in obtaining more
complete and rapid characterization of the arrhythmogenic
substrate (Section 8), allowing for superior characterization
of low-amplitude local electrograms from thin endocardial
myocardium, which can be obscured by large far-ﬁeld
potentials from adjacent myocardium if catheters with large
electrodes with distant interelectrode spacing are used
(S9.5.5.46–S9.5.5.49). Further studies are required to
assess the effect of these mapping techniques on ablation
outcomes.
Finally, imaging is of major importance for identifying
scars and the critical arrhythmogenic substrate within the
scar. The use of various imaging modalities has been detailed
in Section 5. Numerous studies have demonstrated a good
correlation between CMR-deﬁned scars and EAM-deﬁned
scars. The same is true for CT in which the wall thickness
has been employed to identify scars in patients post infarction. Increased tissue heterogeneity within the scar demonstrated by CMR has helped to identify critical sites that can
be selectively targeted (S9.5.5.50), resulting in decreased
VT recurrences. Likewise, CT-deﬁned scar topography helps
to identify critical VT target sites (S9.5.5.51). Critical areas
are often located in myocardial ridges that are separated by
areas of thinning (S9.5.5.51).
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1) Scar dechanneling
targeting entrance
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between scar and mitral
annulus)
3) Ablation of VT-related
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1) Scar dechanneling
— Achieved in 85 pts
(84.2%)
— Noninducible after 1)
55 pts (54.5%)
2) Noninducibility
—achieved in 78%

RF time endocardial median
z25 min epicardial z6
min
Procedure time
Median 210–270 min
Complications
3.1%
In-hospital mortality
2.5%

VT recurrence 32% after
median 82 (16–192)
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VT recurrence according to
endpoint 1+2 achieved
(16.4%)
Endpoint 2 achieved (46%)
No endpoint achieved
(47.4%)

RF time 36 6 20 min
Procedure time 250 6 78
min
Complications 7.5% (4
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Procedure-related mortality
1.3%

VT-free survival 55% during
47 months (33–82)
Outcome according to
endpoints:
LAVA abolished vs not
abolished 63% vs 44%
VT-free survival at 1 year
73%
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Silberbauer et al. 160
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(S9.5.5.15)
One center
observational

VT recurrence 27% after a
RF time
median follow-up of 21
24 6 10 min only scar
months (11–29)
dechanneling (31 6 18
min + additional RFCA) 1-year VT-free survival
according to endpoint:
Procedure time
scar dechanneling
227 6 69 min
complete vs incomplete
Complications 6.9%
(z82% vs z65%)
No death
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Porta-Sanchez et 20
al. (2018)
(S9.5.5.34)
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2) Recurrent VT

60
de Riva et al.
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(S9.5.5.33)
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Study

N

Inclusion

Access mapping
catheter

Mapping strategy

Procedural endpoint

1) Targeting areas with
DEEP
2) Ablation of VT-related
sites discretion of
operator

1) Noninducibility—
achieved in 80% after
DEEP ablation
— Remains 80% after
additional ablation in
those inducible

RF time 30.6 6 21.4 min
Procedure time and
complications not
reported

VT recurrence 25% at 6month follow-up

1) Targeting EDPs only
2) Ablation of VT-related
sites based on
activation/pace
mapping

1) Elimination of EDPs —
achieved in all
2) Noninducibility of
targeted VT (fast VT
with VTCLzVERP not
targeted)
— Achieved in 67% after
EDP ablation
— Achieved in 90% after
additional ablation

RF time
15 min (10–21)
Procedure time
173 min (150–205)
Complications
3.3%
One procedure-related
death

VT recurrence 22% at
median follow-up of 16
months (8–23)
Subgroup of patients with
EDPs in normal-voltage
areas at baseline
(hidden substrate)
compared to historical
matched group without
EDP mapping
VT-free survival at 1 year
89% vs 73%

Included studies: post myocardial infarction (or data for patients post myocardial infarction provided).
AAD 5 antiarrhythmic drug; BV 5 bipolar voltage; BZ 5 border zone; CABG 5 coronary artery bypass grafting; CE-MRI 5 contrast-enhanced magnetic resonance imaging; DC 5 delayed component; DEEP 5 decremental evoked potential; ECG 5 electrocardiogram; EDP 5 evoked delayed potential; EF 5 ejection fraction; EGM 5 electrogram; ICD 5 implantable cardioverter deﬁbrillator; LAVA 5 local abnormal ventricular activity;
MI 5 myocardial infarction; PEA 5 pulseless electrical activity; PES 5 programmed electrical stimulation; pts 5 patients; PVC 5 premature ventricular complex; RCT 5 randomized controlled trial; RF 5 radiofrequency;
RFCA 5 radiofrequency catheter ablation; RV 5 right ventricle; SHD 5 structural heart disease; SR 5 sinus rhythm; VT 5 ventricular tachycardia.
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RF time procedural duration VT recurrence and burden
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Ablation strategy
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9.5.5. Epicardial Mapping and Ablation
The role of postinfarction epicardial mapping and ablation is
not clearly deﬁned.
Despite a predominant subendocardial substrate in most
patients, reentry circuits can be conﬁned to the subepicardial
layer (S9.5.5.3). The current incidence of epicardial substrate
in patients referred for catheter ablation is unknown. ECG
features are not reliable for predicting epicardial LV-VT
exit in postinfarction VT (S9.5.5.52). Epicardial circuits
might also be interrupted from the endocardium, particularly
in areas with wall thinning, and evidence of this phenomenon
is more frequently observed in post-MI patients than in patients with DCM (S9.5.5.53). Some 42%–57% of all postMI patients included in multicenter studies (S9.5.5.18,S9.5.
5.29,S9.5.5.40,S9.5.5.54) and 23%–41% of patients from
single-center series (S9.5.5.12,S9.5.5.15,S9.5.5.16) had
previously undergone cardiac surgery. In most patients, the
presence of substantial pericardial adhesions from surgery
or postinfarct pericarditis requires the creation of a surgical
window in the electrophysiology lab or operating room to
access the pericardial space. Even after epicardial access
has been achieved, mapping can be particularly limited
over the anterior wall (S9.5.5.55,S9.5.5.56). Continued oral
anticoagulation and dual antiplatelet therapy raise the
concern for bleeding risks associated with pericardial
puncture (S9.5.5.16).
In experienced referral centers, percutaneous or surgical
epicardial access has been considered appropriate in 9%–
29% of patients (S9.5.5.12,S9.5.5.15,S9.5.5.16,S9.5.5.55).
At least 6% of post-MI patients referred for VT ablation
beneﬁt from an epicardial procedure (S9.5.5.55). A previously failed endocardial ablation preceded most of the epicardial procedures. Caution is advised, however, given the often
associated comorbidities and the large proportion of patients
with insufﬁcient target structures that can be safely ablated in
the epicardium (S9.5.5.55). Furthermore, procedural failure
can be related to reasons other than an epicardial VT origin.
Based on the available data, the relative contribution of ﬁrstline epicardial ablation to a patient’s outcome remains unclear.
For a large number of patients, accessible epicardial ablation
target sites cannot be identiﬁed, and these patients are exposed
to additional procedural risks and discomfort. Considering the
higher risk for procedural complications with an epicardial
approach (S9.5.5.57), careful patient selection is warranted.
Further study is required to determine whether preprocedural
imaging can help to identify post-MI patients who will beneﬁt
from an epicardial approach (S9.5.5.58,S9.5.5.59).

References
S9.5.5.1.

S9.5.5.2.

S9.5.5.3.

de Bakker JM, Coronel R, Tasseron S, et al. Ventricular tachycardia in the
infarcted, Langendorff-perfused human heart: role of the arrangement of
surviving cardiac ﬁbers. J Am Coll Cardiol 1990;15:1594–1607.
de Bakker JM, van Capelle FJ, Janse MJ, et al. Macroreentry in the
infarcted human heart: the mechanism of ventricular tachycardias with a
“focal” activation pattern. J Am Coll Cardiol 1991;18:1005–1014.
Kaltenbrunner W, Cardinal R, Dubuc M, et al. Epicardial and endocardial
mapping of ventricular tachycardia in patients with myocardial infarction.
Is the origin of the tachycardia always subendocardially localized? Circulation 1991;84:1058–1071.

e99
S9.5.5.4.

S9.5.5.5.
S9.5.5.6.

S9.5.5.7.

S9.5.5.8.

S9.5.5.9.

S9.5.5.10.

S9.5.5.11.

S9.5.5.12.

S9.5.5.13.

S9.5.5.14.

S9.5.5.15.

S9.5.5.16.

S9.5.5.17.

S9.5.5.18.

S9.5.5.19.

S9.5.5.20.

S9.5.5.21.

S9.5.5.22.

S9.5.5.23.

S9.5.5.24.

S9.5.5.25.

Downar E, Harris L, Mickleborough LL, Shaikh N, Parson ID. Endocardial mapping of ventricular tachycardia in the intact human
ventricle: evidence for reentrant mechanisms. J Am Coll Cardiol
1988;11:783–791.
Das MK, Scott LR, Miller JM. Focal mechanism of ventricular tachycardia
in coronary artery disease. Heart Rhythm 2010;7:305–311.
de Bakker JM, van Capelle FJ, Janse MJ, et al. Slow conduction in the
infarcted human heart. “Zigzag” course of activation. Circulation 1993;
88:915–926.
de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988;77:589–606.
Wijnmaalen AP, Schalij MJ, von der Thusen JH, Klautz RJ, Zeppenfeld K.
Early reperfusion during acute myocardial infarction affects ventricular
tachycardia characteristics and the chronic electroanatomic and histological substrate. Circulation 2010;121:1887–1895.
Piers SR, Wijnmaalen AP, Borleffs CJ, et al. Early reperfusion therapy affects
inducibility, cycle length, and occurrence of ventricular tachycardia late after
myocardial infarction. Circ Arrhythm Electrophysiol 2011;4:195–201.
Della Bella P, De Ponti R, Uriarte JA, et al. Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular
tachycardia; long-term outcome in relation to acute electrophysiological
ﬁndings. Eur Heart J 2002;23:414–424.
Yokokawa M, Kim HM, Baser K, et al. Predictive value of programmed
ventricular stimulation after catheter ablation of post-infarction ventricular
tachycardia. J Am Coll Cardiol 2015;65:1954–1959.
de Riva M, Piers SR, Kapel GF, et al. Reassessing noninducibility as ablation endpoint of post-infarction ventricular tachycardia: the impact of left
ventricular function. Circ Arrhythm Electrophysiol 2015;8:853–862.
Di Biase L, Burkhardt JD, Lakkireddy D, et al. Ablation of stable VTs
versus substrate ablation in ischemic cardiomyopathy: the VISTA randomized multicenter trial. J Am Coll Cardiol 2015;66:2872–2882.
Yoshida K, Liu TY, Scott C, et al. The value of deﬁbrillator electrograms for
recognition of clinical ventricular tachycardias and for pace mapping of postinfarction ventricular tachycardia. J Am Coll Cardiol 2010;56:969–979.
Silberbauer J, Oloriz T, Maccabelli G, et al. Noninducibility and late potential abolition: a novel combined prognostic procedural end point for
catheter ablation of postinfarction ventricular tachycardia. Circ Arrhythm
Electrophysiol 2014;7:424–435.
Wolf M, Sacher F, Cochet H, et al. Long-term outcome of substrate modiﬁcation in ablation of post-myocardial infarction ventricular tachycardia.
Circ Arrhythm Electrophysiol 2018;11:e005635.
Kuck KH, Tilz RR, Deneke T, et al. Impact of substrate modiﬁcation by
catheter ablation on implantable cardioverter-deﬁbrillator interventions in
patients with unstable ventricular arrhythmias and coronary artery disease:
results from the Multicenter Randomized Controlled SMS (Substrate
Modiﬁcation Study). Circ Arrhythm Electrophysiol 2017;10:e004422.
Stevenson WG, Wilber DJ, Natale A, et al. Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular
tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.
Calkins H, Epstein A, Packer D, et al; Cooled RF Multi Center Investigators Group. Catheter ablation of ventricular tachycardia in patients
with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol 2000;
35:1905–1914.
Tanner H, Hindricks G, Volkmer M, et al. Catheter ablation of recurrent
scar-related ventricular tachycardia using electroanatomical mapping and
irrigated ablation technology: results of the prospective multicenter
Euro-VT-study. J Cardiovasc Electrophysiol 2010;21:47–53.
Ghanbari H, Baser K, Yokokawa M, et al. Noninducibility in postinfarction ventricular tachycardia as an end point for ventricular tachycardia
ablation and its effects on outcomes: a meta-analysis. Circ Arrhythm Electrophysiol 2014;7:677–683.
Watanabe M, de Riva M, Piers SRD, et al. Fast nonclinical ventricular tachycardia inducible after ablation in patients with structural heart disease: deﬁnition and clinical implications. Heart Rhythm 2018;15:668–676.
Soejima K, Suzuki M, Maisel WH, et al. Catheter ablation in patients with
multiple and unstable ventricular tachycardias after myocardial infarction:
short ablation lines guided by reentry circuit isthmuses and sinus rhythm
mapping. Circulation 2001;104:664–669.
Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions
for control of unmappable ventricular tachycardia in patients with ischemic
and nonischemic cardiomyopathy. Circulation 2000;101:1288–1296.
Wrobleski D, Houghtaling C, Josephson ME, Ruskin JN, Reddy VY. Use
of electrogram characteristics during sinus rhythm to delineate the

e100
endocardial scar in a porcine model of healed myocardial infarction. J Cardiovasc Electrophysiol 2003;14:524–529.
S9.5.5.26. Reddy VY, Wrobleski D, Houghtaling C, Josephson ME, Ruskin JN. Combined epicardial and endocardial electroanatomic mapping in a porcine model
of healed myocardial infarction. Circulation 2003;107:3236–3242.
S9.5.5.27. Wijnmaalen AP, van der Geest RJ, van Huls van Taxis CF, et al. Head-tohead comparison of contrast-enhanced magnetic resonance imaging and
electroanatomical voltage mapping to assess post-infarct scar characteristics in patients with ventricular tachycardias: real-time image integration
and reversed registration. Eur Heart J 2011;32:104–114.
S9.5.5.28. Verma A, Marrouche NF, Schweikert RA, et al. Relationship between successful ablation sites and the scar border zone deﬁned by substrate mapping for ventricular tachycardia post-myocardial infarction. J Cardiovasc
Electrophysiol 2005;16:465–471.
S9.5.5.29. Marchlinski FE, Haffajee CI, Beshai JF, et al. Long-term success of irrigated radiofrequency catheter ablation of sustained ventricular tachycardia: post-approval THERMOCOOL VT trial. J Am Coll Cardiol
2016;67:674–683.
S9.5.5.30. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for
the prevention of deﬁbrillator therapy. N Engl J Med 2007;357:2657–2665.
S9.5.5.31. Jais P, Maury P, Khairy P, et al. Elimination of local abnormal ventricular
activities: a new end point for substrate modiﬁcation in patients with scarrelated ventricular tachycardia. Circulation 2012;125:2184–2196.
S9.5.5.32. Acosta J, Andreu D, Penela D, et al. Elucidation of hidden slow conduction
by double ventricular extrastimuli: a method for further arrhythmic substrate identiﬁcation in ventricular tachycardia ablation procedures. Europace 2018;20:337–346.
S9.5.5.33. de Riva M, Naruse Y, Ebert M, et al. Targeting the hidden substrate unmasked by right ventricular extrastimulation improves ventricular tachycardia ablation outcome after myocardial infarction. JACC Clin
Electrophysiol 2018;4:316–327.
S9.5.5.34. Porta-Sanchez A, Jackson N, Lukac P, et al. Multicenter study of ischemic
ventricular tachycardia ablation with decrement-evoked potential (DEEP)
mapping with extra stimulus. JACC Clin Electrophysiol 2018;4:307–315.
S9.5.5.35. Tilz RR, Makimoto H, Lin T, et al. Electrical isolation of a substrate after
myocardial infarction: a novel ablation strategy for unmappable ventricular tachycardias–feasibility and clinical outcome. Europace 2014;
16:1040–1052.
S9.5.5.36. Tzou WS, Frankel DS, Hegeman T, et al. Core isolation of critical
arrhythmia elements for treatment of multiple scar-based ventricular tachycardias. Circ Arrhythm Electrophysiol 2015;8:353–361.
S9.5.5.37. Berruezo A, Fernandez-Armenta J, Andreu D, et al. Scar dechanneling:
new method for scar-related left ventricular tachycardia substrate ablation.
Circ Arrhythm Electrophysiol 2015;8:326–336.
S9.5.5.38. Arenal A, Glez-Torrecilla E, Ortiz M, et al. Ablation of electrograms with
an isolated, delayed component as treatment of unmappable monomorphic
ventricular tachycardias in patients with structural heart disease. J Am Coll
Cardiol 2003;41:81–92.
S9.5.5.39. Irie T, Yu R, Bradﬁeld JS, et al. Relationship between sinus rhythm late
activation zones and critical sites for scar-related ventricular tachycardia:
systematic analysis of isochronal late activation mapping. Circ Arrhythm
Electrophysiol 2015;8:390–399.
S9.5.5.40. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before deﬁbrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial.
Lancet 2010;375:31–40.
S9.5.5.41. Yokokawa M, Desjardins B, Crawford T, Good E, Morady F, Bogun F.
Reasons for recurrent ventricular tachycardia after catheter ablation of
post-infarction ventricular tachycardia. J Am Coll Cardiol 2013;61:66–73.
S9.5.5.42. Brice~
no DF, Romero J, Villablanca PA, et al. Long-term outcomes of
different ablation strategies for ventricular tachycardia in patients with
structural heart disease: systematic review and meta-analysis. Europace
2018;20:104–115.
S9.5.5.43. Di Biase L, Santangeli P, Burkhardt DJ, et al. Endo-epicardial homogenization of the scar versus limited substrate ablation for the treatment of electrical storms in patients with ischemic cardiomyopathy. J Am Coll Cardiol
2012;60:132–141.
S9.5.5.44. Nakahara S, Tung R, Ramirez RJ, et al. Distribution of late potentials
within infarct scars assessed by ultra high-density mapping. Heart Rhythm
2010;7:1817–1824.
S9.5.5.45. Anter E, Tschabrunn CM, Buxton AE, Josephson ME. High-resolution
mapping of postinfarction reentrant ventricular tachycardia: electrophysiological characterization of the circuit. Circulation 2016;134:314–327.
S9.5.5.46. Berte B, Relan J, Sacher F, et al. Impact of electrode type on mapping of
scar-related VT. J Cardiovasc Electrophysiol 2015;26:1213–1223.

Heart Rhythm, Vol 17, No 1, January 2020
S9.5.5.47.

S9.5.5.48.

S9.5.5.49.

S9.5.5.50.

S9.5.5.51.

S9.5.5.52.

S9.5.5.53.

S9.5.5.54.
S9.5.5.55.

S9.5.5.56.

S9.5.5.57.

S9.5.5.58.

S9.5.5.59.

Leshem E, Tschabrunn CM, Jang J, et al. High-resolution mapping of ventricular scar: evaluation of a novel integrated multielectrode mapping and
ablation catheter. JACC Clin Electrophysiol 2017;3:220–231.
Tschabrunn CM, Roujol S, Dorman NC, Nezafat R, Josephson ME,
Anter E. High-resolution mapping of ventricular scar: comparison between
single and multielectrode catheters. Circ Arrhythm Electrophysiol 2016;
9:e003841.
Tung R, Josephson ME, Bradﬁeld JS, Shivkumar K. Directional inﬂuences
of ventricular activation on myocardial scar characterization: voltage mapping with multiple wavefronts during ventricular tachycardia ablation.
Circ Arrhythm Electrophysiol 2016;9:e004155.
Andreu D, Penela D, Acosta J, Fernandez-Armenta J, et al. Cardiac magnetic resonance-aided scar dechanneling: inﬂuence on acute and long-term
outcomes. Heart Rhythm 2017;14:1121–1128.
Ghannam M, Cochet H, Jais P, et al. Correlation between computer tomography-derived scar topography and critical ablation sites in postinfarction
ventricular tachycardia. J Cardiovasc Electrophysiol 2018;29:438–445.
Martinek M, Stevenson WG, Inada K, Tokuda M, Tedrow UB. QRS characteristics fail to reliably identify ventricular tachycardias that require
epicardial ablation in ischemic heart disease. J Cardiovasc Electrophysiol
2012;23:188–193.
Komatsu Y, Daly M, Sacher F, et al. Endocardial ablation to eliminate
epicardial arrhythmia substrate in scar-related ventricular tachycardia. J
Am Coll Cardiol 2014;63:1416–1426.
Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus
escalation of antiarrhythmic drugs. N Engl J Med 2016;375:111–121.
Sarkozy A, Tokuda M, Tedrow UB, et al. Epicardial ablation of ventricular
tachycardia in ischemic heart disease. Circ Arrhythm Electrophysiol 2013;
6:1115–1122.
Soejima K, Couper G, Cooper JM, Sapp JL, Epstein LM, Stevenson WG.
Subxiphoid surgical approach for epicardial catheter-based mapping and
ablation in patients with prior cardiac surgery or difﬁcult pericardial access. Circulation 2004;110:1197–1201.
Sacher F, Roberts-Thomson K, Maury P, et al. Epicardial ventricular
tachycardia ablation a multicenter safety study. J Am Coll Cardiol 2010;
55:2366–2372.
Acosta J, Fernandez-Armenta J, Penela D, et al. Infarct transmurality as a criterion for ﬁrst-line endo-epicardial substrate-guided ventricular tachycardia
ablation in ischemic cardiomyopathy. Heart Rhythm 2016;13:85–95.
Izquierdo M, Sanchez-Gómez JM, Ferrero de Loma-Osorio A, et al. Endoepicardial versus only-endocardial ablation as a ﬁrst line strategy for the
treatment of ventricular tachycardia in patients with ischemic heart disease.
Circ Arrhythm Electrophysiol 2015;8:882–889.

9.6. Dilated Cardiomyopathy

Key Points
 Identifying the location and extent of scarring on CMR
is beneﬁcial in procedural planning and has improved
the outcomes of ablation in patients with DCM.
 The ablation strategy is similar to postinfarction VT.
 An intramural substrate is more frequently encountered
in DCM than in postinfarction patients and requires a
different ablation strategy than for patients with either
epicardial or endocardial scarring.
 Epicardial ablation is beneﬁcial if the scar is located in
the epicardium of the LV free wall.
 For intramural circuits involving the septum, epicardial
ablation is not beneﬁcial.
 In the absence of CMR, unipolar voltage mapping has
been described as a method to indicate a deeper-seated
scar.

Cronin et al. Catheter Ablation of Ventricular Arrhythmias
In nonischemic DCM, ablation may be considered for
sustained monomorphic VT, recurrent polymorphic VT, or
VF initiated by triggering PVCs (see Section 9.9), and for
frequent nonsustained VT and PVCs that are suspected of
contributing to ventricular systolic dysfunction or interfering
with effective delivery of cardiac resynchronization pacing
(see Section 4.3).
The prevalence of DCM is estimated to be in the range of
37 cases per 100,000 population (S9.6.1). Although the etiology is often clinically obscure, approximately 40% of patients have a genetic cause (S9.6.1). Although uncommon,
sustained monomorphic VT occurs at an annual rate of
approximately 3%–4% in patients with an ICD, a LVEF
0.35, nonsustained VT, and no prior history of sustained
VAs (S9.6.2). In the DANISH trial, fewer than 3% of the patients with class II or III heart failure symptoms and an LVEF
0.35 had sustained VT during a median follow-up of 5.6
years (S9.6.3). In a series of 158 patients with DCM, a
mean LVEF of 0.31, and no history of sustained VT, 13%
of the patients were found to have inducible sustained monomorphic VT (S9.6.4). VT due to DCM is occasionally
encountered in patients with atherosclerotic coronary artery
disease and is suggested by the presence of multiple basal
origin VTs and scar regions extending beyond the distribution expected from an infarct (S9.6.5).
Three VT mechanisms have been identiﬁed in patients undergoing ablation (S9.6.6–S9.6.8), the most common of
which is scar-related reentry, accounting for more than
80% of sustained monomorphic VTs. Reentry involving
the bundle branches or fascicles (see Section 9.4) is encountered in up to 19% of patients, whereas focal VT mechanisms
occur less frequently.
CMR with gadolinium contrast identiﬁes areas of delayed
hyperenhancement consistent with myocardial ﬁbrosis in
30%–50% of patients with DCM, and the presence of this
scarring is associated with an increased risk of sudden death
and VT (S9.6.9–S9.6.11). In patients with monomorphic VT,
CMR also identiﬁes scar areas that are a valuable guide to
potential ablation target regions, given that the reentry
circuit sites are usually associated with .25% scar
transmurality (S9.6.12–S9.6.18). CMR is therefore
particularly helpful in planning and performing ablation
procedures in these patients. Knowledge of the scar
location has improved ablation outcomes in patients with
DCM (S9.6.19).
The approaches to mapping and ablation for scar-related
VTs in DCM are similar to those for postinfarction VTs; however, intramural substrates that are not easily identiﬁable or
accessible for ablation are more common than in the postinfarct population and contribute to procedure failures and recurrences (S9.6.8,S9.6.12,S9.6.20,S9.6.21). The relevant
scar area is identiﬁed from imaging and/or substrate
mapping. When VT can be induced and is sustained and
hemodynamically tolerated, a combination of activation
mapping and entrainment mapping can be used to select the
ablation region in or near the scar area (S9.6.20,S9.6.22).
When VT is not mappable and an area of low voltage
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(bipolar voltage ,1.5 mV) can be identiﬁed that is
consistent in location with the VT QRS morphology, a
substrate type of approach can be used in the endocardium
and/or epicardium (S9.6.23–S9.6.26). Although isolated
LPs and fractionated potentials are encountered less
frequently than in postinfarct VT scars, these electrogram
targets can still be used to guide ablation (S9.6.26,S9.6.27).
Pace mapping can suggest the VT exit region; however, as
with other scar-related VTs, critical parts of the reentry circuit
where ablation may also be successful can be several centimeters distant from the exit region. One study found that when a
low-voltage area is present, extensive ablation over the region
(both endocardially and epicardially) was associated with a
lower risk of VT recurrence compared with targeting only
inducible VTs (S9.6.28). Absence of inducible VT after ablation is associated with a lower risk of VT recurrence (S9.6.
29–S9.6.31). Another study found that the presence of only
rapid VTs after ablation (CL ,30 ms plus the RV effective
refractory period measured at a pacing CL of 400 ms) was
not associated with a greater risk of recurrence (S9.6.32).
Scar-related VTs tend to originate from scar regions along
the mitral annulus or within the interventricular septum (S9.
6.12,S9.6.20,S9.6.22,S9.6.33). Multiple morphologies of
inducible VT and poorly tolerated VTs are common. The
VT circuit can involve the endocardial, epicardial, or
intramural regions of the LV. The ECG morphology of the
VT is a useful guide to the likely target region and can
inform the initial approach. The risk, outcomes, and
approach to ablation also vary with the substrate location.
VTs that originate from an LV scar in the free wall along
the mitral annulus typically have an RBBB conﬁguration and
dominant R waves in the midprecordial leads (V3, V4), with
an axis directed inferiorly (if the VT exit is superior) or superiorly (if the VT exit is inferiorly located) (S9.6.12,S9.6.20).
A qS or QS conﬁguration in lead I often indicates an
epicardial exit, consistent with initial forces directed from
the epicardium to the endocardium. The QRS morphology
can be misleading, however, particularly for fast VTs (S9.
6.14,S9.6.34). Epicardial ablation is often helpful, although
some of these VTs can be successfully ablated from the
endocardium. With LV free wall VTs, some laboratories
start with mapping in the epicardium, obtaining epicardial
access before anticoagulation is administered. Other
laboratories always start on the endocardium to avoid the
risks of epicardial access and obtain this if the endocardial
approach fails. In reported series from experienced centers,
epicardial mapping is performed in 29%–74% of patients
(S9.6.12,S9.6.22,S9.6.35,S9.6.36). The approach to
epicardial ablation is reviewed in Section 6.3. Recognizing
that low voltage can be recorded over epicardial fat and
avoiding the left phrenic nerve and coronary artery injury
are important considerations (S9.6.37).
VTs that originate from the anteroseptal region typically
have a dominant S wave in V1, with an inferior axis and
prominent R waves by V3 to V4 (S9.6.12,S9.6.20). The
frontal plane axis can be inferiorly or superiorly directed. If
the scar extends leftward along the aortic root and toward
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the AMC region, the VT can have a dominant R wave in
V1 with an inferior axis. If the scar extends inferiorly in
the septum, VTs with a superiorly directed axis can be
present. Ablation for VTs that originate in scars at the
anteroseptum has a lower success rate compared with those
from the inferolateral basal LV in a number of studies (S9.
6.12,S9.6.20). Access from the epicardial aspect is limited
by the overlying RVOT, the epicardial fat pad, and the
left coronary arteries. In the septum, ablation can be
limited by proximity to the AV conduction system.
Determining the risk of heart block and managing its
consequences are important considerations. Implementation
of pacing for CRT might be warranted if ablation results in
AV block.
Intramural VTs can occur in any location but are common
in the periaortic region and septum (S9.6.12,S9.6.20,S9.6.33).
Preprocedural CMR is the gold standard for identifying
scarring and is particularly helpful in identifying intramural
scars (Section 5). Identiﬁcation of intramural scars is best
accomplished by a preprocedural CMR. In the absence of
CMR data, intramural scarring is suspected when the endocardial bipolar voltage is .1.5 mV (with 3.5-mm electrode
mapping catheters) over the endocardial region that is closest
to the VT. If located at the LV free wall, an epicardial origin
can be excluded when epicardial mapping fails to identify a
VT substrate in the overlying epicardium. The unipolar endocardial voltage can be helpful for identifying deeper seated
scar tissue. An LV unipolar voltage ,8.3 mV over an area
with an endocardial bipolar voltage .1.5 mV is consistent
with intramural or epicardial scars; however, electrogram
amplitude is also dependent on wall thickness, and there
is substantial variability (S9.6.33,S9.6.38–S9.6.40). As
indicated in Section 8.5.2, different voltage cutoff values
have been reported, and validation studies with CMRdeﬁned scars have demonstrated that there is a substantial
overlap of unipolar low voltage between scar zones and regions without scars. These cutoff values should therefore be
used with caution in the absence of available CMR data. Septal
intramural scars are suggested by a conduction time of .40
ms when pacing is performed on the RV side of the septum,
and recording from the adjacent LV septum (S9.6.41). Use
of intracardiac ultrasound has also been suggested for detecting scars, but data are limited (S9.6.42). The optimal approach
to ablation for these VTs is not deﬁned; however, ablation targeting the closest overlying endocardial and epicardial sites is
effective in some patients.
Overall outcomes are largely from case series published
by experienced centers, a number of which have included results from multiple procedures (S9.6.12,S9.6.20–S9.6.24,S9.
6.26,S9.6.28,S9.6.31,S9.6.36,S9.6.43). Ablation abolishes at
least 1 inducible VT in 60%–74% of patients and all
inducible VTs in 43%–72% of patients. Programmed
stimulation is not performed after ablation in 10%–15% of
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patients, largely due to hemodynamic concerns. Persistent
inducibility of sustained monomorphic VT is associated
with increased recurrences (S9.6.29–S9.6.31). During
median/mean follow-ups ranging from 15 to 48 months,
31%–61% of patients experience at least 1 VT recurrence.
Approximately half of those with recurrent VT experience
fewer VT episodes than prior to ablation (S9.6.12,S9.6.22).
When directly compared in the same center, recurrent VT
is more frequent after ablation for DCM VT than for
postinfarction VT (S9.6.21). Transplant-free survival ranges
from 76% to 89%. Patients with large scar areas associated
with larger areas of low voltage and VTs that have LV apical
exits, often associated with scar extending from base to
near the apex, have increased mortality during follow-up
(S9.6.43,S9.6.44).
Complications, including vascular access bleeding, tamponade, and volume overload, are reported in 4%–11% of patients (S9.6.22,S9.6.23,S9.6.31). Serious complications,
including tamponade requiring surgery, phrenic nerve
injury, and coronary artery injury, are more frequent
when percutaneous epicardial access is performed (S9.6.22,
S9.6.35). Thromboembolic complications appear to be rare,
but pulmonary embolism can occur. In-hospital mortality is
as high as 3% and has been reported due to uncontrollable
VT, refractory heart failure, and tamponade sequelae
(S9.6.23). When LV systolic function is severely depressed,
the option of cardiac transplantation or an LVAD is an important consideration if the arrhythmia cannot be controlled or if
the procedure is complicated by hemodynamic deterioration.
Mechanical support has also been employed during ablation
procedures to prevent hemodynamic deterioration and to
facilitate mapping (Section 6). Ablation that results in
LBBB or AV block can lead to hemodynamic deterioration
due to cardiac dyssynchrony that can warrant implementation
of biventricular pacing. Extensive ablation of areas of normal
myocardium has the potential to further impair ventricular
function, although this risk has not been clearly deﬁned.
It seems prudent to avoid empiric ablation over large regions
that are not known to contain scars.
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9.7. Ventricular Tachycardia Ablation in
Hypertrophic Cardiomyopathy

Key Points
 Polymorphic VT and VF are the most common VAs in
HCM; monomorphic VT is less common.
 The arrhythmogenic substrate in HCM often involves
the septum but can extend to the epicardium, often
necessitating combined endocardial and epicardial
ablation procedures to eliminate the VT.
 VT associated with apical aneurysms is often ablated
endocardially.
Malignant VA contributes to sudden death in patients with
HCM. ICDs are therefore the mainstay of prevention. The
substrate for VAs in HCM is complex. The combination
of myoﬁbrillar disarray and ﬁbrosis likely generates
heterogeneous conduction properties and, together with the
vulnerability of the hypertrophied myocardium to supplydemand ischemia, creates a potentially arrhythmogenic
milieu (S9.7.1–S9.7.3). Interstitial-type ﬁbrosis (compared
with replacement ﬁbrosis), postmyectomy scars, alcohol
ablation, and the presence of an apical aneurysm can also inﬂuence arrhythmogenesis (S9.7.4). The ﬁbrotic areas visualized on CMR that characterize HCM can result in a similar
substrate to scars from ischemic disease, in which case
similar techniques can be applied during VT ablation (S9.7.
5–S9.7.8). However, increased myocardial thickness and
intramyocardial or epicardial sites of ﬁbrosis limit the reach
of classical mapping and ablation methods. The varying
mechanisms (eg, reentrant vs triggered) and morphology
(monomorphic vs polymorphic) of VAs encountered in
HCM represent further challenges. ICD records indicate
that polymorphic VT degenerating to VF is the most
common event (S9.7.9–S9.7.11).
Ablation is generally performed for monomorphic VT that
recurs despite antiarrhythmic therapy, particularly with ICD
shocks. These VAs are only a small proportion of VAs in
HCM, and the ablation experience is limited to case reports
and small case series of highly selected patients. In a series
of 10 patients with preserved LVEF (LVEF of 57% 6
13%), programmed stimulation induced clinical VT in 7 patients (S9.7.12). A mean of 2 VTs per patient (including
nonclinical VTs) were induced. VTs were sometimes stable
and permitted activation and entrainment mapping. Voltage
mapping identiﬁed a combination of epicardial and endocardial scars in most patients. Isolated endocardial or epicardial
scarring rarely occurred. The ablation strategy entailed targeting late or fractionated electrograms and pace mapping
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and/or substrate modiﬁcation targeting low bipolar voltage
(1.5 mV) regions. It is worth noting that epicardial ablation
was required in most patients. During a 3-year follow-up,
30% of the patients underwent recurrent shocks, with repeat
procedures required for 2 patients.
A similar approach was used in another series of 22 patients with more advanced disease (mean LVEF of 35%)
(S9.7.13). Scar-related VTs occurred most often (60%)
from the LV-RV junctions, either at the basal (42%) or apical
(18%) LV segment level (coinciding with the anatomical regions frequently associated with ﬁbrosis). Epicardial ablation
was required in almost two-thirds of the patients, and 73% remained arrhythmia-free at 20 months. In another report of 5
patients with the dilated phase of HCM (LVEF of approximately 35%), VT circuits were predominantly distributed
in the basal septum and the basal anterior to anterolateral
LV. In addition to the endocardial ablation, intracoronary
ethanol ablation and surgical cryoablation were required in
a number of patients (S9.7.14).
Patients with HCM and an LV apical aneurysm have a
greater risk of sudden death, embolic stroke, and progressive
heart failure than the general population with HCM and warrant special consideration (S9.7.15). The thin-walled dyskinetic or akinetic segment can be composed of dense scars
with channels of viable myocardium (resembling ischemic
substrate). Both sustained monomorphic VTs and VTs
with an RBBB or LBBB pattern in lead V1 can occur, the
latter consistent with an exit from the septal aspect of the
aneurysm. Careful imaging is important for deﬁning the
aneurysm and ruling out thrombi prior to the procedure.
Transthoracic contrast echocardiography, left ventriculography, and real-time visualization with ICE can be helpful.
Anticoagulation therapy is a reasonable postprocedure treatment. Ablation strategies can include those techniques used
for ICM (S9.7.16). In a recent series, endocardial ablation
was successful in most patients, and epicardial ablation was
required in only 1 patient (S9.7.17). In a number of cases,
however, the aneurysm does not have low-voltage endocardial or epicardial scars. When ablation is not possible
or is ineffective, surgical approaches could be successful
(S9.7.18,S9.7.19).
Common themes emerge from these reports on ablation
for monomorphic VT in HCM. ECG characteristics might
not be helpful for locating epicardial or intramural circuits
(S9.7.16). Preprocedural imaging is recommended when
deciding on the endocardial vs combined endocardialepicardial approach, as in other VT substrates (see Section 5).
If unavailable, epicardial access can be obtained at the beginning of the case in anticipation of the need for combined
endocardial-epicardial ablation (S9.7.12). Intramural reentry
might be difﬁcult to target because the myocardium is thick.
Mapping methods can include a combination of voltagebased substrate mapping (using conventional voltage ranges)
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and activation, entrainment, and late or fractionated potential
mapping. VTs associated with apical aneurysms are often ablated endocardially. Although the arrhythmia mechanisms for
monomorphic VTs in HCM appear to be mostly scar-related
reentry, reports have also mentioned ablation of BBR, focal
RVOT (S9.7.12,S9.7.16), papillary muscle VTs, and left
posterior fascicular VT (S9.7.20). Reports have not suggested
an increased incidence of major complications compared with
VT ablation in other populations, although cardiac tamponade
can be more of a concern in patients with apical aneurysms. The
results of ablation are encouraging, acutely eliminating VT in
80% of patients, with more than two-thirds of patients free of
VT in the long-term follow-up. If catheter ablation is ineffective, other methods, including transcoronary alchohol and surgical resection and ablation, may be considered. Methods
enhancing lesion size in order to reach the deep arrhythmia substrate will likely facilitate treatment.
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9.8. Brugada Syndrome

Key Points
 PVC-triggered VF or polymorphic VT are the most
prevalent VAs that motivate device therapy in patients
with Brugada syndrome.
 Monomorphic VT is less frequent but can be caused by
BBRVT in patients with Brugada syndrome.
 The arrhythmogenic substrate is located in the RV
epicardium and can be demonstrated by sodium channel blockers.
 Ablation targets include fractionated prolonged electrograms on the epicardial aspect of the RV.

9.8.1. Introduction
Catheter ablation for VA in Brugada syndrome may be
considered for VF, polymorphic VT, sustained monomorphic
VT or PVCs triggering VF or polymorphic VT. Ablation strategies have evolved from initially only targeting the PVC
triggers for VA storms to the current complete elimination
of the arrhythmogenic substrate that is usually located on
the epicardial aspect of the RVOT (S9.8.6.1,S9.8.6.2).
Although quinidine can be effective for VA suppression in
Brugada syndrome, its use is complicated by its limited availability, its difﬁcult pharmacokinetics, and its adverse effects
in two-thirds of patients, leading to discontinuation in a
quarter of patients in a recent randomized double-blind trial
(S9.8.6.3). The clinical indications for catheter ablation in
Brugada syndrome are detailed in Section 4.
The worldwide prevalence of Brugada syndrome ranges
from 0.5 to 35.5 per 1000 inhabitants (S9.8.6.4). Brugada
syndrome was ﬁrst systematically described in 1992 in a
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series of 8 patients with VF arrest. Brugada syndrome is an
inherited arrhythmogenic condition deﬁned on the basis of
its characteristic ECG phenotype (S9.8.6.5). An RBBB-like
pattern with 2 mm coved ST segment elevation in the right
precordial leads constitutes the so-called type I Brugada
pattern necessary for diagnosis (S9.8.6.6). This pattern is dynamic and can ﬂuctuate according to variations in autonomic
tone, body temperature, diurnal inﬂuences, electrolyte levels,
and drug exposure, especially drugs with sodium channel
blocking properties (S9.8.6.7–S9.8.6.9). Additionally, the
ECG pattern can be concealed unless V1 and V2 are
recorded at the higher second and third intercostal spaces
(S9.8.6.10,S9.8.6.11). Multiple conditions can present as a
Brugada phenocopy and need to be ruled out before a
diagnosis of Brugada syndrome can be reached (S9.8.6.12).
The inheritance pattern for Brugada syndrome is usually
autosomal dominant. Although its genetic basis was initially
identiﬁed as a loss-of-function mutation in the SCN5A gene
encoding the a-subunit of the cardiac sodium channel
NaV1.5, numerous genetic culprits have since been recognized (S9.8.6.13).
The mechanism generating the Brugada syndrome phenotype has been the focus of signiﬁcant research, and considerable recent evidence has implicated depolarization
abnormalities in the pathogenesis of Brugada syndrome
(S9.8.6.14). However, repolarization abnormalities have
also been described, with disproportionate shortening of the
epicardial action potential leading to the potential for phase
2 reentry and the induction of polymorphic VT or VF (S9.
8.6.15,S9.8.6.16).
Subtle
but
signiﬁcant
cardiac
ultrastructural alterations, especially on the epicardial
aspect of the RVOT, have also been found in numerous
patients (S9.8.6.17). Electrophysiological and electroanatomical abnormalities have also been described in this location, present both spontaneously and upon provocation
with sodium channel blockers or the pericardial instillation
of warm water (S9.8.6.18–S9.8.6.20). High-frequency,
low-amplitude, long-duration fractionated electrograms are
routinely recorded from this region and are the target of
substrate-based ablation procedures (S9.8.6.18). Complete
elimination of all spontaneous and provoked epicardial fractionation is associated with normalization of the Brugada
ECG phenotype and with elimination of inducible and spontaneous VAs in most patients at the short-term follow-up (S9.
8.6.18,S9.8.6.20–S9.8.6.23).

9.8.2. Approach to Triggering Premature Ventricular
Complexes
For patients with recurrent PVC-triggered VF or polymorphic VT with ongoing spontaneous PVCs, localization of
these focal triggers by activation mapping or pace mapping
has been the dominant procedural strategy (S9.8.6.1).
Patients with Brugada syndrome, however, generally have
little ambient ectopy in between phases of arrhythmic instability, and ablation targeting VF triggers is rarely reported.
Moreover, isoproterenol administration can suppress VF

Heart Rhythm, Vol 17, No 1, January 2020
storms and prevent VF inducibility and is not likely to be
useful for provoking triggering PVCs during an ablation
procedure (S9.8.6.24,S9.8.6.25). In most reported cases,
foci have been mapped to endocardial sites in the RVOT
(S9.8.6.26,S9.8.6.27).
9.8.3. Approach to Sustained Monomorphic Ventricular
Tachycardia
Sustained monomorphic VT can occur but is unusual in Brugada syndrome. Rodriguez-Manero et al. (S9.8.6.28)
observed Brugada syndrome in 4.2% of patients with appropriate ICD interventions, with approximately half of these patients able to be pace terminated. Most of these tachycardias
were mapped to and ablated in the RVOT, although BBR was
observed in 2 of the 8 patients who underwent ablation. Sustained monomorphic VT ablation is approached similarly to
other conditions with reentrant VTs, and CMR imaging is
beneﬁcial for assessing scarring that might be due to another
disease process. The effectiveness of empiric targeting of the
epicardial RVOT substrate when sustained monomorphic VT
is not inducible is not known.
9.8.4. Approach to Polymorphic Ventricular Tachycardia/
Ventricular Fibrillation
Polymorphic VT and VF causing recurrent ICD shocks or
electrical storms are the most pressing arrhythmic indications
for catheter ablation in Brugada syndrome. In the absence of
a triggering PVC, the arrhythmogenic substrate in the RVOT
is the only possible ablation target. The preponderance of
experience ﬁnds this substrate located on the epicardial
aspect of the RVOT, with only 10% of patients having
some potential abnormal substrate identiﬁed from endocardial mapping (S9.8.6.29). For this reason, catheter ablation
for Brugada syndrome should be performed at centers with
experience in the specialized techniques of percutaneous
pericardial access and epicardial mapping (see Section 6).
Percutaneous epicardial access can be obtained in accordance with the operator’s usual technique. The anterior pericardial access approach provides direct access to the
epicardial RVOT, and the best access to this region via a posterior pericardial access approach can be achieved with the
catheter passing through the transverse sinus. Doublewiring the initial access sheath allows for a second pericardial
sheath to be placed, through which a multipolar mapping
catheter can be introduced. The ablation catheter is usually
deployed through a deﬂectable sheath to aid in obtaining
optimal tissue contact.
Once the appropriate catheter set has been deployed, the
relevant anatomy should be deﬁned. Integration of a preacquired CT into the EAM, particularly with the assistance of
ICE, is an efﬁcient means for deﬁning anatomy
(Figure 10A). Virtual epicardial (and/or endocardial RV)
chamber geometry in the EAM system can also be acquired
directly with a roving catheter.
Mapping efforts are then concentrated on the region of interest in the epicardial aspect of the RVOT. Multielectrode
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catheters with small electrodes can provide better deﬁnition
of high-frequency fractionation than ablation catheters.
Although mapping can commence in the basal state if the
Brugada syndrome ECG pattern is present at baseline, several
studies have shown an increase in the area of arrhythmogenic
substrate after administration of a sodium channel blocker
(S9.8.6.21,S9.8.6.22,S9.8.6.30). A similar effect has been
observed with the pericardial instillation of warm water
(S9.8.6.20).
All high-frequency, long-duration, multicomponent, lowamplitude fractionated or isolated late electrograms are
tagged on the substrate map (Figure 10A). Given the potential presence of signiﬁcant epicardial fat, low voltage in isolation is not indicative of underlying substrate. Caudal
extension of the substrate has been associated with the presence of concomitant inferolateral J waves and early repolarization syndrome (S9.8.6.31,S9.8.6.32).
After a complete map has deﬁned the region and extent of
the arrhythmogenic Brugada syndrome substrate, an ablation
strategy can be devised. The most important factor in this regard is the relationship of the surrounding at-risk structures.
Although the phrenic nerve is not usually a consideration, the
proximal large subdivisions of the right coronary artery are
potentially at risk, particularly the conus branch and the
RV marginal arteries (S9.8.6.32). Ablation-induced acute occlusion of the former could potentially result in VF, and
injury to the latter risks infarction of an otherwise normally
contractile RV. Coronary angiography prior to lesion delivery is therefore strongly recommended. Coronary angiography of the left coronary arteries should also be performed
because the disease process can also involve the LV epicardium.
An irrigated RF ablation catheter is used for epicardial lesion delivery, targeting the previously deﬁned fractionated electrograms. Contact force sensing helps to conﬁrm an
optimal catheter contact vector toward the epicardium rather
than outward toward the parietal pericardium. Characteristic
accentuation of Brugada syndrome-type ST elevation in the
right precordial leads is generally observed with RF application (Figure 10B) and usually resolves after RF delivery
ceases. However, acute occlusion of an RV marginal coronary artery needs to be ruled out if it persists. Ablation continues until all electrogram fractionation in the
arrhythmogenic substrate region has been eliminated, both
at rest and with repeat provocation with sodium channel
blockers. When this has been achieved, the Brugada syndrome ECG phenotype has usually normalized (both in the
standard and higher interspace recordings), and polymorphic
VAs are no longer inducible.
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investigators reporting 73%–100% freedom from recurrent
VT/VF during follow-up (S9.8.6.18,S9.8.6.22,S9.8.6.30,
S9.8.6.33). A systematic review of all published cases to
2018 found an overall 96.7% freedom from recurrent VT/
VF (S9.8.6.29). However, given that recurrent VF was
observed in several patients despite an apparently successful
procedure, catheter ablation cannot be recommended as a
replacement for ICD insertion to mitigate the risk of sudden
death in symptomatic Brugada syndrome. Additionally, most
of the reported patients had undergone ablation for symptomatic VA, and there are no controlled outcome data to support a
role for catheter ablation in asymptomatic individuals with
the Brugada syndrome ECG phenotype.
9.8.6. Risks
Catheter ablation for Brugada syndrome is an invasive and
complex procedure with signiﬁcant potential for acute and
delayed complications. These events include those related
to epicardial access and epicardial ablation and the general
risks related to invasive catheter ablation, which are detailed
elsewhere in this document (see Sections 6.3 and 10.2). The
most frequent reported complications are isolated pericardial
effusions and pericarditis (S9.8.6.18,S9.8.6.22,S9.8.6.30,S9.
8.6.33). No procedural deaths, strokes, MIs, or tamponades
have been reported to date, but the early published
worldwide experience includes only approximately 200
cases. It should be noted that these reports are from highvolume centers, and complication rates with more widespread deployment could be higher.
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Figure 10 Epicardial substrate ablation in a patient with Brugada syndrome and appropriate ICD shocks for VF. Image integration of a preacquired CT with the
electroanatomical epicardial substrate map is shown in (A). Purple represents bipolar voltage .1.5 mV. Fractionated potentials (arrows) are tagged with black
dots, and a representative example is displayed. Widespread fractionated potentials were recorded from the epicardial aspect of the RVOT extending down into the
basal RV body. Ablation lesions are tagged with red dots. Some fractionated potentials could not be ablated due to the proximity of the acute marginal branches of
the right coronary artery. Panel (B) shows the signiﬁcant transient accentuation of the Brugada ECG pattern during the application of radiofrequency energy at one
of these sites. CT 5 computed tomography; ECG 5 electrocardiogram; ICD 5 implantable cardioverter deﬁbrillator; PA 5 pulmonary artery; RA 5 right atrium;
RCA 5 right coronary artery; RFA 5 radiofrequency ablation; RV 5 right ventricle; RVOT 5 right ventricular outﬂow tract; VF 5 ventricular ﬁbrillation.
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9.9. Polymorphic Ventricular Tachycardia/
Ventricular Fibrillation Triggers

Key Points
 Recurrent PVC-induced VF is most often triggered by
PVCs originating from Purkinje ﬁbers, located in the
RVOT, the moderator band, or the LV.
 Patients with a single triggering PVC are better ablation
candidates; however, there are often multiple triggers.
 Patients with healed MI often require extensive ablation of the Purkinje ﬁber system within or at the scar
border.
 Ischemia should be ruled out as a trigger for VF prior to
ablation.
Although relatively rare, polymorphic VT and VF can be
triggered by PVCs in patients with or without structural and/
or electrical heart disease (long QT syndrome, catecholaminergic polymorphic VT, Brugada syndrome) (S9.9.1–S9.9.9).
When this occurs, the clinical presentation is often a
polymorphic VT/VF storm (S9.9.4,S9.9.5,S9.9.7–S9.9.9).
The syndrome is recognized when short-coupled, unifocal
PVCs (typically from the RVOT or Purkinje ﬁber system,
including the RV and LV papillary muscles) (S9.9.1,S9.9.
2,S9.9.7) trigger polymorphic VT or VF episodes. Ruling
out acute myocardial ischemia as the cause is important.
Several considerations have emerged from a number of
small studies on catheter ablation in patients with
polymorphic VT or VF refractory to antiarrhythmic therapy
(S9.9.1–S9.9.9): 1) mapping and ablation is facilitated
when the index PVCs are frequent; procedural planning
includes withdrawal of AADs where feasible and minimal
sedation; 2) ablation sites are often associated with
presystolic Purkinje activation; in some instances, there can
be slight variation in PVC morphology and Purkinje
potential to local ventricular activation time, suggesting
different exits from the same source (S9.9.1); 3) in the setting
of MI, successful ablation sites are related to Purkinje activation in the infarct border zone (S9.9.4–S9.9.6,S9.9.8); 4)
multiple ablation lesions are typically delivered, given the
relative imprecision of mapping and the serious
consequences of failed ablation; and 5) although acute
procedural success in experienced centers is high, late
recurrence of PVC-triggered polymorphic VT/VF is
observed in 5%–15% of patients, emphasizing the need for
deﬁbrillator therapy. Multipolar mapping and ICE imaging,
especially for PVCs originating from papillary muscles, is
helpful.
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As discussed in Section 4.3, catheter ablation is indicated for patients with drug-refractory, recurrent, monomorphic PVCs triggering polymorphic VT/VF in the
absence of SHD and for patients with remote MI. In the
acute phase of MI or in the early phase following coronary
revascularization, PVC-triggered polymorphic VT/VF is
initially best treated conservatively, given that these arrhythmias often resolve spontaneously in a relatively short
period.
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9.10. Arrhythmogenic Right Ventricular
Cardiomyopathy

Key Points
 The arrhythmogenic substrate in ARVC is located in
the epicardium and can involve the endocardium in
advanced stages.
 The most commonly affected areas are the subtricuspid
and RV outﬂow regions.
 LV involvement is not uncommon.
 Endocardial-epicardial ablation is often required and
results in higher acute success and lower recurrence
rates compared with endocardial ablation alone.
 Conventional mapping and ablation techniques,
including entrainment mapping of tolerated VT, pace
mapping, and substrate ablation, are used.
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9.10.1. Introduction to the Speciﬁc Disease Substrate
Characteristics
ARVC is a genetically determined myocardial disease characterized by progressive RV ﬁbrofatty replacement, VAs,
heart failure, and sudden cardiac death. Fibrofatty replacement starts at the epicardium or midmyocardium and extends
until becoming transmural (S9.10.4.1). The scar distribution
predominantly affects the subtricuspid and OT regions and,
less frequently, the apex (S9.10.4.2–S9.10.4.4). LV
involvement is present in more than half of all cases and is
more frequent in advanced stages (S9.10.4.5), affecting the
posterolateral subepicardium (S9.10.4.5,S9.10.4.6). ARVC
is typically diagnosed through the established Task Force
Criteria, although there is increasing evidence supporting a
role for invasive EAM to diagnose the early stages of
ARVC when Task Force Criteria are inconclusive (S9.10.4.
7–S9.10.4.9). In the early stages of the disease, VT reentry
circuits are located nearly exclusively in the epicardium
(S9.10.4.4,S9.10.4.5,S9.10.4.10,S9.10.4.11).
In
more
advanced disease, the VT substrate reaches the
endocardium, and areas in the epicardium can be ﬁbrotic
and lack reentry circuits (S9.10.4.4,S9.10.4.5,S9.10.4.10,
S9.10.4.11).
9.10.2. General Management
ICDs are recommended to prevent death in patients with
ARVC and VAs and can also be considered in those with
recognized risk factors who have not yet had VT
(S9.10.4.12). Neither AADs nor catheter ablation provides
sufﬁcient protection against sudden cardiac death. AADs (sotalol and amiodarone) are frequently used to improve symptoms and to prevent recurrent VT episodes, but have limited
efﬁcacy. Sotalol has been shown to reduce VT inducibility in
an electrophysiology study (S9.10.4.13); however, data on its
long-term efﬁcacy are limited. Limited evidence suggests
that amiodarone is the most effective drug for preventing
VAs (S9.10.4.14). Flecainide combined with metoprolol or
sotalol has also been used to suppress arrhythmias
(S9.10.4.15). Catheter ablation is commonly used to reduce
the frequency of arrhythmia episodes.
9.10.3. General Approach for Ablation
Given that ARVC affects the epicardium ﬁrst, endocardial
VT ablation alone is often insufﬁcient (S9.10.4.10,S9.10.4.
16–S9.10.4.19) and can result in VT recurrence. A
combined endoepicardial approach as ﬁrst-line therapy (S9.
10.4.4,S9.10.4.5,S9.10.4.20,S9.10.4.21)
or
adjuvant
epicardial ablation after unsuccessful endocardial ablation
or after VT recurrence results in improved acute and longterm outcomes (S9.10.4.11,S9.10.4.22). After combined or
adjuvant epicardial ablation, VT reoccurs in 16%–29%
of patients after approximately 3 years of follow-up,
with varying proportions of patients in these studies taking
AADs
(S9.10.4.5,S9.10.4.11,S9.10.4.20–S9.10.4.22).
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Predominant LV involvement is an independent predictor
of recurrence after ablation (S9.10.4.5).
Given the variable endocardium-to-epicardium disease
involvement, the beneﬁt of epicardial ablation likely varies
among patients. The presence of an epicardial arrhythmic
substrate in patients with limited or no endocardial VT substrate can be identiﬁed by endocardial unipolar voltage mapping (S9.10.4.23). Areas of endocardial unipolar voltage
,5.5 mV are associated with epicardial low-voltage scar regions. Isolated epicardial involvement with a completely
normal endocardial bipolar map has been observed in
26%–40% of patients (S9.10.4.4,S9.10.4.5,S9.10.4.11,S9.
10.4.18), and these patients might require epicardial
ablation. The low-voltage areas are typically adjacent to the
tricuspid valve annulus and in the free wall of the RVOT.
In contrast, patients with advanced stage ARVC have more
extensive involvement of the RV endocardium (wider areas
of low voltage in the bipolar map) and can have less
arrhythmic substrate in the epicardium, which is likely due
to the progressive ﬁbrofatty replacement of the subepicardial
myocardium, such that the surviving myocardium supporting
reentry is closer to the endocardium (S9.10.4.5). These patients constituted approximately 20% of patients with
ARVC in a recent multicenter study and can be recognized
by an endocardial bipolar vs unipolar low-voltage area ratio
of 0.23 (Figure 11) (S9.10.4.5).
One strategy for guiding the selective use of epicardial
mapping and ablation in ARVC is based on initial endocardial
mapping. Epicardial access is obtained for patients whose
endocardial voltage map shows limited or no endocardial substrate [eg, a bipolar vs unipolar low-voltage endocardial area
ratio of ,0.23 (S9.10.4.5)], which is characteristic of early disease. Initial endocardial ablation is performed for patients with
more extensive endocardial low-voltage substrate characteristic of advanced disease, followed by epicardial access for
epicardial ablation if the VTs that are considered clinically
relevant are still inducible. Alternatively, Santangeli et al.
(S9.10.4.22) found that a strategy of epicardial mapping and
ablation only when VTs are still inducible or recur after endocardial ablation achieved good long-term outcomes.
Conventional mapping and ablation techniques used for
other scar-related VT substrates are also employed in
ARVC. Ablation can be performed during sinus rhythm, targeting the substrate based on electrogram characteristics and
pace mapping (see Section 8) and/or during mappable monomorphic VTs. These ablation strategies have not been directly
compared in patients with ARVC and are complementary and
often combined. The procedure can be started during sinus
rhythm with the hope of reducing radiation exposure and the
need for electrical cardioversion (S9.10.4.24). Complete elimination of all substrate characterized by electrograms with delayed components by targeting the conducting channel
entrances has been shown to be a feasible and efﬁcient strategy, needing only a small amount of RF delivery in some patients (S9.10.4.4,S9.10.4.5,S9.10.4.20). Complete substrate
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elimination and noninducibility of any sustained
monomorphic VT as procedural endpoints are associated
with good long-term results.
Some VTs are catecholamine induced. A recent study
found that high-dose isoproterenol infusions could induce
PVCs that had the same morphology as sustained VTs, and
focal ablation of the PVCs eliminated these catecholaminemediated VTs (S9.10.4.25).
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(ARVC) are shown. Purple represents a voltage .1.5 mV in the bipolar maps (left and right) and .5.5 mV in the unipolar maps (center); red represents a voltage
,0.5 mV in the bipolar maps and ,3.5 mV in the unipolar maps. Moderate ARVC is deﬁned as having a bipolar/unipolar low-voltage area ratio of ,0.23 and is
associated with epicardial arrhythmogenic substrate area (ASA) (deﬁned by the presence of electrograms with delayed components of .10 cm2). Advanced
ARVC displays a bipolar/unipolar endocardial low-voltage area of 0.23, which is associated with an epicardial arrhythmogenic substrate area of 10 cm2
(S9.10.4.5). Adapted with permission from Oxford University Press (S9.10.4.5).
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9.11. Mapping and Ablation in Congenital Heart
Disease

Key Points
 Patients with a VT substrate after congenital heart
defect surgery include those with repaired tetralogy
of Fallot, repaired VSD, and repaired d-transposition
of the great arteries (D-TGA), as well as Ebstein’s
anomaly among other disease processes.
 VT isthmuses are often located between anatomical
barriers and surgical incisions or patch material.
 An AI can be identiﬁed and targeted during sinus
rhythm.
 For tolerated VTs, entrainment mapping is the method
of choice for identifying critical components of the
reentry circuit.

9.11.1. Introduction
As the population of patients with repaired CHD continues
to grow, management of recurrent VT in this population becomes increasingly important (Figure 2). Monomorphic
sustained VT approachable by catheter or surgical ablation
typically occurs in patients with ventricular incisions, surgical scars, and patch materials. Accordingly, for patients
with CHD included in mapping and ablation studies, repair
of tetralogy of Fallot is the most commonly performed procedure, followed by VSD closure and complex D-TGA
repair (S9.11.3.1–S9.11.3.7). As in other patients with
SHD who present with VT, a complete evaluation of
factors that promote arrhythmias is necessary. Cardiac
imaging to identify residual or new lesions is also
important. Hemodynamic abnormalities resulting in
increased wall stress and ischemia can serve as important
triggers for VAs (S9.11.3.8). In particular, signiﬁcant pulmonary regurgitation after prior transannular patching
with subsequent RV enlargement is a common ﬁnding in repaired tetralogy of Fallot (S9.11.3.9) and might require surgery or transcutaneous valve replacement. Treatment of the
underlying hemodynamic abnormalities can reduce the incidence of recurrent VAs by eliminating the triggers; however, the underlying substrate for monomorphic VT in
repaired tetralogy of Fallot remains (S9.11.3.10). Accordingly, concomitant intraoperative cryoablation with (S9.
11.3.9,S9.11.3.11,S9.11.3.12) or without (S9.11.3.13,S9.
11.3.14) intraoperative mapping has been successfully
performed in select patients with tetralogy of Fallot, VT,
and an indication for reoperation.
9.11.2. Mapping and Ablation
Most spontaneous and induced monomorphic VTs in
patients with CHD referred for ablation are due to macroreentry, with a critical isthmus deﬁned by anatomical
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barriers, bordered by unexcitable tissue (S9.11.3.1–S9.11.
3.4,S9.11.3.6,S9.11.3.7); however, focal mechanisms are
occasionally encountered (S9.11.3.3,S9.11.3.4,S9.11.3.6).
The boundaries of AIs are the valve annuli and (unlike
most other acquired heart diseases) patch material and
surgical incisions. Four VT-related AIs in tetralogy of Fallot
have been identiﬁed: isthmus 1, bordered by the tricuspid
annulus and the scar or patch in the anterior RVOT; isthmus
2, between the pulmonary annulus and the RV free wall
incision or RVOT patch, sparing the pulmonary valve
annulus; isthmus 3, between the pulmonary annulus and
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the VSD patch or septal scar; and isthmus 4 (which is rarely
encountered), between the VSD patch or septal scar and the
tricuspid annulus in case of an inferior muscular rim
(S9.11.3.2) (Figure 12). Additional AIs bordered by surgical
scars and valve annuli have been described after surgery for
other CHDs, including complex D-TGA, VSD closure, and
surgery for Ebstein’s anomaly (S9.11.3.4,S9.11.3.6,S9.11.3.
15). Substrate formation might depend on the coincidence
of pathological myocardial remodeling and anatomical
boundaries determined by the type and timing of prior
corrective surgery. Changes in surgical approaches over

No AI2
AI3

AI2
AI1
Large transannular
patch

AI1

RV incision
sparing the
pulmonary annulus

AI4

Muscular rim
between VSD patch
and TA

Transpulmonary
approach
small patch

AI3
no AI1 and no
AI2

Perimembranous
VSD with patch

no AI4
Figure 12 Anatomical isthmuses (AI) in repaired tetralogy of Fallot according to the surgical approach and variation of the malformation. RV 5 right ventricle;
TA 5 tricuspid annulus; VSD 5 ventricular septal defect.
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the past decades (eg, a combined transatrial-transpulmonary
approach avoiding ventriculotomies in tetralogy of Fallot)
are likely to affect the incidence and the potential substrate
for arrhythmias (S9.11.3.16). Therefore, knowledge of the
malformation and careful review of all operation records
before ablation is important.
AIs can be reconstructed during sinus rhythm by noncontact mapping (S9.11.3.3) or by electroanatomical bipolar
voltage mapping combined with high-output pacing (10
mA, 2 ms) at low-voltage sites (,1.5 mV) to identify unexcitable tissue (S9.11.3.2,S9.11.3.4). Noncapture despite good
catheter contact is indicative of patch material or surgical
scars. VT induction and activation mapping for
hemodynamically tolerated VT or pace mapping within
anatomically deﬁned isthmuses can be performed to
conﬁrm that the AI is critical for sustaining VT (S9.11.3.2,
S9.11.3.4,S9.11.3.6). Transection of the AI by connecting
the adjoining anatomical boundaries by linear RF lesions
can be performed during sinus rhythm (S9.11.3.2,S9.11.3.
4,S9.11.3.6,S9.11.3.7). Demonstration of conduction block
after transection of the VT isthmus provides a deﬁned
procedural endpoint similar to that for achieving block in
the cavotricuspid isthmus for atrial ﬂutter and is a valuable
acute procedural endpoint combined with noninducibility
(see below) (S9.11.3.2,S9.11.3.4,S9.11.3.6).
Isthmus dimension and conduction properties likely determine the susceptibility to arrhythmias. In a study that
included 24 patients with tetralogy of Fallot, electroanatomical voltage mapping combined with activation mapping during sinus rhythm demonstrated that relatively narrow and
slowly conducting AIs (calculated conduction velocity
,0.5 m/s) were the substrate for all 37 documented and
induced VTs in patients with preserved cardiac function
(S9.11.3.17). These slowly conducting isthmuses can be
identiﬁed and ablated during sinus rhythm; inducibility of
the clinical arrhythmia and hemodynamic tolerance is no
longer a prerequisite for successful ablation in patients with
AI-dependent macroreentrant VT (S9.11.3.17). Isthmus 3 between the pulmonary annulus and the VSD patch or septal
scar is the most common cause of VT and occasionally requires ablation from both the RV and LV sides of the septum
or SV for transection (S9.11.3.18).
9.11.3. Outcome After Ablation
Four recent series have reported on ablation outcomes,
combining activation mapping with a substrate-based ablation approach and including a total of 99 patients with
CHD (82 of 99 had tetralogy of Fallot) (S9.11.3.3,S9.11.3.
4,S9.11.3.6,S9.11.3.7). VTs were typically fast, with a
median CL of 295–300 ms, requiring a mapping and
ablation approach during the underlying baseline rhythm.
The deﬁnition of complete acute success (noninducibility
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with or without isthmus block) differed among the studies
or changed during the study period (S9.11.3.7) but was
achieved in 73%–82% of the patients. During a mean
follow-up ranging from 33 months to 9.5 years, VT recurred
in 12%–32% of the patients after a single procedure and in
5%–11% after repeat ablation (S9.11.3.6,S9.11.3.7).
In 2 series of adults with CHD (most with tetralogy of Fallot), successful AI ablation (combined endpoint noninducibility and isthmus block) was achieved in 25 of 34 patients
(S9.11.3.4) and in 8 of 14 patients (S9.11.3.6), respectively.
No patients with conﬁrmed conduction block had a recurrence of monomorphic VT during follow-ups of 46 6 29
(S9.11.3.4) and 33 6 7 months (S9.11.3.6), respectively.
Accordingly, noninducibility with conduction block across
the targeted isthmus is a useful ablation procedure endpoint
(S9.11.3.2–S9.11.3.4,S9.11.3.6,S9.11.3.7).
Serious procedure-related complications are rare (S9.11.3.
4,S9.11.3.6,S9.11.3.7); however, high-risk ablation target
sites, including the para-Hisian region with a risk of AV
block, need to be considered (S9.11.3.5,S9.11.3.17).
Ablation failure can result from withholding ablation due to
proximity to the conduction system and coronary arteries,
myocardial hypertrophy, and the protection of portions of
the AIs by patch material (S9.11.3.3,S9.11.3.5,S9.11.3.6,
S9.11.3.18). In particular, a pulmonary homograft can
cover parts of the infundibular septum in patients with
tetralogy of Fallot, preventing isthmus transection from an
RV approach (S9.11.3.18). Although a septal AI can be successfully approached from the LV or aorta after right-sided
ablation failure, proximity to the coronary arteries and potential damage to the aortic valve can increase the procedural
risk (S9.11.3.18). Accordingly, surgical ablation concomitant with repair of residual hemodynamic abnormalities
should be considered in these patients with spontaneous
VT, especially if new patch material will prevent postsurgical
access to the substrate. For these patients, a preoperative electrophysiology study and EAM can be helpful in guiding surgical ablation (S9.11.3.17). The use of empirical
intraoperative linear cryoablation without preoperative or intraoperative mapping, transecting AI III and AI I, has been
reported in patients with and without clinical VT, with mixed
results (S9.11.3.13). However, empiric linear lesions might
not be sufﬁcient. After intraoperative isthmus ablation was
performed in 31 patients who were inducible for VA prior
to pulmonary valve replacement, 47% remained inducible after surgery (S9.11.3.14). Similar to catheter ablation, preoperative mapping, tailored cryoablation, and intraoperative
conﬁrmation of bidirectional conduction block across linear
lesions can improve outcomes.
The strong link between a slowly conducting AI and sustained VT (S9.11.3.17,S9.11.3.18) in tetralogy of Fallot is
intriguing, and preventive ablation of these potential
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isthmus areas with a demonstration of conduction block may
be considered, especially if future surgical procedures might
affect the accessibility of these potential VT isthmus areas.
Whether this would be beneﬁcial for patients with tetralogy
of Fallot remains to be determined and will need to be
demonstrated by randomized studies.
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9.12. Sarcoidosis

Key Points
 The arrhythmogenic substrate in cardiac sarcoidosis is
often intramurally located but can include the endocardium and epicardium.
 A CMR is beneﬁcial in planning an ablation procedure
in cardiac sarcoidosis.
 The arrhythmogenic substrate can be complex and can
include areas of active inﬂammation and chronic scarring.
 The VT recurrence rate after ablation is high.
Cardiac sarcoidosis is a dynamic inﬁltrative noncaseating
granulomatous disease with periods of inﬂammation that
often culminate in ﬁbrosis (S9.12.1–S9.12.4). Patients with
cardiac symptoms and low LVEF fare the poorest among
patients with cardiac sarcoidosis in terms of prognosis and
mortality. In contrast, patients with asymptomatic cardiac
sarcoidosis and normal LVEF have a 10-year survival rate
of 89%–100%. Although only approximately 5% of patients
with systemic sarcoidosis have symptomatic cardiac involvement, autopsy and imaging studies suggest that asymptomatic cardiac involvement occurs in 25%–92% of patients
(S9.12.4–S9.12.6). Isolated cardiac involvement has been
increasingly recognized; a longitudinal study in Finland
found that nearly two-thirds of 110 patients with histologically conﬁrmed cardiac sarcoidosis had isolated cardiac involvement. The initial presentation was associated with AV block
in 48% of cases and with VT or VF in 38% (S9.12.5). The 5year survival probability for patients with cardiac sarcoidosis
treated with immunosuppression has been reported to be as
high as 95%, with the greatest beneﬁts seemingly gained
by those without severe LV systolic dysfunction (S9.12.1,
S9.12.5–S9.12.7). For patients with cardiac symptoms and
low LVEF, the 10-year survival rate is 19%–27% and the
cause of death is often heart failure or arrhythmia (S9.12.
4–S9.12.6). These ﬁndings suggest that early recognition
and treatment could be of value, although there are no
randomized trials on this issue. For patients presenting with
VT, consideration of cardiac sarcoidosis is important, given
the differences in both acute and long-term management, speciﬁcally regarding therapy with immunosuppressive drugs
(S9.12.4). A CMR can be particularly helpful in raising the
suspicion of an inﬁltrative disease process such as cardiac
sarcoidosis (S9.12.8), and obtaining this imaging is recommended in current heart failure guidelines (COR IIa, LOE
B) (S9.12.9). Importantly, cardiac sarcoidosis can mimic
ARVC, and its involvement can be localized to the RV
(S9.12.4,S9.12.10–S9.12.15). There is substantial overlap
in the clinical diagnostic criteria for ARVC and cardiac
sarcoidosis, including imaging characteristics, identiﬁcation
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of epsilon waves, surface ECG characteristics, including
signal-averaged ECG, scar distribution, VT morphologies,
and other substrate characteristics identiﬁed in intracardiac
mapping (S9.12.4,S9.12.10–S9.12.15). There are a number
of clinically useful ﬁndings that can help to differentiate the
2 conditions. In contrast to cardiac sarcoidosis, ARVC rarely
involves the septum, and therefore the conduction system is
rarely involved in ARVC (S9.12.13). The disease process in
ARVC also originates in the epicardium, whereas the granulomas in the inﬂammatory process of sarcoidosis are located
within the myocardium and reach the endocardium/epicardium by extension of the intramural lesions (S9.12.16). Reaching a cardiac tissue diagnosis is often difﬁcult because
granulomatous inﬁltration can be patchy, and the yield of blind
endomyocardial biopsy is ,25% (S9.12.4). Endomyocardial
biopsy targeting areas of abnormal bipolar or unipolar voltage
has shown promise for providing greater diagnostic yield (S9.
12.4,S9.12.17).
The mechanisms of VT in patients with cardiac sarcoidosis include abnormal automaticity and triggered activity
during the inﬂammatory phase and predominantly scarrelated reentry in the chronic phase. Multiple VT mechanisms can be encountered in the same patient (S9.12.15,S9.
12.18–S9.12.27).
When PET scanning identiﬁes active inﬂammation at the
time the VT presents, acute treatment with immunosuppressive agents and AADs may be considered over ablation (S9.
12.1,S9.12.4,S9.12.13,S9.12.22,S9.12.26). There are limited
data supporting the use of steroids or immunosuppressive
therapy alone for managing cardiac sarcoidosis-related VT
(S9.12.12,S9.12.24,S9.12.26). Regimens have included
corticosteroids (prednisolone 1 mg/kg/day or equivalent),
along with steroid-sparing agents (including methotrexate,
cyclophosphamide, cyclosporine, mycophenolate, and inﬂiximab), for a minimum of 3 months, after which the medication may be tapered based on treatment response (S9.12.7,
S9.12.26). A number of studies have suggested that
immunosuppression reduces the burden of VAs (S9.12.13,
S9.12.19,S9.12.24,S9.12.26), whereas others have either
failed to show a beneﬁt or have demonstrated a worsening
of VAs (S9.12.28–S9.12.30). Data suggest that
immunosuppression could be more beneﬁcial for VAs in
early disease with preserved LVEF (S9.12.4). Nevertheless,
the current expert consensus recommendation is to consider
assessing the patients for active inﬂammation using PET
scanning and administering therapy with immunosuppressants and AADs if active inﬂammation is present (S9.12.4).
Medical therapy, including immunosuppression therapy,
has failed for most patients in reports on VT ablation in
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cardiac sarcoidosis (Table 8) (S9.12.12,S9.12.15,S9.12.26).
If urgent imaging is unavailable or the VT persists despite
empiric medical treatment, ablation may also be considered
(S9.12.4).
The ablation approach to scar-related macroreentrant VT
in cardiac sarcoidosis is similar to that employed in other
scar-related VTs (see Sections 8 and 9) and is largely based
on identifying the abnormal substrate during sinus rhythm.
Activation and/or entrainment mapping during VT is
often limited due to hemodynamic instability, multiple VT
morphologies, or noninducibility (S9.12.12,S9.12.15,S9.12.
23–S9.12.26). Substrate-based ablation targets areas with
abnormal electrograms (see Section 8) and favorable
pace maps (see Section 8) (S9.12.12,S9.12.15,S9.12.
23–S9.12.27). A feature common to other nonischemic VT
substrates is the predilection for involvement of the
epicardium (22%–26%) (S9.12.15,S9.12.25–S9.12.27) and
midmyocardium, the latter of which can be difﬁcult to
deﬁne in the absence of a CMR or with standard mapping
techniques. Granulomatous inﬁltration can affect any part
of the myocardium; cardiac imaging studies with CMR,
nuclear perfusion scanning, and PET scanning can
therefore be helpful for locating and assessing the burden
of the complex substrate (S9.12.4,S9.12.11,S9.12.13,S9.12.
25,S9.12.27). The frequent involvement of the basal
septum results in a high prevalence of right septal VTs or
VTs involving the Purkinje ﬁber system (S9.12.24), and
the predominance of a basal substrate gives rise to peritricuspid and perimitral VTs (S9.12.15,S9.12.24). Nonstandard
and investigational adjunctive ablation techniques (see
Section 9.1) designed to create larger and deeper lesions
have been used to attempt the ablation of intramural substrate
when standard ablation fails, including bipolar ablation,
needle-facilitated ablation, the use of half normal saline RF
electrode irrigation, and transcoronary arterial or venous
ethanol ablation (S9.12.28–S9.12.31).
A number of observational studies have investigated the
utility of catheter ablation in patients with cardiac sarcoidosis
(Table 8). Outcomes have varied widely, as have the differences in patient characteristics, the concomitant use of immunosuppression, and follow-up times (S9.12.12,S9.12.15,S9.
12.24–S9.12.27,S9.12.32). In general, freedom from any
recurrent VT is achieved in 45.8% of cases for up to 2
years of follow-up, with multiple procedures required in
12.5%–43% of patients (S9.12.15,S9.12.24–S9.12.27,S9.
12.32); however, the overall VT burden has been reduced
by 88% (S9.12.32). Major procedural complications have
been observed in up to 5% of cases (S9.12.25,S9.12.27,S9.
12.32).
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30
4.5%
28 (90)
16 (52)
22 (71)
42 6 15
31

LVEF 5 left ventricular ejection fraction; N 5 number; NR 5 not reported; VT 5 ventricular tachycardia.

9 (29)
31/8
31/11

24
4.7%
16 (76)
15 (71)
11 (52)
21/5
21/8
12 (57)
36 6 14
21

Median 3
(range 1–8)
Median 3
(range 1–5)

6
NR
7 (88)
1 (13)
NR
NR
NR
NR
36 6 19
8

462

33
NR
NR
6 (43)
4 (29)
14/0
14/0
12 (86)
40 6 12
14

361

20
NR
9 (100)
4 (44)
3 (33)
NR
8/1
8 (89)
42 6 14
9

567

6
NR
4 (44)
6 (75)
1 (13)
8/2
6/2
8

Koplan et al.
(S9.12.26)
Jeﬁc et al.
(S9.12.15)
Naruse et al.
(S9.12.24)
Dechering et al.
(S9.12.12)
Kumar et al.
(S9.12.27)
Muser et al.
(S9.12.25)

462
5 (63)
35 6 15

N

LVEF, %

VTs induced,
mean 6 SD
Concurrent
immunosuppressive
therapy, n (%)
Study

Table 8

Catheter ablation of ventricular arrhythmias in cardiac sarcoidosis

Mapping,
Endo n/
Epi n

Ablation,
Endo n/
Epi n

Patients undergoing
repeated
procedures,
n (%)

VT
recurrence,
n (%)

VT burden
decrease,
n (%)

Major
complications

Follow-up,
months
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9.13. Chagas Disease

Key Points
 The pathogenesis of ChD is poorly understood but
often results in an inferolateral LV aneurysm.
 The arrhythmogenic substrate is located intramurally
and on the epicardial surface, often necessitating an
epicardial ablation procedure.
9.13.1. Chagas Disease
ChD is a chronic parasitosis affecting the heart and other organs and is caused by the protozoan Trypanosoma cruzi.
ChD is transmitted to humans mainly through parasiteladen feces from a hematophagous insect vector found only
in the Americas, where the disease in considered endemic.
The World Health Organization estimates a prevalence of
ChD ranging from 1%–6% in endemic areas, with 10 million
people infected worldwide (mostly in Latin American countries), 100 million at risk of infection, and 300,000 new cases
reported each year. The World Health Organization estimates
that 50,000 CCM-related deaths occur annually, with 60%,
25%, and 15% related to sudden cardiac death, progressive
heart failure, and stroke, respectively (S9.13.3.1,S9.13.3.2).
Cardiac involvement is the most frequent and serious
manifestation of chronic ChD. Although the pathogenesis
of cardiac damage is complex and not completely understood, at least 4 possible mechanisms have been suggested:

cardiac parasympathetic neuronal depopulation, immunemediated myocardial injury, parasite persistence in cardiac
tissue with secondary antigenic stimulation, and coronary
microvascular abnormalities causing myocardial ischemia.
Diffuse arteriolar dilatation found in CCM can result in a coronary steal phenomenon of blood ﬂow from epicardial coronary arteries to dilated arterioles, producing low perfusion
pressure in the distal microvasculature supplying susceptible
areas distal to the coronary branches. The watershed areas between main coronary artery branches would be the most susceptible to this steal phenomenon, causing low perfusion
pressure, secondary ischemia, microinfarctions, and reparative ﬁbrosis. The most frequently observed areas of myocardial scarring in CCM are the posterolateral LV and the LV
apex in the watershed zones between the right coronary
and circumﬂex arteries, and the anterior descending and posterior descending coronary arteries, respectively. VT is typically related to an inferolateral LV aneurysm (S9.13.3.2).
9.13.2. Ventricular Tachycardia in Chagas Cardiomyopathy
Sustained VT is usually due to reentry, associated with an inferolateral LV scar in over 70% of patients. Occasionally,
endocardial radiofrequency ablation can result in transmural
injury, effectively treating all portions of the myocardium
involved in the arrhythmia circuit. However, scars commonly
exist intramyocardially and/or subepicardially in an area with
an associated thick layer of subendocardial myocardium.
Mapping and ablation from the epicardial surface is performed in up to 40% of patients (S9.13.3.3,S9.13.3.4). A
myocardial isthmus of surviving tissue between the
inferolateral LV scar and the mitral valve annulus can be
involved in a macroreentrant submitral circuit, as has been
described for postinfarction VTs (S9.13.3.5). BBR can occur
but is unusual (S9.13.3.6).
In CCM that presents with VT storms, cardiac sympathetic denervation (CSD) can reduce VT episodes and is a
potentially valuable treatment option (S9.13.3.7).
9.13.3. Epicardial Ablation of Sustained Ventricular
Tachycardia in Chagas Heart Disease
The prevalence of epicardial VT origins in patients with
CCM is high (approximately 37%). Electrograms obtained
during epicardial mapping from the areas giving rise to VT
are similar to those observed for other scar-related VTs,
including delayed potentials, mid-diastolic potentials, and
continuous electrical activity during VT. The critical isthmus
of the reentrant circuit can be conﬁrmed by entrainment maneuvers or interruption of VT with RF ablation. With the progressive nature of the disease, VT recurrences are common
(S9.13.3.4,S9.13.3.8).
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9.14. Miscellaneous Diseases and Clinical Scenarios
With Ventricular Tachycardia

Key Points
 Lamin cardiomyopathy often has a poor prognosis,
progressing to end-stage heart failure.
 VT ablation is challenging due to intramural substrates.
 VT recurrence rate is high after ablations.
 VT in patients with noncompaction tends to originate
from regions of noncompacted myocardium where
scar can be identiﬁed in the midapical LV.
 VT ablation in patients with LVAD can be challenging
due to the limitation of preprocedural imaging, and the
electromagnetic noise generated by the LVAD.

9.14.1. Lamin Cardiomyopathy
The cardiac phenotype associated with mutations in the
LMNA gene includes a familial form of DCM with autosomal dominant inheritance and a variety of clinical manifestations ranging from progressive heart failure, AV block to
supraventricular block, and VAs (S9.14.4.1–S9.14.4.3).
Malignant VAs are particularly prevalent in these patients
and can precede the development of overt DCM
(S9.14.4.4). Risk factors for developing VAs include the
presence of AV conduction abnormalities, the male sex,
and the presence of nonmissense mutations in the LMNA
gene (S9.14.4.4–S9.14.4.6). LV dysfunction has also been
reported as a risk factor for developing VAs, although
malignant VAs can occur in up to one-third of cases despite
the presence of normal LV function (S9.14.4.4). Longitudinal studies assessing the natural history of patients with
LMNA DCM have consistently described a poor long-term
prognosis regardless of the initial clinical presentation, with
most patients eventually progressing to end-stage heart failure and the need for advanced therapies including heart transplantation (S9.14.4.1,S9.14.4.4).
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The management of recurrent VAs in patients with LMNA
DCM is challenging owing to the progressive nature of the
disease, the variable response to AAD therapy, and the predominant anteroseptal location of the underlying arrhythmogenic substrates, with a high prevalence of intramural
substrates. The role of catheter ablation in managing recurrent VT in patients with LMNA cardiomyopathy has been
recently evaluated in a multicenter registry (S9.14.4.7). Of
the 25 patients included in the registry, an anteroseptal substrate was found in 82%, with all patients having multiple
inducible VT morphologies. Ablation was challenging,
with most patients having residual VT inducible at the end
of the ablation procedure. Over a relatively short-term
follow-up (median of 7 months), the mortality rate was
26%, 44% of patients were considered for mechanical circulatory support or heart transplantation, and the cumulative
VT recurrence rate was 91%. Of note, a procedure-related
complication occurred in 25% of cases, including anticipated
complete heart block (in the process of ablating septal substrate), asystole, cardiogenic shock, and thromboembolic
events. Given the overall poor success in achieving lasting
VT control, the high risk of procedural complications, and
the rapid progressive nature of the disease, catheter ablation
has only a palliative role for patients with LMNA cardiomyopathy and recurrent drug-refractory VAs.

9.14.2. Left Ventricular Noncompaction
LVNC is a rare primary cardiomyopathy likely caused by an
arrest of the normal embryogenesis of the endocardium and
mesocardium, leading to the formation of prominent trabeculations and deep intertrabecular recesses within the LV wall
communicating with the cavity (S9.14.4.8,S9.14.4.9). The
inferior and lateral walls of the LV from the mid-cavity to
the apex are the most commonly involved regions. The clinical presentation of LVNC is highly variable, ranging from
completely asymptomatic to end-stage heart failure, and is
frequently associated with VAs and thromboembolic events
(S9.14.4.8,S9.14.4.10). The substrate underlying VAs in
these patients is complex and involves pathological
myocardial changes consisting of ﬁbrosis, disruption of
cellular architecture, and noncompacted myocardium.
Reentrant VAs tend to colocalize with the regions of
noncompacted myocardium in the midapical LV cavity,
and patients can have a unique substrate distribution
compared with other forms of NICM, with isolated
involvement of the mid to apical LV segments and sparing
the perivalvular regions (S9.14.4.11). However, signiﬁcant
heterogeneity in the VA substrates has been described, and
VAs can also arise from regions remote from the noncompacted myocardial segments (S9.14.4.11,S9.14.4.12). Small
observational studies and isolated reports of patients with
drug-refractory VA have shown that catheter ablation can
be performed safely and can achieve long-term arrhythmia
control (S9.14.4.11–S9.14.4.16). Owing to the high
thromboembolic risk associated with LVNC, long-term oral
anticoagulation is usually warranted, and it is important
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that patients undergo a careful preprocedural imaging evaluation to rule out the presence of intracavitary thrombi, which
can be challenging to identify due to the presence of dense
trabeculations. Catheter ablation can be performed on uninterrupted oral anticoagulation or with efforts to minimize
the time off of oral anticoagulation using periprocedural
bridging with heparin (S9.14.4.11).
9.14.3. Congenital Left Ventricular Aneurysms
Congenital LV aneurysms and diverticula are rare and
believed to be the result of the disrupted embryogenesis of
portions of the ventricular myocardium (S9.14.4.17,S9.14.
4.18). The diagnosis of congenital ventricular aneurysms
and diverticula is typically reached through noninvasive
imaging studies after ruling out secondary aneurysmal
evolution from myocardial insults such as coronary artery
disease, inﬂammatory cardiomyopathies, and trauma.
Congenital ventricular aneurysms and diverticula can be
asymptomatic or can present with thromboembolic
complications, heart failure, myocardial rupture, or
malignant VAs and sudden cardiac death (S9.14.4.17–S9.
14.4.19). Monomorphic reentrant VTs can originate from
congenital ventricular aneurysms or diverticula (S9.14.4.
20–S9.14.4.22), and isolated reports have demonstrated
that catheter ablation can achieve arrhythmia control (S9.
14.4.20,S9.14.4.23,S9.14.4.24).
9.14.4. Left Ventricular Assist Devices
Patients with permanent LVADs have a high incidence
of recurrent VT, with an estimated incidence of 22%–53%,
with the highest incidence in patients with a history of
sustained VT prior to LVAD placement (S9.14.4.25–S9.14.
4.27). Recurrent sustained VT has been associated with
increased mortality in a select number of studies (S9.14.4.
27–S9.14.4.29). Sustained VT has negative hemodynamic
consequences in some patients, possibly due to the
deterioration of RV function. Whenever a patient with an
LVAD presents with new-onset VA, it is important to rule
out mechanical triggers such as mechanical interaction between the inﬂow cannula and the adjacent apical-septal
myocardium, “suction events,” and mechanical pump failure
resulting in worsening heart failure (S9.14.4.30,S9.14.4.31).
These issues can typically be ruled out with a transthoracic
echocardiogram, LVAD interrogation, and blood tests for
hemolysis, which can be a marker of pump thrombosis.
However, most patients presenting with repetitive sustained
VAs, particularly those with a history of VAs before the
LVAD implantation (S9.14.4.29,S9.14.4.32), have no
identiﬁable mechanical trigger and usually require therapy
to achieve VA suppression. Although antiarrhythmic
therapies have not been well studied, an observational
study by Raasch et al. (S9.14.4.32) of 61 patients undergoing
LVAD implantation reported that 9 of 15 (60%) patients in
whom amiodarone was initiated after the occurrence of
VAs remained free of recurrent arrhythmias; however, the
follow-up duration in this subgroup was not speciﬁed. In
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the patients experiencing recurrent VAs despite therapy
with amiodarone, the authors reported no convincing beneﬁts
for adjuvant therapy with other antiarrhythmic agents,
including sotalol, lidocaine, mexiletine, and procainamide.
In particular, mexiletine was added to amiodarone in 4 patients but was effective in only 1.
For recurrent VAs despite AAD therapy, catheter ablation
should be considered. Multiple observational studies and a
large multicenter registry have shown that catheter ablation
can be performed safely and effectively in patients with
LVADs (S9.14.4.33,S9.14.4.34), although there are several
important considerations. The preprocedural deﬁnition
of the substrate can be challenging due to signiﬁcant
imaging artifacts from ICD devices and the LVAD
cannula. LVADs that have a magnetically levitated impeller
introduce substantial electromagnetic noise that can render
the QRS morphology of VT from the body surface ECG uninterpretable. The aortic valve often has minimal or no motion in patients with LVADs, cusp fusion can develop, and,
in some instances, the aortic valve is surgically oversewn
to abolish aortic insufﬁciency. The SVs can be sources of
thrombi. A transseptal approach to access the LV is usually
preferred, and is the only option in some cases (S9.14.4.
33–S9.14.4.35), although the resulting atrial septal
communication can potentially cause clinically signiﬁcant
right to left shunting, with systemic oxygen desaturation in
some patients who have concomitant RV failure and
increased right atrial pressure.
Sacher et al. (S9.14.4.33) have reported on a multicenter
study of catheter ablation in 34 patients with LVADs who underwent 39 procedures (25 with a transseptal and 14 with a
retrograde aortic approach). Of note, the targeted VT was
related to the LVAD cannula in only 9% of the cases, whereas
the remaining VAs were associated with the underlying disease substrate. After a mean follow-up of 25 6 15 months, 7
patients underwent heart transplantation, 10 died, and 13
(76%) of the remaining 17 patients remained free from recurrent VT. These results are in line with other single-center
observational series (S9.14.4.34–S9.14.4.39) and support
the beneﬁts of catheter ablation as an important treatment
option for patients with LVADs and recurrent VT.
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9.15. Surgical Therapy

Key Points
 Surgery-facilitated access to the epicardium via a
limited subxiphoid incision can be helpful in the case
of adhesions.
 Cryoablation via thoracotomy is possible for posterolateral substrates and via sternotomy for anterior substrates.
In some patients, standard endocardial approaches combined with percutaneous epicardial catheter ablation remain
ineffective in providing VA control due to deep intramural
circuits (S9.15.1). Percutaneous epicardial access might not
be feasible for patients with prior pericarditis or cardiac surgery, and epicardial VTs might not be easily targeted using
standard ablation approaches (S9.15.2). Alternative treatment methods need to be considered for patients with failed
endocardial and epicardial ablation procedures (S9.15.3).
The threshold for a surgical approach might be lower if a
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concomitant surgical procedure is indicated. For patients with
an inaccessible epicardial space, percutaneous catheter ablation in the electrophysiology laboratory can be facilitated by
a surgically created epicardial window allowing entry into
the pericardial space (S9.15.4). This approach is most
straightforward in patients with an apical or inferior VA substrate, because the area of the heart closest to the window is
most easily accessed, and pericardial adhesions can limit
extensive mapping. Surgical cryoablation can also be conducted in the operating room utilizing a lateral thoracotomy
or sternotomy (S9.15.5,S9.15.6). Thoracotomy is the
preferred approach to lateral and posterior substrates,
whereas sternotomy is often needed for anterior substrates.
Portable EAM can be utilized to help to localize the
substrate, and VT can be inducible when the patient is off
the cardiopulmonary bypass. When possible, preprocedural
planning should include CT imaging of grafts for patients
with prior bypass surgery to prevent injury to these
structures. The use of surgical VT ablation has also been
described in patients undergoing percutaneous LVAD
implantation (S9.15.7,S9.15.8). Recently, there has been
growing concern regarding the increased rates of LVAD
thrombosis among patients who undergo both endocardial
and epicardial surgical cryoablation at the time of LVAD
implantation (S9.15.9). In highly selected patients with
epicardial LVOT VAs refractory to standard techniques due
to overlying epicardial fat and/or proximity to coronary arteries, open (S9.15.10) or minimally invasive (S9.15.11,S9.
15.12) approaches have been used. The full characterization
of the efﬁcacy and safety of these approaches is pending.
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9.16. Sympathetic Modulation

Key Points
 Sympathetic modulation targeting the stellate ganglia
by video-assisted thoracoscopy may be considered for
failed VT ablation procedures or VF storms.
 A temporary effect can be obtained with the percutaneous injection or infusion of local anesthetics.
The autonomic nervous system (ANS) has a central role in
regulating heart rate and cardiac function and contributes to the
pathogenesis of VA in structurally normal hearts, abnormal
hearts, and channelopathies (S9.16.1). The ANS includes the
parasympathetic component mediated by the vagus nerve
and a sympathetic component mediated by cervicothoracic paravertebral sympathetic ganglia. The ANS undergoes remodeling and becomes dysfunctional in SHD (S9.16.1). In most
situations, ANS imbalances contribute to the onset and/or
maintenance of VAs, especially through the activation of
efferent sympathetic pathways. Interventions that decrease
sympathetic tone are often beneﬁcial.
Sympathetic activation and vagal withdrawal are associated with diminished respiratory sinus arrhythmia and heart
rate variability. Iodine-123 metaiodobenzylguanidine and
11C-meta-hydroxyepinephrine imaging provide an indication of sympathetic nerve distribution and local noradrenaline reuptake that reﬂects sympathetic activity (S9.16.1).
Although iodine-123 metaiodobenzylguanidine and 11Cmeta-hydroxyepinephrine (S9.16.2) imaging ﬁndings are
associated with VA in various settings, the clinical utility
of using these ﬁndings for risk stratiﬁcation and to guide therapy has yet to be proven (S9.16.1).
Beta blockers are a ﬁrst-line therapy for VA sensitive to
ANS inﬂuences. Beta blockers often decrease idiopathic
RVOT PVCs in healthy individuals (S9.16.3) and reduce the
rate of sudden cardiac death after MI (S9.16.4,S9.16.5).
Conversely, in electrical storms due to Brugada syndrome or
idiopathic VF, beta-adrenergic stimulation by isoproterenol
infusion can abolish recurrent arrhythmia (S9.16.6,S9.16.7).
Transient CSD achieved by high thoracic epidural anesthesia with bupivacaine administered at the T1–T2 or
T2–T3 level into the epidural space can be employed as a
bridge to more deﬁnitive therapy (S9.16.8). An 80% reduction in VA episodes was observed in 6 of 8 patients undergoing thoracic epidural anesthesia, with infusion durations
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ranging from 48 to 96 hours (S9.16.8). Partial denervation can
be achieved by percutaneous stellate ganglion block and can
also quiet post-MI electrical storms (S9.16.5). A recent metaanalysis of nonrandomized studies found that temporary
percutaneous stellate ganglion block was associated with a
major acute reduction in the VA burden and supports its potential use as a bridge to more deﬁnitive therapy (S9.16.9).
Persistent CSD is achieved at open surgery (or by videoassisted thoracoscopy) by resecting the lower third to half of
the stellate ganglia and the T2 to T4 or T5 thoracic ganglia,
as well as transecting the nerve of Kuntz when present
(S9.16.10). Potential complications include Horner syndrome,
Harlequin syndrome, dyshydrosis, and regional temperature
changes (S9.16.11,S9.16.12). In a series of heterogeneous
patients with drug-refractory VA storms undergoing unilateral
or bilateral surgical CSD, ICD shocks were reduced by 90% in
90% of the patients, with left CSD less efﬁcient (50% shock
free) than bilateral CSD (S9.16.10,S9.16.13,S9.16.14). CSD
has also been shown to be effective in CCM (S9.16.15). However, denervation through stellate ganglion ablation surgery is
not always complete, and VA can recur. Nonetheless, in
patients with VA storms for whom beta blockers, antiarrhythmic medications, and catheter ablation are ineffective or
not tolerated, CSD can be considered a reasonable option, provided the treating physicians have expertise with these techniques (S9.16.4,S9.16.13,S9.16.15).
Surgical CSD can be considered for high-risk patients
with contraindications for beta blockers, for patients with
symptomatic long QT syndrome when beta blockers are
not effective, or when ICD therapy is contraindicated or
declined (S9.16.11,S9.16.12,S9.16.16–S9.16.18). CSD is
associated with a signiﬁcant reduction of events in patients
with high-risk long QT syndrome, with a reported 50%–
80% long-term success rate (S9.16.17–S9.16.21). A
signiﬁcant decrease in QTc duration is usually observed
after CSD (S9.16.11,S9.16.17).
CSD can also be considered for patients with catecholaminergic polymorphic VT and recurrent symptomatic VA
(syncope or ICD shocks) while undergoing optimal drug
therapy with beta blockers and ﬂecainide and for patients
with a contraindication for beta blockers (S9.16.12,S9.16.
22,S9.16.23). In catecholaminergic polymorphic VT with
recurrent VA despite optimal therapy, CSD achieved 80%
event-free survival at 2 years and has been advocated as an
alternative to an ICD (S9.16.21).
Spinal cord stimulation of T1 to T5 with an external stimulator appears to modulate autonomic activity, possibly via both
sympathetic inhibition and an increase in vagal activity
(S9.16.2). Spinal cord stimulation reduced VA episodes
75%–100% in a small number of patients with cardiomyopathy
and high VA burden (S9.16.17). The spinal cord stimulation
mechanism is not completely understood, and the long-term
clinical effects and safety have not been studied in humans.
Low-level stimulation of the cervical vagosympathetic trunks
or carotid body can antagonize proarrhythmic sympathetic
surges and decrease VAs in animal models, but there is no
experience for this with humans (S9.16.2).
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Renal denervation decreases both central sympathetic activity and systemic catecholamine excretion, possibly mediated through either afferent or efferent renal sympathetic
nerves and independent of the effect on blood pressure (S9.
16.2,S9.16.24). In small series or isolated cases with
various cardiomyopathies and refractory VA, catheterbased percutaneous renal denervation was observed to reduce
VAs and appeared safe (S9.16.25–S9.16.28). Techniques
and acute procedural endpoints need further evaluation, and
randomized trials are needed to assess the efﬁcacy and safety.
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9.17. Endpoints of Catheter Ablation of
Ventricular Tachycardia

Key Points
 Noninducibility of VT by PES after ablation is a
reasonable endpoint and predictor for VT recurrence
after VT ablation in patients with SHD.
 Due to the limitations of programmed stimulation, endpoints other than noninducibility have been described,
including elimination of excitability, elimination of
LPs or LAVA, dechanneling, substrate homogenization, core isolation, image-guided ablation, and
anatomically ﬁxed substrate ablation.
9.17.1. Historical Perspective
In the early days of electrophysiology testing to study arrhythmias, PES was recognized as a tool for evaluating the efﬁcacy
of treatments (at that time, drugs and surgical ablation). For
both supraventricular arrhythmia and VA, elimination of
inducible sustained tachycardia following drug or surgical
intervention, when the arrhythmia had been reproducibly
induced with PES prior to intervention, correlated with successful treatment at least by the short-term follow-up (S9.17.
4.1,S9.17.4.2). PES was known to be a somewhat unreliable
assessment tool in that 1) it did not perfectly predict
outcomes (sensitivity or speciﬁcity) and 2) signiﬁcant dayto-day variability in the results was demonstrable in the
absence of an intervention (S9.17.4.3). In addition, varying
deﬁnitions of “noninducibility” have been used, including
noninducible VA of any type using up to triple extrastimuli
from 2 RV sites and 2 drive CLs; initiation of only “nonclin-
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ical” VTs that had morphologies and/or CLs that had not been
previously observed spontaneously; and rendering a previously easily inducible VT no longer inducible at that step of
the PES protocol but without performing the complete PES
protocol. Despite these shortcomings, VA noninducibility
was regarded for over 2 decades as the standard means for assessing the efﬁcacy of therapeutic interventions, including
catheter ablation (S9.17.4.4,S9.17.4.5).
9.17.2. Programmed Electrical Stimulation
PES at the end of the ablation procedure is still employed and
remains a reasonable predictor of VT recurrence. In particular,
patients in whom relatively slow VTs (CL .300 ms) remain
inducible at the end of the procedure are more likely to experience recurrence than those in whom no VT (or only rapid, unmappable VT) is inducible (S9.17.4.6). In a recent study,
inducible nonclinical VT that has a CL longer than the RV
effective refractory period plus 30 ms was associated with
recurrent VTs, whereas faster inducible nonclinical VTs were
not associated with recurrence (S9.17.4.7). A meta-analysis
of post-MI VT ablation studies found that the absence of inducible VT was associated with a substantially lower risk of recurrent VT compared with the inducibility of nonclinical VT (odds
ratio [OR] 0.49) and clinical VT (OR 0.10) (S9.17.4.5).
The predictive capacity of immediate postablation PES
was recently challenged by Frankel et al. (S9.17.4.8), who
have shown that NIPS using the patient’s ICD a few days after the ablation procedure yielded a more accurate picture of
the likelihood of VT recurrence after ablation than the acute
end-of-procedure stimulation protocol. In this study, 18% of
patients without inducible VT at the end of the ablation procedure had inducible clinical VT using subsequent NIPS, and
another 37% had inducible nonclinical VT. Each group had
shorter recurrence-free survival than those without inducible
VT at delayed NIPS. Similar results were recently reported
by Oloriz et al. (S9.17.4.9). Numerous potential causes of
postablation recurrent VT episodes have been proposed,
including ablation lesion healing, development of new circuits, withdrawal of AADs that had suppressed some VTs,
and emergence of VTs at the periphery of ablation zones
(S9.17.4.10). The optimal management of patients found to
have inducible VT has not yet been deﬁned.
9.17.3. Current Ablation Strategies and Assessment of Results
For focal arrhythmias (such as nonsustained or sustained VT
or PVCs, typically observed in individuals without SHD),
activation and/or pace mapping are generally adequate
guides for ablation (assuming the arrhythmia was present
spontaneously or inducible prior to ablation). Assessment
of efﬁcacy is termination of VT, or elimination of PVCs,
and subsequent noninducibility of VT or PVCs by catecholamine infusion or electrical stimulation that had reliably provoked episodes prior to ablation.
For patients with SHD in whom reentry is the primary VT
mechanism, the effectiveness of ablation has usually been
assessed by PES (typically through triple ventricular extrastimuli at 1 or 2 RV sites and 1–2 drive CLs), with or without an
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adjunctive catecholamine infusion. In addition to these mapping tools, a variety of substrate-based strategies are
currently in use for ablation for VA, each with their own procedural endpoints (almost all combined with end-ofprocedure PES). A short description of these strategies is provided below (S9.17.4.11,S9.17.4.12). In many of these
studies, substrate ablation was combined with ablation
guided by activation and entrainment mapping when a
hemodynamically tolerated VT was inducible. For all of
these approaches, data are largely limited to small series
from single centers or groups of investigators.
1) Elimination of electrical excitability (S9.17.4.13): Targeting VT isthmuses between areas of electrically unexcitable scar and ablation to the extent that isthmus tissue
cannot be stimulated with unipolar pacing output of 10
mA (the endpoint of this strategy) has been shown to
result in fewer VT recurrences in follow-up. This
approach has the drawbacks of contact dependency and
time expense, especially in cases with more extensive
areas of ablation in which repeated cycles of stimulation
and ablation can be tedious and time-consuming.
2) Elimination of LPs (S9.17.4.14): Elimination of all
recordable LPs (high-frequency electrogram components
inscribed after the end of the surface QRS complex that
reﬂect slowed conduction or block) has been shown to
improve freedom from recurrent VT compared with cases
in which LPs were not eliminated (S9.17.4.15). This
approach is limited by sampling density and the time
required for remapping to assess the absence of LPs.
3) Elimination of LAVAs (S9.17.4.16): LAVAs are deﬁned
as electrograms with 2 or more distinct components that
might be evident in the resting rhythm or can be revealed
by a stimulation wavefront arriving from a different direction. LAVAs thus include standard LPs but also the split
potentials (those with an isoelectric interval between components of at least 30 ms) that are not late and even some
normal-appearing electrograms for which stimulation
might reveal previously unobserved abnormalities.
Whereas elimination of LPs has generally been performed
on the endocardium, LAVA mapping and ablation requires endocardial and (when possible) epicardial mapping and ablation. Elimination of all LAVAs (the
endpoint of this strategy) has been correlated with high
rates of freedom from spontaneous recurrence of VT.
Problems with this approach include the lack of standard
programmed stimulation methods to detect LAVA at sites
without these potentials during sinus rhythm, the extent of
ablation needed to treat all LAVAs (endocardial and
epicardial ablation, the latter might not always be
feasible), and the inability to know when all LAVAs
had been ablated successfully (sampling bias). Additionally, the mapping catheter used can affect LAVA detection, with small, closely spaced electrodes detecting
LAVA and LP more readily than standard ablation electrodes. However, this might necessitate double access to
the chamber in question or repeated catheter exchanges.
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4) Dechanneling: Using this method, EAM is used to identify sites with high-frequency delayed (not necessarily
“late”) potentials inscribed after a far-ﬁeld component in
sinus rhythm and targets those with relatively short intervals from potential entry sites into channels within scars
that can participate in reentry. Endpoints of this “dechanneling” approach are the elimination of delayed potentials
or reversal of the activation sequence of delayed potentials when recorded with multipolar catheters. VT-free
outcomes were better when complete dechanneling could
be affected (S9.17.4.17).
5) Substrate homogenization (S9.17.4.18): This strategy is
similar in principle to LP and LAVA ablation but more
broadly targets the entire region in which low-amplitude
(,1.5 mV bipolar) abnormal electrograms are observed
with very extensive ablation on both the endocardium and
epicardium when abnormal epicardial substrate is identiﬁed. The endpoint is electrogram elimination (amplitude
reduction to the background noise level or below) and noninducibility of VT. In a small randomized trial of patients
with prior MI and a nonrandomized series of patients
with post-MI and NICM, VT recurrence was less likely
with extensive substrate ablation than with ablation guided
by activation and entrainment mapping targeting only the
clinical VT (S9.17.4.18,S9.17.4.19). However, it is not
known whether this technique would be superior to the
targeting of clinical VT(s) plus more limited substrate
ablation using the other described techniques. This
approach necessarily requires extensive ablation (with
more ﬂuid volume administered if irrigated ablation is
employed) and potentially longer procedural times. The
technique is not applicable to diseases that do not have
identiﬁable low-voltage scar regions.
6) Core isolation (S9.17.4.20,S9.17.4.21): The principle
underlying this strategy is that endocardial VT circuits
can be somewhat “compartmentalized” by layers of
midmyocardial scar tissue, such that conduction is
largely spread on the endocardial surface. The
encircling of the region with abnormal electrograms that
contain the VT circuits need only reach the
midmyocardial barrier to isolate the area (ie, damage
need not be transmural). In the study by Tzou et al.
(S9.17.4.21), core isolation was usually achievable and
was associated with improved freedom from VT recurrence compared with a nonrandomized reference group.
This approach is not always feasible and requires extensive ablation in some patients. The extent to which these
core elements reconnect with healing of the ablation lesions and resolution of the edema is unknown.
7) Imaging-guided lesion assessment: Estimating the acute
extent (particularly depth) of ablation-related damage,
particularly in normal ventricular tissue, has been shown
to be feasible with intracardiac ultrasound (S9.17.4.22),
CMR
(S9.17.4.23),
near-infrared
spectroscopy
(S9.17.4.24), and by elevations in the pacing threshold
(S9.17.4.25), as well as with other methods. Lesion size
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assessment has promise for future applications as an indicator of the adequacy of ablation but has not been studied
in detail as a procedural endpoint.
8) Identiﬁcation of a largely anatomically ﬁxed substrate
during baseline rhythm by pace mapping (S9.17.4.26)
and by locating isolated potentials (S9.17.4.14) has
been beneﬁcial in identifying a critical isthmus. Targeting
the arrhythmogenic substrate by combining pace mapping
and electrogram mapping has further demonstrated a
reduction in VT recurrence in patients post infarction
(S9.17.4.27).

S9.17.4.2.

As noted, most strategies also use PES to assess for VT
inducibility at the end of the procedure. It is important to
note that the assessment of efﬁcacy of these ablation strategies is predicated on the assumption that ablation lesions
have permanent effects, which cannot be known.

S9.17.4.6.

S9.17.4.3.

S9.17.4.4.

S9.17.4.5.

S9.17.4.7.

S9.17.4.8.

9.17.4. Summary
The preponderance of experience for assessing the results of
VT ablation is with PES, despite its inherent limitations. Multiple methods of substrate ablation have been described, each
with its own procedural endpoint (but almost always with
PES assessment at the end of the procedure). Several observations can be made based on available data:

S9.17.4.9.

S9.17.4.10.

S9.17.4.11.

1) Some method of assessing success (prespeciﬁed endpoints) should be employed at the end of any ablation procedure for treating VA, insofar as possible (constrained by
patient safety considerations). Scar-based reentrant VT
usually incorporates PES using 3 extrastimuli at 2 drive
CLs from 1 or more RV stimulation sites or at least as
vigorous a stimulation protocol as was required to initiate
arrhythmia prior to ablation, as well as achieving
endpoints particular to whichever substrate-based ablation strategy is used.
2) If a “clinical” (spontaneously occurring) VT remains
inducible at the end of the procedure, the likelihood of
postprocedure recurrence is high.
3) Nonclinical VTs induced at the end of an ablation procedure have a recurrence rate during follow-up lower than
persistently inducible clinical VTs but higher than if no
VT is induced at the end of the ablation procedure. Clinicians should carefully consider the risks and beneﬁts of
targeting these nonclinical VTs, which entail longer procedure time and potential risk.
4) It is reasonable to consider using NIPS 2–3 days after
ablation to reﬁne the prognosis (see Section 10.4). If clinical VT can be initiated at that time, repeat ablation may
be considered, although the risks and beneﬁts of this
approach have not been deﬁned.
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Section 10 Postprocedural Care
10.1. Postprocedural Care: Access,
Anticoagulation, Disposition
10.1.1. Postprocedural Care: Access
Recommendations for management of venous access sites after catheter ablation of VA
COR

LOE

I

A

IIa

B-R

Recommendations

References

1. Manual compression is effective in achieving hemostasis after venous access for VT
ablation.
2. Venous access closure using temporary purse-string or ﬁgure-of-8 suture techniques
can be useful in achieving faster hemostasis and earlier ambulation and reducing
pain or discomfort associated with hemostasis compared to manual compression.

S10.1.2.1–S10.1.2.3

Recommendation-Speciﬁc Supportive Text
1. Although little has been written on postprocedural management of access sites speciﬁcally after catheter VT ablation, practices have been adapted by extrapolating results
from other procedures requiring femoral venous or arterial
access. Manual compression has been the standard of care
for achievement of hemostasis after venous sheath
removal. In randomized studies of other electrophysiology procedures comparing manual compression with
temporary suture closures or a vascular closure device,
comparable high rates of hemostasis had been achieved
(S10.1.2.1–S10.1.2.3). Extrapolating these results to
ventricular ablation procedures, manual compression is
effective in achieving hemostasis, though time to
hemostasis can be expected to be shorter with temporary
suture techniques compared with manual compression
(S10.1.2.1–S10.1.2.3).
2. The use of a temporary purse-string or ﬁgure-of-8 suture
that can be removed after achieving hemostasis has been
studied after venous access in other ablation procedures,
such as for AF, in which procedures are routinely performed on uninterrupted anticoagulation and/or with
large-bore catheters (S10.1.2.4–S10.1.2.8). Compared
with manual compression, temporary suture techniques
can yield faster hemostasis and ambulation times and
reduce the pain or discomfort associated with hemostasis.

S10.1.2.1,S10.1.2.2

Two randomized studies have shown shorter times to
hemostasis and ambulation, with one reporting reduced
rates of access complications compared with manual
compression (S10.1.2.1,S10.1.2.2).
Vascular closure device-based methods for venous closure
have not been speciﬁcally studied for electrophysiology
procedures (S10.1.2.9–S10.1.2.11). One randomized
study compared manual compression to an extravascular
closure system that delivers resorbable polyethylene
glycol sealant external to the vessel at the sheath access
point in 208 patients with a 5, 6, or 7 Fr sheath in the
common femoral vein (S10.1.2.3). There were no vascular
complications in either arm. Time to hemostasis was significantly shorter in the device arm (0.12 6 0.89 vs 7.6 6 5.7
minutes; P , .001).
When the writing committee was surveyed regarding
venous access hemostasis, all the respondents used manual
compression, approximately half (53%) used temporary
ﬁgure-of-8 or purse-string sutures some of the time, and
only 1 (6%) had used a vascular closure device.
Given that venous access complications are driven primarily by insertion difﬁculties or concomitant arterial access, reduction in venous access complication outcomes
might be best achieved with methods such as use of ultrasound at insertion, rather than by device- or suture-based
methods.
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Recommendation for management of arterial access sites after catheter ablation of VA
COR

LOE

I

A

Recommendation

References

1. Achieving arterial access site hemostasis using either manual compression or a vascular
closure device is recommended.

S10.1.2.12,S10.1.2.13

Recommendation-Speciﬁc Supportive Text
1. Arterial access after VT ablation is typically closed by
manual compression or use of vascular closure devices,
with comparably high success rates in achieving hemostasis. Though not speciﬁcally studied for VT ablation access
closure, manual compression and vascular closure device
use have been extensively studied for coronary or structural intervention procedures. Several systematic reviews
and randomized trials have demonstrated shorter time to
hemostasis, with little need for compression, shorter
time to mobilization, and lower hematoma rates with
use of vascular closure devices for arterial closure
compared with manual compression, with no differences
in vascular injury, thrombosis, or infection (S10.1.2.12,
S10.1.2.13). Extrapolating these results to arterial
closure after VT ablation, vascular closure device use
could reduce the time to hemostasis and ambulation and

reduce the risk of hematoma, compared with manual
compression. Vascular injury rates for pseudoaneurysm,
dissection, or arteriovenous ﬁstula might be more
reﬂective of insertion difﬁculties rather than of closure
methods.
Use of vascular closure devices is generally avoided if
the arteriotomy site is at or distal to the common
femoral bifurcation, if contamination of the sheath is
suspected, or if the posterior wall of the artery is
suspected to have been punctured.
When the writing committee was surveyed regarding
arterial access hemostasis, 42% of the respondents had
used manual compression 100% of the time, 29% had
used temporary ﬁgure-of-8 or purse-string sutures 1%–
25% of the time, and 67% had used a vascular closure device at least some of the time (24% had used a vascular
closure device over half the time).

Recommendations for management of epicardial access sites after catheter ablation of VA
COR

LOE

Recommendations

I

C-EO

IIa

B-NR

IIa

B-NR

IIb

C-EO

1. If pericardial bleeding or cardiac tamponade has occurred during epicardial VT
ablation, a pericardial drain should be left in place until bleeding has resolved.
2. The instillation of intrapericardial corticosteroids can be effective in reducing
pericarditic chest pain after epicardial VT mapping or ablation.
3. To reduce pericardial pain after epicardial VT ablation, unless pericardial
bleeding or cardiac tamponade has occurred, it is reasonable to remove all
pericardial access sheaths at the end of the procedure.
4. Leaving a pericardial drain in place might be reasonable in patients at high risk
for late bleeding or cardiac tamponade after epicardial VT ablation.

Recommendation-Speciﬁc Supportive Text
1. If pericardial bleeding or cardiac tamponade has occurred
during the procedure, the pericardial drain should ideally
be left in place until there is minimal drainage output. This
often requires observation in an intensive care unit and
follow-up echocardiograms to assess for residual or loculation of ﬂuid.
2. Epicardial access for VT ablation can be associated with
postprocedure pericarditic pain and acute pericarditis.
The use of steroids can reduce the incidence of postprocedure pericardial chest pain. In an animal model, triamcinolone 2 mg/kg signiﬁcantly attenuated inﬂammation and
postprocedure inﬂammatory adhesion formation after
epicardial mapping and ablation (S10.1.2.16). Della Bella
et al. (S10.1.2.14) compiled the epicardial VT ablation
experience of 6 European high-volume VT ablation centers. Of 218 patients, postprocedural precordial pain
occurred in 21% and was considered severe in half of
these. Oral steroids were used by 1 center routinely after

References

S10.1.2.14,S10.1.2.15
S10.1.2.14,S10.1.2.15

2007; 1 center routinely used intrapericardial steroids;
and 4 centers did not use steroids. Dyrda et al.
(S10.1.2.15) retrospectively evaluated the use of 3 therapeutic approaches on the incidence of pericarditis and AF
after epicardial mapping and ablation for VT in 85 cases.
The approach evolved over time from no steroids to systemic oral or intravenous steroids (1 mg/kg/day for 3
days) to intrapericardial steroids (triamcinolone acetate
2 mg/kg, injected into the pericardial space via a pigtail
catheter and left in place by capping of the pigtail).
Compared with no steroids, the incidence of pericarditic
chest pain was lower with intrapericardial steroids
(21.1% vs 58.8%; P 5 .006), but not with intravenous
or oral steroids (43.4% vs 58.8%, P 5 0.31). No difference was found in the occurrence of ECG ﬁndings for
pericarditis with steroid therapy (36.8%, 30.0%, and
41.2% for intrapericardial steroids, intravenous or oral
steroids, or no steroids, respectively), and a nonsigniﬁcant
reduced incidence of chest pain with ECG changes was
found with steroid use (13.2%, 10.0%, and 29.4% for
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intrapericardial steroids, intravenous or oral steroids, or
no steroids, respectively).
Among the writing committee members, 75% reported
instilling steroids in the pericardial space after epicardial
mapping/ablation, with 2 reporting this practice only after
extensive epicardial ablation. Methylprednisolone, triamcinolone, or triamcinolone acetate were used by 40%–
50%, and 9% had used dexamethasone. Only 8% instilled
lidocaine into the pericardial space after ablation. In the
absence of bleeding or tamponade, 38% leave a pericardial drain in place after epicardial ablation, usually for
8–24 hours (89%) or .24 hours (11%).
3. Whether or not to leave a pericardial drain in place after
epicardial ablation can be a difﬁcult decision and is based
on concerns for late cardiac tamponade. However, Della
Bella et al. (S10.1.2.14) noted that precordial pain could
be due to the pigtail left in the pericardium for continuous
drainage. In the Dyrda et al. (S10.1.2.15) study the pigtail
catheter was left in place ,3 hours in 8% and 24 hours
in 44%. More chest pain occurred if the pigtail was left in
place 24 hours (51% vs 25%; P 5 .012); however, ECG
changes were noted less frequently (19% vs 48%; P 5
.006).
4. In deciding whether to remove the pericardial drain, leaving a guidewire in the pericardial space after pericardial
sheath removal and observing several minutes with intracardiac or transthoracic echo might be useful. This can
exclude a “through and through” puncture of the RV,
which will present with early signiﬁcant hemorrhage after
sheath removal.
A pericardial drain may be left in place after epicardial
ablation based on concerns for late cardiac tamponade.
Della Bella et al. (S10.1.2.14) noted that 4 of 8 patients
with cardiac tamponade occurred late, which provided
the rationale for leaving a pericardial drain in place.
In the study by Dyrda et al. (S10.1.2.15), postprocedure
pericardial effusion or tamponade occurred in 13 patients, observed 18 6 14 hours after the procedure.
There were 4 cases of severe pericardial bleeding,
occurring acutely in 2 and delayed in 2. The delayed
cases were given low-molecular-weight heparin or heparin plus dual antiplatelet therapy.
If the drain is left in place, longer duration can be associated with pericarditic chest pain (see above), and
removal of the drain within 24 hours might reduce
the incidence of pericarditic chest pain.
10.1.2. Atrial Fibrillation After Epicardial Ventricular
Arrhythmia Ablation
The use of amiodarone might be reasonable to lower the risk
of new-onset AF after epicardial VT ablation in patients with
evidence of acute pericarditis. AF is reported to occur in
4.1%–19.5% (S10.1.2.16–S10.1.2.18) of patients after
epicardial VT ablation and tends to occur more commonly
in those with signs of pericarditis. In the study by Dyrda
et al. (S10.1.2.15), AF occurred in 8.3% of patients with no
prior history of it. Median time to new-onset AF was 36
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hours. Patients with pericarditic ECGs tended to be at greater
risk of AF (16.7 vs 3.6%; P 5 .091). Mahapatra et al.
(S10.1.2.18) reported a new AF incidence of 19.5%, and
all had clinical symptoms of pericarditis. New AF was associated with younger age, longer epicardial ablation time (424
6 169 vs 867 6 450 seconds; P , .001), longer epicardial
mapping time (103 6 28 vs 135 6 51 minutes; P 5 .02),
RV puncture (9.1% vs 50.0%; P 5 .02), and pericarditis
pain score at 24 hours (1.58 6 0.79 vs 2.25 6 0.16; P 5
.03). Prolonged drainage .24 hours was not associated
with AF incidence (P 5 .28). The occurrence of pericarditis
renders anticoagulation decisions challenging; however,
the use of steroids was not associated with a lower incidence
of AF after epicardial VT ablation in these studies (S10.1.2.
16,S10.1.2.18). In contrast, the use of amiodarone
was associated with lower rates of AF in this population
(87.9% vs 12.5%; P , .001 in the study by Mahapatra
et al.) (S10.1.2.16,S10.1.2.18). New-onset AF tends to be
paroxysmal and self-limited after epicardial VT ablation.
Amiodarone was used by only 1 writing committee member
(4%) for AF prophylaxis after epicardial ablation. The
writing committee did not feel there was sufﬁcient evidence
to make a recommendation about amiodarone use in this
setting.

References
S10.1.2.1.

S10.1.2.2.

S10.1.2.3.

S10.1.2.4.

S10.1.2.5.

S10.1.2.6.

S10.1.2.7.

S10.1.2.8.

S10.1.2.9.

S10.1.2.10.

S10.1.2.11.

Jackson N, McGee M, Ahmed W, et al. Groin haemostasis with a purse
string suture for patients following catheter ablation procedures (GITAR
study). Heart Lung Circ 2018 March 20; https://doi.org/10.1016/
j.hlc.2018.03.011 [Epub ahead of print].
Pracon R, Bangalore S, Henzel J, et al. A randomized comparison of
modiﬁed subcutaneous “Z”-stitch versus manual compression to achieve
hemostasis after large caliber femoral venous sheath removal. Catheter
Cardiovasc Interv 2018;91:105–112.
Ben-Dor I, Craig P, Torguson R, et al. MynxGrip vascular closure device
versus manual compression for hemostasis of percutaneous transfemoral
venous access closure: results from a prospective multicenter randomized
study. Cardiovasc Revasc Med 2018;19:418–422.
Aytemir K, Canpolat U, Yorgun H, et al. Usefulness of ‘ﬁgure-of-eight’
suture to achieve haemostasis after removal of 15-French calibre femoral
venous sheath in patients undergoing cryoablation. Europace 2016;
18:1545–1550.
Lakshmanadoss U, Wong WS, Kutinsky I, Khalid MR, Williamson B,
Haines DE. Figure-of-eight suture for venous hemostasis in fully anticoagulated patients after atrial ﬁbrillation catheter ablation. Indian Pacing
Electrophysiol J 2017;17:134–139.
Cilingiroglu M, Salinger M, Zhao D, Feldman T. Technique of temporary
subcutaneous “ﬁgure-of-eight” sutures to achieve hemostasis after
removal of large-caliber femoral venous sheaths. Catheter Cardiovasc Interv 2011;78:155–160.
Okada M, Inoue K, Tanaka K, et al. Efﬁcacy and safety of ﬁgure-of-eight
suture for hemostasis after radiofrequency catheter ablation for atrial
ﬁbrillation. Circ J 2018;82:956–964.
Akkaya E, Berkowitsch A, Zaltsberg S, et al. Safety and feasibility of
percutaneous skin closure using purse-string suture compared with
compression bandage after pulmonary vein isolation. J Cardiovasc Electrophysiol 2017;28:1048–1057.
Shaw JA, Dewire E, Nugent A, Eisenhauer AC. Use of suture-mediated
vascular closure devices for the management of femoral vein access after
transcatheter procedures. Catheter Cardiovasc Interv 2004;63:439–443.
Coto HA. Closure of the femoral vein puncture site after transcatheter
procedures using Angio-Seal. Catheter Cardiovasc Interv 2002;
55:16–19.
Dou E, Winokur RS, Sista AK. Venous access site closures using the
VASCADE Vascular Closure System. J Vasc Interv Radiol 2016;
27:1885–1888.

e130
S10.1.2.12.

S10.1.2.13.

S10.1.2.14.

S10.1.2.15.

Heart Rhythm, Vol 17, No 1, January 2020
Robertson L, Andras A, Colgan F, Jackson R. Vascular closure devices
for femoral arterial puncture site haemostasis. Cochrane Database Syst
Rev 2016;3:CD009541.
Jiang J, Zou J, Ma H, et al. Network meta-analysis of randomized trials on
the safety of vascular closure devices for femoral arterial puncture site
haemostasis. Sci Rep 2015;5:13761.
Della Bella P, Brugada J, Zeppenfeld K, et al. Epicardial ablation for ventricular tachycardia: a European multicenter study. Circ Arrhythm Electrophysiol 2011;4:653–659.
Dyrda K, Piers SR, van Huls van Taxis CF, Schalij MJ,
Zeppenfeld K. Inﬂuence of steroid therapy on the incidence of pericarditis and atrial ﬁbrillation after percutaneous epicardial mapping

S10.1.2.16.

S10.1.2.17.

S10.1.2.18.

and ablation for ventricular tachycardia. Circ Arrhythm Electrophysiol 2014;7:671–676.
d’Avila A, Neuzil P, Thiagalingam A, et al. Experimental efﬁcacy of pericardial instillation of anti-inﬂammatory agents during percutaneous
epicardial catheter ablation to prevent postprocedure pericarditis. J Cardiovasc Electrophysiol 2007;18:1178–1183.
Sugrue A, Killu AM, Hodge DO, et al. Signiﬁcance and clinical characteristics of atrial ﬁbrillation post epicardial access. J Interv Card Electrophysiol 2017;48:141–146.
Mahapatra S, LaPar DJ, Bhamidipati CM, et al. Incidence, risk factors,
and consequences of new-onset atrial ﬁbrillation following epicardial
ablation for ventricular tachycardia. Europace 2011;13:548–554.

10.1.3. Postprocedural Care: Anticoagulation
Recommendations for anticoagulation after VA ablation procedures
COR

LOE

Recommendations

References

IIa

C-LD

S10.1.4.1,S10.1.4.2

IIa

C-LD

IIb

C-LD

IIb

C-EO

1. After less extensive endocardial VT ablation, treatment with an antiplatelet
agent for a limited period of time is reasonable.
2. Heparin reversal with protamine for sheath removal after ablation is
reasonable.
3. After extensive endocardial VT ablation, treatment with an oral
anticoagulant for a limited period of time might be reasonable.
4. The use of heparin bridging after endocardial VT ablation may be considered
but can be associated with an increased risk of periprocedural bleeding.

Recommendation-Speciﬁc Supportive Text
1. Antiplatelet therapy for less extensive endocardial VT
ablation appears to be safe, with no signiﬁcant bleeding
nor thromboembolism risks. The Multicenter Thermocool
Ventricular Tachycardia Ablation Trial has recommended
antiplatelet therapy with aspirin 325 mg/day or anticoagulation with warfarin for 3 months after ablation, if ablation
has been performed over an area with .3 cm between
ablation sites (S10.1.4.1). No procedure-related thromboembolic complication or stroke had been detected by
neurological examination. In the study by Siontis et al.
(S10.1.4.2), in patients with less extensive ablation, antiplatelet agents with full-dose aspirin or clopidogrel plus
aspirin were used at the physician’s discretion instead of
therapeutic anticoagulation. Among 24 patients discharged on only antiplatelet agents (4 low-dose aspirin,
9 full-dose aspirin, 1 clopidogrel, 10 combination of
aspirin and clopidogrel), no deﬁnite or possible thromboembolic events and no bleeding events were documented
in the ﬁrst 3 months. Among the writing committee, over
90% prescribe either antiplatelets or anticoagulants after
endocardial VA ablation, with various criteria used to
decide which. When antiplatelets were used (almost
exclusively aspirin), the most common duration was 4
to 6 weeks.
2. Anticoagulation during left-sided VT ablation procedures
is generally reversed for sheath removal, typically with
protamine. In a retrospective cohort study of 158 patients
undergoing RF catheter ablation, including 11 for VAs,
116 received protamine and 42 did not (S10.1.4.3). No
signiﬁcant difference in thrombotic events was observed
between groups (one pulmonary embolism in the

S10.1.4.3,S10.1.4.4
S10.1.4.1,S10.1.4.2

protamine group and 0 thrombotic events in the control
group). Among 150 patients undergoing AF ablation, a
randomized trial reported that compared to control, protamine reversal of heparin led to a trend toward shorter
duration of manual compression (20 6 9 vs 24 6 16 minutes; P 5 .06) and a shorter time to ambulation (316 6
80 vs 480 6 92 minutes; P , .001), with no differences
in vascular access complications or thromboembolic
events (S10.1.4.4).
3. After extensive endocardial VT ablation, use of anticoagulation for a period of time has frequently been included
as part of postprocedural practice, although there are no
comparison studies. In the Multicenter Thermocool Ventricular Tachycardia Ablation Trial, antiplatelet therapy
with aspirin 325 mg/day or anticoagulation with warfarin
was administered for 3 months after ablation if ablation
was performed over an area with .3 cm between ablation
sites (S10.1.4.1). No procedure-related thromboembolic
complication or stroke was detected. The anticoagulation
regimens used in other major prospective clinical trials are
described in Table 9. Siontis et al. (S10.1.4.2) evaluated
an anticoagulation protocol after VT ablation of large
LV endocardial ablation areas (.3 cm between ablation
sites) in 217 patients with infarct-related VT without evidence of procedure-related pericardial effusion. Starting 8
hours after access site hemostasis, an infusion of lowdose, slowly escalating unfractionated heparin 600–900
U/h was administered for 6 hours, along with initiation
of warfarin. This was followed by 3 months of anticoagulation, or longer if another indication was present. If a
direct oral anticoagulant had been administered prior to
the procedure, it was resumed as early as 48 hours after
sheath removal if there was no bleeding. With this

Postprocedural care in prospective studies of ventricular tachycardia catheter ablation

Study

Postprocedure
NIPS

Bleeding and
thromboembolic events
(ablation arm)

AAD type

AAD duration

Follow-up

ICD programming

Anticoagulation post
ablation

Patients were continued
on the type of
antiarrhythmic therapy
they had received
before ablation.
No patient received an
AAD (other than beta
blockers) before the
primary endpoint was
reached.
The previously ineffective
AAD was continued for
the ﬁrst 6 months, after
which time drug
therapy was left to the
discretion of the
investigator.
Drug management during
follow-up was at the
discretion of the
investigator.

At least the ﬁrst 3 months
after hospital discharge

Evaluation at 1, 3, 6, 9,
12, and 24 months after
ablation

Not speciﬁed

Not speciﬁed

Four of 146 (2.7%) stroke
or TIA, 4 (2.7%)
episodes of pericardial
tamponade

N/A

Followed in the ICD clinic
at 3, 6, 9, 12, 18, and
24 months;
echocardiography at 3
and 12 months
Echocardiogram and
neurologist
examination before and
after ablation; ofﬁce
visit at 2 and 6 months,
with ICD interrogation
where applicable
At 2, 6, and 12 months,
with ICD interrogation
where applicable

Not speciﬁed

Oral anticoagulation 4–6
weeks, aspirin if fewer
than 5 ablation lesions

Not speciﬁed

Three months with either
325 mg/day aspirin or
warfarin if ablation had
been performed over an
area over 3 cm in
length.

One pericardial effusion
without tamponade,
managed
conservatively; 1 deep
venous thrombosis
Vascular access
complications in 4.7%;
no thromboembolic
complications

Investigators were
encouraged to program
ICD detection for slow
VT for at least 20 beats
or 10 seconds to allow
nonsustained VT to
terminate before
therapy is triggered.
VF zone with a cutoff rate
of 200–220 bpm and a
VT zone with a cutoff CL
of 60 ms above the
slowest documented VT
and ATP followed by
shock.
Investigators were
required to ensure that
VT detection in the ICD
is programmed at least
10 beats below the rate
of the slowest
documented VT.
Not dictated by the study
protocol

Not speciﬁed

No major bleeding or
thromboembolic
complications

Not speciﬁed

One transient ischemic STsegment elevation;
1 TIA

Calkins 2000
(S10.1.4.5)

No

SMASH-VT 2007
(S10.1.4.6)

No

Stevenson 2008
(S10.1.4.1)

No

Euro-VT 2010
(S10.1.4.7)

No

VTACH 2010
(S10.1.4.8)

No

Discouraged

Discouraged

Every 3 months from ICD
implantation until
completion of the study

CALYPSO 2015
(S10.1.4.9)

No

Discouraged

Discouraged

At 3 and 6 months

Marchlinski 2016
(S10.1.4.10)

Not required

Not dictated by the study
protocol

Not dictated by the study
protocol

At 6 months and at 1, 2,
and 3 years

Six months, after which
time drug therapy was
left to the discretion of
the investigator

Drug management during
follow-up was at the
discretion of the
investigator.
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Table 9

At the discretion of the
treating physician,
anticoagulation
recommended with
aspirin or warfarin for
6–12 weeks
Per clinical conditions and
physician preference

Cardiac perforation
(n51), pericardial
effusion (n53)
(Continued )
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(Continued )

Study

Postprocedure
NIPS

AAD type

AAD duration

Follow-up

ICD programming
VT detection at 150 bpm or
with a 10–20 bpm
margin if the patient
was known to have a
slower VT. ATP was
recommended in all
zones. The protocol was
modiﬁed to recommend
prolonged arrhythmia
detection duration for
all patients.
VF zone at 200–220 bpm,
detection 18 of 24
beats, shock only; VT
zone detection at least
16 consecutive beats,
ATP, and shocks. Where
VT rates were
exclusively .220 bpm,
VT zone at 160–180
bpm was
recommended; where
VT rates were ,220
bpm, VT zone with a CL
60 ms above the
slowest VT was
recommended

VANISH 2016
(S10.1.4.11)

No

Continued preprocedure
antiarrhythmic
medications

Not speciﬁed

A 3-month ofﬁce visit,
echo, ICD check; a 6month ofﬁce visit, ICD
check; every 6 months
thereafter, an ofﬁce
visit, ICD check

SMS 2017
(S10.1.4.12)

No

At the discretion of the
investigator

At the discretion of the
investigator

At 3, 6, 9, and 12 months,
and at 3- or 6-month
intervals until
completion of the study
or until 33-month
follow-up was reached

Anticoagulation post
ablation

Bleeding and
thromboembolic events
(ablation arm)

Intravenous heparin
(without bolus) 6 hours
after sheath removal,
then warfarin if
substrate-mapping
approach used or if
more than 10 minutes
of RF time

Major bleeding in 3
patients; vascular
injury in 3 patients;
cardiac perforation in 2
patients

Aspirin (250 mg/day) or
warfarin as
necessitated by the
underlying heart
disease

Two tamponades requiring
pericardiocentesis
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Table 9

AAD 5 antiarrhythmic dug; ATP 5 antitachycardia pacing; CL 5 cycle length; ICD 5 implantable cardioverter deﬁbrillator; NIPS 5 noninvasive programmed stimulation; RF 5 radiofrequency; TIA 5 transient
ischemic attack; VF 5 ventricular ﬁbrillation; VT 5 ventricular tachycardia.
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regimen, in-hospital bleeding occurred in 6% and an arterial thromboembolic event occurred in 1 (0.6%) patient
who had received bridging anticoagulation. Among the
214 patients discharged, 89% were prescribed systemic
anticoagulation, and no deﬁnite or possible thromboembolic events were documented in the ﬁrst 3 months; 1 patient had a major bleeding event. Of the writing committee
members, approximately two-thirds initiate anticoagulation after LV endocardial ablation in some patients, generally after more extensive lesions. The postprocedural
anticoagulation protocols in the major prospective studies
of VT catheter ablation are outlined in Table 9.
4. Heparin bridging to oral anticoagulation or ambulation
has been practiced but can be associated with a small
risk of periprocedural bleeding after VT ablation. Among
patients bridged with low-molecular-weight heparin to
oral anticoagulation after VT ablation, Siontis et al.
(S10.1.4.2) reported in-hospital bleeding in 6% of the patients. Of the two-thirds of writing committee members
who initiate anticoagulation after endocardial LV ablation, 60% initiate heparin until this has been established,
and a further 20% if starting warfarin until the international normalized ratio is .2, but not if starting a direct
oral anticoagulant. See Section 5.5 for further discussion
of this topic, including the writing committee’s practices.
10.1.4. Postprocedural Care: Disposition
After completion of VT ablation, patients are generally monitored on telemetry in the hospital for at least one day, and
often longer for VT ablation in cases of SHD or heart failure.
Patients who are hemodynamically unstable, who require hemodynamic or ventilator support, or who have had pericardial bleeding, cardiac tamponade, or a pericardial drain left
in place are usually monitored and stabilized in an intensive
care unit prior to transfer to a regular telemetry ﬂoor. Selected
right-sided ablation patients may be discharged the same day,
if stable, but patients with signiﬁcant comorbidities, any
instability, or left-sided VA ablation are typically monitored
.24 hours. Transtelephonic or CIED remote monitoring is
often used to facilitate follow-up (see Section 10.4). Outpatient follow-up generally occurs by 1–4 months after the procedure.
A survey of the writing committee showed that 42%
routinely have patients monitored in an intensive care unit after ventricular ablation. Stable patients are kept in the hospital
for 1 day (overnight) by 35%, 2 days by 52%, 3 days by 9%,
and .3 days by 4% of the writing committee members.
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10.2. Incidence and Management of Complications
10.2.1. Introduction
Ablation of VAs is an invasive procedure that can be performed in patients with or without SHD. Despite new technologies and progress in techniques in recent years,
complications are expected, especially in patients with
more severe disease. In fact, the incidence of complications
related to VT ablation is higher in patients with SHD than
in idiopathic VT (S10.2.9.1–S10.2.9.3).
For the purpose of this document, major complications are
deﬁned as those that result in prolongation of hospital stay or
another hospitalization, those that require additional intervention for treatment, and/or those that result in signiﬁcant
injury or death. All other complications, such as small hematomas not requiring intervention, are deﬁned as minor. A
recent meta-analysis reported major complication rates of
8%–10% after VT ablations (S10.2.9.4). Slightly higher
complication rates have been reported in administrative and
registry real-world studies compared with clinical trials
(9.39% vs 7.97%) (S10.2.9.4). The most common complication reported is vascular damage, followed by pericardial
complications (cardiac tamponade, hemopericardium, pericarditis). Although new technologies and techniques have
been incorporated for VT ablations, the rate of complications
has not decreased, perhaps because more patients at high risk
have been scheduled for ablation (S10.2.9.2). It is also
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notable that in one recent study, the complication rates were
independently related to operators and to timing of the procedure, with signiﬁcantly higher complication rates when
the ablation was begun after 2 pm (10% vs 5%; P , .0001)
(S10.2.9.5).
10.2.2. Mortality
Interpretation of mortality in the setting of VT ablations in
patients with SHD is difﬁcult, given mortality can be a consequence of procedure-related complications but can also be
related to procedural failure (incessant or recurrent VT).
Table 10 shows the incidence of in-hospital or early mortality
in patients who underwent VT ablation. Some clinical trials
have shown no mortality, whereas other studies have reported rates of in-hospital or early mortality as high as 3%
(S10.2.9.1,S10.2.9.2,S10.2.9.6–S10.2.9.10). Some of the
following predictors of in-hospital or early mortality have
been reported: smoking, hypothyroidism, ﬂuid and electrolyte disturbances, chronic renal failure, peripheral vascular
disease, lower LVEF, history of AF, ICM, and multiple
slow VTs (S10.2.9.1,S10.2.9.6,S10.2.9.7). It is also
important to note that VT ablation in low- or mediumvolume centers has been shown to be an independent predictor of mortality in these complex ablations (S10.2.9.1).
10.2.3. Acute Periprocedural Hemodynamic Decompensation
and Cardiogenic Shock
Periprocedural AHD, deﬁned as sustained systolic hypotension despite optimized doses of vasopressors or requiring mechanical HS and procedure discontinuation, can occur in up
to 11% of VT ablations in patients with SHD (S10.2.9.10).
The occurrence of AHD is associated with increased inhospital and long-term mortality, higher recurrence of VT,
and procedure failure (S10.2.9.10,S10.2.9.12–S10.2.9.14).
Some of the following predictors of AHD have been
reported, although they were tested only in a univariate
analysis: older age, diabetes mellitus, ICM, NYHA class
III/IV, VT storm, lower EF, prolonged procedure duration,
and general anesthesia. Ablation should be carefully
planned in these patients (S10.2.9.10). A score was developed to identify higher-risk patients, who might beneﬁt
from periprocedural HS. The PAAINESD score is further
discussed in Section 5.1.
Some measures can help to prevent these complications:
close monitoring of ﬂuid balance and diuresis, careful attention to hemodynamic status, optimization of medical status
before ablation, avoidance of VT induction in higher-risk patients, preferring substrate mapping ablation, and avoidance
of general anesthesia and certain drugs that can result in
myocardial depression, including propofol. Use of a pLVAD,
as discussed in Section 6.4, might be helpful in speciﬁc cases
(S10.2.9.11–S10.2.9.14).
The pLVAD has been used in two scenarios: prophylactic,
when higher-risk patients are identiﬁed, and for rescue during
an acute complication. When used prophylactically, the
pLVAD has been shown to prevent AHD and has a lower
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30-day mortality (4.2% vs 58%). Mathuria et al.
(S10.2.9.15) showed a similar 30-day mortality among patients with prophylactic use compared to the non-pLVAD
group (4.2% vs 3.1%), although the ﬁrst group showed a
higher PAAINESD score (16.5 vs 13.5; P 5 .02). Other
studies have failed to demonstrate the beneﬁt of pLVAD,
although the fact that these devices are selected for patients
with more severe disease is a bias that is not possible to
rule out (S10.2.9.11,S10.2.9.13–S10.2.9.16). Furthermore,
few randomized, prospective, controlled trials exist to
identify the appropriate utility of this device in the setting
of VA ablation.
10.2.4. Neurological Complications
Neurological complication is a rare but devastating event due
to cerebral emboli or intracerebral hemorrhage that can occur
with VA ablation, with a reported incidence of 0% to 2.7%
(S10.2.9.1,S10.2.9.6–S10.2.9.9). It can occur during or
shortly after the ablation procedure, usually in the ﬁrst 24
hours, although in the 2 subsequent weeks following the
procedure the risk is still present. Possible mechanisms for
thromboembolic complications include thrombus formation
on the catheter or on the tissue, air embolism, plaque
disruption in the aortic arch, displacement of endocardial
thrombus adhered to LV prior to ablation, char formation
and/or tissue disruption during ablation, or generation of
calciﬁc emboli while passing a catheter through a heavily
calciﬁed aortic valve. Optimal anticoagulation during the
procedure targeting ACT .300 seconds and adequate
control of RF energy delivery parameters are important
practices that could help to prevent thrombus formation
during ablation. Given that air embolism can also occur,
careful attention to sheath management is crucial. In the
presence of speciﬁc neurological symptoms suggesting
stroke or transient ischemic attack after ablation, brain
MRI, CT, or cerebral angiography should be performed. If
stroke is conﬁrmed, thrombolytic therapy or endovascular
mechanical or pharmacological therapy might be useful.
A possible neurological complication is asymptomatic microembolism that results from thrombus formation, gas, tissue and/or fat dislodgement, and/or air embolism
(S10.2.9.17). The long-term consequences of this phenomenon are unknown.
10.2.5. Pericardial Complications: Cardiac Tamponade,
Hemopericardium, and Pericarditis
Pericardial complication is the second most common reported complication of VT ablation in patients with SHD, being reported in 0% to 4.5% of procedures, although it can be
higher in the subgroup of procedures in which pLVAD is
used (S10.2.9.1,S10.2.9.6,S10.2.9.8,S10.2.9.9,S10.2.9.15,
S10.2.9.16). In one study by Turagam et al. (S10.2.9.13),
however, the incidence of cardiac tamponade was 5% vs
1.8% when HS was used in VT ablation procedures. A
greater incidence of pericardial effusion is expected in epicardial compared with endocardial approaches (S10.2.9.18).
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Possible mechanisms of this complication are cardiac perforation due to overheating, direct trauma due to catheter
manipulation, transseptal accident when this approach is chosen, or accident when using a pericardial approach. The level
of anticoagulation can also inﬂuence the possibility of hemopericardium, facilitating the perpetuation of bleeding. Cardiac tamponade must be suspected if there is a drop in
blood pressure; thus, an arterial line for continuous blood
pressure monitoring is important, and previous recordings
of cardiac silhouette in the left anterior oblique view can be
helpful. ICE can help to prevent or quickly detect this complication, allowing earlier initiation of appropriate treatment
that might prevent more serious and irreversible consequences. The use of ICE in this setting is discussed in
Section 8.6. When pericardial drainage is needed, anticoagulation therapy should be reevaluated, and reversing heparin
effects with protamine might be necessary. Percutaneous
pericardiocentesis and placement of a pericardial drain are
frequently mandatory in cardiac tamponade. The aspirated
pericardial blood can be returned to the central vein when
the cardiac tamponade is diagnosed during the procedure,
although this approach has not been systematically evaluated. The ablation procedure is usually interrupted unless
bleeding stops shortly after drainage. In some cases, surgical
repair might be necessary if the bleeding is not controlled.
After drainage and clinical stability, a pericardial drain
should be maintained during the ﬁrst 24 hours, and echocardiography should be used for further evaluation and decisions regarding the timing of removing the pericardial
drain. It is also important to carefully evaluate the appropriate
timing of reintroducing anticoagulation therapy as needed.
Another pericardial complication that can be found after
VT ablation is pericarditis. It can be the sole complication
or it might follow pericardial drainage due to cardiac tamponade. Symptoms of chest pain and low-grade fever, leukocytosis, and elevated C-reactive protein levels are commonly
observed; diagnosis can be conﬁrmed with ECG or echocardiogram. Pericarditis is also typically more frequent when an
epicardial approach is used. Steroid administration in the
pericardial space might be useful to prevent pericarditis
(see Section 10.1). Treatment with nonsteroidal antiinﬂammatory drugs, colchicine, and/or steroids is useful.

10.2.6. Vascular Injury
The incidence of vascular injury after VT ablation ranges
from 0% to 8.6% and is the most common major complication reported after VT ablation procedures (S10.2.9.4).
Vascular complications after VT ablation are typically
related to vascular access and include hematoma, retroperitoneal hematoma, pseudoaneurysm, arteriovenous ﬁstula, and
dissection or occlusion of the artery accessed. Prior to sheath
deployment, conﬁrmation that the guide wire used for arterial
access is indeed in the lumen and not in the arterial wall is
important to avoid retrograde dissection of the iliac artery
and aorta. This can be accomplished with techniques such
as ultrasound or angiography. Furthermore, longer sheaths
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are preferable in the setting of tortuous peripheral vessels
to avoid damage of the vessel wall with the catheter tip. Imaging of the aortic arch (with transesophageal echocardiography or CT) prior to ablation using a retrograde approach
could help to identify patients at risk for thromboembolic
events in the presence of mobile atheromas or thick plaque
material. ICE can also be beneﬁcial to identify plaque material in the ascending aorta prior to a planned retrograde
approach. Many electrophysiologists curve the ablation catheter to a “J” shape in the descending aorta to minimize trauma
to the aortic valve when mapping the LV with a retrograde
approach. The catheter is then prolapsed into the LV.
In higher-risk patients, such as those with high body mass
index, body surface area ,1.6 m2, hypertension, age .70
years, baseline anemia, and known peripheral vascular disease, ultrasound-guided percutaneous access and careful
management of anticoagulation status should be strongly
considered (S10.2.9.19). Reversal of heparin with protamine
before sheath removal can also be useful to prevent groin hematoma. There are no conclusive data demonstrating that the
use of vascular closure devices decreases this complication
compared with manual compression (S10.2.9.20).
Large hematomas after sheath removal are the most
common complication and are usually self-limited, but
they can be large enough to result in blood transfusion.
When femoral arterial pseudoaneurysm and arteriovenous
ﬁstulas are suspected, ultrasound Doppler or CT scan are
useful imaging tools for diagnosis. A CT scan can also
be useful in patients with back pain and acute anemia after
ablation to evaluate for retroperitoneal hematoma. Percutaneous thrombin injection, surgical repair of pseudoaneurysm and arteriovenous ﬁstula, and surgical evacuation of
large hematomas are possible interventions for these
vascular complications.
10.2.7. Myocardial Ischemia, Coronary Artery Damage
Myocardial ischemia can occur during VT ablation due to hypotension after VT induction or other causes. MI was reported in 1.7% in a large retrospective database study
(S10.2.9.1). Caution is crucial especially in patients with
known nontreatable ischemia, possibly with avoidance of
VT induction. Coronary artery damage can also cause
myocardial ischemia. Although injury to coronary arteries
is rare, it can occur while crossing the aortic root with the
catheter when using the retrograde aortic approach, with
ablation in the coronary cusps, or with dislodgement of the
ablation catheter in the LVOT. ICE, as discussed in Section
8.6, can be useful for continuous visualization of the ablation
catheter and the coronary artery ostium. Coronary angiography and continuous protection using a coronary angioplasty wire can be useful when the ablation site is close to
a coronary ostium (S10.2.9.21).
10.2.8. Valve Injury
Valve injury is a rare but potentially fatal complication of VT
ablation (Table 10). The incidence of valve injury is reported
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Table 10
Complication

Incidence

Mechanisms

Presentation

Prevention

Treatment

Ref.

In-hospital mortality

0%–3%

Not applicable

S10.2.9.1,S10.2.9.
6–S10.2.9.9

3%–35% (12–
39
months of
follow-up)

Correct electrolyte disturbances and
optimize medical status before
ablation
Identiﬁcation of patients with
indication for heart
transplantation

—

Long-term mortality

VT recurrence, heart failure,
complications of catheter
ablation
VT recurrence and progression of
heart failure

—

S10.2.9.6–S10.2.9.
9

Neurological
complication
(stroke, TIA, cerebral
hemorrhage)

0%–2.7%

Emboli from left ventricle, aortic
valve, or aorta; cerebral
bleeding

Thrombolytic
therapy

S10.2.9.1,S10.2.9.
6–S10.2.9.9

Pericardial
complications:
cardiac tamponade,
hemopericardium,
pericarditis

0%–2.7%

Catheter manipulation, RF
delivery, epicardial
perforation

Abrupt or gradual
fall in blood
pressure; arterial
line is
recommended in
ablation of
complex VT

Careful anticoagulation control; ICE
can help detection of thrombus
formation, and of aortic valve
calciﬁcation; TEE to assess aortic
arch
Contact force can be useful, careful
in RF delivery in perivenous foci
and RVOT

S10.2.9.1,S10.2.9.
6–S10.2.9.9

AV block

0%–1.4%

Energy delivery near the
conduction system

Fall in blood
pressure and ECG
changes

Careful monitoring when ablation is
performed near the conduction
system; consider cryoablation

Coronary artery
damage/MI

0.4%–1.9%

Heart failure/pulmonary
edema

0%–3%

Ablation near coronary artery,
unintended coronary damage
during catheter manipulation
in the aortic root or crossing
the aortic valve
External irrigation, sympathetic
response due to ablation, and
VT induction

Acute coronary
syndrome;
conﬁrmation
with coronary
catheterization
Heart failure
symptoms

Valvular injury

0%–0.7%

Catheter manipulation,
especially retrograde
crossing the aortic valve and
entrapment in the mitral
valve; energy delivery to
subvalvular structures,
including papillary muscle

Acute
cardiovascular
collapse, new
murmurs,
progressive heart
failure symptoms

Limit power near coronary arteries
and avoid energy delivery ,5 mm
from coronary vessel; ICE is
useful to visualize the coronary
ostium
Urinary catheter and careful
attention to ﬂuid balance and
diuresis, optimize clinical status
before ablation, reduce irrigation
volume if possible (decrease ﬂow
rates or use closed irrigation
catheters)
Careful catheter manipulation; ICE
can be useful for identiﬁcation of
precise location of energy
delivery

Pericardiocentesis;
if necessary,
surgical
drainage,
reversal heparin;
steroids and
colchicine in
pericarditis
Pacemaker; upgrade
to a biventricular
pacing device
might be
necessary
Percutaneous
coronary
intervention

Cardiac
nonarrhythmic
death (heart
failure) and VT
recurrence
Focal or global
neurological
deﬁcits

S10.2.9.1,S10.2.9.
6–S10.2.9.8

S10.2.9.1,S10.2.9.
6–S10.2.9.9

S10.2.9.6–S10.2.9.
9

Echocardiography is
essential in the
diagnosis;
medical therapy,
including
vasodilators and
dobutamine
before surgery;
IABP is useful in
acute mitral
regurgitation
and is
contraindicated
in aortic
regurgitation

S10.2.9.6–S10.2.9.
9

(Continued )
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New/increased
diuretics

7%–14.7%

3.8%–11.24%

Overall major
complications with
SHD
Overall all complications

AV 5 atrioventricular; ECG 5 electrocardiogram; HS 5 hemodynamic support; IABP 5 intra-aortic balloon pump; ICE 5 intracardiac echocardiography; MI 5 myocardial infarction; pLVAD 5 percutaneous left
ventricular assist device; RF 5 radiofrequency; RVOT 5 right ventricular outﬂow tract; SHD 5 structural heart disease; TEE 5 transesophageal echocardiography; TIA 5 transient ischemic attack; VT 5 ventricular
tachycardia.

S10.2.9.2,S10.2.9.
7,S10.2.9.11

S10.2.9.1,S10.2.9.
6–S10.2.9.9

S10.2.9.1,S10.2.9.
6–S10.2.9.9
Ultrasound-guided
compression,
thrombin
injection, and
surgical closure
Groin hematomas,
groin pain, fall in
hemoglobin
Access to femoral arterial and
catheter manipulation
Vascular injury:
hematomas,
pseudoaneurysm, AV
ﬁstulae

0%–6.9%

Sustained
hypotension
despite
optimized
therapy
Acute periprocedural
hemodynamic
decompensation,
cardiogenic shock

0%–11%

Fluid overloading, general
anesthesia, sustained VT

Close monitoring of ﬂuid infusion
and hemodynamic status
-Optimize medical status before
ablation
-pLVAD
-Substrate mapping preferred,
avoid VT induction in higher-risk
patients
Ultrasound-guided access

Mechanical HS

S10.2.9.6–S10.2.9.
10
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in up to 0.7% of cases (S10.2.9.6–S10.2.9.9); when using the
retrograde aortic approach, it can occur while crossing the
aortic valve with the ablation catheter. Entrapment of the
ablation catheter in the mitral or tricuspid valve can also
occur using transseptal or retrograde approaches. Energy
delivery direct to the valve apparatus can lead to valve
injury. Ablation of the papillary muscle could result in this
complication, and it can occur with both RF energy and
cryoablation (S10.2.9.22,S10.2.9.23).
Clinical presentations of this complication include acute
cardiovascular collapse, new murmurs, and symptoms of
worsening congestive heart failure. It is important to note
that this complication can occur immediately after the ablation when resulting from entrapment or mechanical damage,
but when resulting from direct energy delivery to the papillary muscle, symptoms can appear weeks after the ablation
procedure.
To prevent valve damage, one should be careful whenever
manipulating the catheter when crossing the aortic valve and
mapping near the mitral valve. ICE is useful to continuously
visualize catheter position and its relationship with the valve
apparatus and papillary muscle (see details of ICE in Section
8.6). Surgical intervention might be needed for removal of an
entangled catheter or for repair of a damaged valve. Given the
acute damage of the valve, repair instead of valve replacement is always preferable whenever possible.
10.2.9. Atrioventricular Block
AV block is reported in up to 1.4% of the VT ablations (S10.
2.9.1,S10.2.9.6–S10.2.9.9), and it can occur when ablation is
performed in the septal region near the conduction system. It
can be anticipated in patients with a known diseased
conduction system, especially in patients with previous
complete bundle branch block (either right or left) and
energy delivered to the basal septum (either left or right
sided). If the ablation is performed during VT, monitoring
of AV conduction is not possible, and ablation during sinus
rhythm might be preferable. Although many VT ablations
are performed in patients with a CIED, the need for RV
pacing could worsen LVEF, and upgrade to CRT might be
required.
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10.3. Hemodynamic Deterioration and
Proarrhythmia
Recommendation for echocardiography after VA ablation
COR

LOE

Recommendation

Reference

I

C-LD

1. Echocardiography should be performed in case of hemodynamic deterioration
post-VT ablation to assess for pericardial effusion and cardiac tamponade.

S10.3.1

Recommendation-Speciﬁc Supportive Text
1. Cardiac tamponade is a serious and potentially reversible
cause of hemodynamic deterioration after VA ablation. It
can present intraprocedure, postprocedure, or late. When
suspected, immediate transthoracic, transesophageal, or
ICE should be performed to assess for the presence of a
pericardial effusion or thrombus (S10.3.1).
Synopsis
Extensive ablation in viable myocardium and repeated VT
episodes with hypotension that can cause myocardial
ischemia can lead to worsening of heart failure or cardiogenic
shock in patients with impaired ventricular function. In patients with scar-related VT, particularly after MI, heart failure
accounts for more than one-third of mortality during followup late after ablation and exceeds 10% per year in some
studies (S10.3.2–S10.3.10). In the Multicenter Thermocool
Ventricular Tachycardia Ablation Trial, 35% of 1-year mortality was due to heart failure (S10.3.3). In another study,
despite the lack of a difference in the EF for the entire group,
14 of 62 (22.5%) patients did have a decline in EF when a

repeat echocardiogram was performed within 7 days of the
ablation (S10.3.10). However, some observations suggest
that VT ablation might not be the sole nor major cause of
the heart failure, given several studies that assessed preand postablation LV function did not report adverse effects
on LVEF before and after ablation (S10.3.11,S10.3.12).
Clinical pre- and intraprocedural variables indicating
poorer clinical status, such as low LVEF, chronic kidney
disease, VT storm, and unmappable VTs can predict
mortality after VT ablation. The International VT Ablation
Center Collaborative Group Study reported that patients
with more severe illness who have multiple comorbidities
who received HS during ablation had higher mortality
(S10.3.13). Therefore, the reported heart failure mortality
could be in line with expectations for these patients. Of 100
early mortality cases, 48 (48%) patients had early recurrent
VT preceding death, although the time course from time of
ﬁrst VT recurrence to death was highly variable. Refractory
VT was the cause of death in 22% of cases, with another
39% dying of other cardiac causes (most commonly
advanced heart failure) (S10.3.14).
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Nevertheless, hemodynamic deterioration and early mortality from heart failure after ablation remain concerns, especially in patients with fragile hemodynamic status, patients
with evident hemodynamic deterioration, or patients who
required extensive ablation in areas of normal ventricular
myocardium or near coronary arteries. Close monitoring of
LV function and potential need for continued hemodynamic
monitoring and/or support might be necessary after such ventricular ablation procedures.
Nontransmural and incomplete lesions can form a new or
modiﬁed substrate, promoting arrhythmia after ablation;
indeed, the majority of VTs recurring after ablation of postinfarction VT are new VTs, as determined by analysis of
ICD electrograms and repeat ablation procedures (S10.3.15).
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10.4. Follow-up of Patients Post Catheter Ablation
of Ventricular Tachycardia
Recommendation for NIPS after catheter ablation of VT
COR

LOE

IIa

B-NR

Recommendation

References

1. NIPS can be useful in the several days following VT catheter ablation to
inform further management, including ICD programming, predicting the risk
of VT recurrence, and/or considering a repeat VT catheter ablation.

S10.4.1,S10.4.2

Recommendation-Speciﬁc Supportive Text
1. Some advocate for routine PES, largely NIPS, shortly after VT catheter ablation and before discharging patients.
However, there are no data from RCTs on the clinical usefulness of such a practice. Data on NIPS after VT catheter
ablation were generated by two observational studies. In
one such study, 132 patients with SHD underwent NIPS
an average of 3 days after VT catheter ablation; 59
(44.7%) patients had no inducible VT, 49 (37.1%) had
inducible nonclinical VT, and 24 (18.2%) had inducible
clinical VT. At 1 year, patients with inducible clinical
VT had a signiﬁcantly lower VT-free survival than patients with no inducible VT (,30% vs .80%; P ,
.001). The authors concluded that when patients with
VT and SHD have no VT or have only inducible nonclinical VT at the end of ablation or if they are too unstable to
undergo ﬁnal programmed stimulation during ablation,

NIPS can be useful in the subsequent several days to
further deﬁne the risk of VT recurrence, and if clinical
VT is inducible during NIPS, to consider repeating VT
catheter ablation due to the high risk of recurrence during
follow-up (S10.4.1). In another study, 218 PESs (186
noninvasive and 32 invasive) were performed an average
of 6 days after ablation on beta-blocker therapy in 210
consecutive patients. The positive and negative predictive
values of PES for VT recurrence over 1 year of follow-up
were 53% and 88%, respectively, and the negative predictive value was highest among patients with IHD and those
with an LVEF .35% (S10.4.2). However, these studies
were single-center, retrospective studies that did not
include a large number of patients and that did not subject
all patients undergoing VT catheter ablation to PES (S10.
4.1,S10.4.2). As such, the routine performance of NIPS is
currently not standard of care, and decisions regarding
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NIPS should be individualized until more data from
prospective studies, preferably RCTs, emerge on the
clinical usefulness of NIPS post-VT catheter ablation.
Summary
Close follow-up of patients after VT catheter ablation is critically important because complications can be detected and
addressed during this period, and decisions regarding postprocedure management are made. These decisions relate to
whether to perform NIPS, whether to maintain the patient
on an AAD, and how to best program and follow ICDs in patients with such devices.
Another important decision after VT catheter ablation is
whether to maintain a patient on an AAD, and if so, what
medication to choose and for what duration. No RCTs have
speciﬁcally addressed these issues, and RCTs of VT catheter
ablation implemented different protocols related to postprocedure use of AADs (Table 9). In 3 clinical trials of VT catheter ablation, preablation AADs (mostly amiodarone) were
continued either for 3 to 6 months or for an unspeciﬁed period
of time (S10.4.3–S10.4.6). In 3 other clinical trials of VT
ablation, the use of AADs post-VT catheter ablation was
either discouraged or left to the discretion of the treating
physician (S10.4.7–S10.4.9). In the SMASH-VT trial, no patient received an AAD (other than beta blockers) before the
primary endpoint was reached (S10.4.10). Given this variability in the use of AADs post-VT ablation in prior RCTs,
there is no standard of care for their use in this scenario; as
such, decisions in this regard should be individualized based
on patient characteristics and ﬁndings of the PES at the end of
the VT catheter ablation (or later), keeping in mind the toxicities of these medications and their potential detrimental effects on survival (S10.4.11). In particular, given its
toxicities, many favor discontinuing amiodarone after ablation. In fact, amiodarone use had decreased in several prospective cohort studies of VT ablation (S10.4.4,S10.4.6,
S10.4.9), and dose reduction or discontinuation had been
feasible in patients who were not inducible post ablation in
1 single-center experience (S10.4.12).
Data on the best programming parameters of ICDs postVT catheter ablation are scarce, given that studies of optimal
ICD programming were conducted largely in patients with no
prior VT (S10.4.13–S10.4.15). In a few clinical trials of VT
catheter ablation, information on ICD programming was not
provided (S10.4.3,S10.4.4,S10.4.10). In the clinical trials
that provided information on ICD programming,
programming instructions to the sites were variable
(Table 9). However, based on current practice, ICDs may
be programmed with a 10–20 bpm margin if the patient has
slower VT and, where appropriate, with ATP and prolonged
arrhythmia detection durations and higher detection rates for
VF. Although not speciﬁc to post-VT catheter ablation programming, the HRS document on optimal programming of
ICDs can be a useful resource (S10.4.15). Given the risk of
VT recurrence after VT ablation, it is imperative to follow
ICDs closely, preferably with remote monitoring that allows
earlier detection and treatment of VT recurrences (S10.4.16).
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10.5. Assessing the Outcomes of Catheter Ablation
10.5.1. Introduction
Important outcomes of clinical trials for VA catheter ablation
include procedure-related complications and mortality,
recurrent VA, long-term mortality, and quality of life. It is
also important to recognize that outcomes are also impacted
by the many factors following ablation that have the potential
to inﬂuence the frequency and nature of arrhythmia recurrences (Figure 13).
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10.5.2. Recurrent Arrhythmias
Recurrence of any sustained VT is an important endpoint for
patients who have ICDs. In patients with SHD and ICDs, the
QRS morphology of recurrent VT compared with preablation
VT is frequently difﬁcult to assess and is not usually reported
in clinical trials. The ECG morphology of spontaneous VTs
terminated by ICDs is often unknown, and the QRS
morphology of VTs can be altered by changes in the arrhythmia
substrate and AAD therapy after ablation. Any spontaneous
sustained VT might be of clinical signiﬁcance, whether it
was observed previously or not. Clinical trials assessing the effect of catheter ablation on recurrent sustained VT have reported the time from the ablation procedure to the ﬁrst
recurrence of VT in Kaplan–Meier curves (S10.5.7.1–S10.5.
7.4). These curves provide important information and are
widely understood. They fail, however, to capture other
potential beneﬁts of the procedure, including reduction in VT
burden, prevention of VT storm, conversion of symptomatic
episodes causing ICD shocks to asymptomatic episodes
terminated by ATP, and reductions in medications.
For patients with nonsustained VAs and PVCs, outcome
assessment is determined by ambulatory monitoring of a
duration sufﬁcient to detect recurrences, based on the frequency of the arrhythmia prior to treatment, and considering
the goals of therapy.
10.5.3. Arrhythmia Burden
Several studies have reported arrhythmia burden using the patient as their own reference during a speciﬁed time prior to
ablation and comparing the arrhythmia frequency after ablation in patients who have ICDs (S10.5.7.5–S10.5.7.7). This
type of analysis can be challenging. The number of VT
episodes before and after ablation can be inﬂuenced by
programmed ICD detection criteria and AAD management.
It is also difﬁcult to know how to assign a “frequency” to
preablation incessant VT or VT storm for comparison with
single VT recurrences post ablation. Prior ICD
interrogations are not always available to conﬁrm the
arrhythmia burden. The VT burden that has clinical
relevance has not been deﬁned and likely would vary
depending on other patient factors. Further work on methods
by which arrhythmia burden can best be assessed and
compared in patients undergoing VT ablation is needed.
10.5.4. Ventricular Tachycardia Storm
VT storm has been deﬁned as 3 or more separate episodes of
sustained VT in a 24-hour period, and it has been associated
with poorer outcomes (S10.5.7.8). Prevention of VT storm is
an important goal. Again, ICD programming has an important inﬂuence on detection and counting of these events.
10.5.5. Hospitalizations
Hospitalizations for cardiovascular disease and recurrent
VA are also potentially important outcomes. Recurrent
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arrhythmias can be precipitated by intercurrent illness.
Whether a patient requires hospitalization for a recurrence
is sometimes a subjective assessment.

10.5.6. Patient-Reported Outcomes
Assessing the impact of therapies on quality of life and
measuring patient-reported outcomes is endorsed by the
AHA and the European Society of Cardiology (S10.5.7.9,
S10.5.7.10). In the United States, the Food and Drug
Administration has also recently implemented the Medical
Device Development Tools program in which patientreported outcome tools can be submitted for evaluation
and potential certiﬁcation allowing their use for clinical
outcome assessment in trials of medical devices
(S10.5.7.11).
Assessment of the impact of ablation on quality of life is
likely to reﬂect not only the outcome of ablation therapy,
but also the severity of the arrhythmia’s impact on the patient prior to ablation. For example, a recent trial of left
ventricular assist devices (LVADs) found that LVADs
improved health status in patients with heart failure who
had low self-reported quality of life, but not in those
with acceptable quality of life at the time of LVAD implantation (S10.5.7.12). The measure of quality of life prior to
ablation is potentially useful information for deﬁning who
beneﬁts from ablation.
Although a number of validated tools are available, the
interpretation of ﬁndings can also be challenging. The
VANISH trial assessed quality of life using 4 validated instruments (Short Form 36 Health Survey, the Implantable
Cardioverter Deﬁbrillator Concerns Questionnaire, the Hospital Anxiety and Depression Scale, and the EuroQol ﬁve dimensions questionnaire) (S10.5.7.13). Among 16 different
measures of quality of life at 6 months and 1 year that were
compared with baseline, persistent improvements were
observed in some (energy and fatigue), transient improvements that were no longer present at 1 year in others (eg, social functioning), and no improvement was found in yet
others (eg, general health perceptions scale). How to integrate
multiple measures to assess net beneﬁt of the procedure could
be a challenge.

10.5.7. Mortality
Assessing mortality after ablation is important. Although
mortality is relatively high in many VA ablation populations, and VA recurrence has been associated with
increased mortality, no trial has yet shown a mortality
beneﬁt from catheter ablation. Efforts to enroll a sufﬁcient
number of patients will be key to conclusively establishing
the impact of ablation on mortality in a randomized trial
(S10.5.7.4,S10.5.7.14). Recently, risk scores for predicting
mortality in patients with SHD undergoing VT ablation
have been developed, and await further validation (S10.5.
7.15,S10.5.7.16).
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Figure 13 Factors inﬂuencing outcomes post VA ablation. ICD 5
implantable cardioverter deﬁbrillator; LVAD 5 left ventricular assist device;
VA 5 ventricular arrhythmia; VT 5 ventricular tachycardia.
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Section 11 Training and Institutional
Requirements and Competencies
11.1. Training Requirements and Competencies
for Catheter Ablation of Ventricular Arrhythmias
Recommendation for training requirements and competencies for catheter ablation of VA
COR

LOE

Recommendation

I

C-EO

1. For clinical cardiac electrophysiologists who perform catheter ablation of
VAs, appropriate advanced training and continued lifelong learning is
recommended.

Recommendation-Speciﬁc Supportive Text
1. Catheter ablation of VAs requires advanced skills in clinical cardiac electrophysiology. Physicians performing
these procedures should be trained at electrophysiology
programs with expertise in complex VA ablations
and should meet the general and advanced training
requirements for clinical cardiac electrophysiologists
during training or with an experienced mentor if
novel procedures and approaches have developed after
training.

11.1.1. Training Requirements
For adult electrophysiologists in the United States, these
training competencies are outlined in the 2015 ACC COCATS
4: Task Force 11: Training in Arrhythmia Diagnosis and
Management, Cardiac Pacing, and Electrophysiology report,
the 2015 ACC/AHA/HRS Advanced Training Statement on
Clinical Cardiology Electrophysiology, and the 2009
EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias (S11.1.8.1–S11.1.8.3). For pediatric
electrophysiologists in the United States, these training
competencies are outlined in the 2015 SPCTD/ACC/AAP/
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AHA Task Force 4: Pediatric Cardiology Fellowship
Training
in
Electrophysiology
and
the
2013
Recommendations for Advanced Fellowship Training in
Clinical Pediatric and Congenital Electrophysiology: A
Report from the Training and Credentialing Committee of
the Pediatric and Congenital Electrophysiology Society
(S11.1.8.4,S11.1.8.5). Although these requirements mainly
reﬂect fellowship training in the United States, other
countries have requirements that are similar, including the
Working Group of Pacing, Electrophysiology of the French
Society of Cardiology (S11.1.8.6). Training requirements
vary from country to country, but irrespective of local differences, appropriate advanced training and continued lifelong
learning are strongly recommended for all clinical cardiac electrophysiologists who perform catheter ablation for VAs.
As the ﬁeld of catheter ablation for VAs continues to
evolve with introduction of new approaches, technology,
and application in higher-risk and more complex patients
(ie, adults with VADs and CHD), trainees and practicing operators specializing in these ablations are expected to
continue to maintain their core and specialized competencies
as outlined in the 2017 ACC/HRS Lifelong Learning Statement of Clinical Cardiac Electrophysiology Specialists
(S11.1.8.7). These procedures should be performed by select
qualiﬁed cardiac electrophysiologists with a practice focus on
VAs at programs with expertise.
Physicians performing catheter ablation for VAs should
achieve proﬁciency in 6 core competency domains promulgated by the Accreditation Council of Graduate Medical Education and American Board of Medical Specialties. These 6
core competency domains include Medical Knowledge, Patient Care and Procedural Skills, Systems-Based Practices,
Practice-Based Learning and Improvement, Professionalism,
and Interpersonal and Communications Skills (S11.1.8.8).
11.1.2. Medical Knowledge
A detailed understanding of cardiac anatomy is required,
including the conduction system, the coronary arterial and
venous systems, and anatomical variations due to underlying
heart disease. Knowledge is necessary of the mechanisms
and pathophysiology of VAs, with a particular focus on the
relationship between these arrhythmias and acquired, inherited, or SHD; sympathetic and parasympathetic tone;
and drugs. This understanding, along with proﬁciency in
electrocardiographic interpretation, helps guide appropriate
mapping and ablation approaches. In addition, knowledge
of patient-speciﬁc factors such as disease type, severity,
and comorbidities; procedural risks; and alternative therapies
such as AADs, surgery, or device therapy should be used to
guide appropriate patient selection.
11.1.3. Patient Care and Procedural Skills
A comprehensive and structured approach to the clinical
evaluation and management of patients with VAs undergoing
catheter ablation is necessary across all settings (inpatient
and outpatient) and time points (preprocedural planning,
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periprocedural and intraprocedural care, and postprocedural
follow-up). Trainees should demonstrate and maintain these
proﬁciencies as pertains to their practice area of focus. A
clear understanding of the various approaches and systems
used (mapping, ablation, and imaging) and proﬁcient demonstration of the skills to perform VA ablations are required.
Additional advanced technical skills are needed for those
seeking to perform epicardial ablations or ablations in
CHD. Given patients undergoing complex VA ablations
often have underlying medical conditions and comorbidities,
recognition of the potential need for a multidisciplinary
approach and coordination with other specialists (anesthesiologists, surgeons, interventional cardiologists, cardiologists,
heart failure specialists, and/or intensivists) will ensure
optimal procedural outcomes.
11.1.4. Systems-Based Practice
Complications can occur in catheter ablation procedures for
VAs that can range from minimal to fatal. These can include
vascular injury, thromboembolic events, cardiac tamponade,
malignant VA including electrical storm, acute MI, and hemodynamic instability or collapse. A careful understanding
of the potential procedural complications that might arise
from either the patient’s underlying medical conditions or
the electrophysiology procedure itself is necessary. When
appropriate, the use of a multidisciplinary team for the management of high-risk patients should be in place for prevention, prompt detection, timely intervention, and optimal
management of complications. Functional systems should
be in place to promptly care for patients in case of unanticipated complications.
11.1.5. Practice-Based Learning and Improvement
All trainees should continue to participate in lifelong learning
to maintain and enhance skills and knowledge through selfassessment, regular literature review, updated practice guidelines, consensus document and appropriate use criteria, and
attending appropriate scholarly meetings with a focus on
VAs.
11.1.6. Professionalism
On the basis of personal expertise and technical skills, practicing clinical cardiac electrophysiologists and trainees
should practice within their scope as pertains to the specialized ﬁeld of catheter ablation for VAs.
11.1.7. Interpersonal and Communications Skills
Catheter ablation for VAs can be challenging due to
increased procedural risk and complexity necessitating additional technical expertise. Practicing clinical cardiac electrophysiologists and trainees should engage patients, families,
and interprofessional teams in a shared decision-making
approach. These physicians must develop the skills to
communicate and counsel effectively regarding the
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diagnosis, risks, and beneﬁts of catheter ablation, and alternative management options.
11.1.8. Ionizing Radiation
Awareness is rising of the detrimental effects on patients,
the electrophysiology staff, and the operator of ionizing
radiation during imaging. The use of low-frame rate ﬂuoroscopy equipment, pre- and intraprocedural imaging with
ICE, as well as 3D EAM, all contribute to reduce radiation
exposure. Appropriate education of all personnel involved
in the procedure on the risks and beneﬁts of radiation is
key for safer imaging. Societal recommendations have
emphasized the importance of awareness of the principles
of radiation safety and their implementation on a day-byday basis while using radiation for medical imaging
(S11.1.8.9,S11.1.8.10).

S11.1.8.3.

S11.1.8.4.

S11.1.8.5.

S11.1.8.6.

S11.1.8.7.

S11.1.8.8.
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11.2. Institutional Requirements for Catheter
Ablation of Ventricular Tachycardia
Recommendations for institutional requirements for catheter ablation of VT
COR

LOE

Recommendations

I

C-EO

I

C-EO

I

C-EO

I

C-EO

1. Patients with certain underlying medical conditions and comorbidities
undergoing complex VA ablations who are deemed to have increased
procedural risk should undergo procedures in a hospital-based
electrophysiology laboratory.
2. Onsite interventional cardiology expertise is recommended for
electrophysiology procedures requiring coronary imaging to delineate
coronary anatomy for epicardial ablation, aortography to delineate coronary
ostia for SV VT ablation, and need for placement of HS devices.
3. Onsite cardiothoracic surgical backup is recommended for electrophysiology
procedures requiring pericardial access due to the potential need for
emergent sternotomy and cardiopulmonary bypass.
4. Availability of anesthesia personnel is recommended for all patients
undergoing catheter ablation of VAs.

Recommendation-Speciﬁc Supportive Text
1. High-risk patients include those with advanced heart failure, severe ventricular dysfunction, severe valvular
dysfunction, prosthetic heart valves, CHD, inherited
arrhythmia disorders, recent MI, recent stroke, chronic
kidney disease, severe obstructive pulmonary disease,
pulmonary hypertension, severe/morbid obesity, active
oral anticoagulation, and advanced or pediatric age
groups. Due to the potential risks associated with catheter

ablation in close proximity to the coronary arteries and
epicardial ablation, these procedures should be performed
in a hospital-based electrophysiology lab with immediate
availability of interventional cardiology or cardiothoracic
surgical support (S11.2.1).
2. Interventional procedures, including coronary angiography, aortography, and deployment of percutaneous HS
devices (pLVAD, IABP), requires advanced skills and
should be performed by appropriately trained personnel.
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3. Epicardial ablation and mapping requires pericardial access that carries the risk of ventricular laceration or perforation. Inadvertent injury to the ventricle can result in lifethreatening tamponade and hemodynamic collapse, which
might require emergent surgical intervention via sternotomy. Immediate surgical intervention is critical and
dependent on designated surgical backup (in-room or
onsite with a clear notiﬁcation protocol in place) and immediate access to an emergency surgical tray (S11.2.1).
4. Due to procedural complexities and patient factors,
including underlying medical conditions and comorbidities, the use of anesthesia services (anesthesiologist,
nurse anesthetist, or equivalent trained personnel) provides optimal periprocedural patient care and additional
expertise in the setting of life-threatening complications
(S11.2.1).
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neuromodulation, have not been made (S11.3.1,S11.3.2).
Less than half of the writing committee members’
institutions have a formal capacity to perform VA ablations
outside of regular working hours (necessitating personnel
to be called into the hospital overnight or on weekends),
although two-thirds had performed such a procedure after
hours in exceptional circumstances, almost all between ,1
and 5 times per year. Opinions were divided about whether
a formal on-call schedule for VA ablation was necessary.
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11.3. Ventricular Tachycardia Network and
Ventricular Tachycardia Unit
VT ablation is a domain of specialized centers with high
operational expertise. Within these centers, logistics for optimizing patient ﬂow and referral are crucial. Therefore, many
tertiary referral centers for VT ablation have established their
network of regional referring centers to improve patient
admission and early VT ablation. Few studies have documented their experience with this concept (S11.3.1,S11.3.2).
Conceptionally, “VT networks” centralize around highly
experienced centers capable of all techniques associated
with VT and electrical storm ablation, including epicardial
ablation and HS. Discussion with a multidisciplinary team
and immediate transfer should be possible. Electrophysiology staff should be available on a 24/7 basis. Although
acute ablation, deﬁned as ablation for rhythm stabilization
within 8 hours after onset, is rare, there is a potential need
for catheter ablation on a 24/7 basis (S11.3.1–S11.3.3).
However, very few electrophysiology labs worldwide have
this capacity.
Dedicated VT units have been established in some tertiary
referral centers to expedite the transfer and management of
patients with VT in a specialized intensive care unit. The
optimal technical set-up of a dedicated VT unit has not
been deﬁned, but 12-lead ECG monitoring, online device
telemetry, and intensive care unit facilities are helpful. The
organization of VT units and networks would likely vary substantially across different countries according to the local
health care delivery organization and resources. The ability
to provide 24/7 catheter ablation might be useful for effective
early rhythm stabilization, speciﬁcally in unstable patients
with recurrent VA; however, comparisons with standards
of care, including pharmacological suppression, HS, and

Section 12 Future Directions
12.1. Clinical Trials of Catheter Ablation of
Ventricular Tachycardia
12.1.1. Introduction
The development of high-quality randomized trial evidence
to establish an optimal therapy for VT has been challenging,
despite the clinical importance of the question. Relatively
few RCTs have been published comparing catheter ablation
with noninterventional therapies. Recent consensus and
guideline documents have consistently stressed the importance of further research in the ﬁeld (S12.1.4.1–S12.1.4.3),
particularly the need for prospective randomized trials.
Important clinical questions remain regarding optimal
techniques for catheter ablation, its optimal role and timing
in ischemic and nonischemic cardiomyopathies, as well as
the relative merits of catheter ablation in comparison with
antiarrhythmic or other pharmacological therapy. Published
randomized trials completed thus far have included patients
with ICM. Three trials compared catheter ablation to
standard care in the setting of initial presentations with
VAs (S12.1.4.4), with presentations with tolerated VT
(S12.1.4.5), and with nontolerated VT (S12.1.4.6). One trial
compared ablation to more aggressive AAD therapy for patients with VT despite ﬁrst-line AAD treatment (S12.1.4.7).
At least 8 trials of catheter ablation for VT have been initiated
but were terminated because of insufﬁcient enrollment
(STAR-VT, NCT02130765; VeTAMed, NCT01798277;
INTERVENE, NCT02301390; AVATAR, NCT02114528;
ASPIRE, NCT01557842; CEASE-VT, NCT01097330;
BERLIN-VT, NCT01045668; CALYPSO, NCT01576042),
of which only CALYPSO has published results available.
Trials comparing various methods of VT ablation or treatment have been reported [VISTA (S12.1.4.8); Ultra High
Density mapping, NCT02083016 (S12.1.4.9)] or are listed
as ongoing on trial registry sites [MAGNETIC VT
(S12.1.4.10); Impress, NCT03531502; ZFOVA zero ﬂuoro
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trial, NCT03041519; Ripple Mapping, NCT02216760]. Barriers to completion of research in this area are signiﬁcant, and
include patient and provider biases and preferences (particularly for randomized trials of procedures compared to pharmacotherapy), challenges to standardization of procedural
techniques and endpoints, as well as trial funding and reimbursement (S12.1.4.11).
12.1.2. Ongoing Randomized Controlled Trials
Several randomized trials comparing catheter ablation with
medical therapy are ongoing. The PARTITA trial
(NCT01547208) is enrolling and following 586 patients
with ICD implantation, and randomly allocating 176 who
present with ﬁrst ICD shocks to early catheter ablation vs
withholding ablation until electrical storm occurs, with a primary composite endpoint of heart failure hospitalization and
death from any cause. The PAUSE-SCD trial
(NCT02848781) is enrolling 120 patients with ICM or
NICM and randomly allocating them to ICD implant followed by catheter ablation or medical therapy with a composite endpoint of recurrent VT, cardiovascular rehospitalization, and all-cause mortality. The IMPRESS
TRIAL (NCT03531502) is enrolling 75 patients with cardiomyopathy who experienced a ﬁrst ICD shock and is performing a NIPS procedure with a noninvasive mapping system
(Cardioinsight, Medtronic). If the NIPS procedure is positive,
then patients will be randomized to catheter ablation guided
by noninvasive mapping or standard medical therapy with
a primary endpoint of ICD shocks. The PREVENTIVE VT
Trial (NCT03421834) is a randomized trial of 60 patients
with a subset of ICM (chronic total occlusion of infarctrelated area). Patients will be randomized to ICD alone or
ICD plus catheter ablation, with an endpoint of time to ﬁrst
ICD therapy or VT-related hospitalization. The VANISH2
trial (NCT02830360) is enrolling 366 patients with prior
MI who present with sustained monomorphic VT and is
randomizing them to receive either catheter ablation or
AAD therapy, with a primary composite endpoint of death,
appropriate shock, or VT storm.
12.1.3. Endpoints for Prospective Clinical Trials of Ventricular
Tachycardia Ablation
Although observational studies have demonstrated an association between recurrent VAs and mortality (S12.1.4.12–S12.
1.4.15), no prospective study thus far has demonstrated a
signiﬁcant beneﬁcial effect of VT ablation on survival.
Successful completion of a prospective trial of VT ablation
with a primary outcome of mortality is challenging due to
competing mortality risks in patients with VT. In the
VANISH trial, there was no clear effect of ablation on
mortality in comparison with escalated AAD therapy (S12.
1.4.7,S12.1.4.16), likely because arrhythmia was an
infrequent cause of death in the trial, and because additional
interventions were undertaken when patients experienced
clinical deterioration or recurrent arrhythmia. For
randomized trials enrolling patients with low-frequency VT
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events, the use of time-to-event endpoints (rather than measures of arrhythmia burden) has traditionally been preferred,
given clinicians and patients might not tolerate large burdens
of recurrent arrhythmia events without considering treatment
alternatives to assigned therapy. For randomized trials specifically enrolling patients with high VT burden, the use of
reduction in VT burden provides a meaningful endpoint for
both patient satisfaction and scientiﬁc inquiry.
12.1.4. Future Clinical Studies
Further research is required to identify optimal methods for
arrhythmia suppression and to understand the inﬂuences of
each method on arrhythmia outcomes, as well as on cardiac
function, symptoms, quality of life (S12.1.4.17), costeffectiveness (S12.1.4.18,S12.1.4.19), and long-term outcomes. The best ﬁrst-line therapy for VT, beyond the use
of ICDs, remains undetermined, as does the most appropriate
time to intervene. Ablation outcomes in nonischemic cardiomyopathies, speciﬁc disease states, and patient subgroups
also require further study. Developing, funding, and
executing patient-centered, prospective, and randomized trials are strongly encouraged to move the ﬁeld of VT ablation
forward in ways that promote patient health and minimize
confounding biases.
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12.2. Future Directions in the Treatment of
Patients With Ventricular Arrhythmias
12.2.1. Introduction
Awareness of the importance of VAs as a frequent and potentially modiﬁable cause of death has led to increased development of novel methods to improve VT mapping (both inside
and outside the body), VT treatment (inside and outside the
body), and identiﬁcation of an individual patient’s status,
along the spectrum of cardiac illness.
12.2.2. Advances in Mapping
Cardiac mapping has made an important advance with the
development of tools that employ multiple small, closely
spaced electrodes. These tools provide higher resolution mapping during sustained VT and sinus rhythm (see Section 8.1).
Outside of catheter mapping, tools have been created to take
advantage of coronary vasculature access to intramyocardial
structures. The most common example involves mapping the
perforator veins (S12.2.4.1) facilitated by the use of electrically
protected wires into septal perforating branches (S12.2.4.2),
the use of cold saline (S12.2.4.3), and the use of dual site
pace mapping (S12.2.4.4) to identify intramural VA origins.
Advances in cardiac imaging are enabling a more comprehensive understanding of the 3D nature of cardiac scarring
and the dynamic nature of ventricular electrophysiology. Preprocedural imaging with CMR and CT is increasingly being
used to identify abnormal myocardium, but its value as a
stand-alone ablation guide has not yet been proven. Studies
are underway to address this possibility.
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The synthesis of cardiac imaging with detailed cardiac mapping is furthering the understanding of the relationship between
the VT circuit and myocardial scarring. Important observations
have been made from mapping several surfaces of the heart
simultaneously (S12.2.4.5). Additional observations can be
made by comparing maps and electrograms in sinus rhythm,
RV pacing, LV pacing and sustained VT (S12.2.4.6). However, these detailed maps are time-consuming to create, potentially exposing patients to additional procedural risk. The
translation of these observations into tangible value for the
operator or for improved patient outcomes remains to be
proven and is an area of active investigation.
Entirely noninvasive electrophysiological mapping has
been developed with ECGI. This technology combines
body surface unipolar electrograms obtained from a vest of
electrodes with patient-speciﬁc heart-torso geometry. Local
ECGs are reconstructed on the surface of the heart geometry,
requiring a single beat of arrhythmia. ECGI has been shown
to localize the site of VT origin (S12.2.4.7,S12.2.4.8),
ventricular scar locations (S12.2.4.9), and risk assessment
for future VT events in a small cohort of patients with IHD
and ICDs (S12.2.4.10). Compared with catheter-based mapping, noninvasive ECGI mapping of VT does not provide
similar local bipolar electrogram detail and ECGI does not
image during ventricular diastole. Unipolar ECG reconstructions on the ventricular surface can infer activation patterns
from deeper structures, such as septum or papillary muscles,
but further reﬁnement is needed to reliably map these structures. Advantages include the ability to map both ventricles
simultaneously in a single beat, obtaining an immediate sense
of VT entrance and exit locations, as well as mapping unstable VT/VF. Outside of the electrophysiology lab, ECGI offers possibilities for clinical VT risk stratiﬁcation, such as
was recently demonstrated with Brugada syndrome
(S12.2.4.11), long QT syndrome (S12.2.4.12), and early
repolarization syndrome (S12.2.4.13).

12.2.3. Advances in Ablation
A better understanding of biophysical properties of RF energy to create ablative heat in both normal and abnormal ventricular myocardium has driven important innovations. A
change in the catheter irrigant to half normal saline alters
the local ionic content, which creates a larger ablation lesion
(S12.2.4.14). In prospective clinical use, this approach has
translated into high rates of successful ablations in patients
who failed traditional ablation (S12.2.4.15), although direct
comparisons with conventional irrigant are lacking. Caution
should be exercised, given the authors reported a 12% rate of
steam pop with this technique.
Alternate forms of delivering RF energy have been developed. The most prominent of such technologies is a catheter
with a needle that can be deployed into ventricular myocardium to both map and ablate (S12.2.4.16). Clinical trials in
patients with VA are underway (NCT01791543;
NCT03204981). Advantages include more precise intramyocardial mapping, injection of dye to assess location of

e148
potential ablation using ﬂuoroscopy, and deeper ablation lesions than standard catheter ablation. Disadvantages include
the difﬁculty ensuring safe use and unpredictable energy distribution. A warm saline-infused needle ablation catheter,
capable of creating large lesions, is currently being studied
in patients with ICM and VT (NCT02994446)
(S12.2.4.17). Alternative methods for RF delivery to larger
areas are under development, including expandable catheter
tips that form spheres or round lattice structures.
Beyond RF energy to create thermal ablation, alternative energies have been studied to control VT. These alternatives
include localized intracoronary alcohol injection, locally
applied pulsed ﬁeld direct current electroporation, and noninvasive focused stereotactic radiation. Coronary ethanol infusion has been performed in both an antegrade (S12.2.4.18)
and retrograde fashion (S12.2.4.19) on patients for the treatment of refractory VT. Electroporation using localized direct
current is a technology in rapid development with signiﬁcant
advantages of speed (seconds) and a tissue-selective ablation
effect in preclinical models. Its safety and efﬁcacy in humans
has yet to be established. Stereotactic radioablation is a noninvasive and rapid (minutes) method for delivery of photons (Xrays), protons, or heavy ions (carbon) into selected cardiac tissue. The use of noninvasive photon ablation in humans was
ﬁrst reported in 2015 (S12.2.4.20). The development of an
entirely noninvasive process for mapping and ablating VT,
combining ECGI, cardiac imaging, and stereotactic cardiac
ablation, represents a promising new option in the ﬁeld
(S12.2.4.21).
Outside of a direct ablative effect on the diseased myocardium, modulation of the nervous system can alter the likelihood that VT will occur. Neuromodulation is largely
designed to decrease sympathetic tone and enhance parasympathetic tone. There are many locations at which to manipulate the nervous system, including cervical vagal stimulation,
transcutaneous auricular vagal stimulation, baroreceptor activation therapy, spinal cord stimulation, ganglionated plexus
ablation, renal sympathetic denervation, and left CSD.
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12.2.4. Advances in Patient Evaluation
As we progress into a future where artiﬁcial intelligence becomes increasingly used for predictive analytics, the ﬁeld of
VT ablation is ripe for such advances. In silico multiscale cardiac modeling of patients with ICM has provided an exciting
possibility for the development of a patient-speciﬁc a priori
ablation strategy (S12.2.4.22). Beyond this approach, the use
of predictive tools can further help physicians to identify the
right patients, the proper timing of the procedure, and the expected outcomes with various forms of ablation techniques to
ultimately offer the right patient the right ablation at the right
cardiac location at the right time in the course of the disease.
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